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Genome Engineering Technologies to Change the Genetic Code 
 
 
ABSTRACT 
 
New technologies are making it possible to engineer organisms with fundamentally new 
and useful properties. In vivo genome engineering technologies capable of manipulating 
genomes from the nucleotide to the megabase scale were developed and applied to reassign the 
genetic code of Escherichia coli. Such genomically recoded organisms show promise for 
thwarting horizontal gene transfer with natural organisms, resisting viral infection, and 
expanding the chemical properties of proteins. 
Chapter 1 discusses the boundaries of possible genetic codes and the barriers that must be 
overcome to produce them.  
Chapters 2 and 3 describe mechanistically-driven improvements to λ Red 
recombineering, which is a cornerstone of our approach to genome engineering. Chapter 2 is 
adapted from J. A. Mosberg, et al. Genetics (2010) 186, 791. Chapter 3 is adapted from portions 
of J. A. Mosberg, et al. PLoS One (2012) 7, e44638 and M. J. Lajoie, et al. Nucleic Acids Res. 
(2012) 40, e170. 
Chapter 4 describes how to make hundreds of changes in a genome in order to reassign 
the UAG codon to new function. Multiplex automated genome engineering (MAGE) was used to 
site-specifically replace all known UAG stop codons with synonymous UAA codons in parallel 
across 32 E. coli strains. Conjugative assembly genome engineering (CAGE) was used to 
hierarchically merge these codon changes. This chapter is adapted from F. J. Isaacs, et al. 
Science (2011) 333, 348. 
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Chapter 5 describes the complete reassignment of the UAG codon in E. coli and provides 
preliminary evidence that genetic codes can be changed to resist viruses and to expand the 
chemical diversity of proteins. This chapter is adapted from M. J. Lajoie, et al. Science (2013) 
342, 357. 
Chapter 6 probes the limits of genetic recoding in E. coli by radically recoding 42 
essential genes. Across 80 E. coli strains, all instances of 13 rare codons were removed from 
these genes and all remaining codons were shuffled as possible. The results suggest that in vivo 
genome engineering and genetic diversity will be essential for radically changing genetic codes. 
This chapter is adapted from M. J. Lajoie, et al. Science (2013) 342, 361.  
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Introduction 
The canonical genetic code has been good to us. For decades, biotechnology has relied on 
it to permit the transgenic production of drugs (1), materials (2), and food (3). However, the 
canonical genetic code also supports viruses (e.g., HIV, influenza) and undesired horizontal gene 
transfer [e.g., antibiotic resistance (4) and dissemination of recombinant DNA (5-7)]. 
Furthermore, its mere 20 amino acids stifle the potential for evolving new and useful protein 
functions. 
 
Figure 1-1. Properties of genomically recoded organism (GROs) with a reassigned UAG codon. The GRO provides 
a dedicated UAG codon for plug-and-play translation of nonstandard amino acids (NSAAs). This enables efficient 
expression of GFP variants containing several UAG codons, provides increased resistance to bacteriophages, and 
establishes a basis for the genetic isolation of GROs (8). 
 
Genomically recoded organisms (GROs) possessing alternate genetic codes (8) have the 
potential to solve these problems (Figure 1-1). By interpreting genetic information differently, 
GROs would mistranslate foreign genes based on the canonical genetic code. This would prevent 
viruses from hijacking their translation machinery and thwart the transfer of functional genetic 
information with natural organisms. In addition, GROs could be engineered to incorporate more 
than 70 structurally diverse nonstandard amino acids (NSAAs) that have been developed to 
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enhance enzyme activity (9, 10), to improve the performance of protein drugs (11), and to 
function as molecular probes (12). Redesigning essential proteins to depend on NSAAs for 
proper translation and function would provide a robust strategy for restricting undesired survival 
outside of controlled conditions. Thus, GROs have the potential to be safe and powerful chassis 
for biofermentation, bioremediation, and agriculture: Virus resistance could save hundreds of 
millions of dollars from lost batches (13, 14), genetic isolation can reduce the risk of escape into 
the environment, and NSAAs can improve enzyme functions. 
There are considerable biological and technological challenges that must be addressed in 
order to engineer such organisms with new genetic codes, and this review will focus on 
overcoming these barriers. While principles relevant to the evolution of the genetic code will be 
applied to this analysis, a more comprehensive discussion of how the genetic code originated can 
be found in previous work (15-19).  
 
Central dogma of molecular biology and protein translation 
A number of recent reviews explain the molecular details of the central dogma of 
molecular biology (20, 21) and protein translation (22). Nevertheless, a brief overview of these 
topics provides important exposition for engineering genetic codes. 
 
Central dogma 
Crick (23) stated that nucleic acid sequence information can be transferred to nucleic 
acids and proteins, whereas proteins cannot transfer sequence information (23). A simplistic 
view of the central dogma is as follows: Modern, free-living organisms possess double stranded 
DNA genomes that are copied completely during replication. Additionally, small portions of 
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DNA composed of one or more genes can provide the information to produce RNA during 
transcription. RNA can either function as a ribozyme (e.g., ribosomal RNA, rRNA) or it can 
provide the information to produce proteins during translation (i.e., messenger RNA, mRNA). 
Proteins are highly efficient catalysts that perform most of the cellular chemistry. 
 
Protein translation 
Aminoacyl-tRNA synthetases (aaRSs) are proteins that charge the correct amino acid 
onto the correct transfer RNAs (tRNAs). Each aaRS recognizes specific identity elements (24) 
on its target tRNA and has a binding pocket that determines which amino acid it charges. Each 
tRNA has an anticodon composed of three ribonucleotides that determine which codons it 
decodes. An elongation factor (EF-Tu) helps shuttle aminoacyl-tRNAs into the decoding center 
of the ribosome where the anticodon base pairs with a complementary three-ribonucleotide 
codon on the mRNA, which provides the sequence information for the protein being translated. 
Correct base pairing results in ribosome-catalyzed transfer of the amino acid onto the nascent 
peptide chain. Translation termination is performed with specialized proteins called release 
factors instead of tRNAs. 
Protein translation is extremely complex and energy-intensive, revealing the importance 
of its accuracy for modern life (25). To accomplish this, an aaRS must charge the correct amino 
acid onto the correct tRNA, and the correct aminoacyl-tRNA must pair with the correct codon in 
the ribosomal A site. Ultimately, 3 base pairs (between 6 and 9 H-bonds) introduce the correct 
amino acid 10
3
-10
4 
times for every error (25). 
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Evolutionary barriers to reassignment 
With a few notable exceptions, the genetic code is conserved across all three domains of 
life (26). Understanding this remarkable stability is essential to overcoming it. 
 
Modern organisms have large genomes and require accurate translation 
Evolution increases biological complexity (27), leading to the large genomes of today’s 
free-living organisms [the smallest known genome is 580,070 base pairs, with 470 predicted 
coding regions (28)]. With a few exceptions (29-31), these organism use all 64 codons to encode 
their proteins and to accommodate overlapping non-coding motifs such as protein binding sites, 
promoters, splicing signals, and RNA secondary structure (32). Any change in codon function 
must be tolerated at all instances genome-wide. Furthermore, these larger and more complex 
genomes experience more structural constraints (e.g., overlapping features in polycystronic 
operons), a larger mutational load, and a higher demand for translation fidelity (33-35). Given 
that modern translation systems appear to have improved accuracy compared to primordial 
systems (26), modern proteomes may have traded increased activity for a reduced tolerance for 
mistranslation (26, 33). 
The error minimization theory for the origin of the genetic code proposes that similar 
amino acids are grouped with similar codons, promoting mutational robustness (i.e., single 
nucleotide mutations are likely to incorporate the same amino acid or a similar one) (34), 
increasing translation accuracy (i.e., codon/anticodon mispairing most likely introduces the same 
amino acid or a similar one) (33), and accommodating non-coding information (i.e., redundant 
code maintains protein sequence and allows flexibility for overlapping non-coding motifs) (32). 
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The canonical code does this remarkably well (16, 36), utilizing all 64 codons for translation 
throughout the proteome, providing a disincentive for genetic code expansion (37).  
 
Anticodons are assigned to specific amino acids 
The stereochemical theory for the origin of the genetic code proposes that amino acids 
make direct chemical interactions with their cognate tRNAs (38). Regardless of whether this was 
the case, most amino acids are effectively associated with specific anticodons in the canonical 
genetic code through their aaRSs. With the exceptions of LeuRS, SerRS, and AlaRS, all other 
aaRSs in E. coli recognize tRNA anticodons as tRNA identity elements (24). This means that 
mutations in anticodons do not necessarily reassign the cognate codon function—in fact, the 
mutated tRNA may lose its recognition by the original aaRS and gain recognition from the aaRS 
corresponding to the new anticodon (39). Therefore, even if a codon is available for 
reassignment, the new tRNA must maintain its desired function and escape recognition from 
competing aaRSs. 
 
Collaboration is advantageous 
Horizontal gene transfer (40) and sexual reproduction (41) allow organisms to share 
beneficial traits and to remove deleterious traits on a population level. These processes can only 
happen if interacting organisms speak the same genetic language, providing a strong 
evolutionary incentive to maintain a common genetic code (42).  
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Lessons from naturally noncanonical genetic code 
Despite substantial evolutionary pressures to conserve the genetic code, naturally 
noncanonical genetic codes [extensively reviewed (18, 26, 43-45)] exist, and it is likely that they 
all derive from the same canonical code (43). Studying natural codon reassignment can provide 
insight into how the genetic code evolves and how to synthetically change it. Interestingly, many 
of the same changes appear to have independently evolved several times, suggesting that certain 
codons have a predisposition for reassignment (26). Stop codons may be favored because they 
are only used once at the end of genes, so their reassignment is expected to cause minimal 
damage to the proteome (26). More generally, small tweaks to anticodon modifications that 
change codon assignment without affecting aaRS recognition account for most of the genetic 
code variation (e.g., loss of lysidine from tRNA
Met
CAU allows it to decode both AUG and AUA as 
Met and a 7-methylguanosine modification on tRNA
Ser
GCU allows it to decode all four AGN 
codons) (26).  
Now we know the easiest targets for codon reassignment, but how do natural organisms 
overcome the evolutionary barriers in order to change their function? The codon capture theory 
proposes that codons are eliminated from entire genomes prior to reassignment (46), and the 
ambiguous intermediate theory proposes that codons may initially introduce multiple amino 
acids until a selective pressure causes fixation of the new function (47). While significant 
evidence exists for each mechanism, it seems likely that elements of both mechanisms are 
relevant—a small number of codons may remain prior to codon capture (39), and ambiguous 
decoding must be tolerated at all instances genome-wide. Regardless of the mechanism, the 
change must provide a substantial selective advantage to offset reduced mutational robustness, 
translation fidelity, and horizontal gene transfer. 
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Implementation of codon capture 
Small genomes (48), especially those with extreme biases in GC content (17), provide 
opportunities for codon capture to occur. Mitochondria appear to have a strong selective pressure 
for small, AT rich genomes, which can lead to the spontaneous loss of codons (26). 
Subsequently, anticodon modifications increase the promiscuity of codon recognition, allowing a 
single tRNA to decode multiple codons (26). Examples of free-living organisms with 
noncanonical genetic codes include Mycoplasma species (28, 30) and SR1 uncultured oral 
bacteria (31), which have their UGA stop codons reassigned to Trp and Gly, respectively. Both 
bacteria have small genomes and appear to strongly select for low G + C content (31). G + C 
bias is hypothesized to drive codon reassignment (Trp UGGUGA and Gly GGAUGA 
conversions help reduce G + C content), but these variations in the genetic code may also help 
reduce susceptibility to viruses (31, 49).  
 
Implementation of ambiguous intermediate 
Larger genomes are less likely to spontaneously lose all instances of a given codon. 
Therefore, ambiguous decoding for a given codon must be tolerated at all instances genome-
wide. Indeed E. coli tolerates natural suppressors of its stop codons (47, 50) and C. ablicans (51) 
decodes CUG codons as both Leu (canonical assignment) and Ser. Indeed, related fungi exhibit 
complete reassignment of CUG to encode Ser, suggesting that C. albicans may be a glimpse at 
an ambiguous intermediate (51). Therefore, spontaneous ambiguous intermediates can occur and 
evolve at the mercy of genetic drift. 
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What about when the 20 canonical amino acids are not adequate? While post-
translational modifications can help to tune amino acid properties, two additional naturally-
occurring amino acids have been identified, which are incorporated during translation (26). 
Organisms from all domains of life use selenocysteine (Sec) in essential redox enzymes, and 
Methanosarcinaceae use pyrrolysine (Pyl) in methanogenesis from methylamines (26). 
However, these organisms already use all 64 codons for translation, requiring them to reuse at 
least one codon for these specialized functions. In order to accomplish this, these organisms use 
orthogonal translation machinery that are dependent on unique recognition sequences in the 
mRNA to efficiently introduce Sec or Pyl at specific positions in target proteins (26). Therefore, 
Sec and Pyl are exciting examples of how natural selection added new chemical functionalities to 
the genetic code to expand protein function. 
 
Minimal and maximal genetic codes 
It is now clear that the genetic code continues to evolve, but what are its limits? It may be 
possible to add a new base pair (52, 53) or to engineer a quadruplet genetic code (54-56), which 
could give 6
3
 = 216 or 4
4
 = 256 possible codons, respectively. For this analysis, however, let’s 
consider the minimal and maximal variants of the current genetic code, which possesses triplet 
codons composed of four possible nucleotides (Figure 1-2). Although these hypothetical genetic 
codes may be far from optimal and difficult to implement, it is instructive to consider the 
fundamental biochemical boundaries for the genetic code. In E. coli, 43 unique anticodons and 
release factors unambiguously decode all 64 codons (Figure 1-2A) (57). Codon recognition is 
controlled by base pairing between the codon (mRNA) and anticodon (tRNA), and post-
transcriptional chemical modifications tune which base pairs are recognized (57). Therefore, it is 
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possible to significantly alter the genetic code by altering anticodons. Additionally, orthogonal 
aaRS/tRNA pairs can be introduced to expand the amino acid repertoire (58). 
 
Minimal genetic code 
A minimal genetic code requires one tRNA for each amino acid [including 
formylmethionine for translation initiation (59)] and one release factor for translational 
termination (Figure 1-2B).  As demonstrated by mitochondrial genetic codes, an unmodified 
uracil in the anticodon wobble position can recognize all four codons that are identical at the first 
two positions and differ at the third position (43). In this way, 10 tRNAs are adequate to 
unambiguously assign 40 codons to decode 9 amino acids (in this example, Arg is decoded by 
two separate family groups, and one tRNA could potentially be deleted, leaving four blank 
codons). Anticodons with guanosine, queuosine, or glutamylqueuosine in the wobble position 
use 6 additional tRNAs that unambiguously recognize 12 codons of the form NNY (N = any of 
the four bases; Y = C or U) to translate 6 more amino acids (19). Additionally, mnm
5
U 
modifications on 4 tRNAs unambiguously recognize 8 codons of the form NNR (R = G or A) to 
translate 4 more amino acids (19). This leaves all three stop codons, which can be recognized by 
a single E167K release factor 2 variant (60), in addition to Trp and translation initiation, which 
use their natural tRNAs. Finally, it may be possible to achieve adequate protein function using a 
code composed of fewer than 20 amino acids (61-64). Preliminary studies propose that Ile (65) 
and/or Trp (66) could be replaced by similar amino acids. Therefore, the minimal genetic code 
requires 23 tRNAs and a release factor in order to decode all 64 codons, or 20 tRNAs if Ile and 
Trp are removed and blank codons are tolerated (Figure 1-2B). 
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Figure 1-2. Minimal and maximal genetic codes using triplet codons composed of four nucleotide types (U, C, A, 
G). The proposed genetic codes are one possible permutation representing several possible ways to reassign 
redundant codons (e.g., which of the six Ser codons should maintain Ser function after the others are reassigned). 
Dashed brackets represent anticodon – codon recognition ranges: black is codon recognition agreeing with wobble 
rules (115, 116); gray is empirical data (57); blue and magenta are new tRNAs assigned to new amino acids. Labels 
correspond to the wobble nucleotide at tRNA position 34 (cmo5U = uridine 5-oxyacetic acid, mnm5U = 5-
methylaminomethyluridine, cmnm5U = 5-carboxymethylaminomethyluridine, cmnm5Um = 5-carboxymethylamino-
methyl-2′-O-methyluridine, mnm5s2U = 5-methylaminomethyl-2-thiouridine, cmnm5s2U = 5-carboxymethylamino-
methyl-2-thiouridine, I = inosine, k2C = lysidine, Q = queuosine, GluQ = glutamylqueuosine) (117). Green letters 
indicate natural tRNA identity determinants that may be difficult to change. Red letters indicate natural anticodon 
modifications that increase anticodon promiscuity. Blue and magenta letters represent proposed changes in the 
tRNA wobble position that would alter codon recognition. Amino acid assignments are indicated in the yellow 
sidebars. M refers to Met and fMet (translation initiation). Anticodons available for new amino acids are blue and 
magenta boxes with white numbers. Selenocysteine is not shown. (A) The E. coli genetic code is presented based on 
Björk et al. (57) and tRNA identity determinants are from Giegé et al. (24). All 64 codons are used to encode 20 
amino acids. (B) A minimal genetic code utilizing all 64 codons would require initiation at AUG, one release factor 
[RF2 E167K mutants can terminate all 3 stop codons (60)], and one tRNA for each of the 20 amino acids. 
Unmodified uracils in the wobble positions would allow tRNAs to recognize all codons in a family group, allowing 
redundant tRNAs to be deleted. Gray shaded boxes represent additional anticodons that could be potentially deleted 
[tRNAArgUCG would encode the same amino acid as tRNA
Arg
UCU and it may be possible to remove Ile (65) and/or Trp 
(66) from the genetic code]. Conveniently, the wobble nucleotide is rarely a tRNA identity determinant (24). The 
12 
 
Figure 1-2 (Continued). two relevant exceptions, tRNAPheGAA (G34) and tRNA
Glu
UUG (cmnm
5s2U34), are weak 
identity determinants (24), so the proposed changes may be tolerated by their respective aaRSs. (C) The genetic 
code can be expanded to provide 7 unambiguous and 3 ambiguous anticodons by simply deleting tRNAs and 
introducing orthogonal aaRS/tRNA pairs encoding new amino acids. This analysis assumes that the original 
aaRS/tRNA identity determinants/antideterminants can be overcome by a metagenomic search for an orthogonal 
aaRS/tRNA pair and subsequent directed evolution to optimize their orthogonality. Red shaded boxes represent the 
three codons that would gain ambiguous translation function upon introduction of an orthogonal aaRS/tRNA pair. 
The UAG codon can be liberated by deleting release factor 1 (8). (D) The maximal genetic code would have unique 
amino acid assignments for all NNA and NNG codons [NNA: engineer tilS (70) to lysidinylate additional tRNAs so 
that they only base pair with A. NNG: tRNAs with cytosine in the wobble position only base pair with G]. NNY 
codons could not be split into unambiguous NNU and NNC codons using known anticodon modifications, but such 
modifications have not been ruled out. Additionally, it may be possible to engineer a release factor to terminate 
translation only at UAA codons, thereby liberating both UAG and UGA codons. The proposed changes would 
liberate 27 unambiguous anticodons (47 total amino acids; changes indicated in magenta). This strategy may require 
directed evolution to overcome the tRNA identity determinants for Glu, Gln, and Lys (24). Another potential 
complicating factor is that G + C anticodon content may affect cognate and near-cognate decoding efficiencies, just 
as the G + C rich anticodons for Val, Ala, and Pro break the wobble rules (57). More conservatively, replacing the 
cmo5U [inactivate cmoB (67)] and inosine wobble nucleotides with mnm5U nucleotides [engineer mnmE and mnmG 
to recognize additional tRNAs (68, 69)] could liberate 13 unambiguous anticodons (33 total amino acids; changes 
indicated in blue). 
 
Maximal genetic code 
Expanding the genetic code requires unassigned codons that can be appropriated for new 
functions and orthogonal aaRS/tRNA pairs that can carry out those functions without having 
cross-talk with endogenous ones. For now, we will focus on capturing codons; orthogonal 
translation machinery will be discussed below. Simply by leveraging the degeneracy of genetic 
code, 10 anticodons can be deleted in order to provide 7 unambiguous and 3 ambiguous 
anticodons for reassignment, while maintaining translation initiation, termination, and 
incorporation of all 20 amino acids (Figure 1-2C). Inconveniently, six family groups (CUN, 
GUN, UCN, CCN, ACN, and GCN) are composed of anticodons with overlapping codon 
specificity, making it difficult to unambiguously reassign their function. The overlapping tRNA 
specificities are caused by cmo
5
U wobble bases, which are able to base pair with A, G, and U 
(and sometimes C) (67). In contrast, the GGN codon family group uses a mnm
5
U wobble base to 
decode only GGA and GGG, allowing unambiguous reassignment of GGY to a new function. 
This strategy could be extended to other tRNAs by inactivating cmoB (modifies U34 of tRNAs 
with cmo
5
U) (67), and engineering mnmE and mnmG to modify U34 of additional tRNAs with 
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mnm
5
 (naturally modifies tRNAGln, tRNALys, tRNAGlu, and tRNAArg) (68, 69). These 
modifications could capture 13 unambiguous anticodons (up to 33 total amino acids) (Figure 1-
2C, blue features).  
More aggressively, the NNR codons could be split into unique singlet codons by 
exploiting anticodons modified with lysidine (specifically base pairs with A) and cytosine 
(specifically base pairs with G) to decode NNA and NNG codons, respectively (Figure 1-2D, 
magenta features). In order to accomplish this, tilS would need to be engineered to lysidinylate 
more anticodons in addition to its natural target, tRNA
Ile
 (70). Although wobble codons do not 
tend to coincide with tRNA identity determinants, this could affect the aminoacylation of the 
tRNAs for Glu, Gln, and Lys because mnm
5
-modified wobble bases are minor tRNA identity 
determinants (24). The NNY codons cannot be split into singlet codons based on known 
anticodon modifications, but such modifications have not been ruled out. Finally, a release factor 
could potentially be engineered to terminate translation at UAA codons, but not UAG or UGA 
codons. These proposed changes could capture 27 unambiguous anticodons (up to 47 total amino 
acids). 
 
How do we change the genetic code? 
Knight et al. describe the problem well: “a novel code must be both chemically plausible 
and mutationally accessible from its immediate ancestor” (43). We have now seen that vastly 
simplified and expanded codes are possible from biochemical principles, but the implementation 
of such codes has many evolutionary caveats that must be addressed. Removing the redundancy 
of the canonical genetic code would sacrifice mutational robustness, translational fidelity, and 
sequence flexibility used to accommodate non-coding information (e.g., polycystronic operons 
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would require refactoring in order to move regulatory motifs outside of genes). Such modified 
genetic codes would require robust selective pressures to maintain their new functions despite 
these countervailing evolutionary forces. Additionally, orthogonal translation machinery must be 
provided in order to reassign codons to new amino acids. Finally, the evolutionary incentive for 
horizontal gene transfer must be obviated by providing optimal cultivation conditions for the 
recoded organism. By taking these principles into account, remarkable progress has already been 
made at expanding the genetic code to incorporate more than 70 NSAAs (12). 
 
In vitro translation 
In vitro translation systems offer the ultimate flexibility to implement translation (71, 72). 
In vitro systems provide unique opportunities to use biologically incompatible chemistry to 
prepare component parts. By performing aminoacyl-tRNA charging separately, CA ligation (73) 
and flexizyme (74) can abstract away the need for orthogonal aaRS/tRNA pairs to charge 
tRNAs. Additionally, in vitro systems do not need to support essential cellular functions, so 
suboptimal translation components are better tolerated, and the evolutionary dependence on the 
canonical genetic code is vastly reduced. The extreme genetic codes proposed in Figure 1-2 
could be readily tested in an in vitro system. To date, in vitro translation has been the best way to 
produce synthetic nonribosomal peptide mimetics (75) and non-peptide polymers such as 
polyesters (76). However, in vitro systems can be expensive, complicated, and difficult to scale 
for industrial applications. 
 
In vivo suppression of natural codon function 
15 
 
In vivo systems are well-suited for inexpensive, simple, and scalable translation using 
NSAAs. In the absence of efficient genome engineering technologies to mimic the codon capture 
mechanism for codon reassignment, early in vivo approaches took advantage of an ambiguous 
intermediate (77). Sense codons have been transiently diverted to incorporate diverse NSAAs by 
metabolic labeling (78). In the cases of some NSAAs, this ambiguous intermediate has become 
well-tolerated. While bacteriophages can rapidly evolve tolerance for ambiguous incorporation 
6-fluorotryptophan in place of Trp (79), results have been mixed for autonomous organisms, 
which express a larger pool of proteins that may be disrupted by NSAA incorporation. For 
example, while B. subtilis (80) has been evolved to prefer 4-fluorotryptophan (4fp) over 
tryptophan (Trp), similar experiments have been less successful in E. coli (81).  
The ambiguous intermediate strategy becomes even more difficult when reassigning 
codons to incorporate structurally distinct nonstandard amino acids (NSAAs). In such cases, 
NSAA exclusion may provide a simpler survival mechanism than evolving tolerance for NSAA 
incorporation (82). Recognizing these constraints, the Schultz, Chin, Wang, Liu, Söll, Neumann, 
and Ellington labs have made several advances in engineering the genetic code at the translation 
level, enabling the incorporation of more than 70 NSAAs into proteins [extensively reviewed 
(12, 37, 83)]. The general strategy is to introduce an orthogonal aaRS/tRNA pair that is evolved 
to specifically incorporate a NSAA without cross-charging endogenous aaRS/tRNA pairs. 
Orthogonal aaRS/tRNA pairs must have tRNA identity determinants that differ from those in the 
target organism. Unfortunately, this is difficult to accomplish for most codons in E. coli because 
most of its tRNAs have identity determinants in their anticodons. For instance, a heterologous 
tRNA
Pyl
CCG was mischarged with Arg by the E. coli ArgRS, presumably due to recognition of 
the anticodon (39). In contrast, suppressors of the UAG stop codon have been more successful in 
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the absence of an aaRS that recognizes the CUA anticodon. For this reason, the weak cross-
charging of M. jannaschii TyrRS/tRNACUA with E. coli aaRS/tRNA pairs was readily overcome 
using directed evolution (58). Additional work will be required to identify an effective 
aaRS/tRNA pair for each of the remaining codons (37), and preliminary work with the 
orthogonal selenocysteine translation machinery provides preliminary success at reassigning 58 
of the 64 codons (84). The E. coli tRNA identity determinants have been extensively 
characterized (24), and their antideterminants have been predicted (85), providing a starting point 
for the directed evolution of additional orthogonal aaRS/tRNA pairs. 
Even when orthogonal aaRS/tRNA pairs are available, they must compete with highly 
optimized endogenous translation machinery (37). Therefore, suppression of rare codons like 
UAG (58) and over-expression of the orthogonal aaRS/tRNA pairs (86) are crucial for efficient 
NSAA incorporation. To take this to an extreme, attenuating UAG termination substantially 
increased the efficiency of NSAA incorporation (87, 88). In addition, quadruplet codons can 
provide additional channels for NSAA incorporation (54, 55, 89), and orthogonal ribosomes 
[reviewed in (56)] have been engineered to more efficiently decode UAG (90) and AGGA (55) 
codons. Other innovations include the addition of p-aminophenylalanine biosynthetic machinery 
to create an autonomous bacterium that uses a genetic code composed of 21 amino acids (91), 
and unnatural nucleoside base pairs to create a 65
th
 codon (53). 
 
In vivo reassignment of natural codon function 
How do you implement new amino acids in stable and heritable ways? Ambiguous codon 
suppression methods are most effective for single-batch overexpression of NSAA-containing 
proteins. Furthermore, while preliminary work has successfully incorporated two NSAAs into 
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the same protein, competition with natural codon functions reduces yields (54, 55, 92). 
Therefore, it would be beneficial to completely reassign codon function by removing 
endogenous translation factors before replacing them with new ones; however, this would result 
in deleterious mistranslation at all natural instances in the proteome. This mistranslation can be 
avoided by replacing all instances of the target codon with a synonymous one prior to 
reassignment. At a minimum, all instances of a target codon in essential genes should be changed 
to a synonymous codon (recoded) in order to preserve essential cellular functions (93). This 
strategy is a shortcut to codon capture, but it risks deleterious, proteome-scale misfolding in 
response to particularly disruptive NSAAs such as phosphoserine (8). Therefore, a more general 
and scalable solution to codon reassignment would be to recode all instances of a codon genome-
wide (8). After removing all instances of a given codon, its translation would no longer be 
necessary for normal proteome function, allowing the removal of its natural translation factors 
and the introduction of a new translation function. This strategy has been used to completely 
reassign UAG from a stop codon to a sense codon (8). Furthermore, preliminary evidence 
suggests that this strategy could be extended to capture 12 additional codons for reassignment 
(94). 
 
Genome engineering methods for changing the genetic code 
The past decade has seen many impressive achievements in genome engineering 
[reviewed in (95)], although few attempts have been made introduce synthetic sequences that 
cannot be found in nature. The de novo synthesis and transplantation of an intact Mycoplasma 
mycoides JCVI-syn1.0 genome demonstrated that a small, natural prokaryotic genome can be 
built from simple chemical components (96). Such an approach could allow the synthesis of any 
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user-defined genome sequence, but genome design remains the major barrier. Whole genomes 
are a risky engineering unit because a single, cryptic design flaw could cause them to fail. For 
example, considerable effort was required to identify and correct a single base pair deletion in 
essential gene dnaA, initially preventing the transplantation of M. mycoides JCVI-syn1.0 (96). 
Given the high stakes for design flaws, de novo genome synthesis is most effectively used for 
projects based on exhaustive empirical tests (28, 97, 98) and complete computational models 
(99).  
Engineering the genetic code requires extensive genome manipulation that can affect 
fitness in unpredictable ways (94). With this in mind, our lab has developed multiplex automated 
genome engineering (MAGE) (100) and conjugative assembly genome engineering (CAGE) 
(101) for rapidly prototyping and manufacturing genotypes in vivo. MAGE uses synthetic 
ssDNA oligonucleotides and the phage  Red  recombinase (102) to simultaneously introduce 
defined mutations at multiple locations throughout a replicating bacterial genome (100). CAGE 
uses bacterial conjugation to precisely transfer up to several million base pairs of contiguous 
DNA (101), allowing the assembly of large genomes from small segments that are easier to 
produce and test using MAGE. Together, MAGE and CAGE exploit evolution to 
combinatorially explore a broad pool of synthetically defined genotypes in vivo, allowing natural 
selection to remove deleterious design flaws from the population.  
MAGE and CAGE were used to remove all 321 known instances of the UAG codon from 
E. coli MG1655 at a fraction of the predicted cost for genome synthesis (8). However, DNA 
synthesis can still be effective for radically changed genome sequences (94). When thousands of 
changes are required genome synthesis becomes a more attractive strategy, and chip-based DNA 
synthesis is dramatically reducing its costs (103-105). In fact, small, synthetic genome segments 
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synergize well with MAGE-based troubleshooting of potential design flaws (94). Indeed this 
approach has also been successful for the synthetic yeast 2.0 project (106), and similar 
approaches could be extended to diverse organisms using an ever-growing arsenal of powerful 
genome engineering methods (107). 
 
Outlook and conclusions 
While more than 70 NSAAs have already vastly expanded protein function (12), radically 
different genetic codes will be required to achieve virus resistance, genetic isolation, and stable 
expansion of the genetic code. This will require orthogonal translation machinery (84, 108-111) 
that are engineered to reassign sense codons based on a solid mechanistic understanding of 
biochemical principles (37). It will also require the design and construction of viable genomes 
with thousands of potentially deleterious changes in order to capture codons for reassignment (8, 
94). Advances in understanding codon usage (112) and operon structure (113, 114) will help 
establish better guidelines for genome design, but diversity will remain a crucial aspect in 
prototyping genomes with new and useful biological functions.  
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Abstract 
The phage Lambda-derived Red recombination system is a powerful tool for making 
targeted genetic changes in Escherichia coli, providing a simple and versatile method for 
generating insertion, deletion, and point mutations on chromosomal, plasmid, or BAC targets. 
However, despite the common use of this system, the detailed mechanism by which Lambda Red 
mediates double-stranded DNA recombination remains uncertain. Current mechanisms posit a 
recombination intermediate in which both 5′ ends of double-stranded DNA are recessed by 
Lambda Exonuclease, leaving behind 3′ overhangs. Here, we propose an alternative in which 
Lambda Exonuclease entirely degrades one strand, while leaving the other strand intact as single-
stranded DNA. This single-stranded intermediate then recombines via Beta recombinase-
catalyzed annealing at the replication fork. We support this by showing that single-stranded gene 
insertion cassettes are recombinogenic, and that these cassettes preferentially target the lagging 
strand during DNA replication. Furthermore, a double-stranded DNA cassette containing 
multiple internal mismatches shows strand-specific mutations co-segregating roughly 80% of the 
time. These observations are more consistent with our model than with previously proposed 
models. Finally, by using phosphorothioate linkages to protect the lagging-targeting strand of a 
double-stranded DNA cassette, we illustrate how our new mechanistic knowledge can be used to 
enhance Lambda Red recombination frequency. The mechanistic insights revealed by this work 
may facilitate further improvements to the versatility of Lambda Red recombination. 
 
Introduction 
Over the past decade, Lambda Red recombination (“recombineering”) has been used as a 
powerful technique for making precisely defined insertions, deletions, and point mutations in 
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Escherichia coli, requiring as few as 35 base pairs of homology on each side of the desired 
alteration (1, 2). With this system, single-stranded DNA (ssDNA) oligonucleotides have been 
used to efficiently modify E. coli chromosomal targets (3, 4), BACs (5), and plasmids (6), as 
well as to rapidly optimize a metabolic pathway coding for the production of lycopene (7). 
Furthermore, linear double-stranded DNA (dsDNA) recombineering has been used to replace 
chromosomal genes (8, 9), to disrupt gene function (10), and to develop novel cloning methods 
(11, 12). Large-scale dsDNA recombineering projects include creating a library of single-gene 
knockout E. coli strains (13) and removing 15% of the genomic material from a single E. coli 
strain (14). Linear dsDNA recombineering has also been used to insert heterologous genes and 
entire pathways into the E. coli chromosome (15, 16) and BACs (11, 17), including those used 
for downstream applications in eukaryotes (18, 19). However, despite the broad use of this 
method, the mechanism of Lambda Red recombination has not achieved scientific consensus, 
particularly in the case of dsDNA recombination. A clearer understanding of the mechanism 
underlying this process could suggest ways to improve the functionality, ease, and versatility of 
Lambda Red recombination. 
 Three phage-derived Lambda Red proteins are necessary for carrying out dsDNA 
recombination: Gam, Exo, and Beta. Gam prevents the degradation of linear dsDNA by the E. 
coli RecBCD and SbcCD nucleases; Lambda Exonuclease (Exo) degrades dsDNA in a 5′ to 3′ 
manner, leaving single-stranded DNA in the recessed regions; and Beta binds to the single-
stranded regions produced by Exo and facilitates recombination by promoting annealing to the 
homologous genomic target site (20). Current mechanisms claim that Exo binds to both 5′ ends 
of the dsDNA and degrades in both directions simultaneously to produce a double-stranded 
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region flanked on both sides by 3' overhangs (2, 21). However, a comprehensive explanation of 
how this construct ultimately recombines with the chromosome has not yet been advanced.  
 Initially, it was proposed that this recombination occurs via strand invasion (22). 
However, it has more recently been shown that strand invasion is unlikely to be the dominant 
mechanism in the absence of long regions of homology, as recombination remains highly 
proficient in a recA
-
 background (23). Furthermore, a detailed analysis of Lambda Red 
recombination products showed characteristics consistent with strand annealing rather than a 
strand invasion model (24). Finally, Lambda Red dsDNA recombination has been shown to 
preferentially target the lagging strand during DNA replication, which suggests strand annealing 
rather than strand invasion (25, 26).  
To explain these results, Court et al. (27) proposed a strand annealing model for 
insertional dsDNA recombination (Figure 2-1A), in which one single-stranded 3′ end anneals to 
its homologous target at the replication fork. The replication fork then stalls, due to the presence 
of a large dsDNA non-homology (i.e., the insertion cassette). The stalled replication fork is 
ultimately rescued by the other replication fork traveling in the opposite direction around the 
circular bacterial chromosome. The other 3′ end of the recombinogenic DNA anneals to the 
homology region exposed by the second replication fork, forming a crossover structure, which is 
then resolved by unspecified E. coli enzymes (27). 
 The Court mechanism was challenged by Poteete (25), who showed that the dsDNA 
recombination of a linear Lambda phage chromosome occurs readily onto a unidirectionally-
replicating plasmid, which does not have the second replication fork required by the Court 
mechanism (27). Thus, Poteete proposed an alternate mechanism (25), termed “replisome 
invasion” (Figure 2-1B), in which a 3′ overhang of the Exo-processed dsDNA first anneals to its 
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complementary sequence on the 
lagging strand of the recombination 
target. Subsequently, this overhang 
displaces the leading strand, thereby 
serving as the new template for 
leading strand synthesis. The 
resulting structure is resolved by an 
unspecified endonuclease, after which 
the recombinogenic DNA becomes 
the template for the synthesis of both 
new strands. In the context of 
recombineering using a linear dsDNA 
cassette, the author indicates that a 
second strand switching event must 
occur at the other end of the incoming 
dsDNA. 
 While Poteete's mechanism 
addresses some of the weaknesses of 
the Court mechanism, it remains 
largely speculative. This mechanism 
does not identify the endonuclease responsible for resolving the structure after the first template 
switching event, nor does it explain how the recombinogenic DNA and replication machinery 
form a new replication fork. Additionally, this template switching mechanism would have to 
Figure 2-1. Previously proposed Lambda Red-mediated dsDNA 
recombination mechanisms. Heterologous dsDNA is shown in 
green; Exo is an orange oval, and Beta is a yellow oval. In both 
mechanisms the recombination intermediate is proposed to be a 
dsDNA core flanked on either side by 3' ssDNA overhangs. (A) 
The Court mechanism posits that 1) Beta facilitates annealing of 
one 3' overhang to the lagging strand of the replication fork. 2) This 
replication fork then stalls and backtracks so that the leading strand 
can template switch onto the synthetic dsDNA. The heterologous 
dsDNA blocks further replication from this fork. 3) Once the 
second replication fork reaches the stalled fork, the other 3′ end of 
the integration cassette is annealed to the lagging strand in the same 
manner as prior. Finally, the crossover junctions must be resolved 
by unspecified E. coli enzymes (27). (B) The Poteete mechanism 
suggests that 1) Beta facilitates 3' overhang annealing to the lagging 
strand of the replication fork, and 2) positions the invading strand to 
serve as the new template for leading strand synthesis. This 
structure is resolved by an unspecified host endonuclease, and 3) 
the synthetic dsDNA becomes template for both lagging and 
leading strand synthesis. A second template switch must then occur 
at the other end of the synthetic dsDNA (25). Both figures were 
adapted from the indicated references. 
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operate two times in a well-controlled manner, which may not be consistent with the high 
recombination frequencies often observed (9) for Lambda Red-mediated dsDNA insertion. 
Finally, little experimental evidence has been advanced to directly support this hypothesis. 
  To address the deficiencies in these mechanisms, we propose that Lambda Red dsDNA 
recombination proceeds via a ssDNA intermediate rather than a dsDNA core flanked by 3' 
overhangs (Figure 2-2). In this mechanism, Exo binds to one of the two dsDNA strands and 
degrades that strand completely, leaving behind full-length ssDNA. This ssDNA then anneals to 
its homology target at the lagging strand of the replication fork, and is incorporated as part of the 
newly-synthesized strand as if it were an Okazaki fragment. This process is analogous to the 
accepted mechanism for the Lambda Red-mediated recombination of ssDNA oligonucleotides 
(27), and therefore unifies the mechanisms for ssDNA and dsDNA recombination. Notably, our 
mechanism uses one replication fork for the incorporation of a full-length heterologous cassette, 
thereby addressing Poteete’s criticism of the Court mechanism. 
Figure 2-2. Lambda Red mediated dsDNA recombination proceeds via 
a ssDNA intermediate. Instead of a recombination intermediate 
involving dsDNA flanked by 3' ssDNA overhangs, we propose that one 
strand of linear dsDNA is entirely degraded by Exo (orange oval). Beta 
(yellow oval) then facilitates annealing to the lagging strand of the 
replication fork in place of an Okazaki fragment. The heterologous 
region does not anneal to the genomic sequence. This mechanism could 
account for gene replacement (as shown), or for insertions in which no 
genomic DNA is removed. 
 
  The degradation of an entire strand by Lambda Exo 
is feasible, given the highly processive nature of the 
enzyme (28). Whereas previously proposed mechanisms 
assume that both dsDNA ends are degraded approximately 
simultaneously, our hypothesis implies that some dsDNA 
molecules will be entirely degraded to ssDNA before a 
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second Exo can bind to the other end. In this manuscript, we demonstrate that single-stranded 
DNA is a viable recombinogenic intermediate with lagging strand bias. Furthermore, we show 
that genetic information from one strand of a recombinogenic dsDNA cassette co-segregates 
during Lambda Red-mediated recombination. These results provide strong support of our 
proposed mechanism. 
 
Results 
Testing the predicted ssDNA recombination intermediate: We designed a lacZ::kanR 
cassette (~1.2 kb), consisting of a kanamycin resistance gene (kanR) flanked by 45 bp regions 
homologous to the lacZ gene on the E. coli chromosome. Successful kanR insertion disrupted 
LacZ function, so proper targeting of the lacZ::kanR cassette could be verified by selecting on 
kanamycin and assaying for the inability to cleave X-Gal in order to release a blue chromophore. 
This dsDNA construct was generated by PCR and converted into ssDNA using a biotin capture 
and DNA melting protocol (29), as detailed in File S1. PAGE analysis confirmed the purity of 
the lacZ::kanR ssDNA construct, as no dsDNA band was readily detected. This construct was 
then recombined into EcNR2 (7). The lacZ::kanR ssDNA construct was found to yield 1.3 × 10
-5
 
± 4.5 × 10
-6
 recombinants per viable cell, in comparison with 1.9 × 10
-4
 ± 7.5 × 10
-5
 for the 
corresponding dsDNA construct. Both ssDNA and dsDNA gave over 99% white colonies, 
indicating correct targeting of the recombinogenic cassette. 
 This result confirms that ssDNA—the predicted intermediate for our mechanism—is 
recombinogenic. It is, however, 14.8-fold less recombinogenic than the corresponding dsDNA. 
We hypothesize that this disparity is caused by ssDNA secondary structure and/or the lack of 
Exo-Beta synergy. Previous work has demonstrated that ssDNA oligonucleotides longer than 90 
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bases and/or having secondary structure with ΔG < -12 kcal/mol are likely to have substantially 
reduced recombination frequency (7). Thus, we expect secondary structure to significantly 
diminish the recombination frequency of this ~1.2 kb cassette. Additionally, it has previously 
been suggested (30) that Exo and Beta act synergistically, with Exo facilitating the binding of 
Beta to recessed regions of ssDNA. Since Exo does not readily bind to ssDNA, this synergistic 
action cannot occur; therefore, recombination frequency may decrease. However, even in light of 
these considerations, our predicted ssDNA intermediate is highly capable of recombination. 
 In order to confirm that the observed recombinants arose from the ssDNA rather than 
from dsDNA contamination, this recombination experiment was repeated in SIMD90 (30), a 
strain of E. coli containing Beta, but lacking Exo and Gam. In the absence of Exo and Gam, 
dsDNA recombination frequency should decline significantly due to increased dsDNA 
degradation and inefficient processing into ssDNA. In this strain, lacZ::kanR ssDNA 
demonstrated a recombination frequency of 1.8 x 10
-4
, in comparison with a recombination 
frequency of only 8.7 x 10
-7
 for dsDNA (a 209-fold difference). This result indicates that the 
observed recombinants in EcNR2 also arose from ssDNA. 
Investigating the strand bias of the recombination intermediate: We propose that the 
long ssDNA intermediate recombines by annealing at the replication fork in the same manner as 
ssDNA oligonucleotides (27). It has been demonstrated that lagging-targeting oligonucleotides 
recombine with substantially greater frequency than the corresponding leading-targeting 
oligonucleotides, due to the greater accessibility of the lagging strand for annealing (31). In order 
to test whether long ssDNA recombines in the same manner, we investigated whether several 
pairs of lagging-targeting and leading-targeting ssDNA insertion cassettes demonstrated a similar 
strand bias. We controlled for the effect of differential secondary structure between the two 
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strands by recombining three different antibiotic resistance markers into lacZ – kanamycin 
(lacZ::kanR), zeocin (lacZ::zeoR), and spectinomycin (lacZ::specR). Additionally, in order to 
demonstrate that strand bias was not caused by replichore-specific context or transcriptional 
direction, we constructed two additional kanR cassettes. To this end, tolC::kanR targets a gene 
located on the opposite replichore from lacZ, and malK::kanR targets a gene transcribed from the 
opposite strand of the chromosome as lacZ. As shown in Figure 2-3, the lagging-targeting strand 
was substantially more recombinogenic than the leading-targeting strand for all of the tested 
constructs. As previously observed for oligonucleotides (3), there appears to be a significant 
amount of locus-specific and sequence-specific variability in recombination frequency. 
Interestingly, a significant number of mistargeted recombinants (antibiotic-resistant colonies that 
retained LacZ function) were 
observed for both lacZ::specR 
strands (Table S2-2; discussion in 
File S2). Mistargeted (LacZ
+
) 
colonies were not scored as 
recombinants, and do not affect the 
broader interpretation of our 
results. The overall results of this 
set of experiments clearly indicate 
a robust lagging strand bias, likely 
arising from the greater 
accessibility of the lagging strand 
during DNA replication. This 
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Figure 2-3. Strand bias in Lambda Red ssDNA insertion 
recombination. Recombination frequencies were assessed for several 
leading-targeting and lagging-targeting complementary ssDNA pairs. 
Lagging-targeting strands were found to be more recombinogenic than 
leading-targeting strands. An asterisk indicates P < 0.05. 
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supports our claim that long ssDNA insertion constructs recombine by annealing at the 
replication fork in a manner similar to ssDNA oligonucleotides.  
Testing Mechanistic Predictions by Tracking Designed Mutations: The prior 
experiments provide strong indirect evidence supporting our proposed ssDNA annealing 
mechanism. In order to more directly test the predictions of this mechanism, we designed a 
lacZ::kanR dsDNA cassette with internal mismatches (Figure 2-4), which enables us to 
empirically determine which strand provided genetic information during recombination. This 
construct was generated by annealing two strands of ssDNA and purifying the resulting dsDNA 
by agarose gel extraction. In each of the flanking lacZ homology regions, this construct contains 
two sets of adjacent dinucleotide mismatches that differentiate the two strands. At these loci, 
neither strand’s sequence matches the targeted chromosomal copy of lacZ. Thus, one can infer 
which strand has recombined by observing which strand-specific alleles are present. 
Figure 2-4. Strand-specific 
mismatch alleles were used 
to identify the strand of 
origin for each recombined 
mutation. The mismatched 
lacZ::kanR cassette 
contained two consecutive 
mismatches at two loci in 
both flanking homology 
regions. Strand 1 was the 
lagging-targeting strand and 
strand 2 was the leading-
targeting strand. If Lambda 
Red dsDNA recombination 
proceeds via a ssDNA 
intermediate (left), a) one 
Exo (orange oval) binds to a 
dsDNA end, b) Exo fully 
degrades one strand while helping to load Beta (yellow oval) onto the remaining strand, and c) this strand provides 
all of the genetic information during recombination. This figure shows the case in which the lagging-targeting strand 
is recombined (coding strand genotypes: L1 = AA, L2 = AA, L3 = TT, L4 = TT), but the leading-targeting strand is 
also predicted to be observed (coding strand genotypes: L1 = CC, L2 = CC, L3 = GG, L4 = GG). If the Lambda Red 
recombination intermediate is a heterologous dsDNA core flanked by 3' ssDNA overhangs (right), a) one Exo binds 
to each dsDNA end, b) Exo recesses both strands while helping to load Beta onto both 3' overhangs, and c) both 
strands provide genetic information for each recombination. Since Exo always degrades 5'3', the expected coding 
strand genotypes for the Court and Poteete mechanisms would be L1 = CC, L2 = CC, L3 = TT, L4 = TT. 
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 Our proposed ssDNA annealing mechanism can be distinguished from the prevailing 
dsDNA recombination mechanisms based on the results of this experiment. Our mechanism 
predicts that the mutations contained on a single strand will be inherited together, and that the 
mutations arising from the lagging-targeting strand will be observed more frequently than those 
from the opposite strand. Conversely, as detailed in Figure 2-4, the previously proposed 
mechanisms predict that the alleles on the 3′ ends of both strands would be incorporated. 
 This mismatched lacZ::kanR cassette was transformed into EcNR2, which is deficient for 
mismatch repair. Recombinants were identified by plating on kanamycin, and colonies were 
screened using MAMA PCR (32) in order to identify which strand-specific mutations were 
inherited in each colony. Two replicates were performed, and 48 colonies were screened for each 
recombination (Table 2-1; detailed results in Table S2-3). The accuracy of the MAMA PCR 
assay was confirmed by sequencing the relevant regions of several colonies and by performing a 
complementary MAMA PCR assay to detect unaltered wild-type alleles at the targeted loci. In 
line with our predictions, we found that roughly 80% of the colonies inherited mismatch alleles 
from only one strand. Furthermore, of these colonies, 91% inherited mismatch alleles 
specifically from the lagging-targeting strand, strongly supporting our ssDNA annealing 
mechanism.  
 Table 2-1. Tracking co-segregation in mismatched dsDNA recombination 
Origin of Mismatches 
Number of 
Recombinants 
Observed 
Only strand 1 68 
Only strand 2 7 
Split as Expected for 5' Resection 10 
Split as Expected for 3' Resection 9 
Ambiguous 2 
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 Half of the remaining 20% of the colonies showed an inheritance pattern consistent with 
resection from both 5' ends, and the other half was consistent with resection from both 3' ends. 
Resection from the 5' ends is predicted by the previously proposed mechanisms, and indicates 
that one of these mechanisms may also operate as a disfavored process. However, Exo has not 
been shown to degrade dsDNA in a 3'5' manner, even though our results imply that this occurs 
nearly as often as 5'3' resection. A plausible explanation for this discrepancy is that the 
colonies possessing alleles from both strands have instead undergone two sequential 
recombination events according to our proposed mechanism. The first recombination would 
proceed normally, and the second recombination would involve a partially degraded 
complementary strand. This second recombination event would be expected to occur quite 
frequently – after the first recombination event, the kanR gene is present in the genome, 
providing a large region of homology to which remaining fragments of kanR ssDNA can anneal 
in subsequent rounds of replication.  
 Interestingly, mutations arising from loci one and four (Figure 2-4) are observed only 
rarely in the studied recombinants. This result suggests that a significant portion of the DNA may 
be undergoing slight exonuclease degradation from both the 5′ and 3′ ends, or that annealed 
strands are processed at the replication fork in a manner that degrades or excludes the distal ends 
of the recombined DNA. This is consistent with a previous observation that mutations placed on 
the ends of a 90 bp oligonucleotide are inherited at a substantially lower frequency than 
mutations placed nearer to the center of the same strand. Elucidating the basis of this 
phenomenon may shed more light on the detailed mechanism of Lambda Red recombination. 
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Nevertheless, the results from this experiment provide direct evidence that our proposed 
mechanism is the dominant process by which Lambda Red dsDNA recombination occurs. 
Phosphorothioate Placement Alters Recombination Frequency: Leveraging our 
increased understanding of Lambda Red dsDNA recombination, we enhanced recombination 
frequency by over an order of magnitude. Since the lagging-targeting strand is the most 
important recombinogenic species, we reasoned that protecting this strand would improve 
recombination frequency. It is known that phosphorothioate bonds diminish the ability of many 
exonucleases to degrade DNA 
(33). In order to test whether 
altering phosphorothioate 
placement changes the resulting 
recombination frequencies, we 
made four variants of the 
mismatched lacZ::kanR dsDNA 
cassette, as denoted in Figure 2-
5. These cassettes were 
recombined into EcNR2, and 
recombination frequencies were 
determined (Figure 2-5). 
 These results show that 
protecting the lagging-targeting 
strand with phosphorothioate 
bonds increases the frequency of 
Figure 2-5. Testing the effect of strand protection on recombination 
frequency. Four lacZ::kanR cassettes were tested in order to determine 
whether protecting one strand has a greater effect on recombination 
frequency than protecting the other strand. In each case, protection was 
accomplished through the placement of four phosphorothioate linkages 
on the 5′ end of a strand. Inset: Analysis of variance for lagging-
targeting (Lag) phosphorothioation and leading-targeting (Lead) 
phosphorothioation. An asterisk (*) denotes phosphorothioation. 
Lagging-targeting phosphorothioation was found to significantly enhance 
recombination frequency, whereas leading-targeting phosphorothioation 
did not affect recombination frequency. 
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dsDNA recombination, whereas protecting the leading-targeting strand has no effect. This 
further supports our proposed mechanism, since alternating which of the two strands is protected 
by phosphorothioates would not be expected to have differential effects if resection occurred 
from both 5′ ends. Additionally, our results unexpectedly show that lagging-targeting strand 
protection and dual protection yield approximately equivalent recombination frequencies. This 
suggests that phosphorothioation does not significantly inhibit in vivo Exo degradation, as dual 
protection would prohibit processing by Exo if this were the case. Instead, it is likely that placing 
phosphorothioates on the lagging-targeting strand protects it from host exonuclease degradation 
after Exo processing. This result demonstrates how our improved mechanistic knowledge of 
Lambda Red recombination can facilitate rational improvements of the process. 
 
Discussion 
 This work provides strong empirical support for the proposed mechanism that Lambda 
Red dsDNA recombination operates through a full-length ssDNA intermediate. This mechanism 
appears to be the dominant means of Lambda Red dsDNA recombination, although other 
mechanisms may still occur as minor processes. Notably, a replisome invasion mechanism (25) 
involving a fully single-stranded intermediate is not directly refuted by our work, although a 
strand annealing model is favorable due to its well-precedented (24, 27) and parsimonious 
nature. 
 While our mechanism has not previously been postulated as the manner by which the 
Lambda Red system recombines large dsDNA segments, it is consistent with numerous results 
observed by other groups. By annealing two staggered oligonucleotides, Yu et al. previously 
generated a 106 bp construct consisting of a dsDNA core flanked by 3′ overhangs – the 
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recombination intermediate predicted by the canonical model of Lambda Red dsDNA 
recombination (34). As expected, recombination of this construct did not depend on the presence 
of Exo; however, even in the presence of Exo, the recombination frequency was roughly 4000-
fold lower than that of its corresponding dsDNA. Given that the construct with 3′ overhangs is 
postulated to be a downstream intermediate of this dsDNA, this result casts doubt upon the claim 
that the tested construct is indeed the predominant recombination intermediate. However, this 
result is explained by our proposed mechanism – only the intact dsDNA can generate the full-
length ssDNA needed to undergo recombination, as neither individual strand of the construct 
containing 3′ overhangs is sufficient for recombination (34). We suggest that this 3′ overhang 
construct recombines by a separate and disfavored process. This is supported by the fact that this 
proposed recombination intermediate had no greater recombination frequency than the 
corresponding structure with 5′ (rather than 3′) overhangs. It is unlikely that either of these 
structures represents the predominant intermediate of dsDNA recombination. 
 Muyrers et al. (35) have also provided evidence contrary to a dsDNA recombination 
intermediate containing 3′ overhangs. The authors created a dsDNA construct in which 
phosphorothioate linkages placed between an antibiotic resistance gene and its flanking genome 
homology regions were used to prevent exonuclease degradation beyond these homology 
regions. Two 5′-to-3′ exonucleases other than Exo were then used in vitro to resect the 5' ends of 
this construct, in order to generate the putative intermediate for dsDNA recombination. 
However, it was found that none of the tested resection conditions could produce a construct that 
would recombine in the absence of Exo. In contrast, the predicted intermediate in our proposed 
mechanism is highly recombinogenic – even when prepared in vitro. 
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 Additionally, other prior work supports our proposed mechanism by reinforcing the 
processive nature of Exo. Hill et al. showed that non-replicating Lambda phage in E. coli is 
capable of converting linear dsDNA into ssDNA, creating single-stranded regions that span more 
than 1.4 kb (36). They also demonstrated that exo is sufficient for generating these regions of 
ssDNA, which are similar in length to the ~1.2 kb constructs used in this experiment. An 
additional implication of this result is that a single-stranded intermediate is also present during 
crosses involving an intact Lambda chromosome. These results suggest that our proposed 
mechanism may apply for natural Lambda Red recombination between phage and bacterial 
chromosomes. By extension, this model may also describe crosses between the phage 
chromosome and a plasmid (25), as plasmids present an accessible lagging strand at the 
replication fork in the same manner as the bacterial chromosome. 
The results of Lim et al. (26) further reinforce that Exo generates long strands of ssDNA. 
These researchers created a dsDNA construct in which two antibiotic resistance genes were 
attached via a genome homology region and flanked with two additional regions of genome 
homology. Using this cassette, only about 10% of recombinants incorporated both resistance 
genes, while a majority of recombinants incorporated only one of the two. This implies that a 
majority of recombination events involved the central homology region, which is roughly 1 kb 
away from either end of the dsDNA construct. Given that strand annealing requires exposed 
ssDNA, this result further suggests that Exo can be substantially processive in vivo, degrading 
large stretches of DNA rather than short flanking segments. Indeed, limits to the processivity of 
Exo could explain why recombination frequency declines substantially for increasing dsDNA 
insertion sizes, but not for increasing chromosomal deletion sizes (37). 
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Finally, while this manuscript was in revision, Maresca et al. (37) published 
complementary results, in which strand-specific 5' phosphorylation and phosphorothioation were 
used to bias Exo degradation to each strand of a selectable cassette. For recombination events 
following both in vitro and in vivo digestion, the authors observed a lagging-targeting strand 
bias. Building upon these observations, the authors identified ssDNA as a recombinogenic 
species, and proposed a mechanism consistent with the one advanced in this manuscript. These 
results provide substantial validation of our model. Our experiment involving a mismatched 
dsDNA cassette extends this work by showing that information from a single strand co-
segregates during Lambda Red mediated dsDNA recombination. More importantly than simply 
showing a lagging-targeting strand bias, this experiment provides direct evidence of a single-
stranded intermediate in Lambda Red dsDNA recombination.  
Our proposed mechanism may also describe other recombineering processes mediated by 
Lambda Red. One example is gap repair, in which linearized plasmid DNA is used to capture 
chromosomal DNA (11, 27). Notably, while a detailed mechanism has not yet been advanced for 
Lambda Red-facilitated gap repair, our model involving a single-stranded intermediate provides 
a plausible explanation. Given a full-length ssDNA intermediate, the linearized plasmid would 
anneal to the chromosomal target with its homology regions facing one another. The 3' end 
homology would then be elongated in the direction of the 5' end homology, thereby introducing 
the chromosomal DNA of interest into the plasmid. The linear single-stranded plasmid would be 
circularized by ligase in the same manner as Okazaki fragment joining. The circular ssDNA 
would then be liberated from the chromosome, possibly during chromosomal replication. 
Residual ssDNA from the other strand of the linearized plasmid may be necessary to prime 
replication in order to convert the circular single-stranded plasmid into double-stranded DNA. 
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Notably, this mechanism accounts for the gap repair of large (> 80 kb) genomic sequences (38), 
since the two homology regions could anneal with multiple Okazaki fragments between them. 
These fragments would then be joined by the natural lagging strand replication mechanism. 
In conclusion, a large body of evidence from our current work and from previously 
published studies supports our claim that the predominant mechanism for Lambda Red dsDNA 
recombination involves the annealing of a full-length ssDNA intermediate to the lagging strand 
of the replication fork. However, it is possible that previously suggested mechanisms involving 
the resection of both 5′ ends still operate as a minor process. The mismatched dsDNA approach 
described in this work may be a powerful platform to further explore the extent to which any 
such minor recombination mechanisms may operate. 
 The mechanism of Lambda Red recombination has long been a matter of debate (21). 
This work posits and supports a novel mechanism, which may reveal improved recombination 
parameters that increase the frequency and robustness of recombineering. Just as the mechanistic 
understanding of Red-mediated oligonucleotide recombination facilitated its optimization and 
use in novel and powerful applications (7), similar innovations may provide for transformative 
applications of Lambda Red dsDNA recombination. 
 
Materials and Methods 
 The preparation of the various DNA constructs used in this study is detailed in the 
Supplemental Materials and Methods section (File S1). These DNA constructs were recombined 
into EcNR2 cells {E. coli MG1655 Δ(ybhB-bioAB)::[λcI857 Δ(cro-ea59)::tetR-bla] ΔmutS::cat} 
in a similar manner as previously described (7). Briefly, cells were grown in a rotator drum at 32 
°C in LB-min media (10 g tryptone, 5 g yeast extract, 5 g sodium chloride per 1 L water) until 
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they reached an OD600 of 0.4 – 0.6. At this time, the expression of the Lambda Red proteins was 
induced by vigorously shaking the cells in a 42 °C water bath for 15 minutes. Cells were then 
chilled on ice, washed twice with deionized water, and resuspended in 50 μL of deionized water 
containing the desired DNA construct. For the experiment investigating strand bias, 20 ng of 
DNA was recombined. For all other experiments, 50 ng was used. The DNA was then introduced 
into the cells via electroporation (BioRad Gene Pulser™; 0.1 cm cuvette, 1.78 kV, 25 μF, 200 
Ω). After electroporation, cells were recovered in 3 mL LB-min media for 3 hours in a rotator 
drum at 32 °C.  
Recombinants were identified by plating 50 μL or 1 mL (concentrated to 50 μL) of 
undiluted recovery culture on selective media (LB-min with 30 µg/mL kanamycin sulfate, 95 
µg/mL spectinomycin, or 10 µg/mL Zeocin
TM
). The total viable cell count was determined by 
plating 50 μL of a 10-4 dilution of the recovery culture (in LB-min) onto LB-min + 20 µg/mL 
chloramphenicol plates. For experiments involving lacZ gene disruption, the plates also 
contained Fisher ChromoMax™ X-Gal/IPTG solution at the manufacturer's recommended 
concentration. Recombination frequencies were determined by dividing the extrapolated number 
of recombinants by the total viable cell count. All experiments assessing recombination 
frequency were performed in triplicate, except the series of recombinations in which 
phosphorothioate placement was altered – these were performed in duplicate. The recombination 
frequencies determined for each replicate were averaged and the error of the mean was taken to 
be 
x
x
N

  . We tested our hypothesis that lagging strand recombination frequency is higher 
than leading strand recombination frequency by using a one-tailed t-test assuming unequal 
variances. We used a two-way analysis of variance test with two replicates to assess significance 
of the phosphorothioate protection experiment. Both statistical analyses were calculated with 
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default parameters by MATLAB. Following the lacZ::kanR mismatched dsDNA 
recombinations, mismatch amplification mutation assay (MAMA) PCR (see File S1 for detailed 
description) was used for genotypic analysis. A complete list of primers used in the study can be 
found in the supplemental material (Table S2-1). 
 
Supplemental material 
 Supplemental material for CHAPTER 2 can be found in APPENDIX A or at 
<http://www.genetics.org/content/suppl/2010/09/02/genetics.110.120782.DC1/120782_SI.pdf>.  
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CHAPTER 3 
 
Manipulating Replisome Dynamics and DNA Exonucleases to Enhance Lambda 
Red-Mediated Multiplex Genome Engineering 
 
 
 
 
 
This chapter is adapted from portions of the following published papers: 
 
Mosberg JA
*
, Gregg CJ
*
, Lajoie MJ
*
, Wang HH, Church GM (2012) Improving Lambda Red 
Genome Engineering in Escherichia coli via Rational Removal of Endogenous Nucleases. PLoS 
ONE 7(9): e44638. doi:10.1371/journal.pone.0044638 
 
Lajoie MJ
*
, Gregg CJ
*
, Mosberg JA
*
, Washington GC, Church GM (2012) Manipulating 
Replisome Dynamics to Enhance Lambda Red-Mediated Multiplex Genome Engineering. NAR; 
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Abstract 
The bacteriophage λ Red recombination system is capable of efficiently introducing 
targeted genetic changes in Escherichia coli. Previously, we utilized this system to enable 
multiplex automatable genome engineering (MAGE) for pathway optimization (1). Additionally, 
we demonstrated that desired mutations could be enriched by co-selection with a nearby 
selectable mutation (Co-Selection MAGE, CoS-MAGE) (2, 3). In this chapter, we have 
demonstrated that both synthetic oligonucleotides and accessible ssDNA targets on the lagging 
strand of the replication fork are limiting factors for MAGE. Based on these mechanisms, we 
have engineered strains that exhibit improved genome engineering characteristics. Removing a 
set of five exonucleases (RecJ, ExoI, ExoVII, ExoX, and λ Exo) reduces MAGE oligonucleotide 
degradation, and disrupting the interaction between primase and helicase increases Okazaki 
fragment (OF) length and accessibility at the replication fork due to less frequent primer 
synthesis. By combining these strain improvements, we engineered a strain which displayed 
111% more alleles converted per clone, 527% more clones with five or more allele conversions, 
and 71% fewer clones with zero allele conversions in one cycle of 10-plex CoS-MAGE 
compared to a standard recombineering strain (EcNR2). These improvements will facilitate 
ambitious genome engineering projects by minimizing dependence on time-consuming clonal 
isolation and screening. 
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Introduction 
High throughput genome engineering requires the ability to cheaply and efficiently 
generate exact genomic DNA sequences. In this way, de novo genome synthesis (4, 5) is an 
attractive approach for generating designer organisms. However, the incomplete understanding 
of genome structure and function poses a significant risk of designing non-viable genomes. 
Therefore, it is essential to test many designs. For example, a single nucleotide DNA synthesis 
error in the completely de novo synthesized M. mycoides chromosome caused a frameshift in 
dnaA that prevented the transplanted genome from surviving (5). As de novo synthesis becomes 
commonly used for creating genomes with novel or altered functionalities, the risk of generating 
non-viable genomes will increase. Multiplex Automatable Genome Engineering (MAGE) is a 
powerful alternative strategy for engineering genomes in vivo. MAGE simultaneously introduces 
several synthesized DNA oligonucleotides (oligos), resulting in the efficient modification of the 
Escherichia coli chromosome. This technique relies on phage  Red recombinase, which binds 
to ssDNA oligos, protecting them from ssDNA exonucleases, and facilitating their annealing to 
the lagging strand of the replication fork (6). This highly efficient process generates a diverse 
heterogenic population, which converges toward a fully modified isogenic population after many 
cycles of recombination with non-degenerate oligo pools. Generating a heterogenic population 
has been harnessed for directed evolution of biosynthetic pathways (1) and extensive cycling 
toward isogenic populations has been used to remove all 314 UAG stop codons in subsets across 
32 E. coli strains (7). By integrating evolution with engineering, MAGE combinatorially 
explores a broad pool of viable and non-viable mutations. Since MAGE edits the genome in vivo, 
non-viable mutations never accumulate in the population. Yet, while this attribute of in vivo 
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genome engineering enables increasingly ambitious genome designs, the ability of MAGE to 
efficiently generate those designs is often a limiting factor. 
Several advances have already enhanced Red-mediated recombination from its initial 
~0.2% singleplex allele replacement (AR) frequency up to ~30% (1). Thus far, the predominant 
approach for improving Red-mediated AR has been to optimize oligo design. Such advances 
include targeting oligos to the lagging strand of the replication fork (8), evading mismatch repair 
using modified nucleotides (9), minimizing oligo secondary structure and optimizing homology 
lengths (1), blocking oligo degradation with 5' phosphorothioate bonds (1), and avoiding 
sequences with high degrees of off-target homology elsewhere in the genome (7). Additionally, 
removing the mismatch repair protein MutS to avoid reversion of mutated alleles (10) was a key 
innovation, but little other strain engineering was reported until recently. Such strain engineering 
could significantly augment the power of MAGE.  
Recently, a new strategy (co-selection MAGE, or CoS-MAGE) has been developed to 
engineer highly modified cells. This strategy uses an oligo that repairs a broken selectable 
marker (e.g., antibiotic resistance gene) to enhance AR frequency of nearby non-selectable 
alleles (3, 11). CoS-MAGE enhances the average multiplex allele replacement frequency 
approximately 4-fold by selecting for cells that take up MAGE oligos and that have a permissive 
replication fork in the desired region of the genome (3). Additionally, this approach selects 
against daughter cells with unaltered genomes, as it removes the population that does not revert 
the selectable allele (Figure 3-1).  
Despite the increased efficacy of CoS-MAGE, we hypothesized that intracellular MAGE 
oligonucleotides and accessible ssDNA on the lagging strand of the replication fork are both 
limiting factors for multiplex allele replacement. Therefore, we engineered a strain to overcome 
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these limitations. Many lines of evidence suggest that endogenous nucleases limit recombination. 
As discussed previously, using phosphorothioate bonds to protect oligonucleotides (1) and 
dsDNA cassettes (12, 13) has been shown to improve recombination frequency, suggesting that 
endogenous nuclease degradation antagonizes recombination. This is bolstered by the recent 
observation that knocking out four potent ssDNA exonucleases improves singleplex 
oligonucleotide recombination frequency when low concentrations of oligos are used (14). 
Furthermore, it has been shown that mutations located near the ends of an oligonucleotide (15) or 
dsDNA cassette (12) are inherited less often than mutations located closer to the interior of the 
oligo or cassette. This further implies degradation of oligonucleotides and dsDNA, and suggests 
that this nuclease processing prevents the inheritance of mutations along the full length of a 
cassette. We reasoned that by inactivating certain endogenous nucleases such as the potent ExoI, 
ExoVII, ExoX, RecJ, and Redα exonucleases, we could improve recombination frequency and 
preserve mutations encoded at ends of synthetic DNA.  
 
Figure 3-1. AR optimization via CoS-MAGE. The dividing chromosome is schematized, with integration of a 
MAGE oligo into the genome at a replication fork [adapted from Costantino and Court (37)]. An oligo 
electroporated into the cell is bound by multiple copies of the λ bacteriophage β recombinase and anneals to the 
lagging strand during DNA replication. When multiple oligos are incorporated into nearby sites (black and gray 
rectangles), they tend to co-segregate and are often inherited by the same daughter cell. Co-selection facilitates the 
removal of unmodified daughter chromosomes from the population, increasing AR frequency in the co-selected 
population. This figure is from Carr et al. (3). 
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In parallel, the fact that CoS-MAGE is most effective for oligos targeted in close 
proximity to the selectable marker suggests that replication fork position and accessibility are 
limiting factors in λ Red-mediated recombination (3). Thus, we reasoned that we could improve 
AR frequencies by manipulating replication fork dynamics to increase the amount of ssDNA on 
the lagging strand of the replication fork. Since Okazaki Fragment (OF) size can be modulated 
by the frequency of OF primer synthesis by DnaG primase (16), we hypothesized that 
attenuating the interaction between DnaG primase and the replisome would increase the amount 
of accessible ssDNA on the lagging strand of the replication fork and enhance multiplex AR 
frequencies (Figure 3-2). Tougu et al. (17) have reported E. coli primase variants with impaired 
helicase binding, resulting in less-frequent OF 
initiation, but normal replication fork rate, 
priming efficiency, and primer utilization during 
in vitro replication. These variants, K580A and 
Q576A, resulted in in vitro OFs that were 
approximately 1.5- and 8-fold longer 
(respectively) than those initiated by wild-type 
DnaG (18). These strains were therefore chosen 
to explore whether increasing accessible ssDNA 
on the lagging strand can improve multiplex AR 
frequency.  
 In this work, we demonstrate that 
intracellular MAGE oligonucleotides and 
accessible ssDNA on the lagging strand of the 
Figure 3-2. Effect of dnaG attenuation on replication 
fork dynamics. (A) Schematic showing the replication 
fork in E. coli, including the leading and lagging 
strands undergoing DNA synthesis. DnaG synthesizes 
RNA primers (red) onto the lagging template strand, 
which in turn initiate Okazaki fragment synthesis 
(blue) by PolIII. Compared to wt DnaG primase, the 
variants tested in this study have lower affinities for 
DnaB helicase (17). Since the DnaG-DnaB interaction 
is necessary for primase function, primer synthesis 
occurs less frequently, thereby exposing larger 
regions of ssDNA on the lagging template strand (18). 
(B) A schematic representing the E. coli MG1655 
genome with the origin (oriC) and terminus (T) of 
replication indicated, splitting the genome into 
Replichore 1 and Replichore 2. Each oligo set 
converts 10 UAG codons to UAA codons within the 
genomic regions indicated in gray. Co-selection 
marker positions are denoted by radial lines. 
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replication fork are both limiting factors for multiplex allele replacement, and that inactivating 
nucleases and disrupting the interaction between DnaG primase and DnaB helicase significantly 
improves multiplex allele replacement frequencies. We further describe the creation of an 
optimized strain for CoS-MAGE, which combines approaches to increase intracellular oligo 
concentration and to expose accessible ssDNA on the lagging strand of the replication fork. This 
strain demonstrates greatly improved CoS-MAGE performance, and provides a foundation for 
genome engineering projects of a much more ambitious scope. 
 
Results 
Nuclease Knockouts Improve MAGE Performance: It has previously been shown (14) 
that removing the four potent E. coli ssDNA exonucleases (ExoI, ExoVII, ExoX, and recJ) 
improves singleplex recombination frequency, but only when low concentrations of oligo are 
used.  Since oligonucleotide concentration can easily be increased, this has little practical benefit.  
However, nuclease removal may provide a greater benefit when multiple oligonucleotides are 
recombined simultaneously, as in MAGE (1).  Previous results (3) have shown that the 
recombination frequency of a given oligo is directly proportional to the mole fraction of that 
oligo in a complex mixture, even when the oligo is present at concentrations that would be 
saturating for singleplex oligo recombination.  We hypothesize that this apparent competition 
between oligonucleotides is due to a limited number of oligos entering each cell during 
electroporation.  Thus, if several oligos are simultaneously co-electroporated, the resulting 
intracellular concentration of any given oligo will be low.  Presynaptic (i.e., prior to 
incorporation) nuclease degradation may therefore have a large negative impact on 
recombination frequency in MAGE. 
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 To investigate this, we compared the MAGE performance of EcNR2, EcNR2.xseA
-
, and 
Nuc5
-
, which is ExoI
-
, ExoVII
-
, ExoX
-
, recJ
-
, and λ Exo-. In addition to the four potent 
exonucleases described above, λ Exo was also inactivated in this strain because it has been 
shown (19) to have trace activity against ssDNA and is not required for oligo recombination.  
CoS-MAGE (3) was used in these experiments, so as to determine whether the nuclease 
knockout strains are able to improve upon the current best practices for MAGE.  Three sets of 
recombineering oligos (designed in (7) to convert UAG codons to UAA and renamed herein for 
clarity as Sets 1-3) were used in order to control for potential oligo-, allele-, region-, and 
replichore-specific effects (Figure 3-2B) (7). Each of the three oligo sets was paired with a co-
selection oligo which restored the function of a nearby mutated antibiotic resistance gene (cat for 
Set 1, bla for Set 2, and tolC for Set 3), thereby selecting for high recombination frequency in the 
vicinity of the targeted loci.  All recombineering oligos had two PT bonds on each end, as was 
previously optimized for MAGE (7).  Targeted loci were screened by mascPCR (7) to determine 
which alleles were converted in a given clone. 
 For all three recombineering oligo sets (Set 1 in Figure 3-3A, Set 2 in Figure 3-3B, and 
Set 3 in Figure 3-3C), Nuc5
-
 significantly outperforms EcNR2 (*** P < 0.0001, *** P < 0.0001, 
* P = 0.002, respectively).  An average of 46% more alleles are converted per clone in Nuc5-, 
and the frequency of clones with 5 or more conversions is increased by 200%.  Furthermore, 
Nuc5
-
 reduces the frequency of clones with no conversions by 35%.     
The EcNR2.xseA
-
 strain appears to have properties intermediate between those of EcNR2 
and Nuc5
-
.  Although EcNR2.xseA
-
 exhibits a statistically significant increase in MAGE 
performance with Set 1 (1.47 ± 0.13) compared to EcNR2 (0.96 ± 0.07, ** P = 0.0001), this 
strain’s performance with Sets 2 and 3 was not statistically different from EcNR2 (P = 0.7 and 
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0.2, respectively).  Given that Set 1 exhibited the largest difference in performance between 
EcNR2 and Nuc5
-
 (65% higher allele conversion in Nuc5
-
), it is possible that Set 1 is the most 
susceptible to nuclease repression, and therefore that the effect of removing ExoVII would be 
most apparent for this set.  Overall, using these three tested sets, Nuc5
-
 is superior to 
Figure 3-3. Effect of Nuclease Genotype on CoS-MAGE Performance. CoS-MAGE was carried out in three 
strains (EcNR2, EcNR2.xseA-, and Nuc5-), using sets of ten oligos encoding UAGUAA mutations, and a co-
selection oligo designed to revert a mutated selectable marker located within 500 kb of the targeted loci.  (A) Set 1 
was co-selected with chloramphenicol acetyltransferase (cat, inserted at the mutS locus).  In comparison with 
EcNR2 (n = 319), both EcNR2.xseA- (** P = 0.0001, n = 135) and Nuc5- (*** P < 0.0001, n = 257) show 
statistically significant increases in mean oligo conversion, a decreased proportion of clones exhibiting no allele 
conversions, and more clones with 5+ conversions.  (B) Set 2 was co-selected with beta lactamase (bla, inserted 
with the λ prophage).  Here, Nuc5- (n = 142) shows a statistically significant increase in recombineering 
performance compared to both EcNR2 (*** P < 0.0001, n = 268) and EcNR2.xseA- (*** P < 0.0001, n = 184).  (C) 
Set 3 was co-selected with tolC.  Here, Nuc5- (n = 139) shows a statistically significant increase in mean allele 
conversion compared to EcNR2 (* P = 0.002, n = 327).  EcNR2.xseA- (n = 92) shows an intermediate phenotype 
between EcNR2 (P = 0.2) and Nuc5- (P = 0.3).  All oligos used in this experiment had two PT bonds on both ends.  
Data shown in the right panels are presented as the mean with the standard error of the mean.  Statistical 
significance is denoted using a starred system where ns denotes a non-significant variation, * denotes P < 0.003, ** 
denotes P < 0.001, and *** denotes P < 0.0001. 
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EcNR2.xseA
-
.  This suggests that the action of ExoVII somewhat compromises CoS-MAGE 
frequency, but that some or all of the other exonucleases removed in Nuc5
-
 also have a role in 
oligo degradation.    
Impaired primase activity enhances multiplex allele replacement frequency:  It is 
generally accepted that Redβ mediates annealing of exogenous DNA to the lagging strand of the 
replication fork prior to extension as a nascent Okazaki Fragment (6, 12, 20, 21). Therefore, we 
sought to increase the amount of ssDNA on the lagging strand by disrupting the ability of DnaG 
primase to initiate OFs. Prior work (18) has shown that DnaG K580A and Q576A mutations 
increase OF length in vitro by approximately 1.5-fold and 8-fold, respectively (see Table S3-2 
for further explanation).  
To investigate whether longer OFs could improve CoS-MAGE, we compared the 
performance of EcNR2, EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, and Nuc5-.dnaG.Q576A 
using Sets 1-3 as described above. EcNR2.dnaG.Q576A robustly outperformed EcNR2, yielding 
a significantly increased mean number of alleles converted (mean ± std. error of mean) for Set 1 
(Figure 3-4, left panel, 1.43 ± 0.12 vs. 0.96 ± 0.07, ** P = 0.0003), Set 2 (Figure 3-4, middle 
panel, 2.63 ± 0.13 vs. 2.04 ± 0.10, ** P = 0.0003), and Set 3 (Figure 3-4, right panel, 2.54 ± 0.14 
vs. 1.22 ± 0.07, *** P < 0.0001). Additionally, EcNR2.dnaG.K580A (intermediate-sized OFs) 
appears to have intermediate performance between EcNR2 (normal OFs) and 
EcNR2.dnaG.Q576A (longest OFs). This suggests that OF length correlates with AR frequency, 
and supports our hypothesis that exposing more ssDNA at the lagging strand of the replication 
fork enhances λ Red-mediated annealing.  
Visualizing AR frequency for individual alleles in all three Sets (Figure 3-4C) reinforces 
the relationship between OF size and MAGE performance. Compared to EcNR2, the K580A 
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variant trends toward a modest increase in individual AR frequency, whereas the Q576A variant 
starkly improves AR frequency. Finally, the Nuc5-.dnaG.Q576A strain yielded the highest 
observed AR frequencies for all oligo sets, suggesting a combined effect of decreasing oligo 
Figure 3-4. DnaG variants improve CoS-MAGE Performance. EcNR2, EcNR2.dnaG.K580A, 
EcNR2.dnaG.Q576A, and Nuc5-.dnaG.Q576A were tested for their performance in CoS-MAGE using three sets 
of 10 oligos as described in Figure 3-2B. For each set, all 10 alleles were simultaneously assayed by mascPCR in 
recombinant clones after one cycle of CoS-MAGE. (A) The data are presented using stacked AR frequency plots, 
which show the distribution of clones exhibiting a given number of allele conversions. (B) Mean number of alleles 
converted for each strain are shown with P-values indicated above the bars. Statistical significance is denoted 
using a star system where * denotes P < 0.003, ** denotes P < 0.001, and *** denotes P < 0.0001.  The data are 
presented as the mean (reported numerically inside each bar) ± standard error of the mean. (C) AR frequencies for 
each individual allele are shown for all tested strains. Overall, the relative performance of each strain was Nuc5-
.dnaG.Q576A > EcNR2.dnaG.Q576A > EcNR2.dnaG.K580A > EcNR2. This trend reflects an improvement 
commensurate with the severity of primase attenuation (i.e., the Q576A variant has more severely disrupted 
primase and larger OFs than the K580A variant). Furthermore, Nuc5-.dnaG.Q576A combines the benefits of the 
DnaG Q576A variant and the benefits of the inactivation of 5 potent exonucleases (Mosberg, J.A., Gregg, C.J., et 
al., in review). For Set 1: EcNR2, n=319; EcNR2.dnaG.K580A, n=93; EcNR2.dnaG.Q576A, n=141; Nuc5-
.dnaG.Q576A, n=47. For Set 2: EcNR2, n=269; EcNR2.dnaG.K580A, n=111; EcNR2.dnaG.Q576A, n=236; Nuc5-
.dnaG.Q576A, n=191. For set 3: EcNR2, n=327; EcNR2.dnaG.K580A, n=136; EcNR2.dnaG.Q576A, n=184; 
Nuc5-.dnaG.Q576A, n=92. 
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degradation through nuclease inactivation and increasing the amount of exposed target ssDNA at 
the lagging strand of the replication fork. Interestingly, EcNR2.dnaG.Q576A strongly 
outperformed Nuc5- for Set 3 (*** P < 0.0001), whereas EcNR2.dnaG.Q576A performance was 
not significantly different than that of Nuc5- for Sets 1 (P = 0.33) and 2 (P = 0.26) (Tables 3-1 
and 3-2). This suggests that the relative importance of replication fork availability and oligo 
protection can vary for MAGE targets throughout the genome, possibly due to oligo and/or 
locus-specific effects that have not yet been elucidated. Since both factors are important, 
combining impaired primase mutants with nuclease knockouts should reliably improve CoS-
MAGE performance. 
 
 Table 3-1. Summary of mean number of alleles converted per clone for each MAGE oligo set 
Set 
EcNR2 Nuc5- EcNR2.dnaG.Q576A Nuc5-.dnaG.Q576A 
Mean ± SEM  
(n) 
Mean ± SEM  
(n) 
Mean ± SEM  
(n) 
Mean ± SEM  
(n) 
1 
0.96 ± 0.07  
(319) 
1.58 ± 0.10  
(257) 
1.43 ± 0.12  
(141) 
2.30 ± 0.25  
(92) 
2 
2.04 ± 0.10  
(269) 
2.89 ± 0.19  
(142) 
2.63 ± 0.13  
(236) 
3.72 ± 0.17  
(191) 
3 
1.22 ± 0.07  
(327) 
1.61 ± 0.12  
(139) 
2.54 ± 0.14  
(184) 
2.59 ± 0.19  
(92) 
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 Table 3-2. CoS-MAGE Allele Replacement performance of modified strains  
 (presented as fold change from EcNR2) 
Metric Set Nuc5- E2.dnaG.Q576A Nuc5-.dnaG.Q576A 
A
ve
ra
ge
 
1 1.65 1.49 2.40 
2 1.41 1.29 1.82 
3 1.32 2.08 2.12 
Average 1.46 1.62 2.11 
5
+ 
C
o
n
ve
rs
io
n
s 1 5.28 3.96 10.18 
2 2.65 2.01 4.11 
3 1.07 4.20 4.52 
Average 3.00 3.39 6.27 
0
 C
o
n
ve
rs
io
n
s 1 0.67 0.68 0.24 
2 0.58 0.79 0.35 
3 0.71 0.40 0.30 
Average 0.65 0.62 0.29 
 
Okazaki fragment location is not a major determinant of available ssDNA on the 
lagging strand of the replication fork: Given the significant enhancement of CoS-MAGE 
performance in EcNR2.dnaG.Q576A, we sought to determine whether localizing all 10 targeted 
alleles to a single putative OF would result in "jackpot" recombinants with all 10 alleles 
converted. We hypothesized that nascent Okazaki Fragments sometimes obstructed target alleles, 
leading to a non-accessible lagging strand. According to this hypothesis, successful replacement 
of one allele would indicate permissive OF localization, greatly increasing the chance that other 
alleles occurring within the same OF could be replaced. Therefore, we speculated that the larger 
OF size in EcNR2.dnaG.Q576A might allow many changes to occur within 1 large OF. To test 
this, we designed 10 MAGE oligos that introduce inactivating nonsense mutations into a region 
spanning 1829 bp of lacZ. Despite their close proximity, all 10 alleles were spaced far enough 
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apart that their corresponding MAGE oligos would not overlap. Given the difference in average 
OF sizes between strains, it is unlikely for all 10 alleles to be located in the same OF in EcNR2, 
but quite likely that all 10 alleles would be located in the same OF in EcNR2.dnaG.Q576A. A 
tolC cassette (T.co-lacZ) was installed ~50 kb upstream of lacZ for efficient co-selection. Prior 
to use, this cassette was inactivated using the tolC-r_null_mut* oligo. Since the placement of 
these mutations is not compatible with mascPCR analysis, we used Sanger sequencing for 
analysis of white colonies. Blue colonies were scored as having zero conferred mutations. For 
EcNR2, 59% of the clones were white with 1.24 ± 0.23 (mean ± standard error of the mean) 
conversions per clone, whereas 84% of the EcNR2.dnaG.Q576A clones were white with 2.52 ± 
0.25 allele conversions per clone (Figure 3-5). While EcNR2.dnaG.Q576A exhibits  more mean 
allele conversions in CoS-MAGE than EcNR2 (*** P < 0.0001), the magnitude of this 
improvement (Figure 3-5B) is comparable with those observed for Sets 1-3 (Figure 3-4) where 
non-selectable oligos were spread across 70, 85, and 162 kb, respectively. Moreover, “jackpot” 
clones with 7+ converted alleles were not frequently observed for EcNR2.dnaG.Q576A using 
this oligo set. Thus although replication fork position is relevant, OF placement is not the 
predominant limiting factor for multiplex allele replacement. Other important factors could 
include target site occlusion by single stranded binding proteins or the availability of oligos, 
Redβ recombinase, or host factors.  
Improved strains have larger optimal oligo pool size for multiplex allele 
replacement: A MAGE oligo pool size of approximately 10 was found to be most effective in 
prior studies (7). However, given the enhanced Red-mediated recombination in our Nuc5- and 
dnaG strains, we tested whether an expanded set of oligos would lead to more alleles converted 
in average and top clones. Therefore, we designed 10 additional MAGE oligos (Set 3X) that 
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swapped synonymous AGA and AGG codons in alleles within the same region targeted by the 
Set 3 oligos. The ygfT allele (Set 3X) was not successfully assayed by mascPCR, so a maximum 
of 19 allele replacements could be detected out of the 20 conversions attempted. One round of 
CoS-MAGE using the combined oligo Sets 3 and 3X with tolC as a selectable marker improved 
Figure 3-5. Placing all targeted alleles within one Okazaki Fragment does not cause a bimodal distribution for 
recombination frequency. EcNR2 and EcNR2.dnaG.Q576A were tested for their performance in CoS-MAGE using 
a set of 10 non-overlapping oligos that introduce 10 premature stop codons in the first 1,890 bp of lacZ. The 
targeted region of the genome is likely to be small enough to be frequently encompassed within a single Okazaki 
Fragment in EcNR2.dnaG.Q576A. After one cycle of CoS-MAGE, LacZ- recombinant clones were Sanger 
sequenced to assay all 10 alleles. Recombinations were performed in triplicate to estimate the frequency of white 
colonies (lacZ-), but sequencing was only performed on a single replicate. (A) EcNR2.dnaG.Q576A (n=715, 
5.33:1) exhibited a significant increase in the lacZ-:lacZ+ ratio compared to EcNR2 (n=485, 1.46:1). (B) 
EcNR2.dnaG.Q576A exhibited an AR distribution similar to those observed with Sets 1-3 (which span 70 kb, 85 
kb, and 162 kb, respectively). (C) Compared to EcNR2, EcNR2.dnaG.Q576A exhibited a higher mean number of 
alleles converted (unpaired t-test, *** P < 0.0001). For EcNR2, n = 39, and for EcNR2.dnaG.Q576A, n = 55. (D) 
Compared to EcNR2, AR frequencies increased for 9 out of 10 individual alleles in EcNR2.dnaG.Q576A. The 
alleles are represented by their positions in lacZ (e.g., “+61” means that this oligo introduces a nonsense mutation 
by generating a mismatch at the 61st nucleotide of lacZ). Taken together, all of these results demonstrate improved 
CoS-MAGE in EcNR2.dnaG.Q576A compared to EcNR2, but no significant enhancement was obtained from 
targeting all oligos to a single putative OF. 
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AR frequency in all strains (Figure 3-6). The mean number of alleles converted (and fold 
increase over 10-plex means for Set 3 alone) per clone are as follows: 1.65 (1.35-fold) for 
EcNR2; 1.97 (1.02-fold) for EcNR2.dnaG.K580A; 2.96 (1.17-fold) for EcNR2.dnaG.Q576A; 
and 4.50 (1.74-fold) for Nuc5-.dnaG.Q576A (Figure 3-6B). Notably, Nuc5-.dnaG.Q576A 
exhibited the greatest improvement with the expanded oligo set, suggesting that preventing oligo 
Figure 3-6. Testing DnaG variants with a 20-plex CoS-MAGE oligo set. EcNR2, EcNR2.dnaG.K580A, 
EcNR2.dnaG.Q576A, and Nuc5-.dnaG.Q576A were tested for their performance in CoS-MAGE using an 
expanded set of 20 oligos (Sets 3+3X). Genotypes of recombinant clones were assayed by mascPCR after one 
cycle of CoS-MAGE (ygfT could not be assayed by mascPCR). (A) AR frequency distributions. (B) Mean number 
of alleles converted ± standard error of the mean, with P-values indicated above the bars. Statistical significance is 
denoted using a star system where * denotes P < 0.003, ** denotes P < 0.001, and *** denotes P < 0.0001.  (C) 
Mean individual AR frequencies. As seen with the smaller oligo sets, the dnaG variants reduce the number of 
clones with zero conversions and increase the average number of conversions per clone. Nuc5-.dnaG.Q576A 
strongly outperforms all other strains, with a mean of 4.50 alleles converted and fewer than 10% of clones having 
zero conversions. Notably, Nuc5-.dnaG.Q576A has strongly improved performance with Sets 3+3X compared to 
Set 3, whereas EcNR2.dnaG.Q576A does not. EcNR2, n=96; EcNR2.dnaG.K580A, n=113; EcNR2.dnaG.Q576A, 
n=95; Nuc5-.dnaG.Q576A, n=96. 
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degradation is important when the intracellular concentration of each individual oligo is low. 
Longer OFs then increase the probability that scarce oligos will find their genomic target. This 
observation assumes that a limited number of oligos are internalized during electroporation, 
which is consistent with the fact that the mole fraction of an oligo in a multiplex experiment 
affects its relative AR frequency at saturating oligo concentrations (3). Notably, the Set 3X 
oligos yielded lower recombination frequencies compared to the Set 3 alleles that converted 
UAG codons to UAA, and Nuc5-.dnaG.Q576A strongly elevated the AR frequency of these 
alleles (Figure 3-6C). Nuc5-.dnaG.Q576A exhibited the largest number of simultaneous allele 
conversions reported to date in a single recombination (tolC plus 12 additional alleles converted). 
Although CoS-MAGE in Nuc5-.dnaG.Q576A was able to simultaneously convert an 
unprecedented number of alleles, the lack of clones with allele replacements near the maximum 
of 19 suggests that CoS-MAGE is approaching a practical maximum for oligo pool complexity, 
where further increases in oligo pool size may not substantially improve AR frequency or 
increase the mean number of alleles converted. 
 Disrupting DnaG primase activity enhances leading strand recombination: Since 
DnaG primase synthesizes RNA primers only at the lagging strand of the replication fork, we 
expected its alteration to have minimal effect on Red-mediated annealing to the leading strand. 
To examine this hypothesis, we tested oligos designed to target the Set 3 alleles on the leading 
strand (reverse complements of the Set 3 oligos described above). The tolC-reverting co-
selection oligo was also re-designed to target the leading strand so that the correct strand would 
be co-selected. Although the number of tolC-reverted co-selected recombinants were few, of the 
tolC+ clones, EcNR2 gave 0.85 ± 0.13 allele conversions per clone (mean ± std. error of the 
mean, n = 88), whereas EcNR2.dnaG.Q576A gave 1.39 ± 0.18 conversions (n = 91), which was 
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significantly different (P = 0.018). Similar to lagging targeting Set 3, we observed a reduction in 
zero conversion events for EcNR2.dnaG.Q576A, as well as a broadening of the distribution of 
total allele conversions per clone and a greater maximum number of alleles converted (Figure 
S3-1A). Thus, leading-targeting CoS-MAGE yields recombination frequencies nearly within 
two-fold of those attained with lagging-targeting CoS-MAGE (1.22 ± 0.07 vs. 2.54 ± 0.14 for 
EcNR2 and EcNR2.dnaG.Q576A, respectively). Furthermore, contrary to our expectations, 
EcNR2.dnaG.Q576A exhibited significantly enhanced AR frequency over EcNR2 at 9 out of 10 
alleles on the leading strand (Figure S3-1C). Interestingly, using leading targeting oligos, the co-
selection advantage quickly diminished with distance (Figure S3-1B, top panel). In contrast, co-
selection using lagging targeting oligos increases the AR frequency of other alleles spanning a 
large genomic distance (~0.5 Mb; (3)), as observed for the lagging-targeting Set 3 oligos (Figure 
S3-1B, bottom panel).  
Disrupting DnaG primase activity enhances deletions but not insertions: MAGE is 
most effective at introducing short mismatches, insertions, and deletions, as these can be 
efficiently generated using  Red-mediated recombination without direct selection (1). However, 
large deletions and gene-sized insertions are also important classes of mutations that could 
increase the scope of applications for MAGE. For example, combinatorial deletions could be 
harnessed for minimizing genomes (22) and efficient insertions could increase the ease of 
building biosynthetic pathways by removing the need for linking inserted genes to selectable 
markers (23-26). Large deletions require two separate annealing events often spanning multiple 
OFs, but large insertions should anneal within the same OF, as the heterologous portion loops 
out and allows the flanking homologies to anneal to their adjacent targets (12, 20). Maresca et al. 
(20) have demonstrated that the length of deletions have little effect on Red-mediated 
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recombination, but that insertion frequency is highly dependent on insert size (presumably due to 
constraints on Exo-mediated degradation of the leading-targeting strand and not the lagging-
targeting strand). Therefore, we investigated whether diminishing DnaG primase function would 
enhance deletion and/or insertion frequencies.  
Based on the ssDNA intermediate model for Red recombination (12, 20), we expected 
enhanced deletion frequency in EcNR2.dnaG.Q576A especially for intermediate-sized deletions 
(500 bp – 10 kb), since less frequent priming would increase the probability of both homology 
regions being located in the same OF. Therefore, we designed three oligos that deleted 100 bp, 
1,149 bp, or 7,895 bp of the genome, including a portion of galK. In addition to galK, oligo 
galK_KO1.7895 deleted several nonessential genes (galM, gpmA, aroG, ybgS, zitB, pnuC, and 
nadA). The recombined populations were screened for the GalK
-
 phenotype (white colonies) on 
MacConkey agar plates supplemented with galactose as a carbon source. EcNR2.dnaG.Q576A 
significantly outperformed EcNR2 for the 100 bp (* P = 0.03) and 1,149 bp (* P = 0.03) 
deletions, but there was no difference detected between the two strains for the 7,895 bp deletion 
(P = 0.74, Figure S3-2). The lack of improvement using galK_KO1.7895 may be due to reduced 
target availability if the two homology sites are split across two or more OFs even in 
EcNR2.dnaG.Q576A. 
Finally, if λExo degradation most strongly impacts λRed-mediated insertions of large 
cassettes, modifying the replisome should not significantly impact their insertion frequency. 
Therefore, we quantified the insertion frequency of a selectable kanamycin resistance cassette 
(lacZ::kanR, 1.3 kb) targeted to lacZ. Insertion of lacZ::kanR (1, 12) in three replicates yielded 
recombination frequencies of 1.81E-04 ± 6.24E-05 in EcNR2 versus 1.28E-04 ± 4.52E-05 in 
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EcNR2.dnaG.Q576A (P = 0.30 by unpaired t-test). Therefore, modifying DnaG primase function 
does not appear to significantly affect  Red-mediated gene insertion. 
 
Discussion 
 MAGE is a powerful technique that can be used to generate combinatorial sets of 
designed mutations in a population (1) and/or modify hundreds of alleles in a single strain (7). 
We have engineered optimized strains for multiplex genome engineering in an effort to 
streamline extensive genome editing. Previously, we showed that converting a selectable allele in 
the vicinity of multiple non-selectable alleles enriches the candidate pool for highly modified 
clones (3). In this work, we demonstrated that exonucleases are capable of degrading single 
stranded MAGE oligos even when these oligos are protected using phosphorothioate bonds. 
Inactivating ExoI, ExoVII, ExoX, RecJ, and λExo significantly enhanced multiplex AR 
frequencies. This showed that intracellular MAGE oligos are a limiting factor in λ Redβ-
mediated recombination. We also demonstrated that available ssDNA on the lagging strand of 
the replication fork is a limiting factor that can be increased by disrupting the interaction 
between DnaG primase and DnaB helicase on the replisome. 
In order to increase ssDNA on the lagging strand of the replication fork, we introduced 
two known mutations in primase (DnaG)—K580A and Q576A. These mutations have been 
shown in vitro to increase OF size by interrupting the primase-helicase interaction on the 
replisome (18). Based on the measurements of Tougu et al. (18), we estimate that the K580A 
mutation increases OF length by ~1.5-fold and the Q576A mutation increases OF length by ~8-
fold (see Table S3-2). EcNR2.dnaG.K580A and EcNR2.dnaG.Q576A exhibited significant 
increases in the mean number of alleles converted and decreases in the proportion of clones with 
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zero non-selectable alleles converted. Furthermore, the strongest enhancement was observed in 
EcNR2.dnaG.Q576A (the variant with the longest OFs of the strains reported herein), with an 
intermediate enhancement observed in EcNR2.dnaG.K580A (the variant with intermediate-sized 
OFs). This relationship between recombination frequency and OF length further supports the 
model in which Redβ mediates annealing at the lagging strand of the replication fork (6, 12, 20, 
21), and our hypothesis that ssDNA on the lagging strand of the replication fork is a limiting 
factor during this process. With this in mind, we unsuccessfully attempted to generate a DnaG 
Q576A/K580A double mutant, suggesting that such an extensive manipulation of the DnaG C-
terminal helicase interaction domain (27) was lethal. 
Our results indicate that intracellular concentrations of MAGE oligos and the 
accessibility of their genomic targets are both limiting. To further increase the number of 
simultaneous mutations that can be generated by CoS-MAGE, it is helpful to understand whether 
the AR frequency is limited predominantly by the number of oligos that enter the cytoplasm, or 
whether kinetics are also relevant. Since a maximum of 9 allele replacements was observed for 
the 10-oligo sets compared to a maximum of just 12 allele replacements for the 20-oligo set, 
oligo uptake may be limiting. However, the fact that primase modulation—in addition to 
nuclease inactivation—enhances AR frequency underscores the kinetic constraints regarding 
Redβ-mediated annealing. Each missed opportunity to anneal 1) increases the number of wt 
alleles in the population due to replication and 2) decreases the number of MAGE oligos 
available, via dilution (cell division) and degradation (nucleases). Increasing the concentration of 
each reactant (i.e., intracellular oligos and accessible genomic targets) would increase the 
kinetics of annealing. Therefore, the number of intracellular oligos may limit the maximum 
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number of possible mutations, but kinetics appear to be a significant force limiting the 
population-wide AR frequency average. 
Interestingly, the nuclease-deficient Nuc5- strain (Mosberg, J.A., Gregg, C.J., et al., in 
review) performed statistically similarly to the EcNR2.dnaG.Q576A strain for Sets 1 and 2, 
while EcNR2.dnaG.Q576A strongly outperformed the nuclease-deficient strain for Set 3 (Tables 
3-1 and 3-2). While oligo design parameters such as type of designed mutation (1), oligo length 
(1), oligo secondary structure (1) and off-target genomic homology (7) are major determinants of 
AR frequency, our results highlight the relevance of genomic context. This has previously been 
difficult to demonstrate, but is apparent from the discrepancy in performance of the same oligo 
sets tested in Nuc5-, EcNR2.dnaG.Q576A, and Nuc5-.dnaG.Q576A. For example, different 
regions may have different replication fork speed or priming efficiency. These factors could 
locally modulate OF length, thus affecting Redβ-mediated AR frequency (although replication 
fork speed did not appear to be a major factor in vitro (18)). Therefore, increasing the region that 
must be replicated by a single OF may profoundly increase AR frequency for oligos targeting 
such regions. Alternatively, certain oligos may be more susceptible to nuclease degradation, so 
removing the responsible nucleases would disproportionately improve AR frequency for such 
oligos. With this in mind, we tested whether combining primase modification and nuclease 
removal would enhance MAGE performance more than either strategy used individually. Indeed, 
Nuc5-.dnaG.Q576A consistently performed the best (Figures 3-4 and 3-6) of all tested strains. 
Therefore, these two disparate strategies can be combined for a larger and more robust MAGE 
enhancement (Figure 3-7).  
To explore the extent to which OF localization impacts CoS-MAGE performance, we 
tested whether placing 10 oligos within a single putative OF would yield subpopulations of 
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unmodified (few alleles converted) and "jackpot" 
(most alleles converted) recombinants. However, 
CoS-MAGE using the densely-clustered lacZ 
oligos (Figure 3-5) produced a similar AR 
distribution to the ones observed for Sets 1-3 
(Figure 3-4), which target regions of the genome 
spanning several putative OFs. Since mutations 
within a single putative OF behaved similarly to 
mutations spread across many OFs, nascent OF 
placement does not appear to be a critical 
determinant of multiplex AR frequency. A 
number of hypotheses could explain why the 
expected "jackpots" are not observed. Most 
likely, MAGE oligos are limiting due to 
degradation and/or lack of uptake. Thus, it is 
possible that most cells lack some of the oligos 
necessary for generating a majority of the 
desired mutations. Additionally, OF extension 
may occur too fast for all of the MAGE oligos to 
anneal before the OF occludes their targets. Still another explanation could be that ssDNA 
binding proteins occlude ssDNA on portions of the lagging strand, rendering these regions non-
accessible for Redβ-mediated annealing. Finally, it is also possible that several MAGE oligos 
annealed within a single OF could destabilize lagging strand synthesis, leading to selection 
Figure 3-7. Averaged CoS-MAGE performance by 
strain. CoS-MAGE, nuclease deletion, and replisome 
manipulation all independently improve 
recombination frequency. (A) The distributions of the 
number of alleles converted per MAGE or CoS-
MAGE cycle were averaged across Sets 1, 2, and 3 
for each specified condition. These averaged results 
give the approximate expected performance of a 10-
plex recombination. (B) The mean allele conversions 
per recombination is reported for each distribution 
that was shown in (A). 
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against highly-modified "jackpot" clones. Indeed, Corn et al. (28) hypothesize that DnaG 
primase has evolved to only initiate synthesis when multiple DnaG units are bound to DnaB 
Helicase, as OF synthesis away from the replisome could be detrimental. Since polIIIlag 
dissociates from the replisome after completing an OF (29), the rapid and repeated dissociation 
of polIIIlag caused by multiple nearby MAGE oligos could inhibit lagging strand synthesis as the 
replisome proceeds beyond the target region. In the absence of the rest of the replisome, a 
cytosolic PolIII holoenzyme alone can synthesize 1.4 kb on a ssDNA template primed by 30 nt 
DNA oligos (30), but this activity is considerably diminished compared to that of an intact 
replisome. Therefore, if OFs are not completed while the replisome is in close proximity, this 
could result in persisting ssDNA that could destabilize the chromosome and/or cause lesions 
when the next replication fork passes through.  
 We also investigated whether targeting a greater number of alleles would increase the 
resulting number of conversions in our enhanced strains (Figure 3-6). Although the mean number 
of alleles converted (mean ± std. error of the mean) increased from 2.59 ± 0.19 with 10-oligo Set 
3 to 4.50 ± 0.30 (1.74-fold) with 20-oligo Sets 3+3X for Nuc5-.dnaG.Q576A, the mean number 
of alleles converted for EcNR2.dnaG.Q576A only increased from 2.54 to 2.96 (1.17-fold). The 
superior enhancement for the nuclease-depleted Nuc5-.dnaG.Q576A strain suggests that the 
intracellular oligo concentration is a limiting factor for highly multiplexed MAGE (>10 alleles 
targeted). Therefore, enhancing DNA uptake and/or preservation may be a fruitful means of 
further improving MAGE. However, the greater multiplexibility of Nuc5-.dnaG.Q576A could 
also be due to the 10 new Set 3X oligos being more responsive to decreased exonuclease 
degradation than to increased lagging strand ssDNA availability. Additionally, there may be 
other limiting factors such as insufficient Redβ or unidentified host proteins. Although there is 
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no known precedent for limiting amounts of λ Red proteins during recombination (31), our new 
ability to attain 12 simultaneous non-selectable allele replacements (Figure 3-6A) shows that our 
improved strains are in uncharted territory for probing the limits of λ Red recombination. 
 Given that DnaG primase acts solely on the lagging strand of the replication fork, we 
expected that the primase modifications would only enhance lagging strand recombination. 
Therefore, the performance of leading-targeting CoS-MAGE in our strains was surprising, as 
EcNR2.dnaG.Q576A significantly outperformed EcNR2 (P = 0.018). Furthermore, while the 
total number of tolC+ recombinants was far smaller (~10
2
-fold) for leading-targeting CoS-
MAGE, the AR frequency of non-selectable alleles in these recombinants was still quite 
impressive, especially in extremely close proximity to the selectable allele. This suggests that 
one leading strand recombination event strongly correlates with multiple additional 
recombinations. Two possible explanations for the superior performance of EcNR2.dnaG.Q576A 
in leading-targeting CoS-MAGE are that 1) an impaired primase-helicase interaction increases 
accessible leading strand ssDNA, or 2) infrequent Redβ-mediated strand invasion initiates a new 
replication fork that travels in the opposite direction and swaps which strand is the lagging 
strand.  
There is strong support for primase function affecting the dynamics of replication on both 
the lagging and leading strands (29, 30, 32). Lia et al. (29) observed phases in which OF 
synthesis is faster than helicase progression at the replication fork, alternating with phases in 
which helicase progression outstrips the rate of OF synthesis by PolIIIlag. These results 
demonstrate that DnaB-PolIIIlead does not progress at the same instantaneous speed as PolIIIlag 
(29). Furthermore, Yao et al. (32) showed that the velocity of leading-strand synthesis decreases 
during lagging strand synthesis, while its processivity increases. Perhaps less frequent primase-
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helicase binding leads to transient asynchrony of the helicase and PolIIIlead. Given that PolIII 
tends to release from the replication fork more readily than does DnaB helicase (32), a 
transiently increased fork rate and decreased PolIIIlead processivity could exacerbate such an 
asynchrony, creating a leading strand trombone loop similar to those observed during lagging 
strand synthesis. However, the effects of lagging strand synthesis on leading strand replication 
have been historically difficult to demonstrate in experiments beyond single-molecule studies 
(32). Given that instantaneous changes in replication dynamics appear to occur on timescales 
relevant to Redβ-bound oligo recombination, it is conceivable that snapshots of exposed ssDNA 
on the leading strand template could be recorded by measuring rates of leading-targeting AR. 
Single-molecule analysis of the Q576A variant could explore this hypothesis. 
Alternatively, Redβ has been reported to facilitate strand invasion in vitro (33). If this 
also occurs in vivo, such strand invasion would produce a D-Loop that could act as a new origin 
of replication (34). Therefore, invasion of one leading-targeting MAGE oligo could initiate a 
replication fork traveling in the opposite direction. In the reverse orientation, the leading strand 
would become the lagging strand so that upstream oligos would become lagging targeting and 
much more likely to recombine. This could lead to the highly modified clones that we observed 
during leading-targeting CoS-MAGE (Figure S3-1). If this is the case, the non-selectable alleles 
would be upstream of the tolC selectable marker. Since co-selection is most effective 
downstream of the selectable marker (3), this may explain why co-selection enhancements decay 
rapidly with distance on the leading strand.   
 In this manuscript, we have identified intracellular MAGE oligo stability and availability 
of ssDNA on the lagging strand of the replication fork as a limiting factor in multiplex genome 
engineering. Compared to a single round of CoS-MAGE with ten synthetic oligonucleotides in a 
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standard recombineering strain (EcNR2), Nuc5- displays on average 46% more alleles converted 
per clone, 200% more clones with five or more allele conversions, and 35% fewer clones without 
any allele conversions. Additionally, EcNR2.dnaG.Q576A displays on average 62% more alleles 
converted per clone, 239% more clones with five or more allele conversions, and 38% fewer 
clones with zero allele conversions (Table 3-2). We combined these strain enhancements, 
generating Nuc5-.dnaG.Q576A, which has extended Okazaki Fragments and reduced 
exonuclease activity. These modifications exploited two distinct mechanisms that together 
increased the robustness and potency of CoS-MAGE, enabling an average of 4.50 and a 
maximum of 12 allele replacements in single cells exposed to a pool of 20 different synthetic 
allele replacement oligos (Figure 3-6). Additionally, 48% of recombinants had five or more 
allele replacements and only 8% had zero modified non-selectable alleles. Furthermore, in a 
given round of CoS-MAGE with ten synthetic oligos, Nuc5-.dnaG.Q576A displays on average 
111% more alleles converted per clone, 527% more clones with five or more allele conversions, 
and 71% fewer clones with zero allele conversions in comparison with EcNR2 (Table 3-2). This 
improvement in MAGE performance will be highly valuable for increasing the diversity 
explored during the directed evolution of biosynthetic pathways (1) and for enabling the rapid 
generation of desired genotypes involving tens to hundreds of allele replacements (7). 
 
Materials and Methods 
 Table S3-1 presents a full list of DNA oligos used in this work. All oligos were ordered 
with standard purification and desalting from Integrated DNA Technologies. Cultures were 
grown in LB-Lennox media (LB
L
; 10 g tryptone, 5 g yeast extract, 5 g NaCl per 1 L water).  
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Strain Creation: Oligo-mediated λ Red recombination was used to generate all 
mutations as described below. All of the strains used in this work were generated from EcNR2 
(1) {E. coli MG1655 Δ(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-bla] ΔmutS::cat}. Strain Nuc5- 
was generated using knockout oligos (Table S3-1) that introduced a premature stop codon and a 
frameshift mutation at the beginning of the nuclease gene, thereby rendering the nuclease 
inactive. Strain Nuc5-.dnaG.Q576A was generated by recombining oligo dnaG_Q576A into 
strain Nuc5-. EcNR2.DT was created by deleting the endogenous tolC gene using the tolC.90.del 
recombineering oligo (7). EcNR2.T.co-lacZ was created by recombining a tolC cassette (T.co-
lacZ) into the genome of EcNR2.DT, upstream of the lac operon. CoS-MAGE strains were 
prepared by inactivating a chromosomal selectable marker (cat, tolC, or bla) using a synthetic 
oligo. Clones with a sensitivity to the appropriate antibiotic or SDS (25) were identified by 
replica plating. The growth rate of strains EcNR2, EcNR2.dnaG.K580A, and 
EcNR2.dnaG.Q576A are approximately equivalent, while Nuc5-.dnaG.Q576A has a doubling 
time that is only ~7% longer than the others. 
Generating dsDNA Recombineering Cassettes: The T.co-lacZ dsDNA recombineering 
cassette was generated by PCR using primers 313000.T.lacZ.coMAGE-f and 
313001.T.lacZ.coMAGE-r (Table S3-1). The PCR was performed using KAPA HiFi HotStart 
ReadyMix, with primer concentrations of 0.5 µM and 1 µL of T.5.6 (7) used as template (a 
terminator was introduced downstream of the stop codon in the tolC cassette). PCRs (50 µL 
total) were heat activated at 95 °C for 5 min, then cycled 30 times at 98 °C (20 sec), 62 °C (15 
sec), and 72 °C (45 sec). The final extension was at 72 °C for 5 min. The Qiagen PCR 
purification kit was used to isolate the PCR products (elution in 30 µL H2O). Purified PCR 
products were quantitated on a NanoDrop™ ND1000 spectrophotometer and analyzed on a 1% 
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agarose gel with ethidium bromide staining to confirm that the expected band was present and 
pure.  
In vitro dsDNA Digestion by Lambda Exo: LacZ::kanR dsDNA (20 ng) with zero, one, 
or both ends phosphorothioated (VPT1, VPT2, and VPT4, respectively; see Figure S3-1A) was 
added to 9 µL of 1X Lambda Exonuclease Buffer (New England Biolabs).  Lambda Exonuclease 
(New England Biolabs) was serially diluted in 1X Lambda Exonuclease Buffer as needed and 1 
µL was then added to the reaction.  Reactions were incubated at 37 °C for 30 min, heat 
inactivated at 75 °C for 10 min, and then analyzed on an Invitrogen 6% TBE non-denaturing 
PAGE gel (180 V, 40 min, post-stained in Invitrogen SYBR Gold for 15 min). 
Performing λ Red Recombination: λ Red recombinations of ssDNA and dsDNA were 
performed as previously described (1, 12). Briefly, 30 µL from an overnight culture was 
inoculated into 3 mL of LB
L
 and grown at 30 °C in a rotator drum until an OD600 of 0.4-0.6 was 
reached (typically 2-2.5 hrs). The cultures were transferred to a shaking water bath (300 rpm at 
42 °C) for 15 minutes to induce λ Red, then immediately cooled on ice for at least 3 minutes. For 
each recombination, 1 mL of culture was washed twice in ice cold deionized water (dH2O). Cells 
were pelleted between each wash by centrifuging at 16,000 rcf for 20 seconds. The cell pellet 
was resuspended in 50 µL of dH2O containing the DNA to be recombined. For recombination of 
dsDNA PCR products, 50 ng of PCR product was used. Recombination using dsDNA PCR 
products was not performed in Nuc5- strains, since λ Exo is necessary to process dsDNA into a 
recombinogenic ssDNA intermediate prior to β-mediated annealing (12, 20). For experiments in 
which a single oligo was recombined, 1 µM of oligo was used. For experiments in which sets of 
ten or twenty recombineering oligos were recombined along with a co-selection oligo, 0.5 µM of 
each recombineering oligo and 0.2 µM of the co-selection oligo were used (5.2 µM total for 10-
80 
 
plex and 10.2 µM total for 20-plex). A BioRad GenePulser™ was used for electroporation (0.1 
cm cuvette, 1.78 kV, 200 Ω, 25 µF), and electroporated cells were allowed to recover in 3 mL 
LB
L
 in a rotator drum at 30 °C for at least 3 hours before plating on selective media. For MAGE 
and CoS-MAGE experiments, cultures were recovered to apparent saturation (5 or more hours) 
to minimize polyclonal colonies (this was especially important for strains based on Nuc5-, which 
exhibit slow recovery after λ Red induction/electroporation). MAGE recovery cultures were 
diluted to ~5000 cfu/mL, and 50 µL of this dilution was plated on non-selective LB
L
 agar plates. 
To compensate for fewer recombinants surviving the co-selection, CoS-MAGE recovery cultures 
were diluted to ~1E5 cfu/mL and 50 µL of this dilution was plated on appropriate selective 
media for the co-selected resistance marker (LB
L
 with 50 µg/mL carbenicillin for bla, 20 µg/mL 
chloramphenicol for cat, or 0.005% w/v SDS for tolC). Leading-targeting CoS-MAGE recovery 
cultures were diluted to ~5E6 cfu/mL before plating.
 
Analyzing Recombination: GalK activity was assayed by plating recovered 
recombination cultures onto MacConkey agar supplemented with 1% galactose as a carbon 
source. Red colonies were scored as galK+ and white colonies were galK-. LacZ activity was 
assayed by plating recovery cultures onto LB
L
 agar + X-gal/IPTG (Fisher ChromoMax IPTG/X-
Gal solution). Blue colonies were scored as lacZ+ and white colonies were lacZ-. 
Kapa 2G Fast ReadyMix was used in colony PCRs to screen for correct insertion of 
dsDNA selectable markers. PCRs had a total volume of 20 µL, with 0.5 µM of each primer. 
These PCRs were carried out with an initial activation step at 95 °C for 2 min, then cycled 30 
times at 95 °C (15 sec), 56 °C (15 sec), 72 °C (40 sec), followed by a final extension at 72 °C (90 
sec). 
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Allele-specific colony PCR (ascPCR) was used to detect the nuclease and primase 
mutations. Multiplex allele-specific colony PCR (mascPCR) (35) was used to detect the 1-2 bp 
mutations generated in the MAGE and CoS-MAGE experiments. Each allele is interrogated by 
two separate PCRs—one with a forward primer whose 3' end anneals to the wild-type allele, and 
the other with a forward primer whose 3' end anneals to the mutated allele (the same reverse 
primer is used in both reactions). Primers are designed to have a Tm ~ 62 °C, but a gradient PCR 
is necessary to optimize annealing temperature (typically between 63 °C and 67 °C) to achieve 
maximal specificity and sensitivity for a given set of primers. A wild-type allele is indicated by 
amplification only in the wt-detecting PCR, while a mutant allele is indicated by amplification 
only in the mutant-detecting PCR. For mascPCR assays, primer sets for interrogating up to 10 
alleles are combined in a single reaction. Each allele has a unique amplicon size (100 bp, 150 bp, 
200 bp, 250 bp, 300 bp, 400 bp, 500 bp, 600 bp, 700 bp, and 850 bp). Template is prepared by 
growing monoclonal colonies to late-log phase in 150 uL LB
L
 and diluting 2 uL of culture into 
100 uL dH2O. Typical mascPCR reactions use KAPA2GFast Multiplex PCR ReadyMix and 
10X Kapa dye in a total volume of 10 µL, with 0.2 µM of each primer and 2 µL of template. 
These PCRs were carried out with an initial activation step at 95 °C (3 min), then cycled 27 
times at 95 °C (15 sec), 63-67 °C (30 sec; annealing temperature optimized for each set of 
mascPCR primers), and 72 °C (70 sec), followed by a final extension at 72 °C (5 min). All 
mascPCR and ascPCR assays were analyzed on 1.5% agarose/EtBr gels (180 V, duration 
depends on distance between electrodes) to ensure adequate band resolution. 
We performed at least two independent replicates for all strains with each oligo set in 
CoS-MAGE experiments. All replicates for a given strain and oligo set were combined to 
generate a complete data set. Polyclonal or ambiguous mascPCR results were discarded from our 
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analysis. Mean number of alleles replaced per clone were determined by scoring each allele as 1 
for converted or 0 for unmodified. Given the sample sizes tested in the CoS-MAGE experiments 
(n > 47), we used parametric statistical analyses instead of their non-parametric equivalents, 
since the former are more robust with large sample sizes (36). We used a one way ANOVA to 
test for significant variance in CoS-MAGE performance of the strains (EcNR2, 
EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, Nuc5-, and Nuc5-.dnaG.Q576A) for a given oligo 
set.  Subsequently, we used a Student’s t-test to make pairwise comparisons with significance 
defined as P < 0.05/n, where n is the number of pairwise comparisons.  Here, n = 15 as this data 
set was planned and collected as part of a larger set with 6 different strains although only 
EcNR2, EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, Nuc5-, and Nuc5-.dnaG.Q576A are 
presented here.  As such, significance was defined as P < 0.003 for the analyses presented in 
Figures 3-4 and 3-6.  Statistical significance in Figures 3-4 and 3-6 are denoted using a star 
system where * denotes P < 0.003, ** denotes P < 0.001, and *** denotes P < 0.0001.  In the 
case of the experiment comparing EcNR2 and EcNR2.dnaG.Q576A using leading targeting 
oligos (Figure S3-1), we tested for statistical significance using a single t-test with significance 
defined as P < 0.05.   
For the experiment in which 10 oligos were targeted within lacZ, recombinants were 
identified by blue/white screening. The frequency of clones with 1 or more alleles replaced (# of 
white colonies / total # of colonies) was determined for every replicate. For white colonies only, 
a portion of lacZ gene was amplified with primers lacZ_jackpot_seq-f and lacZ_jackpot_seq-r 
(Table S3-1), using KAPA HiFi HotStart ReadyMix as described above. PCR purified (Qiagen 
PCR purification kit) amplicons were submitted to Genewiz for Sanger sequencing in both 
directions using either lacZ_jackpot_seq-f or lacZ_jackpot_seq-r. Combined, the two sequencing 
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reads for each clone interrogated all 10 alleles (i.e., unmodified or mutant sequence). Three 
replicates of recombinations and blue/white analysis were performed to ensure consistency, but 
only one replicate was sequenced (n = 39 for EcNR2 and n = 55 for EcNR2.dnaG.Q576A). Mean 
number of alleles replaced per clone were determined as described above. We tested for 
statistically significant differences in mean allele conversion between the strains using a 
Student’s t-test with significance defined as P < 0.05.  Statistical significance in Figure 3-5C is 
denoted using a star system where *** denotes P < 0.0001. 
 
Supplemental material 
 Supplemental material for CHAPTER 3 can be found in APPENDIX B or at 
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0044638#s5> and 
<http://nar.oxfordjournals.org/content/suppl/2012/07/26/gks751.DC1/nar-01176-met-k-2012-
File007.pdf>.  
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CHAPTER 4 
 
Genome-wide Codon Replacement Using Synthetic Oligonucleotides and 
Engineered Conjugation 
 
 
 
 
 
This chapter is reproduced with permission from its initial publication and with minor 
corrections: 
 
Isaacs FJ
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, Carr PA
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, Wang HH
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, Lajoie MJ, Sterling B, Kraal L, Tolonen AC, Gianoulis TA, 
Goodman DB, Reppas NB, Emig CJ, Bang D, Hwang SJ, Jewett MC, Jacobson JM, Church GM 
(2011) Genome-wide Codon Replacement Using Synthetic Oligonucleotides and Engineered 
Conjugation. Science: 333, 348-353. 
 
For clarity and consistency, all mentions of TAG and TAA codons have been changed to UAG 
and UAA. 
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Abstract 
 We present genome engineering technologies that are capable of fundamentally 
reengineering genomes from the nucleotide to the megabase scale. We used multiplex automated 
genome engineering (MAGE) to site-specifically replace all 314 UAG stop codons with 
synonymous UAA codons in parallel across 32 Escherichia coli strains. This approach allowed 
us to measure individual recombination frequencies, confirm viability for each modification, and 
identify associated phenotypes. We developed hierarchical conjugative assembly genome 
engineering (CAGE) to merge these sets of codon modifications into genomes with 80 precise 
changes, which demonstrate that these synonymous codon substitutions can be combined into 
higher-order strains without synthetic lethal effects. Our methods treat the chromosome as both 
an editable and an evolvable template, permitting the exploration of vast genetic landscapes. 
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Introduction 
The conservation of the genetic code, with minor exceptions (1), enables exchange of 
gene function among species, with viruses, and across ecosystems. Experiments involving 
fundamental changes to the genetic code could substantially enhance our understanding of the 
origins of the canonical code and could reveal new subtleties of how genetic information is 
encoded and exchanged (1, 2). Modifying the canonical genetic code could also lead to 
orthogonal biological systems with new properties. For instance, a new genetic code could 
prevent the correct translation of exogenous genetic material and lead to the creation of virus-
resistant organisms. Additionally, a recoded genome could enhance the incorporation of 
unnatural amino acids into proteins, because existing suppressor systems must compete with 
native translation factors (3-5). 
The construction of a new genetic code requires methods to manipulate living organisms 
at a whole-genome scale. Such methods are only now becoming attainable through the advent of 
advanced tools for synthesizing, manipulating, and recombining DNA (6). This has led to a 
number of impressive genome-scale studies, which include removing transposable elements (7), 
refactoring phage genomes (8), genome merging (9), whole-genome synthesis (10), and 
transplantation (11). Whole-genome de novo synthesis offers the ability to create new genomes 
without a physical template. Its main limitations are the cost of accurate in vitro DNA assembly 
and introduction of synthetic DNA into organisms (12). For this reason, de novo synthesis is 
chosen when trying to create a small number of new DNA constructs of modest size (<10 kb) 
and high fidelity (8, 10, 12, 13). Notably, however, the digital template used in de novo synthesis 
currently originates almost exclusively from sequences found in nature or minor variants thereof.  
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Redesigned genomes require approaches that reconcile the desired biological behavior 
with challenges inherent to biological complexity. Engineering biological systems can be 
unpredictable, as a single misplaced or misdesigned allele can be lethal. To address these 
challenges, we have developed approaches that integrate synthetic DNA and recombination 
methods to introduce genome-wide changes dynamically in living cells, thereby engineering the 
genome through viable intermediates. In recent work, we developed multiplex automated 
genome engineering (MAGE), which rapidly generates genetic diversity for strain and pathway 
engineering (14). To augment MAGE’s ability to introduce nucleotidescale mutations across the 
genome, a complementary method was required to assemble modified chromosomes in vivo. 
Here, we report the development of a hierarchical conjugative assembly genome 
engineering (CAGE) method and its integration with MAGE toward reengineering the canonical 
genetic code of E. coli (Figure 4-1) – an organism with broad utility in basic and applied 
research. The E. coli genetic code contains three stop codons (UAG, UAA, and UGA) whose 
translation termination is mediated by two release factors, RF1 and RF2. RF1 recognizes the 
termination codons UAA and UAG, whereas RF2 recognizes UAA and UGA. We hypothesized 
that replacing all UAG codons with synonymous UAA codons would abolish genetic 
dependence on RF1 and permit the newly reassigned UAA codons to be recognized by RF2. This 
will enable us to test and leverage the redundancy of the genetic code by deleting RF1 (ΔprfA), 
providing a blank UAG codon that could be cleanly reassigned to new function. Given that 
codon utilization bias has been shown to affect translation efficiency (15, 16) and viral 
infectivity (13), we sought to determine whether E. coli could maintain viability with the 
systematic replacement of the 314 UAG codons.  
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Figure 4-1. Strategy for reassigning all 314 UAG codons to UAA in E. coli. First, the genome was split into 32 
regions each containing 10 UAG stop codons. In parallel, MAGE was used to execute all 10 UAG::UAA codon 
modifications in a single strain for each genomic region. These partially recoded strains were paired such that a 
targeted genomic region of one strain (donor) was strategically transferred into a second strain (recipient), 
permitting the hierarchical consolidation of modified genomic regions using CAGE (see Figure 4-4A). This five-
stage process transfers genomic fragments ranging in size from ~154 kb to ~2.3 Mb in a controlled manner until a 
single recoded strain is constructed that lacks the UAG stop codon throughout. Thus far, 28 of 31 conjugations have 
been completed, where the dotted arrows denote outstanding conjugation steps and dotted genomes represent half- 
and full-genome strains that have not yet been completed. Once all UAG codons have been converted to UAA, the 
prfA gene will be deleted to inactivate UAG translational termination.  
 
Results and Discussion 
On the basis of the MG1655 genome annotation, we identified 314 E. coli genes that 
contain the UAG stop codon (Figure S4-1 and Table S4-1). We focused initially on reassigning 
all 314 stop codons (UAG) to the synonymous stop codon (UAA) in a modified E. coli MG1655 
strain {EcNR2: E. coli MG1655 Δ(ybhB-bioAB)::[λ cI857 Δ(cro-ea59)::tetR-bla] ΔmutS::cat}. A 
mismatch repair deficient (ΔmutS) strain was used to achieve high-frequency allelic replacement 
(17). We used MAGE to simultaneously introduce subsets of the UAG-to-UAA codon changes 
into 32 separate strains (Figure 4-1). Specifically, the EcNR2 genome was divided into 32 
regions; 31 of these contained 10 targets, and the other contained the remaining four targets. This 
division was pursued for four reasons. First, pilot experiments (Figure S4-2) and associated 
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computational predictions showed that the use of pools of 10 or more oligonucleotides (oligos) 
for MAGE (14) achieves highly efficient allelic replacement. Second, limiting the number of 
MAGE cycles for codon conversions minimizes the total number of cell divisions (six to eight 
per cycle) in the presence of λ red proteins (which promote recombination and are mutagenic) 
and deficient mismatch repair (MMR) (18). This reduces the number of undesired secondary 
mutations. Third, the use of smaller oligo pools enabled rapid accumulation of the desired codon 
conversions in parallel and quantitative measurements of conversion frequencies. Finally, we 
anticipated that certain codons might be recalcitrant to codon conversion or cause an aberrant 
phenotype, so it was advantageous to test mutations in small subsets. Candidates included 43 
essential genes (19) that are terminated by UAG (Figure S4-1) and 39 genes in which the UAG 
stop codon overlaps a second reading frame (Table S4-2). Thus, parallel allelic replacement 
across the 32 regions in separate strains would enable rapid identification of potentially 
troublesome alleles. 
The 314 oligonucleotides encoding the specified UAG-to-UAA codon mutations (Table 
S4-3) were computationally designed by means of a software tool (optMAGE, 
http://arep.med.harvard.edu/optMAGE) on the basis of prior MAGE optimization experiments 
(14). These oligos were repeatedly applied over 18 MAGE cycles to introduce the codon 
replacements across 32 cultures (10 targets per culture). We developed two methods based on 
mismatch amplification mutation assay polymerase chain reaction (MAMA-PCR) (20) to quickly 
assay target codons. Multiplex allele specific colony quantitative PCR (MASC-qPCR) (21) 
(Figure S4-3) was used to identify clones that contain the greatest number of codon conversions, 
and multiplex allele specific colony PCR (MASC-PCR) (21) (Figure S4-4) was used to measure 
frequencies of allele replacement at each targeted position. MASC-PCR permitted simultaneous 
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single–base pair (1 bp) measurements (UAG versus UAA) at 10 chromosomal sites per clone 
(Figure S4-4).  
After 18 MAGE cycles, allelic replacement frequencies were analyzed for all 314 UAG-
to-UAA mutations (Figure 4-2) in 1504 clones (47 clones for each of the 32 recoded segments). 
Allelic replacement frequencies exhibited a high degree of variability among the targets (Figure 
4-2, outer ring; Table S4-4). The average allelic replacement frequency observed was 37 ± 19% 
after 18 cycles, and 42% of the population was unconverted after 18 cycles; we observed 1 to 10 
converted alleles per clone across the remaining population (Figure 4-3A). These measurements 
suggest the evolution of two types of cells 
in our mixed cultures: one that appears 
largely resistant to allelic replacements, 
and another that readily permits them. 
With this knowledge, future MAGE 
methodology could be modified to select 
highly recombinogenic clones after fewer 
cycles (e.g., 5 versus 18). Notably, 
comparable distributions of allelic 
replacement frequencies were observed 
for UAG codons present in essential 
genes, codons overlapping a second 
reading frame, and codons distributed at 
various positions throughout both 
replicating arms (Table S4-5). Moreover, 
Figure 4-2. Frequency map of oligo-mediated UAG::UAA 
codon replacements and genetic marker integrations across the 
E. coli genome at each replacement position. Circular map 
illustrates (from inner circle outward): (i) frequency of 
dsDNA selectable marker integrations; (ii) genome 
coordinates (in Mb): position of origin (Ori) and terminus 
(Term) and direction of the two replication forks (R1 and R2); 
(iii) location of the 32 targeted chromosomal segments; and 
(iv) frequency of UAG::UAA replacements across all UAG 
codons—after 18 MAGE cycles—denoted by height- and 
color-coded bars (scale bar indicates integration frequency). 
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Figure 4-3.  Clonal rate and distribution of genome modifications 
after 18 cycles of MAGE. (A) Histogram of the frequencies of 
clones containing 1 to 10 conversions found among 1504 clones 
screened. A Poisson fit is shown (solid yellow line) for a 
subpopulation that excludes the zero-conversion group. (B) 
Distribution of modifications among the group of top clones (one 
for each of the 31 groups of 10 targeted modifications; one 
additional strain not shown had conversion at all four codon 
sites). (C) Distribution of the 314 90-mer oligos by their extent of 
total secondary sequence similarity to the E. coli genome. Inset 
box plot: Oligos with a mistarget score of more than 600 bp 
show, on average, a 32% decrease in allelic replacement (AR) 
frequency relative to oligos scoring less than 600 bp (25.6% 
versus 37.6%, P < 0.003). 
allelic replacement frequencies did not correlate with 
distance from the origin of replication (oriC), nor 
with recombination hotspots [e.g., Chi-sites, DNA 
motifs (5′-GCTGGTGG-3′) in the genome where 
homologous recombination could be enhanced] or 
direction and level of transcription.  
All individual UAG-to-UAA conversions 
were observed, indicating that no UAG stop codon in 
E. coli is required for survival or robust growth. Of 
314 codon targets, 298 could be assayed using 
MASC-PCR, whereas the remaining modifications 
were confirmed by direct DNA sequencing. By screening to identify maximally modified cells 
(Figure 4-3B, 5 to 10 modifications per clone with a median of 8) and minimizing aberrant 
phenotypes (i.e., auxotrophy, decreased fitness) across 1504 clones, we isolated the top clone 
from each of the 32 populations after 18 MAGE cycles. These clones collectively accumulated 
246 of 314 (78%) desired mutations after 18 MAGE cycles. Clones that did not contain all of the 
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codon changes were subjected to an additional 6 to 15 MAGE cycles to convert the remaining 
UAG codons.  
Given that λ Red facilitates highly efficient recombination using short regions of 
complementary sequences, it was important to assess the potential effects of oligonucleotide 
hybridization to other (unintended) regions of the genome. We found that 90-mer oligos that 
have multiple regions of high sequence similarity throughout the genome have a reduced 
recombination frequency (Figure 4-3C) but that these oligos rarely cause mutagenesis at those 
other locations (see below). To estimate this effect quantitatively, we performed BLAST 
alignments of each oligo against the entire genome. To compute a mistarget score, we summed 
the lengths of the BLAST matches for each oligo sequence against the rest of the E. coli genome 
(blastn, word size = 11, expectation value =10). Although the majority of oligos (~270) showed 
only minor sequence similarity to the genome (mistarget score < 600), we found that the score 
strongly correlated with the frequency of allelic replacement (Figure 4-3C). Recombination 
frequencies were decreased by more than 30% for oligos having many regions of high sequence 
similarity in the genome (mistarget scores > 600 bp; P < 0.003). This information will be useful 
as a predictor of allele replacement frequency for future oligo designs and can be incorporated 
into automated design software such as optMAGE. 
To directly verify the presence of codon conversions and to obtain a snapshot of 
secondary mutations accumulated during the MAGE process, we performed Sanger sequencing 
of ~300 bp surrounding each modified UAG replacement site (96 kb overall, ~3 kb in each of the 
32 top strains). Sequencing confirmed the accuracy of our MASC-PCR method and verified the 
16 UAG-to-UAA conversions not detected by this assay. Background mutations outside of the 
90 bp regions targeted by MAGE oligos consisted of 6 substitutions, 0 insertions, and 3 
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deletions; in contrast, mutations within the targeted regions included 4 substitutions, 1 insertion, 
and 28 deletions (Figure S4-5). The use of a MMR-deficient (ΔmutS) strain rendered the 
expected bias toward substitution mutations in the nontargeted regions. Deletion mutations are 
probably enriched in oligo-targeted regions because internal deletions are common errors in 
many oligonucleotide chemical synthesis processes (22, 23). We have developed strategies to 
minimize both sources of error: (i) optimized oligo synthesis to reduce deletions (e.g., Figure S4-
7), and (ii) the use of chemically modified oligos that are not recognized by MMR to achieve 
efficient allelic replacement in the presence of a functional MMR pathway.  
Because we initially performed codon changes in small subsets, we could easily identify 
candidate mutations that lead to aberrant phenotypes. Growth rates across all 32 top strains 
(Figure S4-6 and Table S4-6, average of 47 min per doubling) showed modest deviations from 
the growth rate of the ancestral strain (42 min per doubling). These changes in growth could be 
attributed to either the codon changes or the accumulation of secondary mutations in our MMR-
deficient strain. Additional phenotypic assays showed a sustained high recombination frequency 
and a 2.8% frequency of auxotrophy on minimal M9–glucose minimal medium after ~366 
generations (Table S4-6). These values compare favorably to previous studies (24) in which 
serial passage of a ΔmutS strain resulted in 9% frequency of auxotrophy after ~250 generations. 
After converting all UAG codons to UAA across 32 E. coli strains, we initiated a five-
stage hierarchical assembly (Figure 4-1 and Table S4-7) of the modified chromosomal segments 
into a single strain (Figure 4-4). To accomplish this, we developed the hierarchical CAGE 
method, which is rooted in conjugation, a key mechanism for gene transfer in bacteria (25, 26). 
In contrast to natural mechanisms of conjugal DNA transfer where the oriT sequence and 
conjugal factors act as a contiguous genetic construct, our approach physically decouples the 
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episomally expressed conjugal factors from the chromosomally integrated oriT sequence. The 
oriT sequence is fused with a kanamycin resistance gene (oriT-kan) so that it can be easily 
integrated into any permissible locus across the E. coli genome via λ Red–mediated double-
stranded DNA (dsDNA) recombination (27). Thus, we can precisely control the genomic 
Figure 4-4.  Hierarchical CAGE methodology for controlled genome transfer. (A) Two pairs of strains illustrate 
the design and methodology of CAGE, with recoded genomic regions in red. Partially recoded strains are split 
into conjugation pairs. The donor strain (D) contains the following: oriT-kan cassette (O, blue triangle); positive 
selection gene (Pn, n = 1, 2, or 3, black rectangle); and pRK24 (F
+). The recipient strain (R) contains the 
following: positive-negative selection gene (PN) and Pn, flanking its recoded region. DNA transfer is initiated at 
O in the donor genome, ensuring transfer of the desired codon mutations and downstream Pn. After conjugation, a 
specific set of three simultaneous selections is applied to yield a recombinant strain that contains the recoded 
genomic fragment from the donor strain while retaining the other recoded region in the recipient genome. 
Placement of the PN marker downstream of the oriT sequence in the recipient genome ensures that the entire 
desired region of the donor genome is inherited in the recombinant strain. All conjugation factors are maintained 
episomally on pRK24, so only a ~2 kb oriT-kan sequence must be inserted onto the genome to generate a highly 
controllable Hfr donor strain. Because there is no scar between the two recoded regions from the conjugation 
parents, only one recombination is required to insert the O (donor) or PN (recipient) directly into Pn for the next 
round of conjugation. This conjugation assembly selection strategy is implemented in five stages to merge the 
genomes of 32 recoded strains into a single strain (see Figure 4-1). (B) Genome transfer frequency as a function 
of the distance from O. Plots of two conjugations of genome segments illustrating the transfer of ~120 kb with 
positive and negative selection (blue) and ~360 kb with only positive selection (green) to assemble recoded 
genomic DNA from donor and recipient genomes. (C and D) MASC-PCR images of UAA alleles transferred 
under positive selection alone (C) and positive and positive-negative selection (D). Yellow arrows indicate the 
genomic point of transfer, which illustrate the inheritance of the donor UAA alleles in the conjugated strain. 
UAG and UAA codons are assayed with primers that utilize 3’ TAG and TAA DNA sequences, respectively. 
98 
 
position at which conjugal transfer is initiated (Figure 4-4A). This strategy allowed us to use a 
tractable ~2 kb cassette in place of a cumbersome 30 kb Hfr fragment for consecutive 
manipulations throughout the genome. 
Before conjugation, we converted the 32 strains that collectively contain all UAG-to-
UAA modifications into 16 pairs of strains primed for large-scale genome transfer (Figure 4-1). 
Within each conjugation pair, a donor strain transfers its recoded genomic region to a recipient 
strain, which inherits the donor genome and retains its recoded genomic region. Genome transfer 
is controlled by the precise placement of positive and positive-negative selectable markers 
integrated with an engineered conjugation strategy to obtain the desired recombinant genomes. 
Precise placement of these markers into “safe insertion regions” (SIRs: intergenic regions that 
are not annotated for any coding or regulatory function) by dsDNA recombination (27) was 
intended to maintain genomic integrity and to attain the desired combination of recoded donor 
and recipient genomes in the recombinant strain (Figure 4-4A). In total, two genetic markers 
were inserted into each of the donor and recipient strains, yielding a total of 64 markers across 
the 32 modified strains. In the donor strain, the recoded region was flanked by an upstream oriT-
kan cassette and a downstream positive selectable marker (P1, e.g., zeo
R
, spec
R
, gent
R
). In the 
recipient strain, the recoded region was flanked with a different positive selectable marker (P2) 
and a positive-negative selectable marker (PN) such as tolC (28) or galK (29). The frequencies of 
integration among selectable marker cassettes exhibited a high degree of site-specific variability 
(Figure 4-2, inner ring). On average, 59 clones (~10
-6
 frequency) were observed per 
recombination. However, dsDNA recombination frequencies spanned >3 logs across 81 
integration sites tested. Twelve intergenic sites yielded no observable recombinants despite 
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repeated (three or more) attempts. The remaining 69 sites performed as follows: 23 sites at ~10
-7
, 
38 sites at ~10
-6
, and 8 sites at ~10
-5
 recombination frequencies. 
Placement of complementary selectable markers across all 32 strains served as anchor 
points that enabled hierarchical assembly of recoded genomic fragments. By design, this permits 
the use of modular oriT-kan and tolC cassettes throughout the assembly process. Rather than 
having to prepare a cassette for each SIR, three oriT-kan cassettes and three tolC cassettes that 
insert directly into the three positive markers (zeo
R
, spec
R
, and gent
R
 genes) are sufficient to 
guide the remaining four stages of hierarchical assembly. Because oriT-kan and tolC are not 
inherited by the recipient strain, each strain can be prepared for subsequent conjugations by 
simply inserting an oriT-kan (donor) or a PN (recipient) directly into one of the strain’s inherited 
positive markers (Figure 4-4A). 
In the first stage of the hierarchical conjugation strategy (Figure 4-1 and Table S4-7), 32 
strains each containing 10 codon modifications were merged to produce 16 strains with 20 
modifications. Transfer of 1/32 of the genome (~150 kb) occurs at a frequency of ~10
-4
 (Figure 
4-4B), 2 logs greater than half-genome transfer (21). This result supports prior findings that the 
probability of transferring a specific marker decreases exponentially with its distance from oriT 
(26). The relationship between genome transfer efficiency and the distance from oriT revealed 
useful parameters for designing our engineered conjugation scheme. In the absence of a positive-
negativemarker in the recipient strain, MASC-PCR analysis showed reduced transfer frequency 
from loci that are in close proximity (<10 kb) to oriT, resulting in the uncontrolled transfer of the 
donor genome—specifically, the loss of mutated UAA codons from the donor genome and the 
retention of one to four UAG codons from the recipient genome (Figure 4-4C). Upon the 
inclusion of a positive-negative marker [e.g., tolC (28), galK (29)] in the recipient genome, 
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desired postconjugal strains were readily selected; that is, full transfer of mutated UAA codons 
from the donor genome was achieved by selecting for the loss of tolC or galK placed among the 
UAG codons in the recipient genome (Figure 4-4D). Together, these results demonstrate the 
requirement for robust positive and positive-negative selectable markers that strategically flank 
the recoded genomes in the donor and recipient strains (Figure 4-4A). Moreover, MASC-PCR 
analysis across all codon loci shows that conjugation efficiency is sustained throughout the 
region of transfer, indicating contiguous transfer of the donor genomic fragment. 
Using CAGE, we then consolidated the 32 original strains into eight recoded strains, each 
with 1/8 of the genome recoded. Two of these eight strains exhibited a dysfunctional tolC 
phenotype (i.e., they simultaneously passed both positive and negative tolC selections). Although 
mutations conferring simultaneous novobiocin sensitivity and colicin E1 resistance have been 
identified (28), there is no literature precedence for the phenotype that we observed. We have 
discovered two routes to this phenotype. In one strain, the causative allele was present in tolC, 
and we corrected the phenotype by replacing the dysfunctional copy with a functional one. In the 
other strain, the causative allele appears to be outside of tolC. Indeed, tolC works in concert with 
a number of other genes (e.g., btuB, tolA, tolQ, and tolR) that have been implicated in 
dysfunctional negative selection (30). Recognizing that the ancestral strains also carried the 
dysfunctional allele, we reconstructed this1/8th strain using MAGE, and used it to complete the 
full set of 1/4 genomes (28 of 31 conjugations).These four strains, which contain up to 80 
modifications per genome, can be combined to complete the assembly of a fully recoded strain 
containing all 314 UAG-to-UAA codon conversions. 
In light of the challenges arising from spontaneous point mutations, we sought to assess 
the effects of MAGE and CAGE on genome stability. Therefore, we performed whole-genome 
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sequencing for the two dysfunctional strains and an additional functional control (Figures S4-8 
and S4-9 and Tables S4-8 to S4-11). These strains have 110, 102, and 128 secondary mutations, 
respectively [total number of single-nucleotide polymorphisms (SNPs) and indels; Figure S4-8]. 
After ~960 cell divisions (Table S4-11), the majority of SNPs were transition mutations (98.4% 
transitions and 1.6% transversions; Table S4-9) and the overall background mutation rate was 
2.5 × 10
-8
 per bp per replication (1 error per genome per ~9 replications; Table S4-10). These 
results are consistent with a ΔmutS phenotype (31). Our measured error rate was lower than we 
expected, given that the cumulative potential mutations include contributions from a MMR-
deficient strain, repeated exposure to induction of the λ Red recombination system, and 
conjugation-based genomic manipulations. A mechanistic hypothesis for the lower error rate is 
that the conjugation process acts as a backcross and removes deleterious secondary mutations 
through the isolation of clones that maximize fitness. To examine this idea further, we explored 
the potential functional consequences of these SNPs as indicated by the COG category of the 
gene or regulatory region associated with the SNP (32-34).We used a hypergeometric 
distribution to determine the enrichment level of the three main COG categories across all three 
strains. Both SNPs associated with metabolism (117 SNPs, P < 0.0004) and SNPs associated 
with information storage and processing (29 SNPs, P < 0.05) were shown to be significantly 
enriched, whereas SNPs associated with cell signaling and transduction (98 SNPs, P > 0.05) 
were not (Figure S4-9). Future work will be needed to sequence additional strains throughout the 
ancestral conjugation tree to characterize the frequency, inheritance patterns, and functional bias 
of such mutations. 
 
Discussion 
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This study, which integrates in vivo genome engineering from the nucleotide to the 
megabase scale, demonstrates the successful replacement of all genomic occurrences of the UAG 
stop codon in the E. coli genome. We found that cells can incorporate all individual UAG-to-
UAA codon changes, and that these changes can be assembled into genomes with up to 80 
modifications with mild phenotypic consequences. The scarless introduction of codon changes 
via MAGE enabled the first genome-wide allelic replacement frequency map using single-
stranded DNA oligos in E. coli (Figure 4-2). In addition, our engineered conjugation experiments 
produced a complementary recombination frequency map of intergenic dsDNA integration sites 
across the genome (Figure 4-2). Together, these experiments revealed both highly accessible and 
recalcitrant sites for both small- and large-scale chromosomal modifications. These data could 
serve as valuable resources for future genome engineering efforts. Moreover, synthetic 
approaches such as the one pursued here may help to refine the existing genome annotation by 
revealing unannotated functional genetic loci, such as short peptides (35) or minigenes (36). 
Introducing genome-wide changes dynamically in a living cell permits engineering in the 
cell’s native biological context. In contrast to in vitro genome synthesis (10) and transplantation 
methods (12) that introduce discrete and abrupt changes in a single genome, our genome 
engineering technologies treat the chromosome as an editable and evolvable template and 
generate targeted and combinatorial modifications across many (~10
9
) genomes in vivo (14). 
MAGE is optimal for introducing small modifications in sequence design space, whereas CAGE 
is designed for taking bigger leaps via large-scale assembly of many modified genomes. 
Together, these genome editing methods are advantageous when the designed genomes share 
>90% sequence similarity to existing templates or when many targeted mutations dispersed 
across the chromosome are desired (e.g., genome recoding). 
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Materials and Methods 
Strains and Culture Conditions: The λ prophage was obtained from strain DY330 (27), 
modified to include the bla gene and introduced into wild-type MG1655 E.coli by P1 
transduction at the bioA/bioB gene locus and selected on ampicillin to yield the strain EcNR1 (λ 
Red
+
). Replacement of mutS with the chloramphenicol resistance gene (chloramphenicol acetyl 
transferase, cat) in EcNR1 produced EcNR2 (mutS
-, λ Red+). EcNR2 was grown in low salt LB-
Lennox medium (LB
L
; 10 g tryptone, 5 g yeast extract, 5 g NaCl in 1 L dH2O) for optimal 
electroporation efficiency and compatibility with zeocin selection. EcNR2 was used as the 
ancestral strain for all recoded strains reported in this manuscript.  
Oligonucleotides: All oligonucleotides were obtained from Integrated DNA 
Technologies. Oligonucleotides (Table S4-3) used in the MAGE process were designed 
according to the following specifications: 1) 90 nucleotides in length, 2) contain a single 
mutation to effect the UAG to UAA codon conversion, 3) two phosphorothioate linkages at both 
the 5' and 3' ends to attenuate exonuclease activity and to increase half-life, 4) minimize 
secondary structure (ΔG threshold values, self-folding energy), 5) target lagging strand at the 
replication fork. No additional purification was used following oligonucleotide synthesis. 
Primers were purchased from IDT for the multiplex PCR assays and loci sequencing reactions 
(see description below and Tables S4-12 and S4-13).  
MAGE-generated Codon Conversions: A single clone of the EcNR2 strain was grown 
in liquid cell culture, which was used to inoculate 32 separate cultures for parallel modification 
of all UAG codons. Modification of these codons was achieved through continuous MAGE (14) 
cycling. Each culture was grown at 30°C to mid-logarithmic growth (i.e., OD600 of ~0.7) in a 
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rotor drum at 200 RPM. To induce expression of the λ Red recombination proteins (Exo, Beta 
and Gam), cell cultures were shifted to a 42 °C water bath with vigorous shaking for 15 min and 
then immediately chilled on ice. In a 4 °C environment, 1 mL of cell culture was centrifuged at 
16,000x g for 30 seconds. Supernatant media was removed and cells were re-suspended in 1 mL 
dH2O (Gibco cat# 15230). This wash process was repeated. Supernatant water was removed, and 
the pellet was re-suspended in the appropriate pool of 10 oligos (1 uM per MAGE oligo in 50 uL 
dH2O). The re-suspended oligos/cell mixture was transferred to a pre-chilled 96-well, 2 mm gap 
electroporation plate (BTX, USA) and electroporated with a BTX electroporation system using 
the following parameters: 2.5 kV, 200 Ω, and 25 μF. The electroporated cells were immediately 
transferred to 3 mL of LB
L
 media for recovery. Recovery cultures were grown at 30 °C in a 
rotator drum for 2-2.5 hours. Once cells reached mid-logarithmic growth they proceeded to the 
next MAGE cycle. This approach introduces genomic modifications while allowing cells to 
evolve and adapt to those changes. Moreover, this approach is designed to explore extensive 
genotype and phenotype landscapes by creating combinatorial genomic variants that leverage the 
size of the cell population. After 18 MAGE cycles, cells from each population were isolated on 
LB
L
 agar plates. Forty-seven clones from each of the 32 cycled populations were selected and 
subjected to genotype and phenotype analyses. From each population the clone with the greatest 
number of modifications (an average of 8 modifications per clone) and minimal aberrant 
phenotypes (i.e., auxotrophy, decreased fitness) was selected. Further MAGE cycles were 
employed (typically 6 cycles, but in some cases up to 15) to yield strains with complete sets of 
10 targeted modifications.  
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Genotype Analyses: UAG-to-UAA codon conversions were analyzed using three main 
methods: 1) Multiplex allele specific colony PCR (MASC-PCR), 2) Multiplex allele specific 
colony quantitative PCR (MASC-qPCR) and 3) Sanger DNA sequencing.  
Multiplex Allele Specific Colony PCR (MASC-PCR): Based on previously described 
allele-specific PCR techniques, we developed the MASC-PCR method to test for UAG-to-UAA 
codon conversion in our recoded strains (the ancestral EcNR2 strain was the negative control). 
Three primers were designed for each locus: 1) a forward primer for the UAG sequence, 2) a 
forward primer for the UAA sequence and 3) a reverse primer compatible with both forward 
primers (Table S4-12). Primers were designed for a target Tm of 62 °C. The two forward primers 
were identical except that the most 3' nucleotide hybridized to produce either a GC base pair for 
the wildtype (UAG) codon or an AT base pair for the mutant (UAA) codon. Thus, every clone 
from each of the 32 populations was interrogated via two MASC-PCR reactions, in which each 
reaction assayed 10 different loci (with one set assaying four loci). One reaction assayed the 
wild-type (UAG) sequence and a second reaction assayed the mutant (UAA) sequence, yielding 
two binary reactions that revealed the sequences of the targeted codons (Figure S4-4). A clone 
containing the mutant allele generated PCR products only using the mutant allele primers and not 
the WT primers and vice versa for a clone with the wild-type allele. To minimize nonspecific 
amplification of MASC-PCR primers, a gradient PCR was performed to experimentally 
determine the optimal annealing temperature for each MASC-PCR primer pool (typically 
between 64 – 67 °C). Multiple loci were queried in a single PCR reaction using the multiplex 
PCR master mix kit from Qiagen. Each MASC-PCR primer set produced amplicon lengths of 
100, 150, 200, 250, 300, 400, 500, 600, 700, or 850 bps, corresponding to up to 10 different 
genomic loci. We found that using a 1:50 dilution of saturated clonal culture in water as template 
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generated the best MASC-PCR specificity. Typical 20 uL MASC-PCR reactions included 10uL 
2x Qiagen multiplex PCR master mix, 0.2 uM of each primer, and 1 uL of template. MASC-PCR 
cycles were conducted as follows: polymerase heat activation and cell lysis for 15 min at 95 °C, 
denaturing for 30 sec at 94 °C, annealing for 30 sec at experimentally determined optimal 
temperature (64 – 67 °C), extension for 80 sec at 72 °C, repeated cycling 26 times, and final 
extension for 5 min at 72 °C. Gel electrophoresis on a 1.5% agarose gel (0.5x TBE) produced the 
best separation for a 10-plex MASC-PCR reaction. (See Figure S4-4 for representative gel 
picture of MASC-PCR reaction).  
Mulitplex allele-specific quantitative colony PCR (MASC-qPCR): In complement to 
MASC-PCR analyses, we also developed a highly multiplexed quantitative PCR screen to 
rapidly identify highly modified clones (Figure S4-3). Typical multiplexed qPCR reactions 
employ multiple fluorescence and distinct detection events to assess multiple PCR reactions in 
one sample, and are generally limited by the available optics and fluorescence to 4 channels. 
Instead, we needed a robust, economical test that employed many different non-optimized 
primers, did not require more expensive fluorescently labeled oligos, and would work for 10-
plex reactions. We accomplished these goals with SYBR Green I detection, which gauges the 
total amount of DNA produced in the reaction. Two qPCR reactions were compared for each 
clone evaluated, one with 10 pairs of primers matched to the unmodified UAG genes, and the 
other with 10 primer pairs matched to the intended UAA modifications. The UAG reactions were 
expected to proceed most efficiently with a wild-type template, and the UAA reactions most 
efficiently with a fully modified template. Intermediate values between these extremes also 
provided an effective, though nonlinear gauge of the extent of modification for each clone 
(Figure S4-3A-C).  
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Each colony was used as template for a pair of qPCR reactions comparing the 
amplification efficiency when matched to primers terminating in wild-type or targeted mutant 
sequence. The experimental measurement for a given clone is then compared to the equivalent 
values measured for the unmodified starting (negative control) strain. This reference value is 
subtracted from each ΔCt to yield a ΔΔCt, with unmodified clones scoring close to zero (as with 
the negative control colonies). The largest ΔΔCt values were expected to indicate the most 
modified clones, which we confirmed by genotyping clones with varying ΔΔCt values (Figure 
S4-3C). Large numbers of clones could be quickly assessed using this approach (up to 190 per 
384-well plate, plus 2 negative controls). A typical assessment of MAGE-cycled clones 
comprised of 4 groups per plate, i.e., for each culture targeting 10 modifications, 2-4 control 
colonies and 44-46 queried colonies. After identification of the most promising clones, site-
specific qPCR genotyping  (Figure S4-3D) was used to identify which specific sites had been 
modified, selecting the best clones for further modification.  
Individual bacterial colonies were picked into 0.5 mL sterile distilled deionized water, 
with 5 μL of this suspension used as template in 20 μL qPCR reactions containing 1x NovaTaq 
buffer, 0.5 U NovaTaq Hotstart DNA Polymerase (EMD Biosciences), 250 μM each dNTP, 0.5x 
SYBR Green I (Invitrogen), and 5% DMSO. Primer concentrations were 50 nM for each primer 
(i.e., 500 nM total for10 forward primers and 500 nM total for 10 reverse primers). A typical 
qPCR program included a 10 minute hot start at 95 °C, followed by 40 cycles (95 °C for 30 
seconds, 60 °C for 30 seconds, 72 °C for 30 seconds) finishing with a melt curve analysis. All 
reactions were performed in a 7900 HT system (Applied Biosystems, Inc.). PCR primers for all 
sites were designed to have a melting temperature estimated at 62 °C. Reverse primers were 
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chosen to yield amplicons in the size range of 200-225 bp. No optimization was needed for 
qPCR primer sequences or for multiplex/singleplex reaction conditions.  
Sanger Sequencing of 314 UAG-to-UAA loci: DNA sequencing was employed to 
confirm the results of the above PCR assays and to determine genotypes for 16 sites that gave 
ambiguous results by MASC-PCR. Amplicons 200-300 bp in length surrounding each of the 314 
UAG sites were sequenced from the top-scoring clones by colony PCR as above. Sanger 
sequencing to confirm allelic replacements was performed by Agencourt Bioscience Corporation 
and the Biopolymer Facility in the Department of Genetics at Harvard Medical School. 
Mutations were identified by sequence alignment to the reference MG1655 genome.  
Phenotype Analyses: To ensure that the codon replacements did not introduce any 
significant aberrant phenotypes, we conducted a number of experiments that assessed the fitness 
of the recoded strains. These experiments included measurements of: 1) strain growth rates, 2) 
auxotrophic rates and 3) frequency of recombination. Growth rate measurements were obtained 
by growing replicates of the recoded strains in LB
L
 media in 96-well plates at 30 °C and 
obtaining OD600 measurements using Molecular Devices plate readers (M5 and SpectraMax 
Plus). Auxotrophic rates were obtained by spotting all clonal isolates (1504) from the MAGE-
cycled experiments on M9 minimal media plates (200 mL 5x M9 medium, 1 mL 1 M MgSO4, 5 
mL 40% glucose, 100 μL 0.5% vitamin B1 (thiamine), 1 mL D-biotin (0.25mg/mL), up to 1 L 
water + 15g Agar). The recombination frequency of each isolate was obtained by performing the 
allelic replacement protocol using a lacZ 90-mer oligo that produced a premature stop codon in 
the chromosomal lacZ gene. In general, 250-500 cells were plated on LB
L 
+ Xgal/IPTG (USB 
Biochemicals) agar plates. Frequency of allelic replacement was calculated by dividing the 
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number of white colonies by the total number of colonies on plates. All phenotypic results are 
reported in Table S4-6. 
Hierarchical Conjugation Assembly Genome Engineering (CAGE): Donor and 
recipient strains were grown in 3 mL LB-min containing the appropriate positive selectable 
antibiotics. Once cells reached logarithmic-saturated growth, 2 mL samples of each culture were 
transferred to 2 mL Eppendorf tubes. Cells were washed three times in order to remove 
antibiotics present in the growth cultures. The washing procedure consisted of centrifuging 
samples at 5000 rpm for 2 minutes at room temperature, removing the supernatant, and re-
suspending the cell pellet in fresh LB
L
 containing no antibiotics. After the final wash, the donor 
and recipient pellets were concentrated in 100 μL LBL in order to enhance cell-cell contact 
during conjugation. Conjugation was initiated by combining 80 μL of ~20x concentrated donor 
culture and 20 μL of ~20x concentrated recipient culture. In order to minimize RP2 pilus 
shearing, cells were gently mixed by pipetting. In order to minimize turbulence that can disrupt 
cell-cell contact during conjugation and to maximize genome transfer, the entire 100 μL donor-
recipient mixture was transferred as a series of 2 x 20 μL and 6 x 10 μL spots onto an LBL 
agarose plate lacking antibiotics. This conjugation plate was incubated at 32 °C for 0.5-2 hours, 
then the cells were re-suspended directly off of the plate using 1.5 mL LB
L
 and concentrated into 
a final volume of 250 μL. Desired recombinant genomes were selected by inoculating 5 μL of 
the concentrated post-conjugation culture into LB
L
 containing the correct combination of 
positive selection antibiotics (e.g., 10 μg/mL zeocin, 95 μg/mL spectinomycin, and 7.5 μg/mL 
gentamycin). The conjugated cells that populated the selected culture were then subjected to a 
negative selection using either tolC or galK to ensure proper DNA transfer of UAA codons at 
critical junction points between donor and recipient cells (see Figure 4-4). 
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This engineered conjugation method was tested for the first (1/32 genome, ~143 kb) and 
last (1/2 genome, ~2.3 Mb) chromosomal transfer steps in the hierarchical assembly experiment 
(Figure 4-1). By selecting for different combinations of markers across the donor and recipient 
genomes and subsequent screening of specific genomic loci, recombinant clones were isolated 
that contained the transfer of half or full (otherwise unmodified) genomes at a frequency of ~2.5 
x 10
6
 (from a population of 10
9
-10
10
 cells), indicating the successful DNA transfer from an 
integrated oriT with episomal expression of conjugal factors. Equivalent frequencies were 
observed for full genome transfers. 
Upon completion of the conjugation process, we also observed the anticipated loss of the 
oriT-kan cassette in the recombinant strain. This observation yields a subtle, yet very useful 
feature of our engineered conjugation system. By not inheriting the oriT sequence, the strains are 
positioned to proceed to a subsequent conjugation by a one-step integration of the oriT-kan 
cassette in a new, targeted chromosomal locus (Figure 4-4A). 
Illumina Whole Genome Sequencing: We prepared a paired-end Illumina sequencing 
library for three of the 1/8 genome strains using barcoded Illumina adapters: C21(regions 17-20), 
C22 (21-24), and C23 (25-28). The barcoded library was sequenced on one lane using an 
Illumina GAII. 
Genomic DNA was prepared using a Qiagen Genome Prep kit. The purified gDNA (5 μg) 
was sheared to a target size of 200 bp using a Covaris E210 (estimated median band size 250bp). 
The sheared gDNA was PCR purified using a QIAquick PCR purification kit and end repaired 
(Epicentre End-it
TM
 DNA End-Repair kit). End repair reactions consisted of the DNA sample (35 
μL), 10x End repair buffer (10 μL), 1 mM dNTPs (10 μL), End repair enzyme mix (5 μL), and 
dH2O (40 μL). End repair reactions were incubated at 25 °C for 30 minutes. 
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The end repaired DNA was PCR purified using a QIAquick PCR purification kit and A-
tailed using NEB Klenow Fragment (3'5' exo-). A-tailing was performed with the DNA sample 
(32 μL), Klenow buffer (5 μL), 1 mM dATP (10 μL), and Klenow (3'5' exo-) (3 μL). A-tailing 
reactions were incubated at 37 °C for 30 minutes. 
The A-tailed DNA was purified using a QIAquick PCR purification kit and Illumina PE 
adapters containing 3 bp barcodes (AGC for C21, CTA for C22.DO:T, and TCT for C23) were 
ligated. Ligations consisted of DNA sample (31 μL), 2x Rapid ligase buffer (35 μL), 50 μM 
Illumina PE adapters (2 μL), and Enzymatics Rapid (T4) ligase (2 μL). Ligations were incubated 
at 20 °C for 10 minutes, then buffer PBI was immediately added for PCR purification (QIAquick 
PCR purification kit). 
The adapter-ligated sequencing libraries were gel purified (Qiagen Gel Purification kit) 
using a 2% agarose gel in 0.5x TBE (cut 2 mm bands corresponding to approximately 225 bp). 
The gel-purified DNA was PCR amplified using KAPA HiFi Ready Mix. The PCR reaction 
consisted of 2X KAPA HiFi Ready Mix (25 μL), primer PE_PCR-f (1 μL), primer PE_PCR-r (1 
μL), dH2O (13 μL), and template DNA (4 μL). The PCR reaction was thermocycled as follows: 
95 °C for 5 minutes; 12 cycles of 98 °C for 20 seconds, 62 °C for 15 seconds, and 72 °C for 75 
seconds; 72 °C for 3 minutes. PCR products were purified using QIAquick PCR purification kit 
and validated by cloning using Invitrogen TOPO ZeroBlunt II according to standard protocols. 
The TOPO reactions were transformed into OneShot Top 10 electrocompetent cells, and a subset 
of colonies which were Sanger sequenced by Genewiz (M13 forward sequecing primer = 
GTAAAACGACGGCCAG).  
The sequencing libraries were size-selected for ~225 bp bands (E-Gel® SizeSelect™ 
gels) and PCR purified using Qiagen MinElute columns. The libraries were quantitated by 
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PAGE, using a Low DNA Mass Ladder (Invitrogen), SYBR gold staining, and densitometry on a 
Bio-RAD geldoc.  
The sequencing library was prepared by adding all 3 components (C21, C22.DO:T, and 
C23 sequencing libraries) to a final concentration of 10 nM. Sample QC, Clustering, and 
sequencing were performed by the Harvard Biopolymers Facility using Standard Illumina PE 
Sequencing Primers.  
Genome Sequencing—Read Sorting and Processing: The raw Illumina reads in 
FASTQ format were preprocessed and sorted using the 3-bp barcodes in the paired end adaptors. 
Reads that contained anomalous barcodes were discarded. Reads containing any bases with a 
quality score of 2, also called the Read Segment Quality Control Indicator (based on Illumina 
Quality Scores by Tobia Man), were discarded at this step, but all other reads were kept. After 
preprocessing, all reads were exactly 34 base pairs long.  
Genome Sequencing—Reference-based Assembly: The expected FASTA sequence of 
the EcNR2 parent strain was assembled by manually modifying the FASTA sequence of E. coli 
K-12 strain MG1655 to reflect the removal of mutS and the insertion of the λ prophage into the 
bioAB operon. Next, the preprocessed reads were sorted into separate files by pair group and the 
Burrows-Wheeler Aligner program (BWA) (32) was used to separately align the paired reads 
from each of the three strains to the expected EcNR2 FASTA sequence. The sample algorithm 
was used to align the reads. The distribution of insert sizes was inferred at runtime. During the 
read alignment step of BWA, (the aln command), a value of 10 was used for the suboptimal 
alignment cutoff.  
Genome Sequencing—Indel and SNP Filtering: After alignment, the SAMtools 
package (33) was used to create and sort BAM files for the assemblies. From these BAM files 
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we generated a set of raw SNPs and short indels with respect to this reference assembly. These 
were then filtered using several criteria. First, using the varFilter script within SAMtools, we 
removed SNPs where the root mean squared mapping quality was less than 10, and indels where 
the root mean squared mapping quality was less than 25. We fitted the read coverage of each 
assembly to a gamma distribution and used the 99.95th and 0.05th percentile cutoffs for 
minimum and maximum read depth, beyond which SNPs and indels were discarded. We also 
discarded SNPs within 3 base pairs of a gap, and SNPs that occurred more densely than three 
within one 10 base pair window. 
Genome Sequencing—Region Masking: We used custom scripts to further filter SNPs 
and indels by masking regions of poor assembly. We masked regions containing many truncated 
reads, many incorrect read pairings, many non-unique alignments, and regions with motifs 
known to be problematic in Illumina sequencing (GGCnG). We defined truncated read regions as 
those containing multiple incompletely mapped reads, separated by less than one read length, 
containing at least 4 truncated reads and having a number of truncated reads totaling at least one 
half of the length of the contiguous region in which they were found.  
Regions with incorrect read pairings were defined using the following method. We found 
read pairs whose insert size was outside of the 99.9th and 0.1th percentile of a fitted normal 
distribution of mate pair distance. These reads were counted in a 34 bp rolling window. As a 
thresholding step we chose contiguous regions where 10 or more of these reads were found in 
one window length. Additionally included were contiguous regions where only one read in a pair 
could be mapped, and these were thresholded with a rolling window in a similar fashion, using a 
6 read cutoff. As a final masking step, we removed SNPs stemming from the replacement of 
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amber stop codons as well as SNPs and indels where surrounding context was GGCnC, as these 
regions are known to be hotspots for Illumina sequencing errors.  
Genome Sequencing—Annotation: After removing SNPs and indels in the masked 
regions as described above, we attempted to associate the remaining SNPs and indels with 
functional consequences. We used a modified version of Ensembl’s SNP Effect Predictor 
software (34), and the Ensembl Bacteria database to find SNPs that occurred within genes. We 
further categorized these by synonymous and non-synonymous coding changes, frameshift 
mutations, premature stop mutations, mutations in the 5’ and 3’ UTRs, and mutations less than 
100 base pairs upstream of a transcript start site (Figure S4-8). Coordinates were lifted over from 
ECNR2 to MG1655 to permit annotation of the SNPs and indels. This resulted in C21, C22, and 
C23 having 4, 5, and 5 mutations respectively having no corresponding liftover coordinates in 
ECNR2. These are referred to as the "unmappable" in Figure S4-8. 
 
Supplemental material 
 Supplemental material for CHAPTER 4 can be found in APPENDIX C or at 
<http://www.sciencemag.org/content/suppl/2011/07/13/333.6040.348.DC1/Isaacs.SOM.pdf>.  
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Abstract 
 We describe the construction and characterization of a genomically recoded organism 
(GRO). We replaced all known UAG stop codons in Escherichia coli MG1655 with synonymous 
UAA codons, which permitted the deletion of release factor 1 and reassignment of UAG 
translation function. This GRO exhibited improved properties for incorporation of nonstandard 
amino acids that expand the chemical diversity of proteins in vivo. The GRO also exhibited 
increased resistance to T7 bacteriophage, demonstrating that new genetic codes could enable 
increased viral resistance. 
 
Introduction 
 The conservation of the genetic code permits organisms to share beneficial traits through 
horizontal gene transfer (1), and enables the accurate expression of heterologous genes in 
nonnative organisms (2). However, the common genetic code also allows viruses to hijack host 
translation machinery (3) and compromise cell viability. Additionally, genetically modified 
organisms (GMOs) can release functional DNA into the environment (4). Virus resistance (5) 
and biosafety (6) are among today’s major unsolved problems in biotechnology, and no general 
strategy exists to create genetically isolated or virus-resistant organisms. Furthermore, 
biotechnology has been limited by the 20 amino acids of the canonical genetic code, which use 
all 64 possible triplet codons, limiting efforts to expand the chemical properties of proteins by 
means of  nonstandard amino acids (NSAAs) (7, 8). 
Changing the genetic code could solve these challenges and reveal new principles that 
explain how genetic information is conserved, encoded, and exchanged (Figure S5-1). We 
propose that genomically recoded organisms (GROs, whose codons have been reassigned to 
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create an alternate genetic code) would be genetically isolated from natural organisms and 
viruses, as horizontally transferred genes would be mistranslated, producing nonfunctional 
proteins. Furthermore, GROs could provide dedicated codons to improve the purity and yield of 
NSAA-containing proteins, enabling robust and sustained incorporation of more than 20 amino 
acids as part of the genetic code. 
 
Results 
We constructed a GRO in which all instances of the UAG codon have been removed, 
permitting the deletion of release factor 1 (RF1; terminates translation at UAG and UAA) and, 
hence, eliminating translational termination at UAG codons. This GRO allows us to reintroduce 
UAG codons, along with orthogonal translation machinery [i.e., aminoacyl–tRNA synthetases 
(aaRSs) and tRNAs] (7, 9), to permit efficient and site-specific incorporation of NSAAs into 
proteins (Figure 5-1).  That is, UAG has been transformed from a nonsense codon (terminates 
translation) to a sense codon (incorporates amino acid of choice), provided the appropriate 
translation machinery is present. We selected UAG as our first target for genome-wide codon 
reassignment because UAG is the rarest codon in Escherichia coli MG1655 (321 known 
instances), prior studies (7, 10) demonstrated the feasibility of amino acid incorporation at UAG, 
and a rich collection of translation machinery capable of incorporating NSAAs has been 
developed for UAG (7).  
We used an in vivo genome editing approach (11), which is more efficient than de novo 
genome synthesis at exploring new genotypic landscapes and overcoming genome design flaws. 
Although a single lethal mutation can prevent transplantation of a synthetic genome (12), our 
approach allowed us to harness genetic diversity and evolution to overcome any potential 
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deleterious mutations at a cost considerably less than de 
novo genome synthesis (supplemental text “Time and 
Cost” section). In prior work, we used multiplex 
automated genome engineering [MAGE (13)] to remove 
all known UAG codons in groups of 10 across 32 E. coli 
strains (11), and conjugative assembly genome 
engineering [CAGE (11)] to consolidate these codon 
changes in groups of ~80 across four strains. In this 
work, we overcome technical hurdles (supplemental text) 
to complete the assembly of the GRO and describe the 
biological properties derived from its altered genetic 
code. 
The GRO [C321.ΔA, named for 321 
UAGUAA conversions and deletion of prfA (encodes 
RF1, Table 5-1)] and its RF1
+
 precursor (C321) exhibit 
normal prototrophy and morphology (Figure S5-2) with 
60% increased doubling time compared with E. coli 
MG1655 (Table S5-1). Genome sequencing (GenBank 
accession CP006698) confirmed that all 321 known 
UAGs were removed from its genome and that 355 
additional mutations were acquired during construction 
(10
-8
 mutations per base pair per doubling over ~7340 
doublings; Figure S5-3 and Tables S5-2 to S5-4). 
Figure 5-1. Engineering a GRO with a 
reassigned UAG codon. Wild-type E. 
coli MG1655 has 321 known UAG codons 
that are decoded as translation stops by RF1 
(for UAG and UAA). (1) Remove codons: 
converted all known UAG codons to UAA, 
relieving dependence on RF1 for 
termination. (2) Eliminate natural codon 
function: abolished UAG translational 
termination by deleting RF1, creating a 
blank codon. (3) Expand the genetic code: 
introduced an orthogonal aminoacyl-tRNA 
synthetase (aaRS) and tRNA to reassign 
UAG as a dedicated sense codon capable of 
incorporating nonstandard amino acids 
(NSAAs) with new chemical properties. 
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Although maintaining the E. coli MG1655 genotype was not a primary goal of this work, future 
applications requiring increased genome stability could exploit reversible switching of mutS 
function (14) to reduce off-target mutagenesis. CAGE improved the fitness of several strains in 
the C321 lineage (Figure S5-3), implicating off-target mutations in the reduced fitness.  
C321.ΔA exhibited improved performance compared with previous strategies for UAG 
codon reassignment (15, 16), permitting the complete reassignment of UAG from a stop codon to 
a sense codon capable of incorporating NSAAs into proteins. One previous strategy used a 
variant of release factor 2 (RF2) that exhibits enhanced UAA termination (16) and weak UAG 
termination (17). The second strategy substituted a UAA stop codon in each of the seven 
essential genes naturally terminating with UAG (Table S5-5) and reduced ribosome toxicity by 
efficiently incorporating amino acids at the remaining 314 UAGs (15). For comparative 
purposes, we used MAGE to create strains C0.B*.ΔA::S [expresses enhanced RF2 variant (16)], 
C7.ΔA::S (UAG changed to UAA in seven essential genes), and C13.ΔA::S [UAG changed to 
UAA in seven essential genes plus six nonessential genes (Table S5-5)] (Table 5-1). C refers to 
the number of codon changes, while A and B refer to prfA (RF1) and prfB (RF2) manipulations, 
respectively. In contrast to previous work (15), we deleted RF1 in these strains without 
introducing a UAG suppressor, perhaps because near-cognate suppression is increased in E. coli 
MG1655 (18). Nevertheless, these strains exhibited a strong selective pressure to acquire UAG 
suppressor mutations (see below). 
To assess the fitness effects of RF1 removal and UAG reassignment, we measured the 
doubling time and maximum cell density of each strain (Table S5-1 and Figure S5-4). We found 
that C321 was the only strain for which RF1 removal and UAG reassignment was not deleterious 
(Figure 5-2). Because we did not modify RF2 to enhance UAA termination (16), this confirms 
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that RF1 is essential only for UAG translational 
termination and not for UAA termination or other essential cellular functions. By contrast, RF1 
removal significantly impaired fitness for C0.B*.ΔA::S, and codon reassignment exacerbated 
this effect (Figure 5-2 and Figure S5-5), probably because NSAA incorporation outcompeted the 
weak UAG termination activity (17) exerted by the RF2 variant (16). C7.ΔA::S and C13.ΔA::S 
also exhibited strongly impaired fitness, likely due to more than 300 non-essential UAG codons 
stalling translation in the absence of RF1-mediated translation at UAG codons (15); accordingly, 
p-acetylphenylalanine (pAcF) incorporation partially alleviated this effect (Figure 5-2). 
However, not all NSAAs improved fitness in partially recoded strains; phosphoserine (Sep) 
impairs fitness in similar strains (19), perhaps by causing proteome-scale misfolding. Together, 
these results indicate that only the complete removal of all instances of the UAG codon 
overcomes these deleterious effects; therefore, it may be the only scalable strategy for sustained 
NSAA translation and for complete reassignment of additional codons. 
We tested the capacity of our recoded strains to efficiently incorporate NSAAs [pAcF, p-
azidophenylalanine (pAzF), or 2-naphthalalanine (NapA)] into Green Fluorescent Protein (GFP) 
Figure 5-2. Effects of UAG reassignment at natural 
UAG codons. Ratios of maximum cell densities 
(horizontal axis) and doubling times (vertical axis) 
were determined for RF1+ strains versus their 
corresponding RF1- strains (n = 3) in the presence or 
absence of UAG suppression. Symbol color specifies 
genotype: UAA is the number of UAGUAA 
mutations, and RF2 is “WT” (wild-type) or “sup” 
[RF2 variant that can compensate for RF1 deletion 
(16)]. Symbol shape specifies NSAA expression: 
aaRS (aminoacyl-tRNA synthetase) is “none” (genes 
for UAG reassignment were absent), “-” [pEVOL-
pAcF (9) is present but not induced, so only the 
constitutive aaRS and tRNA are expressed], or “+” 
(pEVOL-pAcF is fully induced using L-arabinose), 
and pAcF is “-” (excluded) or “+” (supplemented). 
Strains that do not rely on RF1 are expected to have a 
RF1+/RF1- ratio at (1,1). RF1- strains exhibiting 
slower growth are below the horizontal gray line, and 
RF1- strains exhibiting lower maximum cell density 
are to the right of the vertical gray line. The doubling 
time error bars are too small to visualize. 
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variants containing zero, one, or three UAG codons (Figure 5-3 
and Figure S5-6). In the presence of NSAAs, the RF1
+
 strains 
efficiently read through variants containing  three UAGs, 
demonstrating that the episomal pEVOL translation system, 
which expresses an aaRS and tRNA that incorporate a NSAA at UAG codons (9), is extremely 
active and strongly outcompetes RF1. In the absence of NSAAs, the RF1
-
 strains exhibited 
detectable amounts of near-cognate suppression (18) of a single UAG. C321.ΔA::S exhibited 
strong expression of UAG-containing GFP variants only in the presence of the correct NSAA, 
whereas C7.ΔA::S and C13.ΔA::S displayed read-through of all three UAG codons even in the 
absence of NSAAs, suggesting efficient incorporation of natural amino acids at native UAGs 
(17). Mass spectrometry indicated that C13.ΔA::S incorporated Gln, Lys, and Tyr at UAG 
codons. DNA sequencing in C7.ΔA::S and C13.ΔA::S revealed UAG suppressor mutations in 
glnV, providing direct genetic evidence of Gln suppression observed by Western blot (Figure 5-
Figure 5-3. NSAA incorporation in GROs. (A) Western blots demonstrate 
that C0.B*.ΔA::S terminates at UAG in the absence of RF1 and that 
C7.ΔA::S and C13.ΔA::S have acquired natural suppressors that allow strong 
NSAA-independent read-through of three UAG codons. When pAcF was 
omitted, one UAG reduced the production of full-length GFP, and three 
UAGs reduced production to undetectable levels for all strains except for 
C7.ΔA::S and C13.ΔA::S, demonstrating that undesired near-cognate 
suppression (18) is weak for most strains even when RF1 is inactivated. 
However, all strains show efficient translation through three UAG codons 
when pAcF is incorporated. Western blots were probed with an antibody to 
GFP that recognizes an N-terminal epitope. UAA is the number of 
UAGUAA mutations; RF2 is “WT” (wild-type) or “sup” [RF2 variant that 
can compensate for RF1 deletion (16)]; RF1 is “WT” (wild-type) or “S” 
(ΔprfA::specR). “GFP” is full-length GFP; “trunc” is truncated GFP from 
UAG termination and is enriched in the insoluble fraction; “ns” indicates a 
non-specific band. (B) Venn diagram representing NSAA-containing 
peptides detected by mass spectrometry in C0.B*.ΔA::S when UAG was 
reassigned to incorporate p-acetylphenylalanine (pAcF, red) or 
phosphoserine (Sep, blue). No NSAA-containing peptides were identified in 
C321.ΔA::S. Asterisk (*) indicates coding DNA sequence possessing two 
tandem UAG codons. (C) Extracted ion chromatograms are shown for UAG 
suppression of the SpeG peptide to investigate Sep incorporation in natural 
proteins. Peptides containing Sep were only observed in C0.B*.ΔA::S, 
C7.ΔA::S, and C13.ΔA::S, as Sep incorporation was below the detection 
limit in EcNR2 (RF1+), and speG was recoded in C321.ΔA::S. 
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3A) and mass spectrometry (Table S5-13). C0.B*.ΔA::S displayed truncated GFP variants 
corresponding with UAG termination in the absence of RF1 (17) (Figure 5-3A).  
We directly investigated the impact of pAcF and Sep incorporation on the proteomes 
(Figure 5-3B) (20) of our panel of strains (Table 5-1) using mass spectrometry (Tables S5-6 to 
S5-12). No Sep-containing peptides were observed for EcNR2, illustrating that RF1 removal is 
necessary for NSAA incorporation by the episomal phosphoserine system (21), which is an 
inefficient orthogonal translation machinery (19) (Figure 5-3C and Table S5-10). By contrast, we 
observed NSAA-containing peptides in unrecoded (C0.B*.ΔA::S) and partially recoded 
(C13.ΔA::S) strains, and not the GRO (C321.ΔA::S), which lacks UAGs in its genome (Figure 
5-3, B and C, Figure S5-7, and Tables S5-6 to S5-12). Such undesired incorporation of NSAAs 
(or natural amino acids) likely underlies the fitness impairments observed for C0.B*.ΔA::S, 
C7.ΔA::S, and C13.ΔA::S. In contrast to the other RF1- strains, C321.ΔA::S demonstrated 
equivalent fitness to its RF1
+
 precursor (Figure 5-2), and efficiently expressed all GFP variants 
without incorporating NSAAs at unintended sites (Figures 5-2, 5-3, and S5-6). Therefore, 
complete UAG removal is the only strategy that provides a devoted codon for plug-and-play 
NSAA incorporation without impairing fitness (Figures 5-2 and 5-3).  
To determine whether this GRO can obstruct viral infection, we challenged RF1
-
 strains 
with bacteriophages T4 and T7. Viruses rely on their host to express proteins necessary for 
propagation. Because hosts with altered genetic codes would mistranslate viral proteins (3), 
recoding may provide a general mechanism for resistance to all natural viruses. Given that UAG 
codons occur rarely and only at the end of genes, we did not expect UAG reassignment to result 
in broad phage resistance. Although the absence of RF1 did not appear to affect T4 (19 of 277 
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stop codons are UAG), it significantly enhanced resistance to T7 (6 of 60 stop codons are UAG) 
(Figure 5-4).  
Table 5-1. Recoded strains and their genotypes 
Strain
a
 
Essential codons 
changed
b
 
Total codons 
changed
c
 
Previously essential codon 
functions manipulated
d 
Expected (obs.) UAG 
translation function
e
 
EcNR2 0 0 None Stop 
C0.B* 0 0 prfB‡ Stop 
C0.B*.ΔA::S 0 0 prfB‡, ΔprfA::specR None (stop*) 
C7 7 7 None Stop 
C7.ΔA::S 7 7 ΔprfA::specR None (sup) 
C13 7 13 None Stop 
C13.ΔA::S 7 13 ΔprfA::specR None (sup) 
C321 7 321 None Stop 
C321.ΔA::S 7 321 ΔprfA::specR None (nc) 
C321.ΔA::T 7 321 ΔprfA::tolC None (nc) 
C321.ΔA 7 321 ΔprfA None (nc) 
aAll strains are based on EcNR2 {E. coli MG1655 Δ(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-bla] ΔmutS::cat} 
which is mismatch repair deficient (ΔmutS) to achieve high frequency allelic replacement; C0 and C321 strains are 
ΔmutS::zeoR; C7 and C13 strains are ΔmutS::tolC; C7, C13, and C321 strains have the endogenous tolC deleted, 
making it available for use as a selectable marker. Spectinomycin resistance (S) or tolC (T) were used to delete prfA 
(A). Bacterial genetic nomenclature describing these strains includes :: (insertion) and Δ (deletion). 
bOut of a total of 7 
cOut of a total of 321 
dprfA encodes RF1, terminating UAG and UAA; prfB encodes RF2, terminating UGA and UAA; prfB‡ = RF2 
variant (T246A, A293E, and removed frameshift) exhibiting enhanced UAA termination (16) and weak UAG 
termination (17). 
eObserved translation function: Stop = expected UAG termination; stop* = weak UAG termination from RF2 
variant; sup = strong selection for UAG suppressor mutations; nc = weak near-cognate suppression (i.e., reduced 
expression compared to C7.ΔA::S and C13.ΔA::S) in the absence of all other UAG translation function. 
 
  RF1
-
 hosts produced significantly smaller T7 plaques independent of host doubling time 
(Figures 5-4A and S5-8). The only exception was C0.B*.ΔA::S, which produced statistically 
equivalent plaque sizes regardless of whether RF1 was present (Figure 5-4A, Table S5-14). 
Consistent with the observation that the modified RF2 variant could weakly terminate UAG 
[(17) and herein], our results suggest that C0.B*.ΔA::S terminates UAG codons well enough to 
support normal T7 infection.  
Given that plaque area and phage fitness (doublings per hour)  do not always correlate, 
we confirmed that T7 infection is inhibited in RF1
-
 hosts by comparing T7 fitness and lysis time 
in C321 versus C321.ΔA (Figure 5-4B). Phage fitness (doublings per hour) is perhaps the most 
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relevant measure for 
assessing phage resistance 
because it indicates how 
quickly a log-phase phage 
infection expands (22). We 
found that T7 fitness was 
significantly impaired in 
strains lacking RF1 (P = 
0.002), and kinetic lysis 
curves (Figure S5-9) 
confirmed that lysis was 
significantly delayed in the 
absence of RF1 (P < 0.0001, Figure 5-4B). Meanwhile, one-step growth curves (Figure S5-10) 
indicated that burst size (average number of phages produced per lysed cell) in RF1
-
 hosts was 
also reduced by 59% (± 9%), and phage packaging was delayed by 30% (± 2%) (Table S5-15). 
We hypothesize that ribosome stalling at the gene 6 (T7 exonuclease) UAG explains the T7 
fitness defect in RF1
-
 hosts, whereas T4 may not possess a UAG-terminating essential gene with 
a similar sensitivity (supplemental text). Abolishing the function of additional codons could 
block the translation of viral proteins and prevent infections entirely. 
 
Discussion 
 Using multiplex genome editing, we removed all instances of the UAG codon and 
reassigned its function in the genome of a living cell. The resulting GRO possesses a devoted 
Figure 5-4. Bacteriophage T7 infection is attenuated in GROs lacking RF1. 
RF1 (prfA) status is denoted by symbol shape: ■ is wt prfA (WT),  is 
ΔprfA::specR (ΔA::S),  is ΔprfA::tolC (ΔA::T), and  is a clean deletion of 
prfA (ΔA). (A) RF1 status affects plaque area (Kruskal-Wallis one-way 
analysis of variance, P < 0.001), but strain doubling time does not (Pearson 
correlation, P = 0.49). Plaque areas (mm2) were calculated with ImageJ, and 
means ± 95% confidence intervals are reported (n > 12 for each strain). In the 
absence of RF1, all strains except for C0.B*.ΔA::S yielded significantly 
smaller plaques, indicating that the RF2 variant (16) can terminate UAG 
adequately to maintain T7 fitness. A statistical summary can be found in Table 
S5-14. (B) T7 fitness (doublings/hr) (22) is impaired (P = 0.002) and mean 
lysis time (min) is increased (P < 0.0001) in C321.ΔA compared to C321. 
Significance was assessed for each metric by using an unpaired t test with 
Welch’s correction. 
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UAG sense codon for robust NSAA incorporation that is suitable for industrial protein 
production. GROs also establish the basis for genetic isolation and virus resistance, and 
additional recoding will help fully realize these goals—additional triplets could be reassigned, 
unnatural nucleotides could be used to produce new codons (23), and individual triplet codons 
could be split into several unique quadruplets (8, 24) that each encode their own NSAA. In an 
accompanying study (25), we show that twelve additional triplet codons may be amenable to 
removal and eventual reassignment in E. coli. However, codon usage rules are not fully 
understood, and recoded genome designs are likely to contain unknown lethal elements. Thus, it 
will be necessary to sample vast genetic landscapes, efficiently assess phenotypes arising from 
individual changes and their combinations, and rapidly iterate designs to change the genetic code 
at the genome level. 
 
Materials and Methods 
 All DNA oligonucleotides were purchased with standard purification and desalting from 
Integrated DNA Technologies (Table S5-19). Unless otherwise stated, all cultures were grown in 
LB-Lennox medium (LB
L
, 10 g/L bacto tryptone, 5 g/L sodium chloride, 5 g/L yeast extract) 
with pH adjusted to 7.45 using 10 M NaOH. LB
L
 agar plates were LB
L
 plus 15 g/L bacto agar. 
Top agar was LB
L
 plus 7.5 g/L bacto agar. MacConkey agar was prepared using BD Difco™ 
MacConkey agar base according to the manufacturer’s protocols. M9 medium (6 g/L Na2HPO4, 
3 g/L KH2PO4, 1 g/L NH4Cl, 0.5 g/L NaCl, 3 mg/L CaCl2) and M63 medium (2 g/L (NH4)2SO4, 
13.6 g KH2PO4, 0.5 mg FeSO4·7H2O) were adjusted to pH 7 with 10 M NaOH and KOH, 
respectively. Both minimal media were supplemented with 1 mM MgSO4·7H2O, 0.083 nM 
thiamine, 0.25 µg/L D-biotin, and 0.2% w/v carbon source (galactose, glycerol, or glucose).  
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The following selective agents were used: carbenicillin (50 µg/mL), chloramphenicol (20 
µg /mL), kanamycin (30 µg/mL), spectinomycin (95 µg/mL), tetracycline (12 µg/mL), zeocin 
(10 µg/mL), gentamycin (5 µg/mL), SDS (0.005% w/v), Colicin E1 (ColE1; ~10 µg/mL), and 2-
deoxygalactose (2-DOG; 0.2%). ColE1 was expressed in strain JC411 and purified as previously 
described (26). All other selective agents were obtained commercially. 
The following inducers were used at the specified concentrations unless otherwise 
indicated: anhydrotetracycline (30 ng/µL), L-arabinose (0.2% w/v). p-acetyl-L-phenylalanine 
(pAcF) was purchased from PepTech (# AL624-2) and used at a final concentration of 1 mM. O-
phospho-L-serine (Sep) was purchased from Sigma Aldrich (# P0878-25G) and used at a final 
concentration of 2 mM. 
Strains: All strains were based on EcNR2 (11) (Escherichia coli MG1655 ΔmutS::cat 
Δ(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-bla]). Strains C321 [strain 48999 
(www.addgene.org/48999)] and C321.ΔA [strain 48998 (www.addgene.org/48998)] are 
available from addgene. 
Selectable marker preparation: Selectable markers were prepared using primers 
described in Table S5-19. PCR reactions (50 µL per reaction) were performed using Kapa HiFi 
HotStart ReadyMix according to the manufacturer’s protocols with annealing at 62 °C. PCR 
products were purified using the Qiagen PCR purification kit, eluted in 30 µL of dH2O, 
quantitated using a NanoDrop™ ND1000 spectrophotometer, and analyzed on a 1% agarose gel 
with ethidium bromide staining to confirm that the expected band was present and pure. 
MAGE and λ Red-mediated recombination: MAGE (13), CoS-MAGE (14), and λ 
Red-mediated recombination (27) were performed as previously described. Briefly, an overnight 
culture was diluted 100-fold into 3 mL LB
L
 plus antibiotics and grown at 30 °C in a rotator drum 
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until mid-log growth was achieved (OD600 ~0.4-0.6). Lambda Red was induced in a shaking 
water bath (42 °C, 300 rpm, 15 minutes), then induced culture tubes were cooled rapidly in an 
ice slurry for at least two minutes. Electrocompetent cells were prepared at 4 °C by pelleting 1 
mL of culture (centrifuge at 16,000 rcf for 20 seconds) and washing the cell pellet twice with 1 
mL ice cold deionized water (dH2O). Electrocompetent pellets were resuspended in 50 µL of 
dH2O containing the desired DNA. For MAGE oligos, no more than 5 µM (0.5 µM of each 
oligo) was used. For CoS-MAGE, no more than 5.5 µM (0.5 µM of each oligo including the co-
selection oligo) was used. For dsDNA PCR products, 50 ng was used. Cells were transferred to 
0.1 cm cuvettes, electroporated (BioRad GenePulser™, 1.78 kV, 200 Ω, 25 µF), and then 
immediately resuspended in 3 mL LB
L
 (MAGE and CoS-MAGE) or 1.5 mL LB
L
 (dsDNA). 
Recovery cultures were grown at 30 °C in a rotator drum. For continued MAGE cycling, cultures 
were recovered to mid-log phase before being induced for the next cycle. To isolate monoclonal 
colonies, cultures were recovered for at least 3 hours (MAGE and CoS-MAGE) or 1 hour 
(dsDNA) before plating on selective media. For tolC and galK negative selections, cultures were 
recovered for at least 7 hours to allow complete protein turnover before exposure to ColE1 and 
2-deoxygalactose, respectively. 
CAGE: CAGE was performed as previously described (11). Briefly, conjugants were 
grown to late-log phase in all relevant antibiotics (including tetracycline in the donor culture to 
select for the presence of conjugal plasmid pRK24 (28)). At mid-log growth, 2 mL of each 
culture was transferred to a 2 mL microcentrifuge tube and pelleted (5000 rcf, 5 minutes). 
Cultures were washed twice with LB
L
 to remove antibiotics, then the pellets were resuspended in 
100 µL LB
L
. Donor (10 µL) and recipient (90 µL) samples were mixed by gentle pipetting and 
then spotted onto a pre-warmed LB
L
 agar plate (6 x 10 µL and 2 x 20 µL spots). Conjugation 
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proceeded at 30 °C without agitation for 1 – 24 hours. Conjugated cells were resuspended off of 
the LB
L
 agar plate using 750 µL liquid LB
L
, and then 3 µL of the resuspended conjugation was 
inoculated into 3 mL of liquid LB
L
 containing the appropriate selective agents. The population 
with the correct resistance phenotype was then subjected to ColE1 negative selection to eliminate 
cells that retained tolC.  
Each round of conjugation, genotyping, and strain manipulation required a minimum of 5 
days to complete. On day 1, the conjugation and positive selections were performed. On day 2, 
the population of cells exhibiting the desired resistance phenotype was subjected to a ColE1 
selection to eliminate candidates that retained tolC. The ColE1-resistant population was then 
spread onto plates to isolate monoclonal colonies. On day 3, candidate colonies were grown in a 
96-well format and screened for the desired genotypes via PCR (to confirm loss of tolC) and 
MASC-PCR (to confirm the presence of the desired codon replacements). On day 4, tolC or 
kanR-oriT was recombined directly into one of the positive markers, and recombinants were 
plated on LB
L
 plates containing SDS or kanamycin, respectively. On day 5, candidate colonies 
were grown in liquid LB
L
 containing SDS or kanamycin and used as PCR template to confirm 
successful replacement of positive selection markers with tolC or kanR-oriT. These strains were 
ready for the next conjugation. 
Positive/Negative selections:  
Positive selection for tolC: TolC provides robust resistance to SDS (0.005% w/v) in LB
L
 
(both liquid and LB
L
 agar).  
Negative selection for tolC: After tolC was removed via λ Red-mediated recombination 
or conjugation, cultures were recovered for at least 7 hours prior to ColE1 selection. This was 
enough time for the recombination to proceed and for complete protein turnover in the 
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recombinants (i.e. residual TolC protein no longer present). ColE1 selections were performed as 
previously described (11). Briefly, pre-selection cultures were grown to mid-log phase (OD600 
~0.4), then diluted 100-fold into 150 µL of LB
L
 and LB
L
 + ColE1. Once growth was detected, 
monoclonal colonies were isolated on non-selective plates and PCR screened to confirm the loss 
of tolC. 
Positive selection for galK: GalK is necessary for growth on galactose (0.2% w/v) as a 
sole carbon source. It is important to thoroughly wash the cells with M9 media to remove 
residual carbon sources prior to selection in M63 + galactose (both liquid and M63 agar). Noble 
agar must be used, since Bacto agar may contain contaminants that can be used as alternative 
carbon sources. 
Negative selection for galK: After galK was removed via λ Red-mediated recombination 
or conjugation, cultures were recovered for at least 7 hours prior to 2-DOG selection. This was 
enough time for the recombination to proceed and for complete protein turnover in the 
recombinants (i.e. residual GalK protein no longer present). 2-DOG selections were performed 
as previously described (29). Briefly, pre-selection cultures were grown to mid-log phase (OD600 
~0.4), washed three times in M9 medium to remove residual nutrients from LB
L
, and then 
inoculated into M63 + 0.2% glycerol and M63 + 0.2% glycerol + 0.2% 2-DOG. Once growth 
was detected, monoclonal colonies were isolated on non-selective plates (LB
L
 agar or 
MacConkey agar) and PCR screened to confirm the loss of galK. When possible, colonies were 
streaked onto MacConkey + 0.2% galactose indicator plates (white colonies are Gal- and red 
colonies are Gal+) prior to PCR screening, but MacConkey media is toxic to strains that do not 
express TolC, which provides resistance to bile salts. We also found that 2-DOG selection was 
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effective in LB
L
, but PCR screening was important because LB
L
 + 2-DOG selection was less 
stringent. 
Screening for galK and malK: Cultures were diluted and plated for single colonies on 
MacConkey agar + 0.2% galactose (galK) or MacConkey agar + 0.2% maltose (malK) indicator 
plates (white colonies are Gal- or Mal-, and red colonies are Gal+ or Mal+). The genotypes were 
confirmed via PCR. 
Genotyping: After λ Red-mediated recombination or conjugation, colony PCR was used 
to confirm the presence or absence of selectable markers at desired positions. Colony PCR (10 
µL per reaction) was performed using Kapa 2G Fast HotStart ReadyMix according to the 
manufacturer’s protocols with annealing at 56 °C. Results were analyzed on a 1% agarose gel 
with ethidium bromide staining. 
Multiplex allele-specific colony PCR (MASC-PCR) was used to simultaneously detect up 
to 10 UAGUAA conversions as previously described (11). Briefly, each allele was 
interrogated by two separate PCRs to detect the UAG/UAA status. The two reactions shared the 
same reverse primer but used different forward primers whose 3′ ends annealed to the SNP being 
assayed. Amplification only in the wt-detecting PCR indicated a UAG allele, whereas 
amplification only in the mutant-detecting PCR indicated a UAA allele. Each primer set 
produced a unique amplicon size corresponding to its target allele (100, 150, 200, 250, 300, 400, 
500, 600, 700 and 850 bp). Template was prepared by growing monoclonal colonies to late-log 
phase in 150 µl LB
L
 and then diluting 2 µl of culture into 100 µl dH2O. Initially, we used Qiagen 
Multiplex PCR kit, but KAPA 2G Fast Multiplex Ready Mix produced cleaner, more even 
amplification across our target amplicon size ranges. Therefore, typical MASC-PCR reactions 
contained KAPA 2G Fast Multiplex ReadyMix (Kapa Biosystems, # KK5802) and 10X Kapa 
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dye in a final volume of 10 µl, including 2 µl of template and 0.2 µM of each primer. PCR 
activation occurred at 95°C (3 min), followed by 27 cycles of 95°C (15 sec), 63–67°C (30 sec; 
annealing temperature was optimized for each set of MASC-PCR primers), and 72°C (70 sec). 
The final extension was at 72°C (5 min). MASC-PCR results were analyzed on 1.5% agarose 
gels with ethidium bromide staining to ensure adequate band resolution. 
Sanger sequencing was performed by Genewiz or Eton Bioscience, Inc. 
Genomic DNA for whole genome sequencing was prepared using a Qiagen Genomic 
DNA purification kit or by simultaneously lysing raw culture and shearing genomic DNA using 
a Covaris E210 AFA Ultrasonication machine. Illumina libraries were prepared as previously 
described (30). Each strain was barcoded with a unique 6 bp barcode for pooling. Up to 16 
strains were pooled for sequencing on a single HiSeq lane, and up to 4 genomes were pooled for 
sequencing on a single MiSeq lane. Whole genome sequencing was performed using Illumina 
HiSeq or MiSeq systems. The HiSeq samples were sequenced with paired end 50 bp or 100 bp 
reads, and the MiSeq samples were sequenced with paired end 150 bp reads. 
Sequencing analysis: In order to analyze the sequencing data from 68 distinct genomes, 
we developed a software pipeline that connects several modular tools and custom scripts for 
analysis and visualization. The goal of our pipeline was to identify SNPs and structural variants 
relative to the reference genome E. coli K-12 MG1655 (U00096.2, GI:48994873). Note that we 
use the term SNP to mean any small mismatches or indels identified by Freebayes (<22 bp). We 
use the term structural variant to refer to large insertions detected by Breakdancer and Pindel, 
deletions, or other significant junction events (confirmed variants of size 170 bp and 776 bp in 
C321.ΔA). 
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FASTQ conversion to SAM/BAM: FASTQ reads were split using individual genome 
barcodes with the FASTX toolkit (31). After splitting and trimming of the 6 bp barcode, FASTQ 
files for individual reads were aligned to the reference genome (E. coli K-12 MG1655 or the 
C321.ΔA predicted genome sequence) using Bowtie2 version 2.0.0-beta5 (32) with local 
alignment and soft-clipping enabled. PCR duplicates were removed using the Picard toolkit 
<http://picard.sourceforge.net/> and reads were realigned around short indels using the Genome 
Analysis Toolkit (33).  
SNP calling using Freebayes: SNPs were called using the Freebayes package 
(arXiv:1207.3907v2 [q-bio.GN]). SNP calls were made using a --ploidy flag value of 2, in order 
to catch SNPs that occur in duplicated regions. These SNPs show up as heterozygous calls in the 
output. The minimum alternate fraction for such calls was set at 0.4. The p-value cutoff was set 
at 0.001. SNPs from all genomes were called simultaneously, using the --no-ewens-priors and --
no-marginals flags. The --variant-input flag was used to provide Freebayes with the recoded 
SNP (UAG-to-UAA) positions as putative variants to call regardless of evidence. Reads 
supporting SNPs were required to have a minimum mapping quality of 10 and a minimum base 
quality of 30. Mapping quality was not otherwise used to assess SNP likelihoods (--use-
mapping-quality was disabled). We ran Freebayes as described above to generate a single VCF 
file containing all variants for all samples. This VCF file was then further analyzed and filtered 
before as described below, before generating the summarizing diagram Figure S5-3.  
SNP Effect using snpEFF: SnpEff 2.0.5d (34) was used to annotate variants and to 
predict effects for called SNPs. First, the reference genome’s annotated GenBank Record 
(GI:48994873) was used to create a genome database, and the VCF records were annotated for 
coding effects only.  
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Final SNP filtering: In addition to the Freebayes SNP identification criteria, we used 
additional metrics to filter out SNPs that could not be called with high confidence. This 
additional filtering helped to reduce the complexity of the relationship of variants across all 
sequenced genomes in order to plot Figure S5-3. Note that this filtering resulted in some low-
evidence variants being temporarily ignored in the aggregate analysis. However, these were 
carefully triaged and identified in the process of generating the sequence annotation file for the 
final C321.ΔA strain. 
i. All 'heterozygous' calls were filtered out, as these represent SNPs whose reads map to 
multiple locations in the genome.  
ii. SNPs that were present in fewer than three samples and could not be called either 
present or absent in >20 strains due to poor coverage or read mapping quality were 
filtered out.  
iii. SNPs were filtered out if they were covered by ≤ 20 reads with good mapping quality 
across all genomes. 
iv. SNPs that could be called absent or present in fewer than three genomes were 
removed. 
Structural variants using Pindel and Breakdancer: Pindel (35) and Breakdancer (36) 
were both used to find potential structural variants in the genomes. First, Picard 
<http://picard.sourceforge.net/> was used to gather insert size metrics per genome. This 
information, along with the aligned BAM data, was run through Pindel. The Pindel output was 
converted to VCF using the pindel2vcf tool. We required at least 20 reads to support a breakpoint 
or junction. The breakdancer_max program in Breakdancer was also used to find structural 
variants. For Breakdancer, at least 8 read pairs were required to support a called structural event.  
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We manually corroborated structural variant calls from Pindel and Breakdancer through 
visual examination of read alignments. Since we observed a high-rate of false-positive and false-
negative calls with these toolswe did not include them in our final strain analysis in the main 
text.  Still, the Pindel and Breakdancer data were useful in  troubleshooting cassette insertions 
and intentional gene knockouts and replacements. 
  Future work to combine evidence from these and additional tools might lead to a more 
robust, comprehensive, and high throughput method to validate structural variants using only 
short-read sequencing data.  
Breakdancer predicted 49 unique events, and 187 total events across 69 strains. Because 
Breakdancer cannot call across multiple strains simultaneously and only gives approximate event 
locations based on read-pair distances, events that occurred in multiple samples were identified 
by using similar event start and end locations. Breakdancer predicted a total of 21 unique 
deletions, 5 unique inversions, and 23 unique translocations.  
Pindel used split read data to predict both uncharacterized breakpoints and whole 
structural events. 258 unique uncharacterized breakpoints were found; 230 of these occur in only 
a single sample. Pindel also predicted 79 unique structural events. 9 were large deletions, 59 
were insertions of unknown size, and 11 were inversions. 
Coverage analysis: Coverage for each genome was analyzed using the bedtools (37) 
programs makewindows and multicov. The genome was split into 50 bp windows and BAM 
coverage was assessed for each window. A custom python script was used to take this 
information and find contiguous windows of low and high coverage, indicative of gene 
amplifications and deletions. These results are included as supplemental Table S5-31. 
138 
 
Confirming cassette insertion sites: Known insertion sites of CAGE antibiotic resistance 
markers were confirmed by selecting the reads that were soft clipped and/or not aligned to the 
MG1655, and aligning them to the known cassette sequences using Bowtie. Cassette insertion 
locations were inferred using the alignment locations of paired reads in which one read mapped 
to a cassette and the other mapped to a location on the genome. 
Visually confirming SNPs and structural variants: The tview tool in the Samtools 
package (38) was used to visually inspect individual UAG SNPs and to assess the veracity of 
low-confidence SNP and structural variant calls.  
Generating genome figures: Figure S5-3 was created using custom software written in R 
and Processing.  
Fitness analysis: To assess fitness, strains were grown in flat-bottom 96-well plates (150 
µL LB
L
, 34 °C, 300 rpm). Kinetic growth (OD600) was monitored on a Biotek H4 plate reader at 
5 minute intervals. Doubling times were calculated by tdouble = c*ln(2)/m, where c = 5 minutes 
per time point and m is the maximum slope of ln(OD600). Since some strains achieved lower 
maximum cell densities, slope was calculated based on the linear regression of ln(OD600) through 
5 contiguous time points (20 minutes) rather than between two pre-determined OD600 values. To 
monitor fitness changes in the CAGE lineage, growth curves were measured in triplicate, and 
their average was reported in Figure 5-2 and Table S5-1. To determine the effect of RF1 removal 
and NSAA incorporation on the panel of recoded strains (Table 5-1), growth curves were 
measured in triplicate (Figure 5-3A, Figure S5-8). Statistics were based on a Kruskal-Wallis one-
way ANOVA followed by Dunn’s multiple comparison test, where *p < 0.05, **p < 0.01, and 
***p < 0.001.  
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To assess re-growth phenotypes from long-term NSAA expression, overnight cultures 
were first grown in LB
L
 supplemented with chloramphenicol to maintain the pEVOL plasmids. 
These cultures were passaged into LB
L
 containing chloramphenicol, arabinose (to induce 
pEVOL), and either pAcF or pAzF depending on whether pEVOL-pAcF or pEVOL-pCNF was 
used. Growth with shaking at 34°C was monitored using a Biotek H1 or a Biotek Eon plate 
reader with OD600 readings every 10 minutes (pAcF) or 5 minutes (pAzF). After 16 hours of 
growth, the expression cultures were passaged into identical expression conditions and the 
growth curves were monitored with the same protocols. 
NSAA incorporation assays:  
Plasmids and strains for NSAA incorporation: p-acetyl-L-phenylalanine (pAcF) 
incorporation was achieved using pEVOL-pAcF (9) which contains two copies of pAcF-RS and 
one copy of tRNA
   
   
. The pEVOL-pAcF plasmid was maintained using chloramphenicol 
resistance. One copy of pAcF-RS and tRNA
   
   
 were constitutively expressed, and the second 
copy of pAcF-RS was under araBAD-inducible control (0.2% L-arabinose).  
O-phospho-L-serine (Sep) incorporation was achieved by expression of tRNA
Sep
 from 
pSepT and both EFSep (EF-Tu variant capable of incorporating Sep) and SepRS from pKD-
SepRS-EFSep (21). To prevent enzymatic dephosphorylation of Sep in vivo, the gene encoding 
phosphoserine phosphatase (serB), which catalyzes the last step in serine biosynthesis, was 
inactivated. Specifically, Glu93 (GAA) was mutated to a premature UAA stop codon via MAGE. 
The pKD-SepRS-EFSep plasmid was maintained using kanamycin resistance and both SepRS 
and EFSep were induced using IPTG. The pSepT plasmid was maintained using tetracycline 
resistance, and tRNA
Sep
 was constitutively expressed. 
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Effect of RF1 deletion, aaRS expression, and NSAA incorporation on fitness: Stationary 
phase pre-cultures were obtained by overnight growth with shaking at 34 °C in 150 µl LB
L
 
supplemented with chloramphenicol for plasmid maintenance. Stationary phase cultures were 
diluted 100-fold into 150 µl LB
L
 containing chloramphenicol and 0.2% L-arabinose and/or 1 
mM pAcF where indicated. Growth was monitored on a Biotek Synergy H1 plate reader. OD600 
was recorded at 10-minute intervals for 16 hours at 34 °C with continuous shaking. All data were 
measured in triplicate. Doubling time was determined for each replicate as described above, and 
replicates were averaged for Figure 5-3A. 
GFP variant synthesis: GFP variants (Table S5-33) were synthesized as gBlocks by IDT 
and modified with an N-terminal 6His tag via PCR. His-tagged GFP variants were isothermally 
assembled (39) into the pZE21 plasmid backbone (40) to yield the array of GFP reporter 
plasmids used in this study. Reporter plasmids were maintained using kanamycin resistance and 
induced using 30 ng/mL anhydrotetracycline (aTc). 
UAG suppression and GFP Fluorescence: Stationary phase pre-cultures were obtained 
by overnight growth with shaking at 34 °C in 150 µl LB
L
 supplemented with appropriate 
antibiotics for plasmid maintenance. Stationary phase cultures were diluted 100-fold into 150 µl 
fresh LB
L
 containing the same antibiotics as the overnight pre-culture. These cultures were 
grown to mid-log phase and diluted 100-fold into 150 µl fresh LB
L
 containing the same 
antibiotics plus 30 ng/ml aTc, 0.2% L-arabinose, and/or 1 mM pAcF (where indicated). Protein 
expression proceeded for 16 hours at 34 °C with continuous shaking. Following 16 hours of 
expression, cultures were transferred to V-bottomed plates, pelleted, and washed once in 150 µL 
of PBS (pH 7.4). Washed pellets were resuspended in 150 µL of PBS (pH 7.4) and transferred to 
a black-walled, clear-bottom plate to measure GFP fluorescence for each strain. Both OD600 and 
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GFP fluorescence (Ex: 485 nm, Em: 528 nm) were measured on a Biotek Synergy H1 plate 
reader. Fluorescence and OD600 measurements were corrected by subtracting background 
fluorescence and OD600 (determined using PBS blanks). Relative fluorescence (in rfu) was 
calculated by the ratio fluorescence/OD600. Reported values represent an average of four 
replicates. After measurements were complete, the cells were pelleted, the supernatant was 
aspirated, and the pellets were frozen at -80 °C for subsequent protein purification and Western 
blot analysis. 
Protein extraction and Western blots: Cell pellets were obtained as described above. 
Cells were lysed using a lysis cocktail containing 150 mM NaCl, 50 mM Tris-HCl, 0.5x 
BugBuster reagent, 5% glycerol, 50 mM Na3VO4, 50 mM NaF, protease inhibitors (Roche), and 
1 mM DTT. The resulting lysates were spun at 4 °C for 15 minutes at 3200 x g only in cases 
where soluble and insoluble fractions were separately analyzed. Protein lysate concentrations 
were determined using the BioRad-DC colormetric protein assay. Lysates were normalized by 
optical density at 600 nm, resolved by SDS-PAGE, and electro-blotted onto PVDF membranes 
(Millipore, # ISEQ00010). Western blot analysis was performed with mouse monoclonal 
antibody directed against GFP (Invitrogen, # 332600), and membranes were imaged with an 
HRP secondary antibody (Jackson Immunoresearch, JAC-715035150) via chemiluminescence 
on a ChemiDoc system (BioRad). 
Mass spectrometry:  
Materials: Urea, Tris-HCl, CaCl2, iodoacetamide (IAA), Pyrrolidine, DL-lactic acid, 
HPLC grade water and acetonitrile (ACN) were from Sigma-Aldrich (St. Louis, MO). 
Chloroform and dithiothretitol (DTT) were from American Bioanalytical (Natick, MA). 
Methanol, trifluoroacetic acid (TFA), ammonium hydroxide and formic acid (FA) were obtained 
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from Burdick and Jackson (Morristown, NH). Sequencing grade modified trypsin was from 
Promega (Madison,WI). Anionic acid cleavable surfactant II (ALS) was from Protea 
(Morgantown, WV). UltraMicroSpin
TM
 columns, both the C18 and the DEAE PolyWAX variety 
were from The Nest Group, Inc. (Southborough, MA). Titaniumdioxide (TiO2) with a particle 
size of 5 µm was obtained from GL Sciences Inc. (Torrance, CA).  
Cell culture and lysis: Strains were routinely grown in LB
L
 media with the following 
concentration of antibiotics when appropriate: tetracycline (12 μg/mL), kanamycin (50 μg/mL), 
chloramphenicol (12 μg/mL), and zeocin (25 μg/mL). Bacterial cell cultures were grown at 30°C 
while shaking at 230 rpm until late log phase, quenched on ice and pelleted at 10,000 x g (10 
min). The media was discarded and the cell pellets were frozen at -80°C to assist with 
subsequent protein extraction. Frozen cell pellets were thawed on ice and lysed in lysis buffer 
consisting of BugBuster reagent, 50 mM Tris-HCl (pH 7.4, 23°C), 500 mM NaCl, 0.5 mM 
EGTA, 0.5 mM EDTA, 14.3 mM 2-mercaptoethanol, 10 % glycerol, 50 mM NaF, and 1 mM 
Na3O4V, Phosphatase inhibitor cocktail 3 and complete protease inhibitor cocktail (Sigma 
Aldrich) were added as recommended by the corresponding manufacturer. Cell suspensions were 
incubated on ice for 30 min and the supernatant was removed after ultracentrifugation. The 
remaining pellet was re-extracted and resulting fractions were combined. 
Protein lysates: Protein was precipitated with the methanol/chloroform method as 
previously described (41). One third of the resulting protein pellet was dissolved in 1.5 ml 
freshly prepared 8 M Urea/0.4 M Tris-HCl buffer (pH= 8.0, 23 °C). 5 mg protein was reduced 
and alkylated with IAA and digested overnight at 37°C using sequencing grade trypsin. The 
protein digest was desalted using C18 Sep-Pak (Waters) and the purified peptides were 
lyophilized and stored at -80°C. 
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 Digestion of intact E. coli for shotgun proteomics: Cells were grown overnight to 
stationary phase, quenched on ice, and 2 ml culture was used for protein extraction and mass 
spectrometry. Cells were pelleted for 2 min at 2000 x g and the resulting pellet was washed twice 
with 1 ml ice cold Tris-HCl buffer pH=7.4, 23°C. The cells were then re-suspended in 100 µl 
Tris-HCl buffer pH=7.4, 23°C, split into 4 equal aliquots of 25 ul and the cell pellet was frozen 
at -80 °C. Frozen pellets were lysed with 40 µl lysis buffer consisting of 10 mM Tris-HCl buffer 
pH = 8.6 (23°C) supplemented with 10 mM DTT, 1 mM EDTA and 0.5 % ALS. Cells were 
lysed by vortex for 30 s and disulfide bonds were reduced by incubating the reaction for 35 min. 
at 55 °C in a heating block. The reaction was briefly quenched on ice and 16 µl of a 60 mM IAA 
solution was added. Alkylation of cysteines proceeded for 30 min in the dark. Excess IAA was 
quenched with 14 µl of a 25 mM DTT solution and the sample was then diluted with 330 µl of 
183 mM Tris-HCl buffer pH=8.0 (23 °C) supplemented with 2 mM CaCl2. Proteins were 
digested overnight using 12 µg sequencing grade trypsin for each protein aliquot, and the 
reaction was then quenched with 64 µl of a 20 % TFA solution, resulting in a sample pH<3. 
Remaining ALS reagent was cleaved for 15 min at room temperature. An aliquot of the sample 
consisting of ~30 µg protein (as determined by UV280 on a nanodrop) was desalted by reverse 
phase clean-up using C18 UltraMicroSpin
 
columns. The desalted peptides were dried at room 
temperature in a rotary vacuum centrifuge and reconstituted in 30 µl 70 % formic acid 0.1 % 
TFA (3:8 v/v) for peptide quantitation by UV280. The sample was diluted to a final concentration 
of 0.6 µg/µl and 4 µl (2.4 µg) were injected for LC-MS/MS analysis of the unfractionated digest 
using a 200 min method.  
Phosphopeptide enrichment: Offline phosphopeptide enrichment was carried out with 
Titanium dioxide (TiO2) using a bulk enrichment strategy adapted from Kettenbach (42). Briefly, 
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between 0.4 and 1 mg of desalted peptide digest was transferred into a 1.5 ml PCR tube and 
dissolved at a concentration of 1mg/ml in “binding solution” consisting of 2 M lactic acid in 50 
% ACN. Activated TiO2 was prepared as a concentrated slurry in binding solution and added to 
the peptide solution to obtain a TiO2 to peptide ratio of 4:1 by mass. The mixture was incubated 
for 2 h at room temperature on an Orbit M60 laboratory shaker operated at 140 rpm. The 
suspension was centrifuged for 20 s at 600 x g and the supernatant was removed. The TiO2 beads 
were washed twice with 50 µl of the binding solution and then 3 times with 100 µl 50 % ACN, 
0.1 % TFA. Stepwise elution of phosphopeptides from the beads was carried out using 20 µl of 
0.2 M sodium phosphate buffer pH=7.8 followed by 20 µl 5 % ammonium hydroxide and 20 µl 
5 % pyrrolidine solution. The pH of the combined extracts was adjusted with 30 µl of ice cold 20 
% TFA resulting in a sample pH <3.0. Peptides were desalted on C18 UltraMicroSpin columns as 
described above and the peptide concentration was estimated by UV280. 
Offline fractionation of tryptic digests: Offline electrostatic repulsion-hydrophilic 
interaction chromatography (ERLIC) (43) was performed on disposable DEAE PolyWAX 
UltraMicroSpin columns. Columns were activated as recommended by the manufacturer and 
then conditioned with 3 x 200 µl washes with 90 % ACN, 0.1 % acetic acid (buffer A). For this 
purpose, the columns were centrifuged for at 200 x g for 1 min at 4°C. The column was then 
loaded with 50 µg of a desalted peptide digest prepared in 25 µl buffer A, and the flow-through 
was collected. Stepwise elution of the peptides was carried out using brief centrifugation steps 
carried out for 30 s at 200 x g with 50 µl eluent unless noted otherwise. The elution steps 
consisted of the following volumetric mixtures of buffer A and buffer B (0.1 % formic acid in 30 
% ACN): (1) 100:0 (2) 96:4 (3) 90:10 (4) 80:20 (5) 60:40 (6) 100 µl of 20:80 (7) 100 µl of 
0:100. Additional elution steps consisted of: (8) 1 M triethylamine buffer adjusted with formic 
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acid to pH=2.0. (9) 0.2 % ammonia (10) 0.2 % ammonia and finally (11) 100 µl 70 % formic 
acid. The collected fractions were dried in a vacuum centrifuge and reconstituted in 15 µl solvent 
consisting of 3:8 by volume of 70 % formic acid and 0.1 % TFA. Fractions were analyzed by 
LC-MS/MS using a 400 min gradient. 
 
Liquid chromatography and mass spectrometry: Capillary LC-MS was performed on an 
Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) connected to a nanoAcquity UPLC 
(Waters, Milford, MA). Liquid chromatography was performed at 35 °C with a vented split setup 
consisting of a commercially available 180 µm x 20 mm C18 nanoAcquity UPLC trap column 
and a BEH130C18 Waters symmetry 75 µm ID x 250 mm capillary column packed with 5 and 
1.7 µm particles respectively. Mobile phase A was 0.1 % formic acid (FA) and mobile phase B 
was 0.1 % FA in acetonitrile. The injection volume was 4-5 µl depending on the sample 
concentration. Up to 2.4 µg peptides were injected for each analysis. Peptides were trapped for 3 
min in 1 % B with and a flow rate of 5 µl/min. Gradient elution was performed with 90, 200 and 
400 min methods with a flow rate of 300 nl/min. Two blank injections were performed between 
samples to limit potential carryover between the runs. The gradient for the 90 min method was 1-
12 % B over 2 min, 12-25 % B over 43 min, 25-50 % B over 20 min, followed by 6 min at 95 % 
B and column re-equilibration in 1 % B. The gradient for the 200 min was 1-10 % B over 2 min, 
10-25 % B over 150 min, and 25-50 % B over 20 min, followed by 7 min at 95 % B and re-
column equilibration at 1 % B. The gradient for the 400 min was 1 min in 1 % B, 1-7 % B over 2 
min, 7-20 % B over 298 min, and 20-50 % B over 60 min, followed by a 1 min flow ramp to 95 
% B. The column was flushed for 9 min using 95 % B and then re-equilibrated for 27 min at 1 % 
B prior to the next injection. Mass spectrometry was performed with a spray voltage of 1.8 kV 
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and a capillary temperature of 270 °C. A top 10 Higher Collisional Energy Dissociation (HCD) 
method with one precursor survey scan (300-1750 Da) and up to 10 tandem MS spectra 
performed with an isolation window of 2 Da and a normalized collision energy of 40 eV. The 
resolving power (at m/z = 400) of the Orbitrap was 30,000 for the precursor and 7500 for the 
fragment ion spectra, respectively. Continuous lock mass calibration was enabled using the 
polycyclodimethylsiloxane peak (m/z = 445.120025) as described (44). Dynamic exclusion 
criteria were set to fragment precursor ions exceeding 3000 counts with a charge state >1 twice 
within a 30 s period before excluding them from subsequent analysis for a period of 60 s. The 
exclusion list size was 500 and early expiration was disabled.  
Proteomics data processing: Raw files from the Orbitrap were processed with Mascot 
Distiller and searched in-house with MASCOT (v. 2.4.0) against the EcoCyc (45) protein 
database release 16.0 for E. coli K-12 substr. MG1655 with a custom database and search 
strategy designed to identify amber suppression (Aerni et al. manuscript in preparation). Forward 
and decoy database searches were performed with full trypsin specificity allowing up to 3 missed 
cleavages and using a mass tolerance of ±30 ppm for the precursor and ±0.1 Da for fragment 
ions, respectively. Cysteines were considered to be completely alkylated with IAA unless 
samples were processed by a gel-based workflow. In that case Propionamide (C) was considered 
as a variable modification. Additional variable modifications for all searches were oxidation (M) 
and deamidation (NQ) for samples processed with urea Carbamyl (K, R, N-term). In order to 
detect pAcF containing peptides, a variable custom modification for Y was introduced with the 
composition C2H2 and monoisotopic mass of 26.015650 Da. Typical FDR were <1 % for 
peptides above identity threshold and <2% considering all peptides above identity or homology 
threshold respectively. The MASCOT search results were deposited in the Yale Protein 
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Expression Database (YPED) (46). The following filter rules were specified in YPED for 
reporting of protein identifications: (i) At least 2 bold peptides and peptide scores ≥20 or (ii) 1 
bold red peptide with a peptide score ≥20 with at least one additional bold red peptide with a 
score between 15 and 20. 
Bacteriophage assays: For all phage experiments, growth was carried out in LB
L
 at 30 
°C. Liquid cultures were aerated with shaking at 300 rpm. Before each experiment, a fresh phage 
lysate was prepared. To do this, Escherichia coli MG1655 was grown to mid-log phase in 3 mL 
of LB
L
, then ~2 uL of T7 bacteriophage (ATCC strain BAA-1025-B2) or T4 bacteriophage 
(ATCC strain 11303-B4) was added directly from a glycerol stock into the bacterial culture. 
Lysis proceeded until it was complete (lysate appears clear after ~4 hours). The entire lysate was 
centrifuged to remove cell debris (10,000 rcf, 10 minutes), and 3 mL of lysate was transferred to 
a glass vial supplemented with 150 mg NaCl for phage preservation. Lysates were prepared 
fresh, titered, and stored at 4 °C for the duration of each experiment. One lysate was used for all 
replicates of a given experiment. 
Phage titering: Phage lysate was titered by serial dilution into LB
L
 (10-fold dilution 
series). Before plating on LB
L
 agar, 10 µL of the diluted phage lysate was mixed with 300 µL of 
mid-log E. coli MG1655 culture and 3 mL of molten top agar. Plaques matured for ~4 hours at 
30 °C. Titers (pfu/mL) were calculated based on the lysate dilutions that produced 20-200 pfu. 
Plaque area: For plaque area assays, bacterial cultures were grown to mid-log phase in 3 
mL LB
L
. To accommodate different doubling times, faster-growing cultures were continually 
diluted until all strains reached OD600 ~0.5. Immediately prior to infection, OD600 was 
normalized to 0.50 for all cultures. Approximately 30 pfu of T7 bacteriophage were mixed with 
300 µL of OD600 = 0.50 culture and 3 mL of molten top agar, and then immediately plated on 
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LB
L
 agar. Plaques were allowed to mature at 30 °C for 7 hours, then the plates were imaged on a 
Bio-Rad Gel Doc system, and plaque areas were measured using ImageJ (47). Statistics were 
based on a Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparison test, 
where *p < 0.05, **p < 0.01, and ***p < 0.001.
 
 
T7 Fitness: Fitness was assessed in triplicate at low MOI based on protocols by 
Heineman et al. (22). Briefly, bacterial glycerol stocks were inoculated directly into 3 mL LB
L
 
and serially diluted in LB
L
. Serial dilutions were grown overnight (30 °C, 300 rpm), so that one 
of the dilutions would be at mid-log growth phase in the morning. Prior to infection, a second 
dilution series was performed so that host strains would be at optimal growth phase over the 
course of the serial infection. Starting cultures were normalized to OD600 = 0.50 by adding LB
L
 
immediately before infecting the cultures (MOI = 0.015) at t = 0. Infected culture was diluted 
1/10 into 3 mL of uninfected mid-log phase culture at 30 minute intervals. Aliquots of the 
infection were taken at t = 4, 10, 60, and 120 minutes. At t = 4, the aliquot was treated with 
chloroform to quantitate non-adsorbed phage particles. For all other time points (t = 10, 60, and 
120), aliquots were immediately mixed with 300 µL of mid-log E. coli MG1655 and 3 mL 
molten top agar and then spread on LB
L
 agar. Plaques were counted after maturing for ~4 hours 
at 30 °C, and then pfu/mL was calculated for each time point, correcting for dilutions. 
Adsorption efficiency was consistently >95% as determined by (Nt=4 – Nt=10) / Nt=10, and fitness 
was determined by [log2(Nt=120/Nt=60)]/(Δt/(60 min/hr)), where N is the number of phages at time 
t minutes and Δt = 60 min.  
Kinetic lysis time: Mean lysis time was determined with 12 replicates based on protocols 
from Heineman et al. (22), except that OD600 was monitored instead of OD540. Mid-log phase 
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cells (as in the fitness assay) were infected at MOI = 5, then 150 µL aliquots of infected culture 
were distributed into a 96-well flat bottomed plate and sealed with Breathe-Easy™ sealing 
membrane. Lysis was monitored at 30 °C with shaking at 300 rpm on a Biotek H4 plate reader 
with OD600 measurements taken every 5 minutes. Each lysis curve was fit to a cumulative normal 
distribution using the normcdf function in MATLAB. Mean lysis time, mean lysis OD600, and 
mean lysis slope were calculated using this cumulative normal distribution function. 
 
Supplemental material 
 Supplemental material for CHAPTER 5 can be found in APPENDIX D or at 
<http://www.sciencemag.org/content/suppl/2013/10/16/342.6156.357.DC1/Lajoie.SM.pdf>. 
Additional supplemental tables can be found at 
<http://www.sciencemag.org/content/342/6156/357/suppl/DC1>.  
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Abstract 
 Engineering radically altered genetic codes will allow for genomically recoded organisms 
that have expanded chemical capabilities and are isolated from nature. We have previously 
reassigned the translation function of the UAG stop codon; however, reassigning sense codons 
poses a greater challenge because such codons are more prevalent, and their usage regulates gene 
expression in ways that are difficult to predict. To assess the feasibility of radically altering the 
genetic code, we selected a panel of 42 highly-expressed essential genes for modification. Across 
80 Escherichia coli strains, we removed all instances of 13 rare codons from these genes and 
attempted to shuffle all remaining codons. Our results suggest that the genome-wide removal of 
13 codons is feasible; however, several genome design constraints were apparent, underscoring 
the importance of a strategy that rapidly prototypes and tests many designs in small pieces. 
 
Introduction 
 The canonical genetic code is nearly universal (1), allowing natural organisms to share 
beneficial traits via horizontal gene transfer. Genetically modified organisms also share this 
code, rendering them susceptible to viruses and capable of releasing recombinant genetic 
material (e.g. resistance genes (2)) into the environment. By redefining the genetic code, we hope 
to produce genomically recoded organisms (GROs) that are safe and useful. 
In separate work, we have completely reassigned the UAG codon in Escherichia coli 
MG1655 (3) UAG was chosen for its rarity and simplicity of function, but our results (3) 
reinforce that sense codons must also be reassigned to achieve robust genetic isolation, broad 
virus resistance, and expanded chemical versatility (4). However, sense codon reassignment 
poses a considerable challenge given that codon usage can strongly affect gene regulation (5), 
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ribosome spacing (6, 7), translation efficiency (7, 8), translation levels (9), translation accuracy 
(10), and protein folding (11, 12). Furthermore, DNA/RNA motifs can provide additional 
noncoding functions such as regulating translation initiation via 5′ mRNA secondary structure 
(13), sharing sequence with overlapping small RNAs (14), pausing the ribosome at internal 
Shine-Dalgarno sequences (15), and regulating mRNA localization (16). Therefore, it is difficult 
to predict the effects of a given codon change, and these factors may substantially constrain the 
malleability of the genome. However, despite the myriad mechanisms by which swapping 
synonymous codons could be deleterious, efforts to express a codon-randomized Klebsiella 
nitrogenase gene cluster in E. coli have been successful, albeit with reduced activity compared 
with wild-type (16). 
Although such information is critical for reassigning the genetic code, genome-wide 
codon essentiality has largely been unexplored, perhaps due to the substantial degree of genetic 
modification necessary for addressing such questions. For example, the complete removal of 13 
codons corresponding to the least frequently used anticodons (Figure 6-1A and supplemental 
text) will require 155,224 changes in E. coli MG1655, several of which may not be tolerated. 
Although it has never been attempted, de novo genome design, synthesis, and transplantation 
(17) seems unlikely to produce a viable genome bearing this unprecedented number of 
potentially deleterious changes. Indeed, lethal genetic elements have been difficult to identify 
and eliminate using de novo genome transplantation (17). Therefore, we have developed in vivo 
multiplex genome editing technologies (18, 19) to rapidly prototype and manufacture genomes. 
Our approach exploits diversity and natural selection, and is highly amenable to our goal of 
testing the flexibility of synonymous codon choices as they pertain to reassigning the genetic 
code.  
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Results 
 To test whether we could radically change codon usage in order to free up codons that 
could be reassigned to alternate translation functions, we attempted to individually recode 42 
Figure 6-1. Codon reassignment across 42 essential genes. (A) E. coli MG1655 codon usage heat map; 
brightness increases as codon usage decreases. Black numbers are total codon usage based on NC_000913.2 
(National Center for Biotechnology Information, 1 September 2011). The anticodon specificities (29, 30) are 
illustrated as dashed brackets; white indicates anticodons that were targeted for eventual removal. Amino acids 
are indicated in the yellow side bars. White boxes denote the 13 forbidden codons, and white numbers report how 
many instances of each codon were in the panel of 42 targeted essential genes. All 405 instances of these 
forbidden codons were successfully recoded across 80 E. coli strains. Additionally, all possible codons were 
swapped to synonymous codons, and gene overlaps were removed by duplication (bottom). (B) Strategy for 
recoding essential genes. Recoded genes (blue rectangles) were synthesized from Agilent oligonucleotide library 
synthesis arrays (24), then transcriptionally fused to kanR (purple rectangles) by isothermal assembly (25). These 
cassettes were recombined into EcNR2 {E. coli MG1655 Δ(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-bla] 
ΔmutS::cat} using λ Red (26), and recombinants were selected on kanamycin. Putative recombinants were 
screened with three sets of primers: wild-type primers (gray) hybridize specifically to the natural gene sequence, 
mutant primers (blue) hybridize specifically to the recoded gene sequence, and boundary primers (black) 
hybridize to the surrounding genomic DNA. Desired recombinants were detected by polymerase chain reaction 
and then verified by Sanger sequencing. We found that kanR (“kanR only”) could be inserted downstream of all 
genes except for rplO without causing major deleterious effects. We attempted to replace all 42 natural genes 
with radically recoded versions (“Fully recoded”; blue rectangles and triangles are recoded sequence). To 
coarsely map problematic design elements in the failed cassettes, we prepared cassettes that preserved natural 
sequence at the N-terminus (“Partially recoded”; gray rectangles and triangles are natural sequence). Finally, all 
remaining forbidden codons were recoded with CoS-MAGE (green triangles) and confirmed with Sanger 
sequencing. 
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essential genes, including all 41 essential ribosomal protein-coding genes (20) and prfB, which 
relies on a programmed frameshift for proper translation (21). Because expression level 
correlates strongly with codon usage bias (9), the highly expressed and tightly regulated (22, 23) 
ribosomal genes should be among the most difficult to change. To study codon essentiality in 
each of these genes, we attempted to remove all instances of the aforementioned 13 codons 
(hereafter referred to as “forbidden” codons). In addition, we gauged tolerance for large-scale 
DNA sequence alterations by shuffling all possible codons to synonymous alternatives. 
Replacement codons were chosen randomly from a weighted distribution, based on their 
frequencies in all E. coli genes (AUG and UGG codons were unchanged because they uniquely 
encode Met and Trp, respectively). Finally, we changed 1 non-AUG start codon to AUG, 
separated six gene overlaps, removed one frameshift, and avoided the use of six restriction sites 
used in gene assembly (supplemental text). Thus, whereas the protein sequence was 100% 
identical in our designs, the nucleotide sequence was on average only 65.4% identical, and the 
codon identity was only 4.44% (corresponding to the unchanged AUG and UGG codons) (Table 
S6-1). Based on these radical design parameters, we did not expect all design elements to be 
tolerated. Therefore, individually recoding each gene was the most biologically relevant scale on 
which to assess the effects of recoding without sacrificing the ability to rapidly map design 
flaws. 
We synthesized recoded genes from DNA microchips (24), transcriptionally fused each 
to a kanamycin resistance gene (kan
R
) by isothermal assembly (25), and replaced the 
corresponding natural gene (one gene per strain) in vivo using λ Red recombination (26) (Figure 
6-1B). We also introduced kan
R
 downstream of the natural genes and found that 41 of 42 (Table 
S6-2) allowed insertion with an average growth defect of 15% in LB-Lennox
 
(12% in Teknova 
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Hi-Def Azure media). Insertion downstream of rplO was unsuccessful, indicating that disrupting 
operon structure—and, by extension, refactoring overlapping genes—is a potential failure mode 
for redesigning genomes. For the recoded genes, we found that 26 of 42 (Table S6-2) were 
successful with an average growth defect of 20% in LB-Lennox (14% in Azure) compared with 
kan
R
 insertion controls (Figure 6-2). In the recoded prfB strain, removing the frameshift and 
recoding an upstream AGG codon that may be involved in pausing translation and enhancing 
frameshifting (15) did not significantly affect fitness (t test, p = 0.86). Finally, to test the 
independence of the growth defects, we inserted a recoded rplM or rpsI gene transcriptionally 
fused to spectinomycin resistance into three recoded strains with varying fitness (rpmC_syn1, 
rplE_syn1, and rplP_syn1). All double-mutant strains exhibited better fitness than predicted 
assuming that the fitness defects were independent, although this does not rule out potential 
cumulative effects from 
combining multiple deleterious 
designs (Figure S6-1).
 
The 16 unsuccessfully 
recoded genes provided an 
opportunity to identify failure 
modes for recoding. We 
coarsely mapped deleterious 
alleles in the remaining genes 
by recoding only the C-
terminal half of each gene 
(successful for 9 of 16 genes) 
Figure 6-2. Recoded strain doubling times in (A) LB-Lennox media and 
(B) Teknova Hi-Def Azure media. Each data point represents the average 
doubling time of a given strain with a portion of a ribosomal gene recoded 
(n = 3). Error bars for each group represent mean +/- SD. Under assay 
conditions, the parental strain {E. coli MG1655 Δ(ybhB-bioAB)::[λcI857 
N(cro-ea59)::tetR-bla ΔmutS::cat], “EcNR2”} exhibited a 49 +/- 4 minute 
doubling time in LB-Lennox and a 84 +/- 5 minute doubling time in 
Teknova Hi-Def Azure. Strain genotypes and doubling times are 
summarized in Tables S6-4 to S6-5. KanR insertion into natural sequences 
(with no recoding) seldom impaired fitness. Still, we could not introduce 
kanR downstream of rplO after three attempts. Fully or partially recoded 
gene recombinants exhibited the broadest range of fitness defects. For 
successful recombinants, position of the recoded gene in its operon did not 
appear to correlate strongly with fitness. The CoS-MAGE recombinants 
exhibited robust fitness, indicating that all tested forbidden codons are 
readily dispensable in small groups. 
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(Table S6-2). Of these 9 genes, 7 were also amenable to recoding all but the first 30 codons 
(Figure 6-1B). Although not conclusive based on the limited sample size, these remaining failed 
replacements may be caused by the disruption of endogenous control mechanisms upstream of 
the gene (23) or by codon bias affecting expression (7, 12). Using the above synthetic 
complementation approaches, we recoded a total of 294 of 405 forbidden codons in 35 of 42 
targeted essential genes across 35 strains (one recoded gene per strain) (Tables S6-2 and S6-3). 
This generated 4375 out of 6496 total desired nucleotide changes and introduced 29 synthesis 
errors and/or spontaneous mutations (1 error per 436 base pairs) (Figure 6-3 and Table S6-4). 
Although synthesis errors sometimes introduced de novo forbidden codons, additional screening 
invariably found alternative clones lacking forbidden codons. We hypothesize that the remaining 
genes (7 of 16) failed due to perturbations in gene expression arising from separating 
overlapping genes, and/or non-viable changes introduced while shuffling codons that were not 
forbidden.  
To determine whether any remaining instances of the forbidden codons were essential, 
we used co-selection multiplex automated genome engineering (CoS-MAGE) (27) to remove all 
remaining forbidden codons in small groups across a population of cells (111 desired mutations 
in 45 clones) (Figure 6-3 and Table S6-5). The CoS-MAGE recombinants exhibited robust 
fitness (Figure 6-2), indicating that none of the forbidden codons provide a systematic barrier to 
removal. Furthermore, this suggests that unsuccessful gene replacements using fully recoded 
cassettes were not due to the removal of forbidden codons. Our initial designs yielded all desired 
mutations except for one (rplQ U162G). Unexpectedly, when we attempted to replace this CUU 
(Leu) codon using a pool of oligos encoding all Leu, Ile, Val, and Ala codons (Table S6-6), only 
CUG (Leu), UUG (Leu), and GUG (Val) were not observed (Table S6-7). Therefore, CUU is not 
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essential, but 3 out of 12 tested replacement codons (all ending in UG) were either deleterious or 
recalcitrant to λ Red-mediated allele replacement in a way that was not anticipated a priori. We 
Figure 6-3. Schematics of all changes introduced in recoded essential genes. Light gray represents natural DNA 
sequence, light blue represents recoded sequence (average nucleotide identity = 65.4%), and dark gray represents 
frameshifted sequences caused by point deletions. Yellow lines indicate missense mutations introduced by gene 
synthesis errors, none of which introduced forbidden codons. Triangles indicate forbidden codons recoded by 
gene replacement (blue) or CoS-MAGE (green). The purple triangle in rplQ indicates the CUU codon that could 
not be converted to CUG as originally designed. We exhaustively tested all possible replacement Leu, Ile, Val, 
and Ala codons, and only CUG, UUG, and GUG were not observed. All 405 instances of the forbidden codons 
were successfully replaced across 80 strains. 
162 
 
note that the native gene sequence at this locus (ACT CTT GCC) contains most of the CTWGG 
Vsr recognition motif [Vsr is a mismatch repair endonuclease that is somewhat MutS-
independent (28)], but that the position (nucleotide 3 instead of nucleotide 2) and identity (T:C 
instead of T:G) of the oligo-mediated mismatch are noncanonical. We mutated codons 23 and 24 
of vsr to in-frame stop codons but were still unable to isolate rplQ recombinants with CUG, 
UUG, or GUG codons at position 162, thus suggesting that Vsr is not the cause of these failed 
replacements. It is likely that further recoding will uncover additional cryptic design flaws; 
nevertheless, our strategy is well suited to rapidly identify alternative solutions that are viable. 
 
Discussion 
 Our results provide three important insights for designing recoded genomes. First, when 
tested individually or in groups, all 405 instances of the forbidden codons were non-essential, 
suggesting that they are amenable to genome-wide removal. Second, our inability to replace 
CUU with CUG, UUG, and GUG at position 162 in rplQ demonstrates that synonymous codons 
can be non-equivalent in unpredictable ways. Nevertheless, our ability to successfully remove all 
instances of 13 codons from a panel of highly expressed essential genes indicates that radical 
genome recoding is feasible. Finally, most of the recoded genes displayed reduced fitness, and 
combining the current designs into a single genome could lead to unacceptable fitness 
impairment. In contrast, we did not observe significantly altered growth rates for the CoS-
MAGE strains in which only forbidden codons were changed (Table S6-5). Therefore, our future 
strategies for genome-wide codon reassignment will only change codons of interest while 
selecting for variants with normal growth. This approach leverages diversity and evolution to 
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overcome such uncharacterized genome design constraints, allowing researchers to focus on 
creating genomes possessing new and useful functions. 
 
Materials and Methods 
 All DNA oligonucleotides (Table S6-8) were purchased with standard purification and 
desalting from Integrated DNA Technologies. The Oligo Library Synthesis (OLS) array used for 
synthesizing radically recoded genes was generated on a DNA microchip, processed, and 
delivered as a ~1-10 pmol lyophilized pool of oligos by Agilent Technologies (Carlsbad, CA). 
 Cultures were grown at 34 °C with aeration in LB-Lennox (LB
L
; 10 g/L Bacto tryptone, 5 
g/L sodium chloride, 5 g/L yeast extract) and colonies were grown on LB
L
-agar plates (LB
L
 with 
15 g/L Bacto agar). LB
L
 media was supplemented with one or more of the following selective 
agents: carbenicillin (50 µg/mL), sodium dodecyl sulfate (SDS; 0.005% w/v), kanamycin (30 
µg/mL). Colicin E1 was obtained via expression in strain JC411 (31), and purified as previously 
described. 
NAT_kan
R
 cassette preparation: Kanamycin resistance (kan
R
) cassettes were inserted 
via λ Red recombination (26, 32) downstream of essential ribosomal genes, in order to test 
whether polar effects from inserting kan
R
 impair fitness. These “NAT_kanR” cassettes were PCR 
amplified using primers that introduced 50 bp of genomic homology on either side of the 
intended kan
R
 insertion site (Kapa HiFi Ready Mix; manufacturer’s protocols). PCR products 
were SPRI purified as previously described (33), eluted in deionized water (dH2O), and checked 
on a 1% agarose gel for correct size and purity before being recombined as described below. 
Recoded gene cassette preparation: Recoded essential genes (Table S6-9) were 
synthesized from an Agilent OLS array as previously described (24). Due to their size, the prfB 
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and rpsA genes were difficult to synthesize in one piece, so they were each synthesized in two 
pieces, which were then assembled via isothermal assembly (34). All synthesized recoded 
cassettes were fused to a downstream kanamycin resistance gene (kan
R
) via isothermal assembly 
(34). The crude isothermal assemblies were PCR amplified using primers (Table S6-8) that 
introduced 50 bp of genomic homology on either side of the recoded gene and kan
R
 (Kapa HiFi 
Ready Mix; manufacturer’s protocols). Full-length cassettes were SPRI purified as previously 
described (33), eluted in dH2O, and checked on a 1% agarose gel for correct size and purity 
before being recombined as described below. 
Partially recoded cassette preparation: Partially recoded gene cassettes were prepared 
using the full-length recoded gene cassettes (described above) as template (Kapa HiFi Ready 
Mix; manufacturer’s protocols). While the same reverse primers were used, new forward primers 
were designed to hybridize inside the recoded cassette and to introduce 50 bp homology regions 
matching the natural sequence, so that only the C-terminal portion of the gene would be recoded 
(Figure 6-1B).  
We prepared two types of partially recoded cassettes. The less stringent version recoded 
exactly half of the gene. The more stringent version recoded all except for the first 30 codons of 
the gene. Partially recoded cassettes were SPRI purified as previously described (33), eluted in 
dH2O, and checked on a 1% agarose gel for correct size and purity before being recombined as 
described below. 
CoS-MAGE selectable marker preparation: To maximize the number of alleles that 
could simultaneously be replaced per recombinant, we used Co-Selection Multiplex Automated 
Genome Engineering (CoS-MAGE) with tolC or bla as co-selectable markers (18, 27). In most 
cases, 90 nt MAGE oligos were designed to replace several forbidden codons. We performed 
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CoS-MAGE in an EcNR2.xseA
- 
background, which has ExoVII inactivated in order to minimize 
allele loss near the 3’ end of the MAGE oligos (35). Since the ribosomal genes are clustered in 
different regions of the genome, selectable markers needed to be placed in multiple different 
genomic locations in order to provide co-selection in adequate proximity (~500 kb) to the target 
ribosomal genes. Therefore, we prepared two tolC cassettes (tolC.3502900 for rpsL, rplQ, rplO, 
rpsG, rplD, rpsD, rpsC, and rplB; tolC.4427600 for rpsR, rplL, and rplJ) using Kapa HiFi Ready 
Mix (manufacturer’s protocols) and PCR primers that introduced 50 bp of flanking genomic 
homology (Table S6-8). The tolC cassettes were purified using Qiagen’s PCR purification kit 
(manufacturer’s protocols, eluted in dH2O) before being recombined as described in the “gene 
and allele replacement” methods section. For rpsA co-selection, bla was already present in the λ 
prophage of EcNR2.  
Gene and allele replacement: All CoS-MAGE oligonucleotides and Nat_Kan
R
, fully 
recoded, and partially recoded cassettes (described above) were recombined into EcNR2 (E. 
coli MG1655 ΔmutS::cat Δ(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-bla]) as previously 
described (18). Briefly, EcNR2 was grown to mid-log phase (OD600 between 0.4 and 0.6), 
induced to express λ Red for 15 minutes in a 42 °C shaking water bath, and chilled on ice. For 
each recombination, 1 mL of induced culture was washed twice in 1 mL cold dH2O, and then the 
cell pellet was  resuspended in 50 µL of dH2O containing the DNA to be recombined. For PCR 
products, 1-2 ng/µL was used; to inactivate selectable markers for CoS-MAGE, a 90mer 
oligonucleotide was used at a final concentration of 1 µM; for CoS-MAGE, 90mer 
oligonucleotides were pooled at a final concentration of ≤ 5 µM. A BioRad GenePulser™ was 
used for electroporation (0.1 cm cuvette, 1.78 kV, 200 Ω, 25 µF), and electroporated cells were 
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allowed to recover in 3 ml LB
L
 in a rotator drum at 34°C for at least 3 hours before plating on 
appropriate selective media.  
 Recombinant clones were selected on LB
L
-agar supplemented with kanamycin, and then 
re-streaked on fresh LB
L
-agar supplemented with kanamycin to ensure monoclonality. 
Monoclonal colonies were then grown in a 96-well format (150 µL LB
L
 supplemented with 
kanamycin) in preparation for genetic analysis. 
To prepare the EcNR2.xseA
-
 strains for CoS-MAGE, we deleted the endogenous tolC 
from the genome using the tolC.90.del oligo and selected for recombinants via Colicin E1 
selection (18).  We then separately introduced the tolC co-selection cassettes (one per CoS-
MAGE strain) and selected on LB
L
 supplemented with SDS. Finally, we inactivated tolC by 
introducing a nonsense mutation and a frameshift using the tolC-r_null_mut* oligo. For bla co-
selection, we used the bla_mut* oligo to inactivate bla (present in the λ prophage) and screened 
for carbenicillin-sensitive recombinants by replica plating on LB
L
 supplemented with 
carbenicillin. 
CoS-MAGE: CoS-MAGE was performed as previously described (27), using 0.5 µM of 
each MAGE oligo and 0.5 µM of the appropriate co-selection oligo to revert tolC.3502900 (rpsL, 
rplQ, rplO, rpsG, rplD, rpsD, rpsC, rplB), tolC.4427600 (rpsR, rplL, rplJ), or bla (rpsA). MAGE 
(without co-selection) (19) was performed on rpsP and rpsB because they were distant from the 
available co-selectable markers and only had 4 codons to be removed. CoS-MAGE recombinants 
were selected on LB
L
-agar supplemented with SDS (for tolC) or LB
L
-agar supplemented with 
carbenicillin (for bla), and MAGE recombinants were grown on LB
L
-agar without selection. 
Monoclonal colonies were picked into a 96-well plate and grown under the appropriate selection 
at 34 °C with shaking. 
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Recombinant clone genotyping: Recombinant clones were first screened by PCR, then 
validated by Sanger sequencing. For the fully recoded genes, we performed 3 PCR reactions for 
each clone. As diagramed in Figure 6-1B, the three sets of primers hybridized to the natural gene 
sequence (NAT), the recoded gene sequence (SYN), and the flanking genomic region (BND). 
PCR reactions (10 µL each) were performed with Kapa 2G Fast Ready Mix according to the 
manufacturer’s protocols. Adequate primer specificity was observed with a 58 °C annealing 
temperature. Desired recombinants had no NAT amplicon, a gene-sized SYN amplicon, and a 
BND amplicon 847 bp larger than that of the wild type negative control. Partially (C-terminally) 
recoded recombinants were screened using the NAT forward and SYN reverse primers (desired 
recombinants had a gene-sized amplicon) and BND primers (desired recombinants showed an 
847 bp increase in amplicon size). All putative recombinants that passed the PCR assay were 
Sanger sequenced (Genewiz or Eton Bioscience Inc.) using the forward BND primers and/or 
kanR.seqOUT-Nr2. 
CoS-MAGE recombinants were typically sequenced without initial Multiplex Allele 
Specific Colony PCR (MASC-PCR (18)) screening because the targeted alleles were too close 
together to allow for the amplification of discrete bands. However, well-separated alleles were 
screened via MASC-PCR with standard protocols (18) prior to Sanger sequencing validation. 
Doubling time analysis: Doubling times (Figure 6-2, Tables S6-4 to S6-5) were 
determined for all recoded clones using LB
L
 and Teknova HiDef Azure media. Kinetic growth 
curves were performed in triplicate on a Biotek H4 plate reader with OD600 measurements at 5 
minute intervals. Cultures were grown in a flat-bottom 96-well plate (in 150 µL of LB
L
 
supplemented with carbenicillin) with shaking at 34 °C. Doubling times were determined by 
tdouble = c*ln(2)/m), where c = 5 minutes per time point and m is the maximum slope of ln(OD600) 
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smoothed across 5 contiguous time points (20 minutes). We typically calculate doubling time in 
this manner so as to accommodate strains that achieve lower maximum optical densities. Each 
data point in Figure 6-2 represents the average doubling time of an individual strain with one 
ribosomal gene partially or fully recoded (n = 3). Each replicate was prepared by passaging from 
the previous one. All strains are based on EcNR2 or EcNR2.xseA
-
 [doubling times under assay 
conditions for these strains are 49 +/- 4 minutes in LB
L
 and 84 +/- 5 minutes in Teknova HiDef 
Azure Media (12 replicates per condition)]. 
 
Supplemental material 
 Supplemental material for CHAPTER 6 can be found in APPENDIX E or at 
<http://www.sciencemag.org/content/suppl/2013/10/16/342.6156.361.DC1/Lajoie2.SM.pdf>. 
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Genome design is the major challenge for engineering genomes possessing new and 
useful properties. How do you fundamentally change the properties of a genome without 
introducing deleterious design flaws? My early graduate work focused on developing efficient in 
vivo genome engineering technologies (1-5) capable of extensively engineering the Escherichia 
coli genome. Important features of these technologies are: (1) in vivo editing allows real time 
assessment of intended and unintended genome alterations, reducing the risk that one synthesis 
or design flaw will cause an entire genome to fail, (2) exploiting evolution to remove deleterious 
alleles from the population makes it possible to test aggressive designs containing potentially 
deleterious alleles, (2) multiplex allele replacement facilitates rapid accumulation of desired 
changes (3), and parallelization makes the unit of engineering smaller (i.e., genome segments vs. 
whole genomes), facilitating efficient genome assembly and rapid mapping of design flaws.  
For my main project, I used these technologies to replace all instances of the UAG stop 
codon with the synonymous UAA codon in E. coli (2, 6). With this strain in hand, I tested our 
hypotheses that genomically recoded organisms (GROs) would improve NSAA incorporation 
and resist viruses. Although the results of these tests were promising, it was clear that additional 
codons must be reassigned in order to fully realize our goals to expand the genetic code, to block 
virus infection, and to mistranslate genetic material transferred to/from natural organisms. 
However, reassigning additional codons was technologically and biologically a daunting task. 
The next-rarest codons in E. coli are 10-fold more abundant than UAG, and there is extensive 
evidence that sense codons perform additional functions beyond choosing an amino acid (see 
Chapter 6). We wondered whether we could find instances of codons that were essential and 
could not be changed to any other codon, so we performed a pilot experiment in which we 
removed 13 rare codons from 42 highly expressed essential genes. Although we were successful 
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in finding many genome designs that were not 
viable, we did not find any codons that could not 
be changed (7), suggesting that it may be 
possible to recode some of these codons 
genome-wide.  
Extrapolating from the first study in 
which we completely reassigned the UAG stop 
codon and the second study in which we 
identified 13 codons that could be potentially 
reassigned, we are currently attempting to 
engineer a genome with 7 codons reassigned, 
requiring 62,733 codon changes (Figure 7-1). To 
accomplish this, we are developing an efficient 
pipeline based on computer-aided genome 
design, chip-based DNA synthesis, in vitro DNA fragment assembly, and in vivo genome 
assembly to synthesize a recoded genome. Even more so than for our previous genetic code 
engineering projects, there is a considerable risk for design flaws, so our pipeline is designed to 
facilitate rapid troubleshooting. This includes crude mapping of design flaws using 
recombineering, fine mapping/troubleshooting of design flaws using MAGE, and efficient 
genome analysis software to track the effects of intended and unintended mutations.  
In addition to producing a powerful chassis organism for biotechnology, it is important to 
ensure safety. Although it is unlikely that GROs would survive well in the environment (even if 
they are resistant to viruses), safeguards can be implemented to ensure their safety. As mentioned 
Figure 7-1. Proposed future genetic code 
reassignment. E. coli MG1655 codon usage heat 
map; brightness increases as codon usage decreases. 
Black numbers are total codon usage based on 
NC_000913.2 (National Center for Biotechnology 
Information, 1 September 2011). The anticodon–
codon pairings (29, 30) are illustrated as dashed 
brackets; blue indicates anticodons that are targeted 
for eventual removal; white indicates additional 
anticodons that could be potentially removed. Blue 
boxes denote the 7 codons that we intend to remove 
from the genome prior to reassignment (62,733 
codon changes required). White boxes denote 
additional codons that could be removed (164,505 
codon changes required). Amino acids are indicated 
in the yellow side bars. 
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above, in the case of accidental horizontal gene transfer, differences in the genetic code would 
genetically isolate the recombinant DNA from functioning in natural organisms. Additionally, 
we are engineering C321.ΔA to be metabolically dependent on NSAAs for survival, ensuring 
that this strain cannot survive in the environment. We are accomplishing this by redesigning 
essential proteins so that they are dependent on the correct incorporation of a NSAA for proper 
translation, folding, and function. Dependence on unnatural compounds that are not produced in 
any known natural environment would provide a more robust alternative to traditional 
auxotrophies that can be overcome in metabolically rich environments.  
We have a number of additional projects underway:  
 Fixing C321.ΔA: Although we have begun work on the second generation of GROs, 
strain C321.ΔA (6) is a useful resource for studying the genetic code and expanding 
protein functions by incorporating unique NSAAs into proteins. Therefore, it would be 
beneficial to improve this strain as a resource for the scientific community. We have 
analyzed the C321.ΔA genome to identify the cause of its reduced fitness. Of the 355 off-
target mutations, we identified a subset of ~100 candidates that are most likely to be 
deleterious, and we have combinatorially reverted them using MAGE. After ~30 cycles 
of MAGE, we improved the doubling time from ~80 minutes/doubling to ~60 
minutes/doubling (the ancestral strain has ~50 minutes/doubling under our assay 
conditions). We are now analyzing the mutations in these improved strains in order to 
identify the causative alleles. We will implement these fixes in C321.ΔA and provide the 
improved strain as a resource for the scientific community. 
 AGR recoding: We are engineering an E. coli strain in which all 123 AGR codons in its 
essential genes are changed to alternative codons. This project will (1) pressure-test the 
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AGR codons that are expected to be most recalcitrant for recoding, (2) provide actionable 
sequence information for a synthetic genome with reassigned AGR codons, and (3) 
illuminate design constraints that will help improve future genome designs. 
 Extending MAGE to other organisms: We have developed powerful technologies for 
engineering Escherichia coli genomes, but we would like to engineer other organisms, 
too. While the bacteriophage λ Red recombination system mediates extremely efficient 
genome engineering in E. coli, it does not extend well to disparate organisms. 
Conveniently, homologs of this system exist across many organisms (8), and there has 
been some success reported for expanding recombineering to other organisms (9-13). We 
have developed a general method to select efficient recombineering activity from a panel 
of metagenomic recombinases in any organism of interest. We piloted this method in E. 
coli and identified additional recombinases that yielded similar recombination 
frequencies to λ Red. We are now applying this method to useful organisms such as P. 
aeruginosa, S. aureus, A. bayli, and cyanobacteria. 
 Improving tolC: In continued effort to improve technologies for efficient in vivo genome 
engineering, we rationally engineered an E. coli strain with improved robustness of the 
tolC dual selectable marker (Gregg, C.J. and Lajoie, M.J. in revision). Previously, the 
negative selection exhibited a failure rate that was too high for continued use without 
intermittent screening for desired recombinants. The improved strain is capable of 
continuous CoS-MAGE cycling, which has made it significantly easier to remove AGR 
codons from essential E. coli genes. 
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APPENDIX A 
 
Supplemental Material for Lambda Red Recombination in Escherichia coli Occurs 
Through a Fully Single-Stranded Intermediate 
 
 
 
 
 
This supplemental material is reproduced with permission from its initial publication: 
 
Mosberg JA
*
, Lajoie MJ
*
, Church GM (2010) Lambda Red Recombination in Escherichia coli 
Occurs Through a Fully Single-Stranded Intermediate. GENETICS: Vol. 186, 791-799 
 
Tables and Figures have been renamed to be consistent with CHAPTER 2. 
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FILE S1: Supplemental Materials and Methods 
Preparation of DNA constructs: PCR primers were ordered from Integrated DNA Technologies and are 
listed and described in Table S2-1.  All primers were ordered with standard desalting, except dual-
biotinylated primers, which were HPLC-purified.  Antibiotic resistance insertion cassettes were generated 
using long PCR primers containing 45 bp genome homology regions on the 5′ end, followed by roughly 
20 bp of homology to the antibiotic resistance gene to be amplified.  The insertion cassettes were 
designed such that the resistance gene was inserted 46 base pairs into the coding DNA sequence in the 
case of lacZ, and directly after the start codon in the cases of malK and tolC.  This set of PCRs was 
performed using Qiagen HotStarTaq Plus Master Mix.  Final primer concentrations were 0.4 μM, and 
templates were resuspended bacterial colonies bearing the desired resistance gene (the tn903 aphA1 gene 
for kanamycin resistance, the Sh ble gene for zeocin resistance, and the tn21 aadA1 gene for 
spectinomycin resistance - each cassette contained promoter and terminator sequences flanking the 
resistance gene).  These PCRs were heat activated at 95 °C for 6:00, and then cycled 30 times using a 
denaturation step of 94 °C for 0:30, an annealing step of 56 °C for 0:30, and an extension step of 72 °C 
for 2:30.  After a final 5:00 extension step at 72 °C, PCRs were held at 4 °C, then purified via 1% agarose 
gel extraction using the Qiagen gel extraction kit.  DNA samples were quantitated using a NanoDrop™ 
ND1000 spectrophotometer. 
 These constructs were used as template for subsequent PCRs to generate dual-biotinylated 
dsDNA constructs.  In each reaction, one primer contained a 5′ dual-biotin tag.  The other primer was 
unmodified, or contained four 5′ phosphorothioate bonds.  Phosphorothioate bonds were used in the 
experiment comparing leading-targeting and lagging-targeting ssDNA, with the rationale that this would 
increase recombination frequency by mitigating exonuclease degradation.  PCR conditions were as above, 
but with 1 μM primers, a 1:30 extension step, and 0.1 ng of the relevant insertion construct used as 
template.  PCR products were purified using the Qiagen PCR purification kit. 
 These dual-biotinylated dsDNA constructs were used to generate ssDNA via a biotin capture 
protocol.  In this method, the dual-biotinylated DNA strand is bound by streptavidin-coated magnetic 
beads.  Next, the dsDNA is chemically melted, allowing the non-biotinylated strand to be collected from 
the supernatant, while the biotinylated strand is retained by the beads.  Invitrogen DynaBeads® MyOne™ 
Streptavidin C1 beads were washed twice with 2x Bind and Wash buffer (10 mM Tris, 1 mM EDTA, 2 M 
NaCl, pH 7.5), then incubated in one initial bead volume of 1x Bind and Wash buffer, with 5 μg of dual-
biotinylated dsDNA for every 100 μL of beads.  This was placed on a tube rotator at room temperature for 
20 minutes, after which the beads were washed twice with 1x Bind and Wash buffer.  Single-stranded 
DNA was then released via incubation with one initial bead volume of chilled 0.125 M NaOH.  Beads 
were vortexed for 30 seconds, incubated for 30 seconds, then placed on a magnet so that the supernatant 
could be collected.  This process was repeated, and then the NaOH supernatants were cleaned using the 
Qiagen PCR purification kit.  The standard PCR purification protocol was used, neutralizing the solution 
with a 3 M solution of pH 5.0 NaOAc, and adding an additional rinse with Buffer PE.  The purity of the 
resulting ssDNA was confirmed by PAGE.  To this end, 10 ng of purified ssDNA was loaded onto a 6% 
TBE non-denaturing PAGE gel (Invitrogen) and post-stained with SYBR® Gold (Invitrogen). 
 A similar strategy was employed for creating the internally mismatched lacZ::kanR dsDNA 
cassette.  Two dual-biotinylated dsDNA constructs were generated, each intended to give rise to one of 
the two strands of the final mismatched construct.  These constructs were generated in an analogous 
manner to those described above, with mutations arising from the PCR primers as described in Table S2-
1.  These dual-biotinylated dsDNA constructs were used to produce ssDNA in the same manner as above.  
The dual-biotin tags were arranged such that complementary strands were purified from the two 
constructs, so that they could be annealed together in order to form the dsDNA construct diagrammed in 
Figure 2-4.  Purified strands were annealed in equimolar amounts (25 nM) in 5 mM Tris, 0.25 M NaCl, 
pH 8.0.  Samples were annealed by heating to 95 °C, and then cooling the samples in a thermocycler. The 
temperature was decreased by 1 °C every two minutes to a final temperature of 25 °C.  The resulting 
annealed dsDNA was purified from a 1% agarose gel using the Qiagen gel extraction kit. 
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 In order to generate phosphorothioated variants of the lacZ::kanR mismatched dsDNA construct, 
the two lacZ::kanR dsDNA constructs containing the designed mutations were each amplified as above, 
this time using phosphorothioated primers opposite the dual-biotinylated primers.  The resulting dsDNA 
constructs were used to purify phosphorothioated strands of ssDNA as above.  The phosphorothioated 
ssDNA and the previously produced unmodified ssDNA strands were then each used in annealing 
reactions, set up so as to generate all four combinations of dsDNA (as given in Figure 2-5).  Annealing 
and purification was carried out as described above. 
Analysis of mismatched dsDNA recombinants by MAMA PCR: The mismatch amplification 
mutation assay (MAMA) PCR method was used to analyze the genotypes of mismatched lacZ::kanR 
dsDNA recombinants (Qiang et al. 2002).  We used 2-bp mismatches in our mismatched lacZ::kanR 
cassette in order to increase the specificity of our MAMA primers and to decrease the chances of 
spontaneous point mutations confounding our results.  We designed four primers for each mismatch locus 
(Figure 2-4): a forward primer corresponding to the strand 1 allele, a forward primer corresponding to the 
strand 2 allele, a forward primer corresponding to the wild type allele, and a universal reverse primer.  
Primers were designed with the 2-bp mismatches at the 3' ends so that amplification would only occur 
when these two nucleotides matched the recombinant colony's genotype.  The L1 amplicon was 799 bp, 
L2 was 591 bp, L3 was 372 bp, and L4 was 205 bp.  Primers were designed with a target Tm of 62 °C, and 
a gradient PCR (annealing temperature between 62 °C and 68 °C) determined that the optimal annealing 
temperature for maximum specificity and yield was 64° C.  MAMA PCR reactions for loci 1&3 and loci 
2&4 were each performed in a single mixture so as to minimize the number of necessary reactions.  Each 
kanR colony was interrogated using 4 MAMA PCR reactions: strand 1 L1&L3, strand 1 L2&L4, strand 2 
L1&L3, and strand 2 L2&L4.  For convenience, both strand 1 reactions and both strand 2 reactions were 
pooled prior to agarose gel analysis.  PCR template was prepared by growing a monoclonal kanR colony 
to stationary phase and performing a 1/100 dilution of this culture into PCR-grade water.  Our 20 μL 
MAMA PCR reactions consisted of 10 μL Qiagen multiplex PCR master mix, 5 μL PCR grade water, 4 
μL primer mix (1 μM each), and 1 μL template.  PCRs were heat activated at 95 °C for 15:00, and then 
cycled 27 times using a denaturation step of 94 °C for 0:30, an annealing step of 64 °C for 0:30, and an 
extension step of 72 °C for 1:20.  After a final 5:00 extension step at 72 °C, PCRs were held at 4 °C until 
they were analyzed on a 1.5% agarose gel stained using ethidium bromide.  Strand 1 reactions for a given 
recombinant were loaded adjacent to corresponding strand 2 reactions for easy visual comparison.  All 48 
recombinants from replicate 1 were screened using wild type MAMA PCR reactions, performed in an 
analogous manner as above.  This experiment verified that all sites that were not detected as mutants were 
wild type alleles.  The accuracy of the MAMA PCR method was also verified by Sanger sequencing all 
four mismatch loci in eight recombinant colonies. 
 
FILE S2: Mistargeted Recombinants in ssDNA Recombination 
 A significant number of mistargeted recombinants (antibiotic-resistant colonies that retained 
LacZ function) were observed for both single-stranded lacZ::specR cassettes in the experiments tracking 
strand bias in ssDNA recombination (Table S2-2).  Such mistargeting also occurred with lacZ::specR 
dsDNA, but only rarely with the other lacZ-targeting cassettes.  These recombinants likely arise when 
microhomology sequences within the specR gene anneal to regions of the E. coli chromosome other than 
lacZ.  The observed strand bias for mistargeting may be due to differing secondary structure between the 
two strands.  Alternatively, a leading strand bias may be observed for mistargeting, since mistargeted 
annealing to regions on the lagging strand could outcompete correctly targeted annealing to the less 
accessible leading strand.  Mistargeted (LacZ+) colonies were not scored as recombinants, and do not 
affect the broader interpretation of our results. 
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TABLE S2-1. Primer Sequences Used in this Study 
Name Use Sequence 
Versions 
used
a
 
LacZ::KanR.full-f  
Forward strand for generation of 
the initial LacZ::KanR construct 
TGACCATGATTACGGATTCACTGG
CCGTCGTTTTACAACGTCGTGCCTG
TGACGGAAGATCACTTCG Unmodified 
LacZ::KanR.full-r 
Reverse strand for generation of 
the initial LacZ::KanR construct 
GTGCTGCAAGGCGATTAAGTTGGG
TAACGCCAGGGTTTTCCCAGTAAC
CAGCAATAGACATAAGCGG Unmodified 
MalK::KanR.full-f 
Forward strand for generation of 
the initial MalK::KanR construct 
AATGTTGCTGTCGATGACAGGTTG
TTACAAAGGGAGAAGGGCATGCCT
GTGACGGAAGATCACTTCG Unmodified 
MalK::KanR.full-r 
Reverse strand for generation of 
the initial MalK::KanR construct 
GACCTCGCCCCAGGCTTTCGTTAC
ATTTTGCAGCTGTACGCTCGCAAC
CAGCAATAGACATAAGCGG Unmodified 
TolC::KanR.full-f 
Forward strand for generation of 
the initial TolC::KanR construct 
AGTTTGATCGCGCTAAATACTGCT
TCACCACAAGGAATGCAAATGCCT
GTGACGGAAGATCACTTCG Unmodified 
TolC::KanR.full-r 
Reverse strand for generation of 
the initial TolC::KanR construct 
GAACCCAGAAAGGCTCAGGCCGAT
AAGAATGGGGAGCAATTTCTTAAC
CAGCAATAGACATAAGCGG Unmodified 
LacZ::ZeoR.full-f  
Forward strand for generation of 
the initial LacZ::ZeoR construct 
TGACCATGATTACGGATTCACTGG
CCGTCGTTTTACAACGTCGTGGGT
GTTGACAATTAATCATCGGC Unmodified 
LacZ::ZeoR.full-r 
Reverse strand for generation of 
the initial LacZ::ZeoR construct 
GTGCTGCAAGGCGATTAAGTTGGG
TAACGCCAGGGTTTTCCCAGTAGC
TTGCAAATTAAAGCCTTCG Unmodified 
LacZ::SpecR.full-f  
Forward strand for generation of 
the initial LacZ::SpecR construct 
TGACCATGATTACGGATTCACTGG
CCGTCGTTTTACAACGTCGTGCAG
CCAGGACAGAAATGC Unmodified 
LacZ::SpecR.full-r 
Reverse strand for generation of 
the initial LacZ::SpecR construct 
GTGCTGCAAGGCGATTAAGTTGGG
TAACGCCAGGGTTTTCCCAGTTGC
AGAAATAAAAAGGCCTGC Unmodified 
LacZ.short-f 
Forward strand for generation of all 
dual-biotinylated LacZ-targeting 
constructs TGACCATGATTACGGATTCACT 
Unmodified, 
Phosphoroth
ioated, Dual-
biotinylated 
LacZ.short-r 
Reverse strand for generation of all 
dual-biotinylated LacZ-targeting 
constructs GTGCTGCAAGGCGATTAA 
Phosphoroth
ioated, Dual-
biotinylated 
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TABLE S2-1 (Continued).   
MalK::KanR.short-f 
Forward strand for generation of 
dual-biotinylated MalK::KanR 
constructs AATGTTGCTGTCGATGACAGG 
Phosphoroth
ioated, Dual-
biotinylated 
MalK::KanR.short-r 
Reverse strand for generation of 
dual-biotinylated MalK::KanR 
constructs GACCTCGCCCCAGGC 
Phosphoroth
ioated, Dual-
biotinylated 
TolC::KanR.short-f 
Forward strand for generation of 
dual-biotinylated TolC::KanR 
constructs AGTTTGATCGCGCTAAATACTG 
Phosphoroth
ioated, Dual-
biotinylated 
TolC::KanR.short-r 
Reverse strand for generation of 
dual-biotinylated TolC::KanR 
constructs GAACCCAGAAAGGCTCAGG 
Phosphoroth
ioated, Dual-
biotinylated 
MM.LacZ::KanR.AA-
f 
Forward strand for generation of 
Construct AA (For the creation of 
mismatched LacZ::KanR) 
TGACCATGAAAACGGATTCACTGG
CCGTCGTTAAACAACGTCGTGCCT
GTGACGGAAGATCACTTCG Unmodified 
MM.LacZ::KanR.AA-
r 
Reverse strand for generation of 
Construct AA (For the creation of 
mismatched LacZ::KanR) 
GTGCTGCAAAACGATTAAGTTGGG
TAACGCCAAAGTTTTCCCAGTAAC
CAGCAATAGACATAAGCGG Unmodified 
MM.LacZ::KanR.CC-
f 
Forward strand for generation of 
Construct CC (For the creation of 
mismatched LacZ::KanR) 
TGACCATGACCACGGATTCACTGG
CCGTCGTTCCACAACGTCGTGCCT
GTGACGGAAGATCACTTCG Unmodified 
MM.LacZ::KanR.CC-
r 
Reverse strand for generation of 
Construct CC (For the creation of 
mismatched LacZ::KanR) 
GTGCTGCAACCCGATTAAGTTGGG
TAACGCCACCGTTTTCCCAGTAAC
CAGCAATAGACATAAGCGG Unmodified 
MM.AA.short-f 
Forward strand for generation of 
dual-biotinylated Construct AA TGACCATGAAAACGGATTCAC 
Unmodified, 
Phosphoroth
ioated 
MM.AA.short.DB-r 
Reverse strand for generation of 
dual-biotinylated Construct AA GTGCTGCAAAACGATTAAGTTG 
Dual-
biotinylated 
MM.CC.short.DB-f 
Forward strand for generation of 
dual-biotinylated Construct CC TGACCATGACCACGGATTC 
Dual-
biotinylated 
MM.CC.short-r 
Reverse strand for generation of 
dual-biotinylated Construct CC GTGCTGCAACCCGATTAAG 
Unmodified, 
Phosphoroth
ioated 
Kan.L1.AA.set1 
Forward MAMA PCR primer 
corresponding to the forward 
strand specific mismatch at 
position 1 in MM.LacZ::KanR CAGGAAACAGCTATGACCATGAAA Unmodified 
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TABLE S2-1 (Continued). 
  
Kan.L2.AA.set1 
Forward MAMA PCR primer 
corresponding to the forward 
strand specific mismatch at 
position 2 in MM.LacZ::KanR GATTCACTGGCCGTCGTTAA Unmodified 
Kan.L3.TT.set1 
Forward MAMA PCR primer 
corresponding to the forward 
strand specific mismatch at 
position 3 in MM.LacZ::KanR ATTGCTGGTTACTGGGAAAACTT Unmodified 
Kan.L4.TT.set1 
Forward MAMA PCR primer 
corresponding to the forward 
strand specific mismatch at 
position 4 in MM.LacZ::KanR GGCGTTACCCAACTTAATCGTT Unmodified 
Kan.L1.AA.set2 
Forward MAMA PCR primer 
corresponding to the reverse strand 
specific mismatch at position 1 in 
MM.LacZ::KanR GGAAACAGCTATGACCATGACC Unmodified 
Kan.L2.AA.set2 
Forward MAMA PCR primer 
corresponding to the reverse strand 
specific mismatch at position 2 in 
MM.LacZ::KanR TCACTGGCCGTCGTTCC Unmodified 
Kan.L3.TT.set2 
Forward MAMA PCR primer 
corresponding to the reverse strand 
specific mismatch at position 3 in 
MM.LacZ::KanR GCTGGTTACTGGGAAAACGG Unmodified 
Kan.L4.TT.set2 
Forward MAMA PCR primer 
corresponding to the reverse strand 
specific mismatch at position 4 in 
MM.LacZ::KanR GCGTTACCCAACTTAATCGGG Unmodified 
Kan.L1.TT.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 1 in 
MM.LacZ::KanR CAGGAAACAGCTATGACCATGATT Unmodified 
Kan.L2.TT.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 2 in 
MM.LacZ::KanR GATTCACTGGCCGTCGTTTT Unmodified 
Kan.L3.CC.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 3 in 
MM.LacZ::KanR GCTGGTTACTGGGAAAACCC Unmodified 
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Kan.L4.CC.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 4 in 
MM.LacZ::KanR GCGTTACCCAACTTAATCGCC Unmodified 
Kan.L1.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L1.AA.set1, Kan.L1.AA.set2, 
and Kan.L1.TT.setWT ATGCATTTCTTTCCAGACTTGTTCA Unmodified 
Kan.L2.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L2.AA.set1, Kan.L2.AA.set2, 
and Kan.L2.TT.setWT 
GCATCAACAATATTTTCACCTGAA
TCA Unmodified 
Kan.L3.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L3.TT.set1, Kan.L3.TT.set2, 
and Kan.L3.CC.setWT CTGTAGCCAGCTTTCATCAACA Unmodified 
Kan.L4.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L4.TT.set1, Kan.L4.TT.set2, 
and Kan.L1.CC.setWT; 
Sequencing primer for MAMA 
PCR validation 
AGGGGACGACGACAGTATC 
Unmodified 
Kan.L1.L2.seq 
Sequencing primer for MAMA 
PCR validation TAGCTCACTCATTAGGCACC Unmodified 
a Phosphorothioated primers contain four phosphorothioate linkages on the 5′ end.  Dual-biotinylated primers contain a dual-
biotin tag on the 5′ end. 
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TABLE S2-2 
 
Mistargeting Frequencies from ssDNA Strand Bias Recombination Experiment 
DNA 
Avg. Lagging-Targeting ssDNA 
Mistargeting Frequency 
(Standard Dev.) 
% Mistargeted 
Recombinants 
Avg. Leading-Targeting ssDNA 
Mistargeting Frequency 
(Standard Dev.) 
% Mistargeted 
Recombinants 
lacZ::kanR 1.1E-07 (+/- 1E-08) 0.19% 5.0E-08 (+/- 1.8E-08) 0.44% 
lacZ::zeoR 1.8E-08 (+/- 3.0E-08) 0.0082% 2.6E-08 (+/- 3.2E-08) 0.18% 
lacZ::specR 3.3E-06 (+/- 3.2E-06) 7.0% 5.5E-06 (+/- 1.7E-06) 76% 
 
 
TABLE S2-3 
 
Full MAMA PCR Results from Mismatched lacZ::kanR Recombination 
Mutation Inheritance Pattern
a 
Count 
(Replicate 1) 
Count 
(Replicate 2) Total 
Grouped by 
Category
b 
1/1/1/1 0 0 0 
68 
1/1/1/WT 10 8 18 
WT/1/1/1 0 3 3 
WT/1/1/WT 24 23 47 
2/2/2/2 0 0 0 
7 
2/2/2/WT 0 1 1 
WT/2/2/2 0 4 4 
WT/2/2/WT 0 2 2 
WT/1/1/2 4 1 5 
10 WT/1/2/WT 4 0 4 
WT/1/2/2 0 1 1 
2/2/1/WT 0 0 0 
9 WT/2/1/WT 5 3 8 
WT/2/1/1 0 1 1 
Ambiguous 1 1 2 2 
Sum 48 48 96 96 
 
 a Loci 1-4 are listed in order.  “1” indicates inheritance from strand 1, “2” indicates inheritance from strand 2, and “WT” 
indicates no mutation (i.e. a wild type allele) 
 
 b Grouped based on the manner of Exo processing that is implied, as detailed in Table 2-1. 
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APPENDIX B 
 
Supplemental Material for Manipulating Replisome Dynamics and DNA 
Exonucleases to Enhance Lambda Red-Mediated Multiplex Genome Engineering 
 
 
 
 
 
This supplemental material is reproduced with permission from its initial publication: 
 
Lajoie MJ
*
, Gregg CJ
*
, Mosberg JA
*
, Washington GC, Church GM (2012) Manipulating 
Replisome Dynamics to Enhance Lambda Red-Mediated Multiplex Genome Engineering. NAR; 
doi: 10.1093/nar/gks751 
 
Tables and Figures have been renamed to be consistent with CHAPTER 3. 
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Supplemental Information 
 
Table S3-1 DNA Oligonucleotides used in this study.  
Name Used for Sequence 
ygaR Set 1.850 
g*c*gaagatcagtaaagatatagaaggtggtatccctggctattaAcaa
ggtcaggttttgattccattcattaaagatccagtaacaa*a*a 
yqaC Set 1.700 
a*t*taaaaattatgatgggtccacgcgtgtcggcggtgaggcgtaActt
aataaaggttgctctacctatcagcagctctacaatgaat*t*c 
gabT Set 1.600 
t*c*accattgaagacgctcagatccgtcagggtctggagatcatcagcc
agtgttttgatgaggcgaagcagtaAcgccgctcctatgc*c*g 
ygaU Set 1.500 
t*g*acgccaattcccattatccagcaggcgatggctggcaattaaTtact
cttccggaatacgcaacacttgccccggataaattttat*c*c 
ygaM Set 1.400 
g*t*aggtatttttatcggcgcactgttaagcatgcgcaaatcgtaAtgca
aaaatgataataaatacgcgtctttgaccccgaagcctg*t*c 
luxS Set 1.300 
t*t*tgaactggcttttttcaattaattgtgaagatagtttactgaTtagatgtg
cagttcctgcaacttctctttcggcagtgccagtt*c*t 
mltB Set 1.250 
a*a*ttttacgaggaggattcagaaaaaagctgattagccagagggaagc
tcacgcccccctcttgtaaatagTtactgtactcgcgcca*g*c 
srlE Set 1.200 
a*c*tgtactgatcgcctggtttgtctccggttttatctatcaataAaggctg
aaacatgaccgttatttatcagaccaccatcacccgt*a*t 
norW Set 1.150 
a*t*cggatgaaagaggcatttggattgttgaaaacattgccgatgtaAgt
gggctactgtgcctaaaatgtcggatgcgacgctggcgc*g*t 
ascB Set 1.100 
a*t*cattctggtggtataaaaaagtgattgccagtaatggggaagatttag
agtaAgtaacagtgccggatgcggcgtgaacgccttat*c*c 
bioD Set 2.850 
t*c*gaagacgcgatctcgctcgcaatttaaccaaatacagaatggTtac
aacaaggcaaggtttatgtactttccggttgccgcatttt*c*t 
moaE Set 2.700 
c*g*taaacgtatgtactgagcggtgaaattgccggacgcagcggtgcct
tatccggctaacaaaaaaTtaccagcgttttgccgcctgc*t*g 
ybhM Set 2.600 
g*c*gatgtgaagtttagttaagttctttagtatgtgcatttacggTtaatga
aaaaaacgcgtatgcctttgccagacaagcgttatag*c*t 
ybhS Set 2.500 
t*t*tatcggcctgacgtggctgaaaaccaaacgtcggctggattaAgga
gaagagcatgtttcatcgcttatggacgttaatccgcaaa*g*a 
ybiH Set 2.400 
c*a*tatcgacctgattttgcaaggattatcgcaaaggagtttgtaAtgatg
aaaaaacctgtcgtgatcggattggcggtagtggtact*t*g 
ybiR Set 2.300 
t*c*tgaattaatcttcaaaacttaaagcaaaaggcggactcataatccgcc
ttttttatttgccagaccTtagttggccgggagtataa*c*t 
yliD Set 2.250 
t*t*tcctgtgaggtgattaccctttcaagcaatattcaaacgtaaTtatcctt
taattttcggatccagcgcatcgcgtaaaccatcgc*c*c 
yliE Set 2.200 g*a*ctgactgtaagtacgaacttattgattctggacatacgtaaaTtactc
ttttactaattttccacttttatcccaggcggagaatg*g*c 
ybjK Set 2.150 
t*c*ggttcaaggttgatgggttttttgttatctaaaacttatctaTtaccctg
caaccctctcaaccatcctcaaaatctcctcgcgcg*a*t 
rimK Set 2.100 c*g*caaaaagcgcaggcaaaaccatgatcagtaatgtgattgcgaTta
accacccgttttcaggcaatattctgtcgtagcgtggcgtt*c*g 
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Table S3-1 (Continued). 
ygfJ Set 3.850 
c*c*ggacgactttattacagcgaaggaaaggtatactgaaatttaAaaa
acgtagttaaacgattgcgttcaaatatttaatccttccg*g*c 
recJ Set 3.700 
g*g*gattgtacccaatccacgctcttttttatagagaagatgacgTtaaat
tggccagatattgtcgatgataatttgcaggctgcggt*t*g 
argO Set 3.600 
c*t*ctggaggcaagcttagcgcctctgttttatttttccatcagatagcgcT
taactgaacaaggcttgtgcatgagcaataccgtctc*t*c 
yggU Set 3.500 
a*a*tccgcaacaaatcccgccagaaatcgcggcgttaattaattaAgta
tcctatgcaaaaagttgtcctcgcaaccggcaatgtcggt*a*a 
mutY Set 3.400 
g*t*ggagcgtttgttacagcagttacgcactggcgcgccggtttaAcgc
gtgagtcgataaagaggatgatttatgagcagaacgattt*t*t 
glcC Set 3.300 
g*c*caccatttgattcgctcggcggtgccgctggagatgaacctgagtta
Actggtattaaatctgcttttcatacaatcggtaacgct*t*g 
yghQ Set 3.250 
a*c*tgagtcagccgagaagaatttccccgcttattcgcaccttccTtaaa
tcaggtcatacgcttcgagatacttaacgccaaacacca*g*c 
yghT Set 3.200 
t*g*gttgatgcagaaaaagcgattacggattttatgaccgcgcgtggttat
cactaAtcaaaaatggaaatgcccgatcgccaggaccg*g*g 
ygiZ Set 3.150 
t*t*ctctgtctatgagagccgttaaaacgactctcatagattttaTtaatag
caaaatataaaccgtccccaaaaaagccaccaaccac*a*a 
yqiB Set 3.100 
a*g*ggttaacaggctttccaaatggtgtccttaggtttcacgacgTtaata
aaccggaatcgccatcgctccatgtgctaaacagtatc*g*c 
ygfJ_AGR Set 3X.850 
c*c*actatgtcagccatcgactgtataattaccgctgccggattatcatca
AGGatggggcaatggaaaatgatgttaccctgggaaca*g*g 
ygfT_AGR Set 3X.700 
g*a*tgccttcgtatcaaacagagttaacatatcgcgcgccgcctgTCTt
cctgcggccattgcagtgacaaccagatccgcgccatgaa*c*t 
ubiH_AGR Set 3X.600 
g*t*gcagagtttgcgccgcattgcccaccagcacggtacgatgggtaat
agaCCTggcggcgtgggttaacgccagcggataagcactg*c*g 
argO_AGR Set 3X.500 
g*g*attcagccaggtcactgccaacatggtggcgataattttccaCCT
gccttgcttcatgacttcggcgctggctaactcaatattac*t*g 
yqgC_AGR Set 3X.400 
g*a*atcctgagaagcgccgagatgggtataacatcggcaggtatgcaa
agcAGGgatgcagagtgcggggaacgaatcttcaccagaac*g*g 
trmI_AGR Set 3X.300 
t*t*ttttacgcagacgacggctacggttctttgccattatttcacTCTctc
gaacattaagtcccatactccgtgaccaagacgatgac*c*a 
glcC_AGR Set 3X.250 
a*c*gatctgctcgacgttcgcgcattactggagggcgaatcggcaAG
Actggcggcaacgctgggaacgcaggctgattttgttgtgat*a*a 
yghT_AGR Set 3X.200 
g*t*gaacatcttattaccgttgtcgaaaaatatggtgctgccgaaAGGg
ttcatttaggaaaacaggccggaaatgtcggtcgtgcagt*g*a 
ygiZ_AGR Set 3X.150 
a*a*tacatatacccaaaactcgaacatttcccgcataaagagtttCCTta
agataagaataataagtggcgtaagaagaaaaaatgctg*c*a 
cpdA_AGR Set 3X.100 c*t*tcgtgcttttgtgcaaacaggtgagtgtcggtaatttgtaaaatcctga
cCCTggcctcaccagccagaggaagggttaacaggct*t*t 
lacZ_KO1 Set lacZ jackpot +61 
T*C*ACTGGCCGTCGTTTTACAACGTCGTGAC
TGGGAAAACCCTtGaGTTACCCAACTTAATCG
CCTTGCAGCACATCCCCCTTTCGCCA*G*C 
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Table S3-1 (Continued). 
lacZ_KO2 Set lacZ jackpot +264 
G*C*TGGAGTGCGATCTTCCTGAGGCCGATAC
TGTCGTCGTCCCCTCAtAaTGGCAGATGCACG
GTTACGATGCGCCCATCTACACCAAC*G*T 
lacZ_KO3 Set lacZ jackpot +420 
C*A*CATTTAATGTTGATGAAAGCTGGCTACA
GGAAGGCCAGACGtaAATTATTTTTGATGGCG
TTAACTCGGCGTTTCATCTGTGGTGC*A*A 
lacZ_KO4 Set lacZ jackpot +602 
T*G*ATGGTGCTGCGCTGGAGTGACGGCAGTT
ATCTGGAAGATCAGtAgATGTGGCGGATGAGC
GGCATTTTCCGTGACGTCTCGTTGCT*G*C 
lacZ_KO5 Set lacZ jackpot +693 
T*A*AACCGACTACACAAATCAGCGATTTCCA
TGTTGCCACTCGCTaaAATGATGATTTCAGCC
GCGCTGTACTGGAGGCTGAAGTTCAG*A*T 
lacZ_KO6 
Set lacZ jackpot 
+1258 
T*A*CGGCCTGTATGTGGTGGATGAAGCCAAT
ATTGAAACCCACtGaATGGTGCCAATGAATCG
TCTGACCGATGATCCGCGCTGGCTAC*C*G 
lacZ_KO7 
Set lacZ jackpot 
+1420 
G*G*GAATGAATCAGGCCACGGCGCTAATCA
CGACGCGCTGTATtGaTGGATCAAATCTGTCG
ATCCTTCCCGCCCGGTGCAGTATGAAG*G*C 
lacZ_KO8 
Set lacZ jackpot 
+1599 
G*T*CCATCAAAAAATGGCTTTCGCTACCTGG
AGAGACGCGCCCGtaGATCCTTTGCGAATACG
CCCACGCGATGGGTAACAGTCTTGGC*G*G 
lacZ_KO9 
Set lacZ jackpot 
+1710 
G*T*TTCGTCAGTATCCCCGTTTACAGGGCGG
CTTCGTCTGGGACTaaGTGGATCAGTCGCTGA
TTAAATATGATGAAAACGGCAACCCG*T*G 
lacZ_KO10 
Set lacZ jackpot 
+1890 
A*G*CGCTGACGGAAGCAAAACACCAGCAGC
AGTTTTTCCAGTTCtGaTTATCCGGGCAAACCA
TCGAAGTGACCAGCGAATACCTGTTC*C*G 
ygfJ_2*:2*_l
ead 
Set 3.850_lead oligo 
G*C*CGGAAGGATTAAATATTTGAACGCAAT
CGTTTAACTACGTTTTTTAAATTTCAGTATAC
CTTTCCTTCGCTGTAATAAAGTCGTCC*G*G 
recJ_2*:2*_l
ead 
Set 3.700_lead oligo 
C*A*ACCGCAGCCTGCAAATTATCATCGACAA
TATCTGGCCAATTTAACGTCATCTTCTCTATA
AAAAAGAGCGTGGATTGGGTACAATC*C*C 
argO_2*:2*_
lead 
Set 3.600_lead oligo 
G*A*GAGACGGTATTGCTCATGCACAAGCCTT
GTTCAGTTAAGCGCTATCTGATGGAAAAATA
AAACAGAGGCGCTAAGCTTGCCTCCAG*A*G 
yggU_2*:2*_
lead 
Set 3.500_lead oligo 
T*T*ACCGACATTGCCGGTTGCGAGGACAACT
TTTTGCATAGGATACTTAATTAATTAACGCCG
CGATTTCTGGCGGGATTTGTTGCGGA*T*T 
mutY_2*:2*
_lead 
Set 3.400_lead oligo 
A*A*AAATCGTTCTGCTCATAAATCATCCTCT
TTATCGACTCACGCGTTAAACCGGCGCGCCA
GTGCGTAACTGCTGTAACAAACGCTCC*A*C 
glcC_2*:2*_l
ead 
Set 3.300_lead oligo 
C*A*AGCGTTACCGATTGTATGAAAAGCAGA
TTTAATACCAGTTAACTCAGGTTCATCTCCAG
CGGCACCGCCGAGCGAATCAAATGGTG*G*C 
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Table S3-1 (Continued). 
yghQ_2*:2*_
lead 
Set 3.250_lead oligo 
G*C*TGGTGTTTGGCGTTAAGTATCTCGAAGC
GTATGACCTGATTTAAGGAAGGTGCGAATAA
GCGGGGAAATTCTTCTCGGCTGACTCA*G*T 
yghT_2*:2*_
lead 
Set 3.200_lead oligo 
C*C*CGGTCCTGGCGATCGGGCATTTCCATTT
TTGATTAGTGATAACCACGCGCGGTCATAAA
ATCCGTAATCGCTTTTTCTGCATCAAC*C*A 
ygiZ_2*:2*_l
ead 
Set 3.150_lead oligo 
T*T*GTGGTTGGTGGCTTTTTTGGGGACGGTT
TATATTTTGCTATTAATAAAATCTATGAGAGT
CGTTTTAACGGCTCTCATAGACAGAG*A*A 
yqiB_2*:2*_l
ead 
Set 3.100_lead oligo 
G*C*GATACTGTTTAGCACATGGAGCGATGGC
GATTCCGGTTTATTAACGTCGTGAAACCTAA
GGACACCATTTGGAAAGCCTGTTAACC*C*T 
exoX.KO* exoX KO oligo 
t*t*c*g*gcctggagcatgccatgttgcgcattatcgatacagaaacT
GAtgcggtttgcagggagggatcgttgagattgcctctgttgatg 
xseA.KO* xseA KO oligo 
g*a*a*t*ttgatctcgctcacatgttaccttctcaatcccctgcaatTGA
tttaccgttagtcgcctgaatcaaacggttcgtctgctgcttg 
recJ.KO* recJ KO oligo 
g*g*a*g*gcaattcagcgggcaagtctgccgtttcatcgacttcacgT
CAcgacgaagttgtatctgttgtttcacgcgaattatttaccgct 
xonA.KO* xonA KO oligo 
a*a*t*a*acggatttaacctaatgatgaatgacggtaagcaacaatcT
GAacctttttgtttcacgattacgaaacctttggcacgcaccccg 
Lexo.KO.M
M* 
Lambda exo KO oligo 
t*g*a*a*acagaaagccgcagagcagaaggtggcagcatgacaccg
taacattatcctgcagcgtaccgggatcgatgtgagagctgtcgaac 
dnaG_Q576
A 
Oligo to make dnaG 
Q576A mutation 
gcacgcatggtttaagcaacgaagaacgcctggagctctggacattaaac
GCggaActggcgaaaaagtgatttaacggcttaagtgccg 
dnaG_K580
A 
Oligo to make dnaG 
K580A mutation 
cgcacgcatggtttaagcaacgaagaacgcctggagctctggacattaaa
ccaggaActggcgGCaaagtgatttaacggcttaagtgcc 
tolC.90.del 
Oligo that deletes 
endogenous tolC 
gaatttcagcgacgtttgactgccgtttgagcagtcatgtgttaaagcttcgg
ccccgtctgaacgtaaggcaacgtaaagatacgggttat 
galK_KO1.1
00 
Oligo to delete 100 bp 
including a portion of 
galK 
C*G*CGCAGTCAGCGATATCCATTTTCGCGAA
TCCGGAGTGTAAGAAAACACACCGACTACAA
CGACGGTTTCGTTCTGCCCTGCGCGAT*T*G 
galK_KO1.1
149 
Oligo to delete 1149 
bp including a portion 
of galK 
C*G*CGCAGTCAGCGATATCCATTTTCGCGAA
TCCGGAGTGTAAGAAACGAAACTCCCGCACT
GGCACCCGATGGTCAGCCGTACCGACT*G*T 
galK_KO1.7
895 
Oligo to delete 7895 
bp including a portion 
of galK, galM, gpmA, 
aroG, ybgS, zitB, 
pnuC, and nadA 
C*G*CGCAGTCAGCGATATCCATTTTCGCGAA
TCCGGAGTGTAAGAACTTACCATCTCGTTTTA
CAGGCTTAACGTTAAAACCGACATTA*G*C 
ygaR_wt-f 
Set 1.850_wt-f 
mascPCR AAGGTGGTATCCCTGGCTATTAG 
yqaC_wt-f 
Set 1.700_wt-f 
mascPCR CGGCGGTGAGGCGTAG 
gabT_wt-f 
Set 1.600_wt-f 
mascPCR TTTTGATGAGGCGAAGCAGTAG 
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ygaU_wt-f 
Set 1.500_wt-f 
mascPCR GTTGCGTATTCCGGAAGAGTAG 
ygaM_wt-f 
Set 1.400_wt-f 
mascPCR GTTAAGCATGCGCAAATCGTAG 
luxS_wt-f 
Set 1.300_wt-f 
mascPCR GTTGCAGGAACTGCACATCTAG 
mltB_wt-f 
Set 1.250_wt-f 
mascPCR GCTGGCGCGAGTACAGTAG 
srlE_wt-f 
Set 1.200_wt-f 
mascPCR GGTTTGTCTCCGGTTTTATCTATCAATAG 
norW_wt-f 
Set 1.150_wt-f 
mascPCR GATTGTTGAAAACATTGCCGATGTAG 
ascB_wt-f 
Set 1.100_wt-f 
mascPCR CCAGTAATGGGGAAGATTTAGAGTAG 
bioD_wt-f 
Set 2.850_wt-f 
mascPCR AGTACATAAACCTTGCCTTGTTGTAG 
moaE_wt-f 
Set 2.700_wt-f 
mascPCR GCGGCAAAACGCTGGTAG 
ybhM_wt-f 
Set 2.600_wt-f 
mascPCR AAGGCATACGCGTTTTTTTCATTAG 
ybhS_wt-f 
Set 2.500_wt-f 
mascPCR CCAAACGTCGGCTGGATTAG 
ybiH_wt-f 
Set 2.400_wt-f 
mascPCR AAGGATTATCGCAAAGGAGTTTGTAG 
ybiR_wt-f 
Set 2.300_wt-f 
mascPCR TTAGTTATACTCCCGGCCAACTAG 
yliD_wt-f 
Set 2.250_wt-f 
mascPCR CGCTGGATCCGAAAATTAAAGGATAG 
yliE_wt-f 
Set 2.200_wt-f 
mascPCR 
TGGGATAAAAGTGGAAAATTAGTAAAAGAG
TAG 
ybjK_wt-f 
Set 2.150_wt-f 
mascPCR TTGAGAGGGTTGCAGGGTAG 
rimK_wt-f 
Set 2.100_wt-f 
mascPCR GCCTGAAAACGGGTGGTTAG 
ygfJ_wt-f 
Set 3.850_wt-f 
mascPCR AGCGAAGGAAAGGTATACTGAAATTTAG 
recJ_wt-f 
Set 3.700_wt-f 
mascPCR TCATCGACAATATCTGGCCAATTTAG 
argO_wt-f 
Set 3.600_wt-f 
mascPCR TGCACAAGCCTTGTTCAGTTAG 
yggU_wt-f 
Set 3.500_wt-f 
mascPCR CAGAAATCGCGGCGTTAATTAATTAG 
mutY_wt-f 
Set 3.400_wt-f 
mascPCR GGCGCGCCGGTTTAG 
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glcC_wt-f 
Set 3.300_wt-f 
mascPCR GCTGGAGATGAACCTGAGTTAG 
yghQ_wt-f 
Set 3.250_wt-f 
mascPCR CTCGAAGCGTATGACCTGATTTAG 
yghT_wt-f 
Set 3.200_wt-f 
mascPCR CGCGCGTGGTTATCACTAG 
ygiZ_wt-f 
Set 3.150_wt-f 
mascPCR TGGGGACGGTTTATATTTTGCTATTAG 
yqiB_wt-f 
Set 3.100_wt-f 
mascPCR CGATGGCGATTCCGGTTTATTAG 
ygfJ_WT 
Set 3X.850_wt-f 
mascPCR GCTGCCGGATTATCATCAAGA 
ygfT_WT 
Set 3X.700_wt-f 
mascPCR GCAATGGCCGCAGGAAGG 
ubiH_WT 
Set 3X.600_wt-f 
mascPCR GCACGGTACGATGGGTAATAGAT 
argO_WT 
Set 3X.500_wt-f 
mascPCR GAAGTCATGAAGCAAGGCAGA 
yqgC_WT 
Set 3X.400_wt-f 
mascPCR CGGCAGGTATGCAAAGCAGA 
trmI_WT 
Set 3X.300_wt-f 
mascPCR AGTATGGGACTTAATGTTCGAGAGG 
glcC_WT 
Set 3X.250_wt-f 
mascPCR AGGGCGAATCGGCAAGG 
yghT_WT 
Set 3X.200_wt-f 
mascPCR GAAAAATATGGTGCTGCCGAAAGA 
ygiZ_WT 
Set 3X.150_wt-f 
mascPCR 
CTTCTTACGCCACTTATTATTCTTATCTTAAG
A 
cpdA_WT 
Set 3X.100_wt-f 
mascPCR TGGCTGGTGAGGCCAGA 
exoX.KO*-
wt-f 
exoX wt-f mascPCR 
primer GCGCATTATCGATACAGAAACCT 
xseA.KO*-
wt-f 
xseA wt-f mascPCR 
primer CTTCTCAATCCCCTGCAATTTTTACC 
recJ.KO*-wt-
f 
recJ wt-f mascPCR 
primer CAACAGATACAACTTCGTCGCC 
xonA.KO*-
wt-f 
xonA wt-f mascPCR 
primer GAATGACGGTAAGCAACAATCTACC 
Lexo_WT-f 
Lambda exo KO wt-f 
mascPCR primer GGCAGCATGACACCGGA 
dnaG_Q576
A_wt-f 
dnaG_Q576A wt-f 
mascPCR primer TGGAGCTCTGGACATTAAACCA 
dnaG_K580
A_wt-f 
dnaG_K580A wt-f 
mascPCR primer CATTAAACCAGGAACTGGCGAA 
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ygaR_mut-f 
Set 1.850_mut-f 
mascPCR AAGGTGGTATCCCTGGCTATTAA 
yqaC_mut-f 
Set 1.700_mut-f 
mascPCR CGGCGGTGAGGCGTAA 
gabT_mut-f 
Set 1.600_mut-f 
mascPCR TTTTGATGAGGCGAAGCAGTAA 
ygaU_mut-f 
Set 1.500_mut-f 
mascPCR GTTGCGTATTCCGGAAGAGTAA 
ygaM_mut-f 
Set 1.400_mut-f 
mascPCR GTTAAGCATGCGCAAATCGTAA 
luxS_mut-f 
Set 1.300_mut-f 
mascPCR GTTGCAGGAACTGCACATCTAA 
mltB_mut-f 
Set 1.250_mut-f 
mascPCR GCTGGCGCGAGTACAGTAA 
srlE_mut-f 
Set 1.200_mut-f 
mascPCR GGTTTGTCTCCGGTTTTATCTATCAATAA 
norW_mut-f 
Set 1.150_mut-f 
mascPCR GATTGTTGAAAACATTGCCGATGTAA 
ascB_mut-f 
Set 1.100_mut-f 
mascPCR CCAGTAATGGGGAAGATTTAGAGTAA 
bioD_mut-f 
Set 2.850_mut-f 
mascPCR AGTACATAAACCTTGCCTTGTTGTAA 
moaE_mut-f 
Set 2.700_mut-f 
mascPCR GCGGCAAAACGCTGGTAA 
ybhM_mut-f 
Set 2.600_mut-f 
mascPCR AAGGCATACGCGTTTTTTTCATTAA 
ybhS_mut-f 
Set 2.500_mut-f 
mascPCR CCAAACGTCGGCTGGATTAA 
ybiH_mut-f 
Set 2.400_mut-f 
mascPCR AAGGATTATCGCAAAGGAGTTTGTAA 
ybiR_mut-f 
Set 2.300_mut-f 
mascPCR TTAGTTATACTCCCGGCCAACTAA 
yliD_mut-f 
Set 2.250_mut-f 
mascPCR CGCTGGATCCGAAAATTAAAGGATAA 
yliE_mut-f 
Set 2.200_mut-f 
mascPCR 
TGGGATAAAAGTGGAAAATTAGTAAAAGAG
TAA 
ybjK_mut-f 
Set 2.150_mut-f 
mascPCR TTGAGAGGGTTGCAGGGTAA 
rimK_mut-f 
Set 2.100_mut-f 
mascPCR GCCTGAAAACGGGTGGTTAA 
ygfJ_mut-f 
Set 3.850_mut-f 
mascPCR AGCGAAGGAAAGGTATACTGAAATTTAA 
recJ_mut-f 
Set 3.700_mut-f 
mascPCR TCATCGACAATATCTGGCCAATTTAA 
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argO_mut-f 
Set 3.600_mut-f 
mascPCR TGCACAAGCCTTGTTCAGTTAA 
yggU_mut-f 
Set 3.500_mut-f 
mascPCR CAGAAATCGCGGCGTTAATTAATTAA 
mutY_mut-f 
Set 3.400_mut-f 
mascPCR GGCGCGCCGGTTTAA 
glcC_mut-f 
Set 3.300_mut-f 
mascPCR GCTGGAGATGAACCTGAGTTAA 
yghQ_mut-f 
Set 3.250_mut-f 
mascPCR CTCGAAGCGTATGACCTGATTTAA 
yghT_mut-f 
Set 3.200_mut-f 
mascPCR CGCGCGTGGTTATCACTAA 
ygiZ_mut-f 
Set 3.150_mut-f 
mascPCR TGGGGACGGTTTATATTTTGCTATTAA 
yqiB_mut-f 
Set 3.100_mut-f 
mascPCR CGATGGCGATTCCGGTTTATTAA 
ygfJ_MUT 
Set 3X.850_mut-f 
mascPCR GCTGCCGGATTATCATCAAGG 
ygfT_MUT 
Set 3X.700_mut-f 
mascPCR GCAATGGCCGCAGGAAGA 
ubiH_MUT 
Set 3X.600_mut-f 
mascPCR GCACGGTACGATGGGTAATAGAC 
argO_MUT 
Set 3X.500_mut-f 
mascPCR GAAGTCATGAAGCAAGGCAGG 
yqgC_MUT 
Set 3X.400_mut-f 
mascPCR GGCAGGTATGCAAAGCAGG 
trmI_MUT 
Set 3X.300_mut-f 
mascPCR GAGTATGGGACTTAATGTTCGAGAGA 
glcC_MUT 
Set 3X.250_mut-f 
mascPCR GAGGGCGAATCGGCAAGA 
yghT_MUT 
Set 3X.200_mut-f 
mascPCR AAAATATGGTGCTGCCGAAAGG 
ygiZ_MUT 
Set 3X.150_mut-f 
mascPCR 
CTTCTTACGCCACTTATTATTCTTATCTTAAG
G 
cpdA_MUT 
Set 3X.100_mut-f 
mascPCR GGCTGGTGAGGCCAGG 
exoX.KO*-
mut-f 
exoX mut-f mascPCR 
primer GCGCATTATCGATACAGAAACTGA 
xseA.KO*-
mut-f 
xseA mut-f mascPCR 
primer CTTCTCAATCCCCTGCAATTGA 
recJ.KO*-
mut-f 
recJ mut-f mascPCR 
primer CAACAGATACAACTTCGTCGTGA 
xonA.KO*-
mut-f 
xonA mut-f mascPCR 
primer GAATGACGGTAAGCAACAATCTGA 
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Lexo_MUT-f 
Lambda exo KO mut-f 
mascPCR primer TGGCAGCATGACACCGTAA 
dnaG_Q576
A_mut-f 
dnaG_Q576A mut-f 
mascPCR primer GGAGCTCTGGACATTAAACGC 
dnaG_K580
A_mut-f 
dnaG_K580A mut-f 
mascPCR primer ACCAGGAACTGGCGGC 
ygaR_rev 
Set 1.850_rev 
mascPCR TAGGTAGAGCAACCTTTATTAAGCTACG 
yqaC_rev 
Set 1.700_rev 
mascPCR TAAAAATATCTACATTTCTGAAAAATGCGCA 
gabT_rev 
Set 1.600_rev 
mascPCR GCGGCGATGTTGGCTT 
ygaU_rev 
Set 1.500_rev 
mascPCR AGGGTATCGGGTGGCG 
ygaM_rev 
Set 1.400_rev 
mascPCR CGCAACGCTTCTGCCG 
luxS_rev 
Set 1.300_rev 
mascPCR ATGCCCAGGCGATGTACA 
mltB_rev 
Set 1.250_rev 
mascPCR AGACTCGGCAGTTGTTACGG 
srlE_rev 
Set 1.200_rev 
mascPCR GGATGGAGTGCACCTTTCAAC 
norW_rev 
Set 1.150_rev 
mascPCR GTGTTGCATTTGGACACCATTG 
ascB_rev 
Set 1.100_rev 
mascPCR CGCTTATCGGGCCTTCATG 
bioD_rev 
Set 2.850_rev 
mascPCR CGGGAAGAACTCTTTCATTTCGC 
moaE_rev 
Set 2.700_rev 
mascPCR CGTCAATCCGACAAAGACAATCA 
ybhM_rev 
Set 2.600_rev 
mascPCR TTACTGGCAGGGATTATCTTTACCG 
ybhS_rev 
Set 2.500_rev 
mascPCR CTGTTGTTAGGTTTCGGTTTTCCT 
ybiH_rev 
Set 2.400_rev 
mascPCR GTCATAGGCGGCTTGCG 
ybiR_rev 
Set 2.300_rev 
mascPCR ATGAGCCGGTAAAAGCGAC 
yliD_rev 
Set 2.250_rev 
mascPCR 
AATAAAATTATCAGCCTTATCTTTATCTTTTC
GTATAAA 
yliE_rev 
Set 2.200_rev 
mascPCR CAGCAATATTTGCCACCGCA 
ybjK_rev 
Set 2.150_rev 
mascPCR AACTTTTCCGCAGGGCATC 
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rimK_rev 
Set 2.100_rev 
mascPCR TACAACCTCTTTCGATAAAAAGACCG 
ygfJ_rev 
Set 3.850_rev 
mascPCR GATGAACTGTTGCATCGGCG 
recJ_rev 
Set 3.700_rev 
mascPCR CTGTACGCAGCCAGCC 
argO_rev 
Set 3.600_rev 
mascPCR AATCGCTGCCTTACGCG 
yggU_rev 
Set 3.500_rev 
mascPCR TAACCAAAGCCACCAGTGC 
mutY_rev 
Set 3.400_rev 
mascPCR CGCGAGATATTTTTTCATCATTCCG 
glcC_rev 
Set 3.300_rev 
mascPCR GGGCAAAATTGCTGTGGC 
yghQ_rev 
Set 3.250_rev 
mascPCR ACCAACTGGCGATGTTATTCAC 
yghT_rev 
Set 3.200_rev 
mascPCR GACGATGGTGGTGGACGG 
ygiZ_rev 
Set 3.150_rev 
mascPCR ATCGCCAAATTGCATGGCA 
yqiB_rev 
Set 3.100_rev 
mascPCR AAAATCCTGACTCTGGCCTCA 
ygfJ_rev 
Set 3X.850_rev 
mascPCR TCTGTTTGCACTGCGGGTAC 
ygfT_rev 
Set 3X.700_rev 
mascPCR TGGTTGGGCAATCTAATAGATTCTCC 
ubiH_rev 
Set 3X.600_rev 
mascPCR atgAGCGTAATCATCGTCGGTG 
argO_rev 
Set 3X.500_rev 
mascPCR CCGTCTCTCGCCAGCTG 
yqgC_rev 
Set 3X.400_rev 
mascPCR AGCACACGACGTTTCTTTCG 
trmI_rev 
Set 3X.300_rev 
mascPCR ATCTGTTCTTCCGATGTACCTTCC 
glcC_rev 
Set 3X.250_rev 
mascPCR CTTCCAGCTCGATATCGTGGAG 
yghT_rev 
Set 3X.200_rev 
mascPCR CACCACCAAAGGTTAACTGTGG 
ygiZ_rev 
Set 3X.150_rev 
mascPCR CACAAACCAGACAAATACCGAGC 
cpdA_rev 
Set 3X.100_rev 
mascPCR CGATGGTATCCAGCGTAAAGTTG 
exoX.KO*-r 
exoX rev mascPCR 
primer GACCATGGCTTCGGTGATG 
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xseA.KO*-r 
xseA rev mascPCR 
primer GGTACGCTTAAGTTGATTTTCCAGC 
recJ.KO*-r 
recJ rev mascPCR 
primer GGCCTGATCGACCACTTCC 
xonA.KO*-r 
xonA rev mascPCR 
primer GAAATGTCTCCTGCCAAATCCAC 
Lexo-r 
Lambda exo KO rev 
mascPCR primer CAAGGCCGTTGCCGTC 
dnaG_seq-r 
dnaG rev mascPCR 
primer for both Q576A 
and K580A GCTCCATAAGACGGTATCCACA 
Rx-P19 
forward screening 
primer for wt tolC 
deletion GTTTCTCGTGCAATAATTTCTACATC 
Rx-P20 
reverse screening primer 
for wt tolC deletion CGTATGGATTTTGTCCGTTTCA 
lacZ_jackpot_
seq-f 
forward sequencing 
primer for lacZ jackpot 
alleles GAATTGTGAGCGGATAACAATTTC 
lacZ_jackpot_
seq-r 
reverse sequencing 
primer for lacZ jackpot 
alleles CCAGCGGCTTACCATCC 
cat_mut* cat inactivation oligo 
G*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTC
AGTTGCTTAATGTACCTATAACCAGACCGTTCAG
CTGGATATTACGGCCTTTTTA*A*A  
cat_restore* cat reactivation oligo 
G*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTC
AGTTGCTCAATGTACCTATAACCAGACCGTTCAG
CTGGATATTACGGCCTTTTTA*A*A 
tolC-
r_null_mut* 
tolC inactivation oligo 
A*G*CAAGCACGCCTTAGTAACCCGGAATTGCGT
AAGTCTGCCGCTAAATCGTGATGCTGCCTTTGAA
AAAATTAATGAAGCGCGCAGTCCA 
tolC-
r_null_revert* 
tolC reactivation oligo 
C*A*GCAAGCACGCCTTAGTAACCCGGAATTGCG
TAAGTCTGCCGCCGATCGTGATGCTGCCTTTGAA
AAAATTAATGAAGCGCGCAGTCCA 
tolC_null_reve
rt* 
tolC reactivation oligo 
(leading targeting) 
T*G*GACTGCGCGCTTCATTAATTTTTTCAAAGGC
AGCATCACGATCGGCGGCAGACTTACGCAATTCC
GGGTTACTAAGGCGTGCTTGCTG 
bla_mut* bla inactivation oligo 
G*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATC
ATTGGAAAACGTTATTAGGGGCGAAAACTCTCAA
GGATCTTACCGCTGTTGAGATCCAG 
bla_restore* bla reactivation oligo 
G*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATC
ATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAA
GGATCTTACCGCTGTTGAGATCCAG 
313000.T.lacZ
.coMAGE-f 
Cassette primer for T.co-
lacZ (lacZ coselection) 
TGCTTCTCATGAACGATAACACAACTTGTTCATG
AATTAACCATTCCGGATTGAGGCACATTAACGCC 
313001.T.lacZ
.coMAGE-r 
Cassette primer for T.co-
lacZ (lacZ coselection) 
ACGGAAACCAGCCAGTTCCTTTCGATGCCTGAAT
TTGATCCCATAGTTTATCTAGGGCGGCGGATT 
312869.seq-f 
Screening primer for 
tolC (lacZ coselection) GAACTTGCACTACCCATCG 
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313126.seq-r 
Screening primer for 
tolC (lacZ coselection) AGTGACGGGTTAATTATCTGAAAG 
1255700.S.12.
13b-f 
Cassette primer for 
S.12.13b 
TTTCATCTTGCCAGCATATTGGAGCGTGATCAATT
TTGATCAGCTGTGAACAGCCAGGACAGAAATGC 
1255701.S.12.
13b -r 
Cassette primer for 
S.12.13b 
CATTAGCAGTGATATAACGTAAGTTTTTGTATCAC
TACACATCAGCCCCCTGCAGAAATAAAAAGGCCT
GC 
1255550.Seq-f 
Screening primer for 
S.12.13b CATTTTTGCATTACTAATAAGAAAAAGCAAA 
1255850.Seq-r 
Screening primer for 
S.12.13b GTCCTAATCATTCTTGTAACATCCTAC 
1710450.Z.16.
17b-f 
Cassette primer for 
Z.16.17b 
TCAGGTTAAAATCATTTAAATTTACACACGCAAC
AAATATTGACCTACAAGGTGTTGACAATTAATCA
TCGGC 
1710451.Z.16.
17b-r 
Cassette primer for 
Z.16.17b 
TTTTTACTAGTGAGATAGTCCAGTTTCTGAAAAAT
AGCCAGTGTAATGTTAGCTTGCAAATTAAAGCCT
TCG 
1710300.Seq-f 
Screening primer for 
Z.16.17b TCAGGTAATCCGTTTGCGG 
1710600.Seq-r 
Screening primer for 
Z.16.17b AACGGCAGATTTTTTCACTGC 
LacZ::KanR.f
ull-f 
Cassette primer for 
lacZ::kanR 
TGACCATGATTACGGATTCACTGGCCGTCGTTTTA
CAACGTCGTGCCTGTGACGGAAGATCACTTCG 
LacZ::KanR.f
ull-r 
Cassette primer for 
lacZ::kanR 
GTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGG
GTTTTCCCAGTAACCAGCAATAGACATAAGCGG 
An asterisk (*) indicates use of a phosphorothioate bond to protect against exonuclease activity (1). 
 
Table S3-2: Estimation of Okazaki fragment length in EcNR2.dnaG.K580A and 
EcNR2.dnaG.Q576A 
 
 [Primase] (nM) WT  dnaG Okazaki Frag (kb) K580A Okazaki Frag (kb) Q576A Okazaki Frag (kb) 
80 2.5 5 23 
160 1.5 2.5 18 
320 1 1 8 
640 0.8 nd 3 
Average Fold effect compared to WT 1.6 8.2 
 
Average Okazaki Fragment length was estimated based on in vitro results (gel images) from 
Tougu et al. (2) for the same DnaG primase variants, tabulated above. We compared the fold 
difference in OF sizes for the specified primase concentrations and determined the average fold 
difference (variant OF length/wt OF length). We estimate in vivo OF lengths of ~2.3-3.1 kb and 
~12-16 kb for the K580A and Q576A mutants, respectively, based on the reported ~1.5-2 kb OF 
lengths in wt cells grown in rich media (3-5). However, these approximations may be imperfect 
since Tougu et al. (2) performed this analysis in vitro and did not use the same 
EcNR2.dnaG.K580A and EcNR2.dnaG.Q576A strains. Other conditions and/or host factors not 
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accounted for in vitro may affect priming efficiency, thereby rendering these calculations 
inaccurate. 
 
Supplemental Figures 
 
 
 
Figure S3-1. Effect of dnaG variants and co-selection on leading-targeting CoS-MAGE. (A) 
EcNR2.dnaG.Q576A (n=91) outperformed EcNR2 (wt, n=88) in leading-targeting Set 3 CoS-
MAGE, with a reduction in zero conversion events as well as a broadening of the distribution of 
total allele conversions per clone. (B) For leading-targeting Set 3 oligos, AR frequency decays 
rapidly with increasing distance from the selectable marker (top panel). In contrast, co-selection 
using the corresponding set of lagging targeting oligos (see also Figure 3C, right panel) provides 
robust co-selection spanning at least 0.162 Mb (bottom panel). For the lagging-targeting oligos 
(bottom panel), linear regression analyses (solid trendline) show that co-selection does not 
decrease with distance for either strain over this 0.162 Mb genomic region.  (C) Individual CoS-
MAGE AR frequency is plotted for each leading-targeting Set 3 oligo in EcNR2 (wt) and 
EcNR2.dnaG.Q576A (Q576A). AR frequency is improved for 9/10 alleles in 
EcNR2.dnaG.Q576A. Note that the most proximal allele to the selectable marker (yqiB) is 
separated from the other alleles with a broken axis, since its AR frequency was much higher than 
that of the others. 
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Figure S3-2. Effect of dnaG attenuation on deletion frequency. DnaG primase disruption 
enhances gene-sized deletion frequency. Oligos that deleted 100 bp, 1,149 bp, or 7,895 bp of the 
genome, including a portion of galK, were recombined into EcNR2 and EcNR2.dnaG.Q576A. 
The recombined populations were screened for the GalK- phenotype (white colonies) on 
MacConkey agar plates supplemented with galactose as a carbon source. EcNR2.dnaG.Q576A 
significantly outperformed EcNR2 for the 100 bp and 1,149 bp deletions, but there was no 
difference detected between the two strains for the 7,895 bp deletion.  
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APPENDIX C 
 
Supplemental Material for Genome-wide Codon Replacement Using Synthetic 
Oligonucleotides and Engineered Conjugation 
 
 
 
 
 
This supplemental material is reproduced with permission from its initial publication: 
 
Isaacs FJ
*
, Carr PA
*
, Wang HH
*
, Lajoie MJ, Sterling B, Kraal L, Tolonen AC, Gianoulis TA, 
Goodman DB, Reppas NB, Emig CJ, Bang D, Hwang SJ, Jewett MC, Jacobson JM, Church GM 
(2011) Genome-wide Codon Replacement Using Synthetic Oligonucleotides and Engineered 
Conjugation. Science: 333, 348-353. 
 
Tables and Figures have been renamed to be consistent with CHAPTER 4. 
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Materials & Methods  
Strains and Culture Conditions 
The -prophage was obtained from strain DY330 (1), modified to include the bla gene 
and introduced into wild-type MG1655 E.coli by P1 Transduction at the bioA/bioB gene locus 
and selected on ampicillin to yield the strain EcNR1 (-Red+). Replacement of mutS with the 
chloramphenicol resistance gene (chloramphenicol acetyl transferase, cmR) in EcNR1 produced 
EcNR2 (mutS
–
, -Red+). EcNR2 was grown in low salt LB-min medium (10 g tryptone, 5 g 
yeast extract, 5 g NaCl in 1 L dH2O) for optimal electroporation efficiency and compatibility 
with zeocin selection. EcNR2 was used as the ancestral strain for all recoded strains reported in 
this manuscript. 
 
Oligonucleotides 
All oligonucleotides were obtained from Integrated DNA Technologies. Oligonucleotides 
(Table S4-3) used in the MAGE process were designed according to the following 
specifications:  1) 90 nucleotides in length, 2) contain a single mutation to effect the TAG to 
TAA codon conversion, 3) two phosphorothioate linkages at both the 5' and 3' ends to attenuate 
exonuclease activity and to increase half life, 4) minimize secondary structure (ΔG threshold 
values, self-folding energy), 5) target lagging strand at the replication fork. No additional 
purification was used following oligonucleotide synthesis.  Primers were purchased from IDT for 
the multiplex PCR assays and loci sequencing reactions (see description below and Tables S4-12 
and S4-13). 
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MAGE-generated Codon Conversions 
A single clone of the EcNR2 strain was grown in liquid cell culture, which was used to 
inoculate 32 separate cultures for parallel modification of all TAG codons.  Modification of these 
codons was achieved through continuous MAGE (2) cycling.   Each culture was grown at 30°C 
to mid-logarithmic growth (i.e., OD600 of ~0.7) in a rotor drum at 200 RPM.  To induce 
expression of the λ Red recombination proteins (Exo, Beta and Gam), cell cultures were shifted 
to a 42°C water bath with vigorous shaking for 15 min and then immediately chilled on ice. In a 
4°C environment, 1 mL of cell culture was centrifuged at 16,000x g for 30 seconds. Supernatant 
media was removed and cells were re-suspended in 1 mL dH2O (Gibco cat# 15230). This wash 
process was repeated. Supernatant water was removed the pellet was resuspended in the 
appropriate pool of 10 oligos (1 uM per MAGE oligo in 50 uL dH2O). The resuspended 
oligos/cell mixture was transferred to a pre-chilled 96-well, 2 mm gap electroporation plate 
(BTX, USA) and electroporated with a BTX electroporation system using the following 
parameters: 2.5 kV, 200 Ω, and 25 µF.  The electroporated cells were immediately transferred to 
3 mL of LB-min media for recovery.  Recovery cultures were grown at 30 °C in a rotator drum 
for 2-2.5 hours. Once cells reached mid-logarithmic growth they proceeded to the next MAGE 
cycle.  This approach introduces genomic modifications while allowing cells to evolve and adapt 
to those changes.  Moreover, this approach is designed to explore extensive genotype and 
phenotype landscapes by creating combinatorial genomic variants that leverage the size of the 
cell population. After 18 MAGE cycles, cells from each population were isolated on LB-min 
agar plates.  Forty-seven clones from each of the 32 cycled populations were selected and 
subjected to genotype and phenotype analyses. From each population the clone with the greatest 
number of modifications (an average of 8 modifications per clone) and minimal aberrant 
204 
 
phenotypes (i.e., auxotrophy, decreased fitness) was selected. Further MAGE cycles were 
employed (typically 6 cycles, but in some cases up to 15) to yield strains with complete sets of 
10 targeted modifications.  
Genotype Analyses  
TAG-to-TAA codon conversions were analyzed using three main methods:  1)  Multiplex 
allele-specific colony PCR (MASC-PCR), 2)  Multiplex allele-specific colony quantitative PCR 
(MASC-qPCR) and 3) Sanger DNA sequencing.   
 
Multiplex Allele Specific Colony PCR (MASC-PCR) 
Based on previously described allele-specific PCR techniques, we developed the MASC-
PCR method to test for TAG-to-TAA codon conversion in our recoded strains (the ancestral 
EcNR2 strain was the negative control). Three primers were designed for each locus:  1) a 
forward primer for the TAG sequence, 2) a forward primer for the TAA sequence and 3) a 
reverse primer compatible with both forward primers (Table S4-12).  Primers were designed for 
a target Tm of 62° C.   The two forward primers were identical except that the most 3' nucleotide 
hybridized to produce either a GC base pair for the wildtype (TAG) codon or an AT base pair for 
the mutant (TAA) codon.  Thus, every clone from each of the 32 populations was interrogated 
via two MASC-PCR reactions, in which each reaction assayed 10 different loci (with one set 
assaying four loci).   One reaction assayed the wild type (TAG) sequence and a second reaction 
assayed the mutant (TAA) sequence, yielding two binary reactions that revealed the sequences of 
the targeted codons (Figure S4-4).  A clone containing the mutant allele generated PCR products 
only using the mutant allele primers and not the WT primers and vice versa for a clone with the 
wild-type allele. To minimize nonspecific amplification of MASC-PCR primers, a gradient PCR 
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was performed to experimentally determine the optimal annealing temperature for each MASC-
PCR primer pool (typically between 64 - 67° C). Multiple loci were queried in a single PCR 
reaction using the multiplex PCR mast2er mix kit from Qiagen.   Each MASC-PCR primer set 
produced amplicon lengths of 100, 150, 200, 250, 300, 400, 500, 600, 700, or 850 bps, 
corresponding to up to 10 different genomic loci.  We found that using a 1:100 dilution of 
saturated clonal culture in water as template generated the best MASC-PCR specificity. Typical 
20 uL MASC-PCR reactions included 10 uL 2x Qiagen multiplex PCR master mix, 0.2 uM of 
each primer, and 1 uL of template.  MASC-PCR cycles were conducted as follows: polymerase 
heat activation and cell lysis for 15 min at 95° C, denaturing for 30 sec at 94° C, annealing for 30 
sec at experimentally determined optimal temperature (64-67° C), extension for 80 sec at 72°C, 
repeated cycling 26 times, and final extension for 5 min at 72°C. Gel electrophoresis on a 1.5% 
agarose gel (0.5x TBE) produced the best separation for a 10-plex MASC-PCR reaction. (See 
Figure S4-4 for representative gel picture of MASC-PCR reaction.)  
 
Mulitplex allele-specific quantitative colony PCR (MASC-qPCR) 
In complement to MASC-PCR analyses, we also developed a highly multiplexed 
quantitative PCR screen to rapidly identify highly modified clones (Figure S4-3). Typical 
multiplexed qPCR reactions employ multiple fluorescence and distinct detection events to assess 
multiple PCR reactions in one sample, and are generally limited by the available optics and 
fluorescence to 4 channels. Instead, we needed a robust, economical test that employed many 
different non-optimized primers, did not require more expensive fluorescently labeled oligos, 
and would work for 10-plex reactions. We accomplished these goals with SYBR Green I 
detection, which gauges the total amount of DNA produced in the reaction. Two qPCR reactions 
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were compared for each clone evaluated, one with 10 pairs of primers matched to the unmodified 
TAG genes, and the other with 10 primer pairs matched to the intended TAA modifications. The 
TAG reactions were expected to proceed most efficiently with a wild-type template, and the 
TAA reactions most efficiently with a fully modified template. Intermediate values between 
these extremes also provided an effective, though nonlinear gauge of the extent of modification 
for each clone (Figure S4-3 A-C).  
 Each colony was used as template for a pair of qPCR reactions comparing the 
amplification efficiency when matched to primers terminating in wild-type or targeted mutant 
sequence. The experimental measurement for a given clone is then compared to the equivalent 
values measured for the unmodified starting (negative control) strain. This reference value is 
subtracted from each ΔCt to yield a ΔΔCt, with unmodified clones scoring close to zero (as with 
the negative control colonies). The largest ΔΔCt values were expected to indicate the most 
modified clones, which we confirmed by genotyping clones with varying ΔΔCt values (Figure 
S4-3C) Large numbers of clones could be quickly assessed using this approach (up to 190 per 
384-well plate, plus 2 negative controls). A typical assessment of MAGE-cycled clones 
comprised of 4 groups per plate, i.e. for each culture targeting 10 modifications, 2-4 control 
colonies and 44-46 queried colonies. After identification of the most promising clones, site-
specific qPCR genotyping (Figure S4-3D) was used to identify which specific sites had been 
modified, selecting the best clones for further modification. 
 Individual bacterial colonies were picked into 0.5 mL sterile distilled deionized water, 
with 5 µL of this suspension used as template in 20 µL qPCR reactions containing 1x NovaTaq 
buffer, 0.5 U NovaTaq Hotstart DNA Polymerase (EMD Biosciences), 250 µM each dNTP, 0.5x 
SYBR Green I (Invitrogen), and 5% DMSO.  Primer concentrations were 50 nM for each primer 
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(i.e. 500 nM total for 10 forward primers and 500 nM total for 10 reverse primers).  A typical 
qPCR program included a 10 minute hot start at 95° C, followed by 40 cycles (95° C for 30 
seconds, 60° C for 30 seconds, 72° C for 30 seconds) finishing with a melt curve analysis. All 
reactions were performed in a 7900 HT system (Applied Biosystems, Inc.). PCR primers for all 
sites were designed to have a melting temperature estimated at 62° C. Reverse primers were 
chosen to yield amplicons in the size range of 200-225 bp. No optimization was needed for 
qPCR primer sequences or for multiplex/singleplex reaction conditions. 
 
Sanger Sequencing of 314 TAG to TAA loci  
DNA sequencing was employed to confirm the results of the above PCR assays and to 
determine genotypes for 16 sites that gave ambiguous results by MASC-PCR. Amplicons 200-
300 bp in length surrounding each of the 314 TAG sites were sequenced from the top-scoring 
clones by colony PCR as above. Sanger sequencing to confirm allelic replacements was 
performed by Agencourt Bioscience Corporation and the Biopolymer Facility in the Department 
of Genetics at Harvard Medical School. Mutations were identified by sequence alignment to the 
reference MG1655 genome. 
 
Phenotype Analyses  
To ensure that the codon replacements did not introduce any significant aberrant 
phenotypes, we conducted a number of experiments that assessed the fitness of the recoded 
strains.  These experiments included measurements of: 1) strain growth rates, 2) auxotrophic 
rates and 3) frequency of recombination.  Growth rate measurements were obtained by growing 
replicates of the recoded strains in LB-min media in 96-well plates at 30C and obtaining OD600 
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measurements using Molecular Devices plate readers (M5 and SpectraMax Plus).  Auxotrophic 
rates were obtained by spotting all clonal isolates (1504) from the MAGE-cycled experiments on 
M9 minimal media plates (200 mL 5x M9 medium, 1 mL 1 M MgSO4, 5 mL 40% glucose, 100 
µL 0.5% vitamin B1 (thiamine), 1 mL D-biotin (0.25 mg/mL), up to 1 L water + 15g Agar). The 
recombination frequency of each isolate was obtained by performing the allelic replacement 
protocol using a lacZ 90-mer oligo that produced a premature stop codon in the chromosomal 
lacZ gene. In general, 250-500 cells were plated on LB-min+Xgal/IPTG (USB Biochemicals) 
agar plates. Frequency of allelic replacement was calculated by dividing the number of white 
colonies by the total number of colonies on plates.  All phenotypic results are reported in Table 
S4-6. 
Hierarchical Conjugation Assembly Genome Engineering (CAGE) 
Donor and recipient strains were grown in 3 mL LB-min containing the appropriate 
positive selectable antibiotics. Once cells reached logarithmic-saturated growth, 2 mL samples of 
each culture were transferred to 2 mL Eppendorf tubes. Cells were washed three times in order to 
remove antibiotics present in the growth cultures. The washing procedure consisted of 
centrifuging samples at 5000 rpm for 2 minutes at room temperature, removing the supernatant, 
and re-suspending the cell pellet in fresh LB-min containing no antibiotics. After the final wash, 
the donor and recipient pellets were concentrated in 100 µL LB-min in order to enhance cell-cell 
contact during conjugation. Conjugation was initiated by combining 80 µL of ~20x concentrated 
donor culture and 20 µL of ~20x concentrated recipient culture.  In order to minimize F pilus 
shearing, cells were gently mixed by pipetting. In order to minimize turbulence that can disrupt 
cell-cell contact during conjugation and to maximize genome transfer, the entire 100 µL donor-
recipient mixture was transferred as a series of 2 x 20 µL and 6 x 10 µL spots onto an LB-min 
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agarose plate lacking antibiotics. This conjugation plate was incubated at 32° C for 0.5-2 hours, 
then the cells were re-suspended directly off of the plate using 1.5 mL LB-min and concentrated 
into a final volume of 250 µL. Desired recombinant genomes were selected by inoculating 5 µL 
of the concentrated post-conjugation culture into LB-min containing the correct combination of 
positive selection antibiotics (e.g., 10 µg/mL zeocin, 95 µg/mL spectinomycin, and 7.5 µg/mL 
gentamycin).   The conjugated cells that populated the selected culture were then subjected to a 
negative selection using either tolC or galK to ensure proper DNA transfer of TAA codons at 
critical junction points between donor and recipient cells (see Figure 4-4). 
This engineered conjugation method was tested for the first (1/32 genome, ~143 kb) and 
last (1/2 genome, ~2.3 Mb) chromosomal transfer steps in the hierarchical assembly experiment 
(Figure 4-1).  By selecting for different combinations of markers across the donor and recipient 
genomes and subsequent screening of specific genomic loci, recombinant clones were isolated 
that contained the transfer of half or full (otherwise unmodified) genomes at a frequency of 
~2.5x10
6
 (from a population of 10
9
-10
10
 cells), indicating the successful DNA transfer from an 
integrated oriT with episomal expression of conjugal factors.  Equivalent frequencies were 
observed for full genome transfers. 
Upon completion of the conjugation process, we also observed the anticipated loss of the 
oriT-kan cassette in the recombinant strain.  This observation yields a subtle, yet very useful 
feature of our engineered conjugation system.  By not inheriting the oriT sequence, the strains 
are positioned to proceed to a subsequent conjugation by a one-step integration of the oriT-Kan 
cassette in a new, targeted chromosomal locus (Figure 4-4A). 
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Illumina Whole Genome Sequencing 
 We prepared a paired-end Illumina sequencing library for three 1/8 genome strains C21 
(regions 17-20), C22 (21-24), and C23 (25-28) using barcoded Illumina adapters. The barcoded 
library was sequenced on one lane using an Illumina GAII. 
 
1. Genome prep (Qiagen Genome Prep kit) 
2. Sheared 5 µg of gDNA to target size = 200 bp using covaris (estimated median band size 
250 bp) 
3. PCR purified DNA (QIAquick PCR purification kit) 
4. End repair (Epicentre End-itTM DNA End-Repair kit) 
 
Component  Volume (1x)  
DNA sample 35 
10x End-Repair Buffer 10  
1 mM dNTPs 10  
End-Repair Enzyme mix 5  
dH2O 40 
Total (µL) 100  
 
5. Incubate at 25 C for 30 minutes 
6. PCR purified DNA (QIAquick PCR purification kit) 
7. A-tailing (NEB Klenow Fragment (3'->5' exo-)) 
 
Component  Volume (1x)  
DNA sample 32  
Klenow buffer 5  
1 mM dATP 10  
Klenow (3'->5' exo-) 3  
Total (µL) 50  
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8. Incubate for 30 minutes at 37 C 
9. PCR purified DNA (QIAquick PCR purification kit) 
10. Adapter ligation (adapters complements of Morten Sommer) 
a. C21: TopPE-1 barcode = AGC 
b. C22.DO:T: TopPE-3 barcode = CTA 
c. C23: TopPE-4 barcode = TCT 
 
Component  Volume (1x)  
DNA sample 31  
Rapid ligase buffer (2x) 35  
PE adapter (50 µM) 2  
Enzymatics Rapid (T4) ligase 2  
 
11. Incubated at 20 C for exactly 10 minutes in a thermocycler, then immediately added PBI 
for the PCR purification 
12. PCR purification (Qiagen MinElute PCR purification kit) 
13. Gel purified adapter-ligated sequencing libraries on 2% agarose gel in 0.5x TBE (cut 2 
mm bands corresponding to approximately 225 bp) (Qiagen Gel Purification kit) 
14. PCR amplified sequencing libraries (2x KAPA HiFi Ready Mix; 11 cycles) 
a. Standard Illumina PE PCR Primers 
 
Component  Volume (1x)  
2X KAPA HiFi Ready Mix 25  
PE_PCR-f 1  
PE_PCR-r 1  
dH2O 13  
Template 4  
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Step  Temp  Time (min)  
1 95 5:00  
2 98 0:20  
3 62 0:15  
4 72 1:15  
5 Go to step 2 11x  
6 72 3:00  
7 4 Forev 
 
15. PCR purified (QIAquick PCR purification kit) 
16. Validated sequencing library 
a. Cloned Illumina libraries using Invitrogen TOPO ZeroBlunt II 
b. Transformed into OneShot Top 10 electrocompetent cells 
c. Genewiz sequenced insert (Sanger sequencing; Seq. primer = M13 forward 
(Invitrogen): GTAAAACGACGGCCAG) 
17. Size-selected sequencing libraries for ~225 bp bands (E-Gel® SizeSelect™ gels) 
18. PCR purified Illumina libraries (Qiagen MinElute) 
19. Quantitated contents of C21, C22.DO:T, and C23 libraries  
a. PAGE, Low DNA Mass Ladder (Invitrogen), and SYBR gold staining 
b. Densitometry 
20. Prepared sequencing library by adding all 3 components to a final concentration of 10 nM  
21. Sample QC, Clustering, and sequencing performed by BPF  
a. Standard Illumina PE Sequencing Primers  
 
Genome Assembly and Sequence Analysis 
Read Sorting and Processing 
The raw Illumina reads in FASTQ format were preprocessed and sorted using the 6-bp 
barcodes in the paired end adaptors. Reads that contained anomalous barcodes were discarded. 
Reads containing any bases with a quality score of 2, also called the Read Segment Quality 
Control Indicator (based on Illumina Quality Scores by Tobia Man), were discarded at this step, 
but all other reads were kept. After preprocessing, all reads were exactly 34 base pairs long. 
Reference-based Assembly 
The expected FASTA sequence of the EcNR2 parent strain was assembled by manually 
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modifying the FASTA sequence of E. coli K-12 strain MG1655 to reflect the removal of mutS 
and the insertion of the lambda prophage genome into the bioAB operon. Next, the preprocessed 
reads were sorted into separate files by pair group and the Burrows-Wheeler Aligner program 
(BWA) (3) was used to separately align the paired reads from each of the three strains to the 
expected EcNR2 FASTA sequence. The sample algorithm was used to align the reads. The 
distribution of insert sizes was inferred at runtime. During the read alignment step of BWA, (the 
aln command), a value of 10 was used for the suboptimal alignment cutoff. 
Indel and SNP Filtering 
After alignment, the SAMtools package (4) was used to create and sort BAM files for the 
assemblies. From these BAM files we generated a set of raw SNPs and short indels with respect 
to this reference assembly. These were then filtered using several criteria. First, using the 
varFilter script within SAMtools, we removed SNPs where the root mean squared mapping 
quality was less than 10, and indels where the root mean squared mapping quality was less than 
25. We fitted the read coverage of each assembly to a gamma distribution and used the 99.95th 
and 0.05th percentile cutoffs for minimum and maximum read depth, beyond which SNPs and 
indels were discarded. We also discarded SNPs within 3 base pairs of a gap, and SNPs that 
occurred more densely than three within one 10 base pair window. 
Region Masking 
We used custom scripts to further filter SNPs and indels by masking regions of poor 
assembly. We masked regions containing many truncated reads, many incorrect read pairings, 
many non-unique alignments, and regions with motifs known to be problematic in Illumina 
sequencing (GGCnG).  We defined truncated read regions as those containing multiple 
incompletely mapped reads, separated by less than one read length, containing at least 4 
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truncated reads and having a number of truncated reads totaling at least one half of the length of 
the contiguous region in which they were found. 
Regions with incorrect read pairings were defined using the following method.  We found 
read pairs whose insert size was outside of the 99.9th and 0.1th percentile of a fitted normal 
distribution of mate pair distance. These reads were counted in a 34-bp rolling window.  As a 
thresholding step we chose contiguous regions where 10 or more of these reads were found in 
one window length. Additionally included were contiguous regions where only one read in a pair 
could be mapped, and these were thresholded with a rolling window in a similar fashion, using a 
6-read cutoff.  As a final masking step, we removed SNPs stemming from the replacement of 
amber stop codons as well as SNPs and indels where surrounding context was GGCnC, as these 
regions are known to be hotspots for Illumina sequencing errors. 
Annotation 
After removing SNPs and indels in the masked regions as described above, we attempted 
to associate the remaining SNPs and indels with functional consequences. We used a modified 
version of Ensembl’s SNP Effect Predictor software (5), and the Ensembl Bacteria database to 
find SNPs that occurred within genes. We further categorized these by synonymous and non-
synonymous coding changes, frameshift mutations, premature stop mutations, mutations in the 5’ 
and 3’ UTRs, and mutations less than 100 base pairs upstream of a transcript start site (Figure 
S4-8). Coordinates were lifted over from ECNR2 to MG1655 to permit annotation of the SNPs 
and indels.  This resulted in C21, C22, and C23 having 4,5, and 5 mutations respectively having 
no corresponding liftover coordinates in ECNR2.  These are referred to as the "unmappable" in 
Figure S4-8. 
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Figure S4-1. Circular representation of the E. coli genome depicting the coordinates and 
orientation of all TAG codons.  TAG codons found in essential genes(6) are shown in red.  The 
outer ring plots all clockwise transcribed TAG codons on the + DNA strand whereas the inner 
ring plots all counterclockwise transcribed TAG codons on the – DNA strand.  The middle ring 
depicts the 32 sections of the genome targeted for TAG-to-TAA conversion.  The inner circle 
plots the genomic coordinates, origin of replication (ORI), terminus (TER) and replichores 1 
(R1) and 2 (R2). 
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Figure S4-2. Multiplexing in MAGE leads to higher aggregate allele replacement (AR) 
frequencies. Multiplex oligo recombineering experiments were performed with equimolar 
oligo pools ranging in complexity from one to 24 oligos. AR frequencies were quantified for 
one conversion site corresponding to one oligo present in all pools. While individual AR 
frequencies (a) decrease as a function of higher complexity, the overall aggregate frequency 
(estimated as the product of individual frequency and pool complexity)  (b) increases. Allele 
frequencies were measured using MASC-qPCR and curves are fit to the formula y=a(1-e
-b/x
) 
for plot a and y=ax(1-e
-b/x
) for plot b. Error bars indicate standard error (n=2). 
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Figure S4-3. Multiplex allele-specific colony quantitative PCR (MASC-qPCR) to rapidly screen 
for the most modified clones. Multiplex reactions were used to determine which clones in the 
complex pool had been most highly modified. A. Clones from cultures receiving 18 cycles of 
MAGE processing (pools of 10 oligos) were sorted by their mutiplex ΔΔCt scores. Small 
numbers of top-scoring clones (typically 3-5) were then assessed at each TAG site of interest. B. 
When only two modifying oligos are used for allele replacement, mutiplex ΔΔCt values are more 
visibly clustered into groups representing 0, 1, or 2 modifications. C. Correlation between 
mutiplex ΔΔCt scores from (A) and the number of specific modifications achieved. The top 
mutiplex ΔΔCt-scoring clone was found to have the most allele conversions roughly 70% of the 
time. The legend indicates the number of modifications observed in the top-scoring clones. D. 
Singleplex reactions were used to genotype the most promising clones. Shown are 7 clones 
assayed at the tfaS stop codon, with singleplex ΔΔCt values of 0.0±0.7 for wild-type TAG and 
12.1±0.7 for modified TAA. 
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Figure S4-4. Multiplex allele-specific colony PCR (MASC-PCR) for the detection of codon 
conversions in each clone.  The gel illustrates results from 3 MAGE-cycled clones.  Ten sites are 
investigated in each lane where two MASC-PCRs are conducted for each clone:  one reaction 
interrogates the TAG loci (-) and another reaction interrogates the TAA loci (+).  Each reaction 
provides a binary output through the presence or absence of an amplicon band.  Together, both 
TAG and TAA reactions provide sufficient information to determine the conversion status of a 
given codon.  Summation of the rows of the 46 clones provides loci frequency data for each 
codon (plotted in Figure 2 in the main text).  Summation of the columns of each clone provides a 
histogram of the mutations per clone (plotted in Figure 4-3 in the main text). 
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Figure S4-5. Off-target mutation in modified strains. From 96.3 kb of total Sanger sequencing, 
the majority of unwanted mutations were observed in regions corresponding to the annealing 
sites for the 90-mer oligonucleotides (blue). Sequenced mutations falling outside these 90 bp 
regions are shown in red. The principal error is a deletion, mostly single base deletions. These 
errors correspond to common defects arising from oligo synthesis. 
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Figure S4-6. Individual growth rates of all 32 "top" recoded strains (10 out of 10 changes each, 
grey, rE1-rE32) following the successful replacement of all TAG-to-TAA codons versus that of 
the ancestral strain (black, EcNR2).  A mix of increased and decreased growth rates was 
observed across the 32 strains with an average of 47 minutes/division.  This is a mild decrease 
versus the growth rate (42 minutes/division) of the ancestral strain.  Our parallelized MAGE 
approach across 32 strains allows us to easily identify strains with notable growth phenotypes 
(e.g., rE5, rE6).  These strains can be investigated further to determine if these growth 
impediments are due to the codon changes or whether they arise from secondary mutations 
elsewhere in the genome.  
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Figure S4-7. Some oligo defects can be fixed by host repair mechanisms. Oligos containing 
internal deletions are likely to result in equivalent mutations in the genome, but oligo synthesis 
chemistry can be optimized to minimize such deletions. In such cases, measures such as more 
aggresive deprotection and coupling conditions can then give rise to damaged oligos containing 
abasic sites. However, this second type of defect is readily repaired in the host. Three similar 
purified oligos were used to modify the selectable chromosomal tolC gene in separate cultures. 
An upstream modification (not shown) in each oligo creates a stop codon in tolC—selection 
against the tolC protein ensures only cells that have incorporated this oligo survive. PCR 
amplification of the resulting population and sequencing of this potentially heterogeneous 
product allows assessment of the effect of modifications at a second site. Top: only the initial 
stop codon was employed for this oligo, leaving the wild-type sequence C97-T102 of the tolC 
gene. Middle: this oligo coded for a deletion of C99, effectively shifting the subsequent peaks 
left one base position. However, a notable fraction (less than one-third) has not been shifted, 
indicating possible repair events (this fraction is very unlikely to arise from a defect in the oligo). 
Bottom: this oligo contained an abasic site at position 99, but the resulting population is almost 
completely wild-type, indicating likely cellular repair. These experiments were performed in 
strain EcNR2, which includes a deletion of the mutS mismatch repair gene. 
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Figure S4-8. Bioinformatics sequencing analysis process and secondary mutation breakdown. 
We sequenced the entire genomes of three 1/8 recoded strains and identified off-target SNPs and 
short (1 bp) indels using BWA sequencing alignment (3). On-target TAG conversions are not 
included in this analysis. We found an average of 113 mutations/genome after each strain went 
through approximately 960 doublings, multiple lambda red inductions, and several conjugations. 
This corresponds to 2E-8 mutations/bp/doubling, which is consistent with the predicted basal 
mutation rate of the ancestral strain (EcNR2). These results indicate that MAGE and CAGE do 
not significantly compromise genome stability.  Also see Figure S4-9 and Tables S4-8 to S4-11 
for supporting data and information. 
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Figure S4-9 Functional annotation of all mutations as indicated by the COG category of the gene 
or regulatory region associated with the SNP or indel.  Functional annotation of all mutations are 
summed across the three sequenced genomes.  See Table S4-8 for complete list of secondary 
mutations. 
 
Supplemental Tables can be found at 
<http://www.sciencemag.org/content/suppl/2011/07/13/333.6040.348.DC1/Isaacs.SOM.pdf> 
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APPENDIX D 
 
Supplemental Material for Genomically Recoded Organisms Impart New 
Biological Functions 
 
 
 
 
 
This supplemental material is reproduced with permission from its initial publication: 
 
Lajoie MJ, Rovner AJ, Goodman DB, Aerni HR, Haimovich AD, Kuznetsov G, Mercer JA, 
Wang HH, Carr PA, Mosberg JA, Rohland N, Schultz PG, Jacobson JM, Rinehart J, Church 
GM, Isaacs FI (2013) Genomically Recoded Organisms Impart New Biological Functions. 
Science 342: 357-60. 
 
Tables and Figures have been renamed to be consistent with CHAPTER 5. 
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A. Materials and Methods 
 
All DNA oligonucleotides were purchased with standard purification and desalting from 
Integrated DNA Technologies (Table S5-19). Unless otherwise stated, all cultures were grown in 
LB-Lennox medium (LB
L
, 10 g/L bacto tryptone, 5 g/L sodium chloride, 5 g/L yeast extract) 
with pH adjusted to 7.45 using 10 M NaOH. LB
L
 agar plates were LB
L
 plus 15 g/L bacto agar. 
Top agar was LB
L
 plus 7.5 g/L bacto agar. MacConkey agar was prepared using BD Difco™ 
MacConkey agar base according to the manufacturer’s protocols. M9 medium (6 g/L Na2HPO4, 
3 g/L KH2PO4, 1 g/L NH4Cl, 0.5 g/L NaCl, 3 mg/L CaCl2) and M63 medium (2 g/L (NH4)2SO4, 
13.6 g KH2PO4, 0.5 mg FeSO4·7H2O) were adjusted to pH 7 with 10 M NaOH and KOH, 
respectively. Both minimal media were supplemented with 1 mM MgSO4·7H2O, 0.083 nM 
thiamine, 0.25 g/L D-biotin, and 0.2% w/v carbon source (galactose, glycerol, or glucose).  
 
The following selective agents were used: carbenicillin (50 g/mL), chloramphenicol (20 g 
/mL), kanamycin (30 g/mL), spectinomycin (95 g/mL), tetracycline (12 g/mL), zeocin (10 
g/mL), gentamycin (5 g/mL), SDS (0.005% w/v), Colicin E1 (ColE1; ~10 µg/mL), and 2-
deoxygalactose (2-DOG; 0.2%). ColE1 was expressed in strain JC411 and purified as previously 
described (26). All other selective agents were obtained commercially. 
 
The following inducers were used at the specified concentrations unless otherwise indicated: 
anhydrotetracycline (30 ng/µL), L-arabinose (0.2% w/v). 
 
p-acetyl-L-phenylalanine (pAcF) was purchased from PepTech (# AL624-2) and used at a final 
concentration of 1 mM. O-phospho-L-serine (Sep) was purchased from Sigma Aldrich (# P0878-
25G) and used at a final concentration of 2 mM. 
 
Strains 
All strains were based on EcNR2 (11) (Escherichia coli MG1655 ΔmutS::cat Δ(ybhB-
bioAB)::[λcI857 N(cro-ea59)::tetR-bla]). Strains C321 [strain 48999 (www.addgene.org/48999)] 
and C321.ΔA [strain 48998 (www.addgene.org/48998)] are available from addgene. 
 
Selectable marker preparation 
Selectable markers were prepared using primers described in Table S5-19. PCR reactions (50 µL 
per reaction) were performed using Kapa HiFi HotStart ReadyMix according to the 
manufacturer’s protocols with annealing at 62 °C. PCR products were purified using the Qiagen 
PCR purification kit, eluted in 30 µL of dH2O, quantitated using a NanoDrop™ ND1000 
spectrophotometer, and analyzed on a 1% agarose gel with ethidium bromide staining to confirm 
that the expected band was present and pure. 
 
MAGE and  Red-mediated recombination 
MAGE (13), CoS-MAGE (14), and  Red-mediated recombination (27) were performed as 
previously described. Briefly, an overnight culture was diluted 100-fold into 3 mL LB
L
 plus 
antibiotics and grown at 30 °C in a rotator drum until mid-log growth was achieved (OD600 ~0.4-
0.6). Lambda Red was induced in a shaking water bath (42 °C, 300 rpm, 15 minutes), then 
induced culture tubes were cooled rapidly in an ice slurry for at least two minutes. 
Electrocompetent cells were prepared at 4 °C by pelleting 1 mL of culture (centrifuge at 16,000 
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rcf for 20 seconds) and washing the cell pellet twice with 1 mL ice cold deionized water (dH2O). 
Electrocompetent pellets were resuspended in 50 µL of dH2O containing the desired DNA. For 
MAGE oligos, no more than 5 µM (0.5 µM of each oligo) was used. For CoS-MAGE, no more 
than 5.5 µM (0.5 µM of each oligo including the co-selection oligo) was used. For dsDNA PCR 
products, 50 ng was used. Cells were transferred to 0.1 cm cuvettes, electroporated (BioRad 
GenePulser™, 1.78 kV, 200 Ω, 25 µF), and then immediately resuspended in 3 mL LBL (MAGE 
and CoS-MAGE) or 1.5 mL LB
L
 (dsDNA). Recovery cultures were grown at 30 °C in a rotator 
drum. For continued MAGE cycling, cultures were recovered to mid-log phase before being 
induced for the next cycle. To isolate monoclonal colonies, cultures were recovered for at least 3 
hours (MAGE and CoS-MAGE) or 1 hour (dsDNA) before plating on selective media. For tolC 
and galK negative selections, cultures were recovered for at least 7 hours to allow complete 
protein turnover before exposure to ColE1 and 2-deoxygalactose, respectively. 
 
CAGE 
CAGE was performed as previously described (11). Briefly, conjugants were grown to late-log 
phase in all relevant antibiotics (including tetracycline in the donor culture to select for the 
presence of conjugal plasmid pRK24 (28)). At mid-log growth, 2 mL of each culture was 
transferred to a 2 mL microcentrifuge tube and pelleted (5000 rcf, 5 minutes). Cultures were 
washed twice with LB
L
 to remove antibiotics, then the pellets were resuspended in 100 µL LB
L
. 
Donor (10 µL) and recipient (90 µL) samples were mixed by gentle pipetting and then spotted 
onto a pre-warmed LB
L
 agar plate (6 x 10 L and 2 x 20 L spots). Conjugation proceeded at 30 
°C without agitation for 1 – 24 hours. Conjugated cells were resuspended off of the LBL agar 
plate using 750 L liquid LBL, and then 3 L of the resuspended conjugation was inoculated into 
3 mL of liquid LB
L
 containing the appropriate selective agents. The population with the correct 
resistance phenotype was then subjected to ColE1 negative selection to eliminate cells that 
retained tolC.  
 
Each round of conjugation, genotyping, and strain manipulation required a minimum of 5 days to 
complete. On day 1, the conjugation and positive selections were performed. On day 2, the 
population of cells exhibiting the desired resistance phenotype was subjected to a ColE1 
selection to eliminate candidates that retained tolC. The ColE1-resistant population was then 
spread onto plates to isolate monoclonal colonies. On day 3, candidate colonies were grown in a 
96-well format and screened for the desired genotypes via PCR (to confirm loss of tolC) and 
MASC-PCR (to confirm the presence of the desired codon replacements). On day 4, tolC or 
kanR-oriT was recombined directly into one of the positive markers, and recombinants were 
plated on LB
L
 plates containing SDS or kanamycin, respectively. On day 5, candidate colonies 
were grown in liquid LB
L
 containing SDS or kanamycin and used as PCR template to confirm 
successful replacement of positive selection markers with tolC or kanR-oriT. These strains were 
ready for the next conjugation. 
 
Positive/Negative selections 
Positive selection for tolC: TolC provides robust resistance to SDS (0.005% w/v) in LB
L
 (both 
liquid and LB
L
 agar).  
 
Negative selection for tolC: After tolC was removed via λ Red-mediated recombination or 
conjugation, cultures were recovered for at least 7 hours prior to ColE1 selection. This was 
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enough time for the recombination to proceed and for complete protein turnover in the 
recombinants (i.e. residual TolC protein no longer present). ColE1 selections were performed as 
previously described (11). Briefly, pre-selection cultures were grown to mid-log phase (OD600 
~0.4), then diluted 100-fold into 150 µL of LB
L
 and LB
L
 + ColE1. Once growth was detected, 
monoclonal colonies were isolated on non-selective plates and PCR screened to confirm the loss 
of tolC. 
 
Positive selection for galK: GalK is necessary for growth on galactose (0.2% w/v) as a sole 
carbon source. It is important to thoroughly wash the cells with M9 media to remove residual 
carbon sources prior to selection in M63 + galactose (both liquid and M63 agar). Noble agar 
must be used, since Bacto agar may contain contaminants that can be used as alternative carbon 
sources. 
 
Negative selection for galK: After galK was removed via λ Red-mediated recombination or 
conjugation, cultures were recovered for at least 7 hours prior to 2-DOG selection. This was 
enough time for the recombination to proceed and for complete protein turnover in the 
recombinants (i.e. residual GalK protein no longer present). 2-DOG selections were performed 
as previously described (29). Briefly, pre-selection cultures were grown to mid-log phase (OD600 
~0.4), washed three times in M9 medium to remove residual nutrients from LB
L
, and then 
inoculated into M63 + 0.2% glycerol and M63 + 0.2% glycerol + 0.2% 2-DOG. Once growth 
was detected, monoclonal colonies were isolated on non-selective plates (LB
L
 agar or 
MacConkey agar) and PCR screened to confirm the loss of galK. When possible, colonies were 
streaked onto MacConkey + 0.2% galactose indicator plates (white colonies are Gal- and red 
colonies are Gal+) prior to PCR screening, but MacConkey media is toxic to strains that do not 
express TolC, which provides resistance to bile salts. We also found that 2-DOG selection was 
effective in LB
L
, but PCR screening was important because LB
L
 + 2-DOG selection was less 
stringent. 
 
Screening for galK and malK: Cultures were diluted and plated for single colonies on 
MacConkey agar + 0.2% galactose (galK) or MacConkey agar + 0.2% maltose (malK) indicator 
plates (white colonies are Gal- or Mal-, and red colonies are Gal+ or Mal+). The genotypes were 
confirmed via PCR. 
 
Genotyping 
After λ Red-mediated recombination or conjugation, colony PCR was used to confirm the 
presence or absence of selectable markers at desired positions. Colony PCR (10 µL per reaction) 
was performed using Kapa 2G Fast HotStart ReadyMix according to the manufacturer’s 
protocols with annealing at 56 °C. Results were analyzed on a 1% agarose gel with ethidium 
bromide staining. 
 
Multiplex allele-specific colony PCR (MASC-PCR) was used to simultaneously detect up to 10 
UAGUAA conversions as previously described (11). Briefly, each allele was interrogated by 
two separate PCRs to detect the UAG/UAA status. The two reactions shared the same reverse 
primer but used different forward primers whose 3′ ends annealed to the SNP being assayed. 
Amplification only in the wt-detecting PCR indicated a UAG allele, whereas amplification only 
in the mutant-detecting PCR indicated a UAA allele. Each primer set produced a unique 
230 
 
amplicon size corresponding to its target allele (100, 150, 200, 250, 300, 400, 500, 600, 700 and 
850 bp). Template was prepared by growing monoclonal colonies to late-log phase in 150 µl LB
L
 
and then diluting 2 µl of culture into 100 µl dH2O. Initially, we used Qiagen Multiplex PCR kit, 
but KAPA 2G Fast Multiplex Ready Mix produced cleaner, more even amplification across our 
target amplicon size ranges. Therefore, typical MASC-PCR reactions contained KAPA 2G Fast 
Multiplex ReadyMix (Kapa Biosystems, # KK5802) and 10X Kapa dye in a final volume of 10 
µl, including 2 µl of template and 0.2 µM of each primer. PCR activation occurred at 95°C (3 
min), followed by 27 cycles of 95°C (15 sec), 63–67°C (30 sec; annealing temperature was 
optimized for each set of MASC-PCR primers), and 72°C (70 sec). The final extension was at 
72°C (5 min). MASC-PCR results were analyzed on 1.5% agarose gels with ethidium bromide 
staining to ensure adequate band resolution. 
 
Sanger sequencing was performed by Genewiz or Eton Bioscience, Inc. 
 
Genomic DNA for whole genome sequencing was prepared using a Qiagen Genomic DNA 
purification kit or by simultaneously lysing raw culture and shearing genomic DNA using a 
Covaris E210 AFA Ultrasonication machine. Illumina libraries were prepared as previously 
described (30). Each strain was barcoded with a unique 6 bp barcode for pooling. Up to 16 
strains were pooled for sequencing on a single HiSeq lane, and up to 4 genomes were pooled for 
sequencing on a single MiSeq lane. Whole genome sequencing was performed using Illumina 
HiSeq or MiSeq systems. The HiSeq samples were sequenced with paired end 50 bp or 100 bp 
reads, and the MiSeq samples were sequenced with paired end 150 bp reads. 
 
Sequencing analysis  
In order to analyze the sequencing data from 68 distinct genomes, we developed a software 
pipeline that connects several modular tools and custom scripts for analysis and visualization. 
The goal of our pipeline was to identify SNPs and structural variants relative to the reference 
genome E. coli K-12 MG1655 (U00096.2, GI:48994873). Note that we use the term SNP to 
mean any small mismatches or indels identified by Freebayes (<22 bp). We use the term 
structural variant to refer to large insertions detected by Breakdancer and Pindel, deletions, or 
other significant junction events (confirmed variants of size 170 bp and 776 bp in C321.ΔA). 
 
FASTQ conversion to SAM/BAM: FASTQ reads were split using individual genome barcodes 
with the FASTX toolkit (31). After splitting and trimming of the 6 bp barcode, FASTQ files for 
individual reads were aligned to the reference genome (E. coli K-12 MG1655 or the C321.ΔA 
predicted genome sequence) using Bowtie2 version 2.0.0-beta5 (32) with local alignment and 
soft-clipping enabled. PCR duplicates were removed using the Picard toolkit 
<http://picard.sourceforge.net/> and reads were realigned around short indels using the Genome 
Analysis Toolkit (33).  
 
SNP calling using Freebayes: SNPs were called using the Freebayes package 
(arXiv:1207.3907v2 [q-bio.GN]). SNP calls were made using a --ploidy flag value of 2, in order 
to catch SNPs that occur in duplicated regions. These SNPs show up as heterozygous calls in the 
output. The minimum alternate fraction for such calls was set at 0.4. The p-value cutoff was set 
at 0.001. SNPs from all genomes were called simultaneously, using the --no-ewens-priors and --
no-marginals flags. The --variant-input flag was used to provide Freebayes with the recoded 
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SNP (UAG-to-UAA) positions as putative variants to call regardless of evidence. Reads 
supporting SNPs were required to have a minimum mapping quality of 10 and a minimum base 
quality of 30. Mapping quality was not otherwise used to assess SNP likelihoods (--use-
mapping-quality was disabled). We ran Freebayes as described above to generate a single VCF 
file containing all variants for all samples. This VCF file was then further analyzed and filtered 
before as described below, before generating the summarizing diagram Figure S5-3.  
 
SNP Effect using snpEFF: SnpEff 2.0.5d (34) was used to annotate variants and to predict effects 
for called SNPs. First, the reference genome’s annotated GenBank Record (GI:48994873) was 
used to create a genome database, and the VCF records were annotated for coding effects only.  
 
Final SNP filtering: In addition to the Freebayes SNP identification criteria, we used additional 
metrics to filter out SNPs that could not be called with high confidence. This additional filtering 
helped to reduce the complexity of the relationship of variants across all sequenced genomes in 
order to plot Figure S5-3. Note that this filtering resulted in some low-evidence variants being 
temporarily ignored in the aggregate analysis. However, these were carefully triaged and 
identified in the process of generating the sequence annotation file for the final C321.ΔA strain. 
 
v. All 'heterozygous' calls were filtered out, as these represent SNPs whose reads map to 
multiple locations in the genome.  
vi. SNPs that were present in fewer than three samples and could not be called either 
present or absent in >20 strains due to poor coverage or read mapping quality were 
filtered out.  
vii. SNPs were filtered out if they were covered by ≤ 20 reads with good mapping quality 
across all genomes. 
viii. SNPs that could be called absent or present in fewer than three genomes were 
removed. 
 
Structural variants using Pindel and Breakdancer: Pindel (35) and Breakdancer (36) were both 
used to find potential structural variants in the genomes. First, Picard 
<http://picard.sourceforge.net/> was used to gather insert size metrics per genome. This 
information, along with the aligned BAM data, was run through Pindel. The Pindel output was 
converted to VCF using the pindel2vcf tool. We required at least 20 reads to support a breakpoint 
or junction. The breakdancer_max program in Breakdancer was also used to find structural 
variants. For Breakdancer, at least 8 read pairs were required to support a called structural event.  
 
We manually corroborated structural variant calls from Pindel and Breakdancer through visual 
examination of read alignments. Since we observed a high-rate of false-positive and false-
negative calls with these toolswe did not include them in our final strain analysis in the main 
text.  Still, the Pindel and Breakdancer data were useful in  troubleshooting cassette insertions 
and intentional gene knockouts and replacements. 
  
Future work to combine evidence from these and additional tools might lead to a more robust, 
comprehensive, and high throughput method to validate structural variants using only short-read 
sequencing data.  
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Breakdancer predicted 49 unique events, and 187 total events across 69 strains. Because 
Breakdancer cannot call across multiple strains simultaneously and only gives approximate event 
locations based on read-pair distances, events that occurred in multiple samples were identified 
by using similar event start and end locations. Breakdancer predicted a total of 21 unique 
deletions, 5 unique inversions, and 23 unique translocations.  
 
Pindel used split read data to predict both uncharacterized breakpoints and whole structural 
events. 258 unique uncharacterized breakpoints were found; 230 of these occur in only a single 
sample. Pindel also predicted 79 unique structural events. 9 were large deletions, 59 were 
insertions of unknown size, and 11 were inversions. 
 
Coverage analysis: Coverage for each genome was analyzed using the bedtools (37) programs 
makewindows and multicov. The genome was split into 50 bp windows and BAM coverage was 
assessed for each window. A custom python script was used to take this information and find 
contiguous windows of low and high coverage, indicative of gene amplifications and deletions. 
These results are included as supplemental Table S5-31. 
 
Confirming cassette insertion sites: Known insertion sites of CAGE antibiotic resistance markers 
were confirmed by selecting the reads that were soft clipped and/or not aligned to the MG1655, 
and aligning them to the known cassette sequences using Bowtie. Cassette insertion locations 
were inferred using the alignment locations of paired reads in which one read mapped to a 
cassette and the other mapped to a location on the genome. 
 
Visually confirming SNPs and structural variants: The tview tool in the Samtools package (38) 
was used to visually inspect individual UAG SNPs and to assess the veracity of low-confidence 
SNP and structural variant calls.  
 
Generating genome figures: Figure S5-3 was created using custom software written in R and 
Processing.  
 
 
Fitness analysis 
To assess fitness, strains were grown in flat-bottom 96-well plates (150 L LBL, 34 °C, 300 
rpm). Kinetic growth (OD600) was monitored on a Biotek H4 plate reader at 5 minute intervals. 
Doubling times were calculated by tdouble = c*ln(2)/m, where c = 5 minutes per time point and m 
is the maximum slope of ln(OD600). Since some strains achieved lower maximum cell densities, 
slope was calculated based on the linear regression of ln(OD600) through 5 contiguous time 
points (20 minutes) rather than between two pre-determined OD600 values. To monitor fitness 
changes in the CAGE lineage, growth curves were measured in triplicate, and their average was 
reported in Figure 5-2 and Table S5-1. To determine the effect of RF1 removal and NSAA 
incorporation on the panel of recoded strains (Table 1), growth curves were measured in 
triplicate (Figure 5-3A, Figure S5-8). Statistics were based on a Kruskal-Wallis one-way 
ANOVA followed by Dunn’s multiple comparison test, where *p < 0.05, **p < 0.01, and ***p < 
0.001.  
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To assess re-growth phenotypes from long-term NSAA expression, overnight cultures were first 
grown in LB
L
 supplemented with chloramphenicol to maintain the pEVOL plasmids. These 
cultures were passaged into LB
L
 containing chloramphenicol, arabinose (to induce pEVOL), and 
either pAcF or pAzF depending on whether pEVOL-pAcF or pEVOL-pCNF was used. Growth 
with shaking at 34°C was monitored using a Biotek H1 or a Biotek Eon plate reader with OD600 
readings every 10 minutes (pAcF) or 5 minutes (pAzF). After 16 hours of growth, the expression 
cultures were passaged into identical expression conditions and the growth curves were 
monitored with the same protocols. 
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NSAA incorporation assays 
 
Plasmids and strains for NSAA incorporation: p-acetyl-L-phenylalanine (pAcF) incorporation 
was achieved using pEVOL-pAcF (9) which contains two copies of pAcF-RS and one copy of 
tRNA
   
   
. The pEVOL-pAcF plasmid was maintained using chloramphenicol resistance. One 
copy of pAcF-RS and tRNA
   
   
 were constitutively expressed, and the second copy of pAcF-RS 
was under araBAD-inducible control (0.2% L-arabinose).  
 
O-phospho-L-serine (Sep) incorporation was achieved by expression of tRNA
Sep
 from pSepT 
and both EFSep (EF-Tu variant capable of incorporating Sep) and SepRS from pKD-SepRS-
EFSep (21). To prevent enzymatic dephosphorylation of Sep in vivo, the gene encoding 
phosphoserine phosphatase (serB), which catalyzes the last step in serine biosynthesis, was 
inactivated. Specifically, Glu93 (GAA) was mutated to a premature UAA stop codon via MAGE. 
The pKD-SepRS-EFSep plasmid was maintained using kanamycin resistance and both SepRS 
and EFSep were induced using IPTG. The pSepT plasmid was maintained using tetracycline 
resistance, and tRNA
Sep
 was constitutively expressed. 
 
Effect of RF1 deletion, aaRS expression, and NSAA incorporation on fitness: Stationary phase 
pre-cultures were obtained by overnight growth with shaking at 34 °C in 150 µl LB
L
 
supplemented with chloramphenicol for plasmid maintenance. Stationary phase cultures were 
diluted 100-fold into 150 µl LB
L
 containing chloramphenicol and 0.2% L-arabinose and/or 1 
mM pAcF where indicated. Growth was monitored on a Biotek Synergy H1 plate reader. OD600 
was recorded at 10-minute intervals for 16 hours at 34 °C with continuous shaking. All data were 
measured in triplicate. Doubling time was determined for each replicate as described above, and 
replicates were averaged for Figure 5-3A. 
 
GFP variant synthesis: GFP variants (Table S5-33) were synthesized as gBlocks by IDT and 
modified with an N-terminal 6His tag via PCR. His-tagged GFP variants were isothermally 
assembled (39) into the pZE21 plasmid backbone (40) to yield the array of GFP reporter 
plasmids used in this study. Reporter plasmids were maintained using kanamycin resistance and 
induced using 30 ng/mL anhydrotetracycline (aTc). 
 
UAG suppression and GFP Fluorescence: Stationary phase pre-cultures were obtained by 
overnight growth with shaking at 34 °C in 150 µl LB
L
 supplemented with appropriate antibiotics 
for plasmid maintenance. Stationary phase cultures were diluted 100-fold into 150 µl fresh LB
L
 
containing the same antibiotics as the overnight pre-culture. These cultures were grown to mid-
log phase and diluted 100-fold into 150 µl fresh LB
L
 containing the same antibiotics plus 30 
ng/ml aTc, 0.2% L-arabinose, and/or 1 mM pAcF (where indicated). Protein expression 
proceeded for 16 hours at 34 °C with continuous shaking. Following 16 hours of expression, 
cultures were transferred to V-bottomed plates, pelleted, and washed once in 150 µL of PBS (pH 
7.4). Washed pellets were resuspended in 150 µL of PBS (pH 7.4) and transferred to a black-
walled, clear-bottom plate to measure GFP fluorescence for each strain. Both OD600 and GFP 
fluorescence (Ex: 485 nm, Em: 528 nm) were measured on a Biotek Synergy H1 plate reader. 
Fluorescence and OD600 measurements were corrected by subtracting background fluorescence 
and OD600 (determined using PBS blanks). Relative fluorescence (in rfu) was calculated by the 
ratio fluorescence/OD600. Reported values represent an average of four replicates. After 
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measurements were complete, the cells were pelleted, the supernatant was aspirated, and the 
pellets were frozen at -80 °C for subsequent protein purification and Western blot analysis. 
 
Protein extraction and Western blots: Cell pellets were obtained as described above. Cells were 
lysed using a lysis cocktail containing 150 mM NaCl, 50 mM Tris-HCl, 0.5x BugBuster reagent, 
5% glycerol, 50 mM Na3VO4, 50 mM NaF, protease inhibitors (Roche), and 1 mM DTT. The 
resulting lysates were spun at 4 °C for 15 minutes at 3200 x g only in cases where soluble and 
insoluble fractions were separately analyzed. Protein lysate concentrations were determined 
using the BioRad-DC colormetric protein assay. Lysates were normalized by optical density at 
600 nm, resolved by SDS-PAGE, and electro-blotted onto PVDF membranes (Millipore, # 
ISEQ00010). Western blot analysis was performed with mouse monoclonal antibody directed 
against GFP (Invitrogen, # 332600), and membranes were imaged with an HRP secondary 
antibody (Jackson Immunoresearch, JAC-715035150) via chemiluminescence on a ChemiDoc 
system (BioRad). 
 
Mass spectrometry 
 
Materials: Urea, Tris-HCl, CaCl2, iodoacetamide (IAA), Pyrrolidine, DL-lactic acid, HPLC 
grade water and acetonitrile (ACN) were from Sigma-Aldrich (St. Louis, MO). Chloroform and 
dithiothretitol (DTT) were from American Bioanalytical (Natick, MA). Methanol, trifluoroacetic 
acid (TFA), ammonium hydroxide and formic acid (FA) were obtained from Burdick and 
Jackson (Morristown, NH). Sequencing grade modified trypsin was from Promega 
(Madison,WI). Anionic acid cleavable surfactant II (ALS) was from Protea (Morgantown, WV). 
UltraMicroSpin
TM
 columns, both the C18 and the DEAE PolyWAX variety were from The Nest 
Group, Inc. (Southborough, MA). Titaniumdioxide (TiO2) with a particle size of 5 µm was 
obtained from GL Sciences Inc. (Torrance, CA).  
Cell culture and lysis: Strains were routinely grown in LB
L
 media with the following 
concentration of antibiotics when appropriate: tetracycline (12 μg/mL), kanamycin (50 μg/mL), 
chloramphenicol (12 μg/mL), and zeocin (25 μg/mL). Bacterial cell cultures were grown at 30°C 
while shaking at 230 rpm until late log phase, quenched on ice and pelleted at 10,000 x g (10 
min). The media was discarded and the cell pellets were frozen at -80°C to assist with 
subsequent protein extraction. Frozen cell pellets were thawed on ice and lysed in lysis buffer 
consisting of BugBuster reagent, 50 mM Tris-HCl (pH 7.4, 23°C), 500 mM NaCl, 0.5 mM 
EGTA, 0.5 mM EDTA, 14.3 mM 2-mercaptoethanol, 10 % glycerol, 50 mM NaF, and 1 mM 
Na3O4V, Phosphatase inhibitor cocktail 3 and complete protease inhibitor cocktail (Sigma 
Aldrich) were added as recommended by the corresponding manufacturer. Cell suspensions were 
incubated on ice for 30 min and the supernatant was removed after ultracentrifugation. The 
remaining pellet was re-extracted and resulting fractions were combined. 
 
Protein lysates: Protein was precipitated with the methanol/chloroform method as previously 
described (41). One third of the resulting protein pellet was dissolved in 1.5 ml freshly prepared 
8 M Urea/0.4 M Tris-HCl buffer (pH= 8.0, 23 °C). 5 mg protein was reduced and alkylated with 
IAA and digested overnight at 37°C using sequencing grade trypsin. The protein digest was 
desalted using C18 Sep-Pak (Waters) and the purified peptides were lyophilized and stored at -
80°C. 
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Digestion of intact E. coli for shotgun proteomics: Cells were grown overnight to stationary 
phase, quenched on ice, and 2 ml culture was used for protein extraction and mass spectrometry. 
Cells were pelleted for 2 min at 2000 x g and the resulting pellet was washed twice with 1 ml ice 
cold Tris-HCl buffer pH=7.4, 23°C. The cells were then re-suspended in 100 µl Tris-HCl buffer 
pH=7.4, 23°C, split into 4 equal aliquots of 25 ul and the cell pellet was frozen at -80 °C. Frozen 
pellets were lysed with 40 µl lysis buffer consisting of 10 mM Tris-HCl buffer pH = 8.6 (23°C) 
supplemented with 10 mM DTT, 1 mM EDTA and 0.5 % ALS. Cells were lysed by vortex for 
30 s and disulfide bonds were reduced by incubating the reaction for 35 min. at 55 °C in a 
heating block. The reaction was briefly quenched on ice and 16 µl of a 60 mM IAA solution was 
added. Alkylation of cysteines proceeded for 30 min in the dark. Excess IAA was quenched with 
14 µl of a 25 mM DTT solution and the sample was then diluted with 330 µl of 183 mM Tris-
HCl buffer pH=8.0 (23 °C) supplemented with 2 mM CaCl2. Proteins were digested overnight 
using 12 µg sequencing grade trypsin for each protein aliquot, and the reaction was then 
quenched with 64 µl of a 20 % TFA solution, resulting in a sample pH<3. Remaining ALS 
reagent was cleaved for 15 min at room temperature. An aliquot of the sample consisting of ~30 
µg protein (as determined by UV280 on a nanodrop) was desalted by reverse phase clean-up using 
C18 UltraMicroSpin
 
columns. The desalted peptides were dried at room temperature in a rotary 
vacuum centrifuge and reconstituted in 30 µl 70 % formic acid 0.1 % TFA (3:8 v/v) for peptide 
quantitation by UV280. The sample was diluted to a final concentration of 0.6 µg/µl and 4 µl (2.4 
µg) were injected for LC-MS/MS analysis of the unfractionated digest using a 200 min method.  
 
Phosphopeptide enrichment: Offline phosphopeptide enrichment was carried out with Titanium 
dioxide (TiO2) using a bulk enrichment strategy adapted from Kettenbach (42). Briefly, between 
0.4 and 1 mg of desalted peptide digest was transferred into a 1.5 ml PCR tube and dissolved at a 
concentration of 1mg/ml in “binding solution” consisting of 2 M lactic acid in 50 % ACN. 
Activated TiO2 was prepared as a concentrated slurry in binding solution and added to the 
peptide solution to obtain a TiO2 to peptide ratio of 4:1 by mass. The mixture was incubated for 
2 h at room temperature on an Orbit M60 laboratory shaker operated at 140 rpm. The suspension 
was centrifuged for 20 s at 600 x g and the supernatant was removed. The TiO2 beads were 
washed twice with 50 µl of the binding solution and then 3 times with 100 µl 50 % ACN, 0.1 % 
TFA. Stepwise elution of phosphopeptides from the beads was carried out using 20 µl of 0.2 M 
sodium phosphate buffer pH=7.8 followed by 20 µl 5 % ammonium hydroxide and 20 µl 5 % 
pyrrolidine solution. The pH of the combined extracts was adjusted with 30 µl of ice cold 20 % 
TFA resulting in a sample pH <3.0. Peptides were desalted on C18 UltraMicroSpin columns as 
described above and the peptide concentration was estimated by UV280. 
 
Offline fractionation of tryptic digests: Offline electrostatic repulsion-hydrophilic interaction 
chromatography (ERLIC) (43) was performed on disposable DEAE PolyWAX UltraMicroSpin 
columns. Columns were activated as recommended by the manufacturer and then conditioned 
with 3 x 200 µl washes with 90 % ACN, 0.1 % acetic acid (buffer A). For this purpose, the 
columns were centrifuged for at 200 x g for 1 min at 4°C. The column was then loaded with 50 
µg of a desalted peptide digest prepared in 25 µl buffer A, and the flow-through was collected. 
Stepwise elution of the peptides was carried out using brief centrifugation steps carried out for 
30 s at 200 x g with 50 µl eluent unless noted otherwise. The elution steps consisted of the 
following volumetric mixtures of buffer A and buffer B (0.1 % formic acid in 30 % ACN): (1) 
100:0 (2) 96:4 (3) 90:10 (4) 80:20 (5) 60:40 (6) 100 µl of 20:80 (7) 100 µl of 0:100. Additional 
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elution steps consisted of: (8) 1 M triethylamine buffer adjusted with formic acid to pH=2.0. (9) 
0.2 % ammonia (10) 0.2 % ammonia and finally (11) 100 µl 70 % formic acid. The collected 
fractions were dried in a vacuum centrifuge and reconstituted in 15 µl solvent consisting of 3:8 
by volume of 70 % formic acid and 0.1 % TFA. Fractions were analyzed by LC-MS/MS using a 
400 min gradient. 
 
Liquid chromatography and mass spectrometry: Capillary LC-MS was performed on an Orbitrap 
Velos mass spectrometer (Thermo Fisher Scientific) connected to a nanoAcquity UPLC (Waters, 
Milford, MA). Liquid chromatography was performed at 35 °C with a vented split setup 
consisting of a commercially available 180 µm x 20 mm C18 nanoAcquity UPLC trap column 
and a BEH130C18 Waters symmetry 75 µm ID x 250 mm capillary column packed with 5 and 
1.7 µm particles respectively. Mobile phase A was 0.1 % formic acid (FA) and mobile phase B 
was 0.1 % FA in acetonitrile. The injection volume was 4-5 µl depending on the sample 
concentration. Up to 2.4 µg peptides were injected for each analysis. Peptides were trapped for 3 
min in 1 % B with and a flow rate of 5 µl/min. Gradient elution was performed with 90, 200 and 
400 min methods with a flow rate of 300 nl/min. Two blank injections were performed between 
samples to limit potential carryover between the runs. The gradient for the 90 min method was 1-
12 % B over 2 min, 12-25 % B over 43 min, 25-50 % B over 20 min, followed by 6 min at 95 % 
B and column re-equilibration in 1 % B. The gradient for the 200 min was 1-10 % B over 2 min, 
10-25 % B over 150 min, and 25-50 % B over 20 min, followed by 7 min at 95 % B and re-
column equilibration at 1 % B. The gradient for the 400 min was 1 min in 1 % B, 1-7 % B over 2 
min, 7-20 % B over 298 min, and 20-50 % B over 60 min, followed by a 1 min flow ramp to 95 
% B. The column was flushed for 9 min using 95 % B and then re-equilibrated for 27 min at 1 % 
B prior to the next injection. Mass spectrometry was performed with a spray voltage of 1.8 kV 
and a capillary temperature of 270 °C. A top 10 Higher Collisional Energy Dissociation (HCD) 
method with one precursor survey scan (300-1750 Da) and up to 10 tandem MS spectra 
performed with an isolation window of 2 Da and a normalized collision energy of 40 eV. The 
resolving power (at m/z = 400) of the Orbitrap was 30,000 for the precursor and 7500 for the 
fragment ion spectra, respectively. Continuous lock mass calibration was enabled using the 
polycyclodimethylsiloxane peak (m/z = 445.120025) as described (44). Dynamic exclusion 
criteria were set to fragment precursor ions exceeding 3000 counts with a charge state >1 twice 
within a 30 s period before excluding them from subsequent analysis for a period of 60 s. The 
exclusion list size was 500 and early expiration was disabled.  
 
Proteomics data processing: Raw files from the Orbitrap were processed with Mascot Distiller 
and searched in-house with MASCOT (v. 2.4.0) against the EcoCyc (45) protein database release 
16.0 for E. coli K-12 substr. MG1655 with a custom database and search strategy designed to 
identify amber suppression (Aerni et al. manuscript in preparation). Forward and decoy database 
searches were performed with full trypsin specificity allowing up to 3 missed cleavages and 
using a mass tolerance of ±30 ppm for the precursor and ±0.1 Da for fragment ions, respectively. 
Cysteines were considered to be completely alkylated with IAA unless samples were processed 
by a gel-based workflow. In that case Propionamide (C) was considered as a variable 
modification. Additional variable modifications for all searches were oxidation (M) and 
deamidation (NQ) for samples processed with urea Carbamyl (K, R, N-term). In order to detect 
pAcF containing peptides, a variable custom modification for Y was introduced with the 
composition C2H2 and monoisotopic mass of 26.015650 Da. Typical FDR were <1 % for 
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peptides above identity threshold and <2% considering all peptides above identity or homology 
threshold respectively. The MASCOT search results were deposited in the Yale Protein 
Expression Database (YPED) (46). The following filter rules were specified in YPED for 
reporting of protein identifications: (i) At least 2 bold peptides and peptide scores ≥20 or (ii) 1 
bold red peptide with a peptide score ≥20 with at least one additional bold red peptide with a 
score between 15 and 20. 
 
Bacteriophage assays 
 
For all phage experiments, growth was carried out in LB
L
 at 30 °C. Liquid cultures were aerated 
with shaking at 300 rpm. Before each experiment, a fresh phage lysate was prepared. To do this, 
Escherichia coli MG1655 was grown to mid-log phase in 3 mL of LB
L
, then ~2 uL of T7 
bacteriophage (ATCC strain BAA-1025-B2) or T4 bacteriophage (ATCC strain 11303-B4) was 
added directly from a glycerol stock into the bacterial culture. Lysis proceeded until it was 
complete (lysate appears clear after ~4 hours). The entire lysate was centrifuged to remove cell 
debris (10,000 rcf, 10 minutes), and 3 mL of lysate was transferred to a glass vial supplemented 
with 150 mg NaCl for phage preservation. Lysates were prepared fresh, titered, and stored at 4 
°C for the duration of each experiment. One lysate was used for all replicates of a given 
experiment. 
 
Phage titering: Phage lysate was titered by serial dilution into LB
L
 (10-fold dilution series). 
Before plating on LB
L
 agar, 10 µL of the diluted phage lysate was mixed with 300 µL of mid-log 
E. coli MG1655 culture and 3 mL of molten top agar. Plaques matured for ~4 hours at 30 °C. 
Titers (pfu/mL) were calculated based on the lysate dilutions that produced 20-200 pfu. 
 
Plaque area: For plaque area assays, bacterial cultures were grown to mid-log phase in 3 mL 
LB
L
. To accommodate different doubling times, faster-growing cultures were continually diluted 
until all strains reached OD600 ~0.5. Immediately prior to infection, OD600 was normalized to 
0.50 for all cultures. Approximately 30 pfu of T7 bacteriophage were mixed with 300 µL of 
OD600 = 0.50 culture and 3 mL of molten top agar, and then immediately plated on LB
L
 agar. 
Plaques were allowed to mature at 30 °C for 7 hours, then the plates were imaged on a Bio-Rad 
Gel Doc system, and plaque areas were measured using ImageJ (47). Statistics were based on a 
Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparison test, where *p < 
0.05, **p < 0.01, and ***p < 0.001.
 
 
T7 Fitness: Fitness was assessed in triplicate at low MOI based on protocols by Heineman et al. 
(22). Briefly, bacterial glycerol stocks were inoculated directly into 3 mL LB
L
 and serially 
diluted in LB
L
. Serial dilutions were grown overnight (30 °C, 300 rpm), so that one of the 
dilutions would be at mid-log growth phase in the morning. Prior to infection, a second dilution 
series was performed so that host strains would be at optimal growth phase over the course of the 
serial infection. Starting cultures were normalized to OD600 = 0.50 by adding LB
L
 immediately 
before infecting the cultures (MOI = 0.015) at t = 0. Infected culture was diluted 1/10 into 3 mL 
of uninfected mid-log phase culture at 30 minute intervals. Aliquots of the infection were taken 
at t = 4, 10, 60, and 120 minutes. At t = 4, the aliquot was treated with chloroform to quantitate 
non-adsorbed phage particles. For all other time points (t = 10, 60, and 120), aliquots were 
immediately mixed with 300 µL of mid-log E. coli MG1655 and 3 mL molten top agar and then 
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spread on LB
L
 agar. Plaques were counted after maturing for ~4 hours at 30 °C, and then pfu/mL 
was calculated for each time point, correcting for dilutions. Adsorption efficiency was 
consistently >95% as determined by (Nt=4 – Nt=10) / Nt=10, and fitness was determined by 
[log2(Nt=120/Nt=60)]/(Δt/(60 min/hr)), where N is the number of phages at time t minutes and Δt = 
60 min.  
 
Kinetic lysis time: Mean lysis time was determined with 12 replicates based on protocols from 
Heineman et al. (22), except that OD600 was monitored instead of OD540. Mid-log phase cells (as 
in the fitness assay) were infected at MOI = 5, then 150 µL aliquots of infected culture were 
distributed into a 96-well flat bottomed plate and sealed with Breathe-Easy™ sealing membrane. 
Lysis was monitored at 30 °C with shaking at 300 rpm on a Biotek H4 plate reader with OD600 
measurements taken every 5 minutes. Each lysis curve was fit to a cumulative normal 
distribution using the normcdf function in MATLAB. Mean lysis time, mean lysis OD600, and 
mean lysis slope were calculated using this cumulative normal distribution function. 
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B. Time and cost 
 
In order to demonstrate the efficiency and cost-effectiveness of our recoding strategy, we 
explicitly present the total full time equivalents (10.75 FTE years) and DNA costs ($20,333) 
required to complete this project. Because much of our research time was spent developing and 
optimizing these genome engineering tools as described below, we estimate the actual time spent 
constructing a fully recoded genome (5.5 FTE years), and the minimum amount of time that it 
would take to repeat its construction with current knowledge (0.5 FTE years) (Tables S10 and 
S11). By contrast, the design, synthesis, and assembly of the 1.08–mega–base pair Mycoplasma 
mycoides JCVI-syn1.0 genome required $40 million and more than 200 FTE years (48). While 
future de novo genome synthesis projects will likely improve on these figures by incorporating 
chip-based DNA synthesis (49), our strategy nevertheless demonstrates considerable advantages 
in the cost and efficiency of making hundreds of genome changes. 
 
 
Table S5-17. Time required to reassign UAG 
Phase 
Technology 
development 
Actual strain 
construction 
Time to 
repeat 
Time with 
CoS-MAGE
a
 
MAGE 3.75 1.50 0.15 0.24 
CAGE 7.00 4.00 0.35 0.12 
Total 10.75 5.50 0.50 0.36 
aSuggested improvements: make 40 changes per strain using improved CoS-MAGE strains (50, 51) 
 
 
Table S5-18. DNA cost for reassigning the UAG codon 
Oligo 
type 
MAGE oligos 
mascPCR 
primers 
Cassette 
amplification 
primers 
Cassette 
screening 
primers 
Deletion 
oligos 
Total 
Descri
ption 
320 x 90-mer 
oligos with 4 
PTO bonds 
978 oligos 
(~23 bp) 
190 x 72-mer 
oligos 
144 x 25-
mer oligos 
25 x 90-
mer oligos 
- 
Yield 
100 nmole 
DNA plate 
25 nmole 
DNA plate 
25 nmole DNA 
plate 
25 nmole 
DNA plate 
100 nmole 
DNA plate 
- 
Price 
per 
base* 
$0.28 per base, 
$3.50 per PTO 
bond 
$0.18 per 
base 
$0.18 per base 
$0.18 per 
base 
$0.28 per 
base 
- 
Total 
price 
$12,544.00 $4,048.92 $2,462.40 $648.00 $630.00 
$20,333.3
2 
*IDT standard price 
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Since we developed MAGE and CAGE at the same time as we were using them to reassign 
UAG, a considerable portion of our effort was devoted to technology optimization and changing 
strategies. For instance, since tolC negative selection yields scarless conjugal junctions, desired 
conjugants can be prepared for subsequent conjugations in one step by inserting kanR-oriT or 
tolC directly into one of the existing positive markers (11). Therefore, 6 modular cassettes 
targeting kanR-oriT or tolC to replace specR (spectinomycin), zeoR (zeocin), or gentR 
(gentamycin) are adequate for all conjugations beginning with the second round. Our initial 
designs did not take this into account, so we first had to remove one or both positive markers via 
a two step replacement and deletion procedure using tolC or galK. However, now that we better 
understand the homology requirements for precisely assembling genome segments of various 
sizes (Table S5-20), selectable markers can be placed to permit one-step turnaround between 
conjugations. Therefore, we report both the FTE time required to complete the construction of 
C321 and the estimated FTE time required to repeat the project with current knowledge (Table 
S5-17). 
 
Table S5-20. Positions of markers for CAGE and window sizes for conjugal junctions 
Conjugation 
Donor 
oriT 
position 
Recipient 
PN marker 
position 
lo Positive 
marker 
position 
hi Positive 
marker 
position 
oriT/tolC 
junction
a
 
Positive 
marker 
junction 
Conj1 4019968 none 3921005 4417928 undefined
 
4142298 
Conj2 4497524 none 4417928 4612628 undefined 4444521 
Conj3 189613 182395 4612628 374608 7218 4238020 
Conj4 480320 474528 36400 629000 5792 4046621 
Conj5 781100 788054 608541 903110 6954 4344652 
Conj6 1145180 1124600 892756 1255700 20580 4276277 
Conj7 1416412 1415470 1255700 1542300 942 4352621 
Conj8 MAGE MAGE MAGE MAGE MAGE MAGE 
Conj11 2438300 2428900 2223738 2627100 9400 4235859 
Conj12 2784761 2783150 2627100 2840467 1611 4425854 
Conj13 2967175 2968028 2840467 3014000 853 4465688 
Conj14 3176034 3184259 3010540 3334920 8225 4314841 
Conj15 3544352 none 3331657 4245059 undefined 3725819 
Conj16 3816822 none 3735445 4245059 undefined 4129607 
Conj17 4417928 4417928 3921005 4612628 0 3947598 
Conj18 374608 36400 4612628 629000 338208 3983628 
Conj19 892756 903110 608541 1255700 10354 3992062 
Conj20 1529620 1542300 1255700 1702450 12680 4192471 
Conj21 MAGE MAGE MAGE MAGE MAGE MAGE 
Conj22 2627100 none 2223738 2840467 undefined 4022492 
Conj23 3014000 3010540 2840467 3334920 3460 4144768 
Conj24 3734278 none 3332800 3921005 undefined 4051016 
Conj25 4610360 4612400 3921005 629000 2040 3292005 
Conj26 1255700 none 608541 1702450 undefined 3545312 
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Table S5-20 (Continued). 
Conj27 2223738 2209114 1710450 2840467 14624 3509204 
Conj28 3332800 3346270 2840467 3921005 13470 3558683 
Conj29 608541 791470 1702450 2627225 182929 924775 
Conj30_Cn2 2848625 2840467 1710450 3921005 8158 2428666 
Conj30_Cn7 2840467 2209114 1710450 3921005 631353 2428666 
Conj30_5 1719000 1663210 608541 3921005 55790 1326757 
Conj31 3864420 3921005 1255700 1719000 56585 463300 
a
Undefined means that there was no selection for the desired crossover position during conjugation 
 
Minimal time required to repeat the construction of C321 with current knowledge 
 
MAGE: 40 days 
 2 days of continuous cycling for 18 cycles 
 16 days to screen 32 MAGE populations (screen 2 populations per day) 
 1 day for 7 additional cycles 
 16 days to screen MAGE populations (screen 2 populations per day) 
 5 days to introduce the remaining UAG alleles and screen for desired clones 
 
CAGE: 90 days 
 1 day to prepare selectable marker cassettes 
 1 day to recombine specR, gentR, or zeoR marker into rEc strains 
 1 day to screen for desired recombinants 
 1 day to recombine marker tolC or kanR-oriT into recombinants 
 1 day to screen for desired double recombinants 
 85 days for 6 conjugations (minimum of 5 days per conjugation, maximum of 2 
conjugations per day) 
o Phase 1: 16 conjugations = 40 days 
o Phase 2: 8 conjugations = 20 days 
o Phase 3: 4 conjugations = 10 days 
o Phase 4: 2 conjugations = 5 days 
o Phase 5: 1 conjugation = 5 days 
o Phase 6: 1 conjugation = 5 days 
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C. Construction of a recoded genome 
 
Starting from EcNR2 (Escherichia coli MG1655 ΔmutS::cat Δ(ybhB-bioAB)::[λcI857 N(cro-
ea59)::tetR-bla]), we removed 305/321 UAG codons across 32 “rEc” strains. Each strain had 10 
adjacent UAG codons that we converted to UAA using MAGE. None of these strains exhibited 
impaired fitness. We then used CAGE to hierarchically assemble the recoded segments (“Conj” 
strains) into a fully recoded strain (summarized in Figure 5-2). We identified and overcame 
several barriers during genome construction. Below, we describe all deviations from our initial 
design, which was to (1) create 32 strains each with 10 UAG codons replaced by UAA, (2) 
hierarchically combine adjacent recoded segments into a strain completely lacking UAG, (3) 
remove release factor 1 (RF1) so that UAG would not cause translational termination. UAG IDs 
are based on Table S5-16. 
 
MAGE phase: 
 
UAGs that were not converted (false positives from MASC-PCR analysis): (Table S5-16) 
rEc4 retained UAGs 4.9 and 4.10. 
rEc5 retained UAGs 5.1 and 5.2. 
rEc12 retained UAG 12.9. 
rEc14 retained UAG 14.5. 
rEc15 retained UAG 15.8. 
rEc19 retained UAG 19.7. 
rEc30 retained UAG 30.3. 
 
UAGs that were converted in addition to the targeted set (Probably from MAGE oligo mix-ups): 
(Table S5-16) 
rEc29 had UAGUAA 16.1-16.4, 30.5 
rEc30 had UAGUAA 6.7 
rEc31 had UAGUAA 6.7 
 
CAGE phase: 
 
CAGE design for Conj1, Conj2, Conj3, Conj31, and Conj32: We were still optimizing the 
conjugation selection criteria at the beginning of the CAGE phase. For the first few conjugations, 
we used no selections or positive selections at conjugal junctions. As the CAGE phase 
proceeded, we adopted tolC negative selection at the conjugal junction between recoded genome 
segments to permit scarless genome assembly. 
 
Conj8 MAGE construction: Instead of conjugating rEc15 + rEc16 to produce Conj8, we 
performed additional MAGE cycling in rEc15 to convert 16.1-16.4. This strain was renamed 
Conj8, and rEc16 was not used in the final recoded genome assembly. 
 
Conj11 IS insertion into tolC: IS5 was inserted into tolC rather than the desired tolC deletion. 
This undesired feature was automatically lost during Conjugation 22. 
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Conj21 and Conj23 dysfunctional tolC: Robust negative selection is important for creating 
scarless conjugal junctions while ensuring that all donor alleles are transferred during CAGE 
(11). We previously reported that two of our 1/8 recoded strains (Conj21 and Conj23) were 
found to simultaneously survive positive selection (SDS resistance) and negative selection 
(Colicin E1 resistance). We were able to correct this phenotype in Conj23 by removing the 
dysfunctional tolC cassette and introducing a functional tolC elsewhere in the genome; however, 
the dysfunctional allele appeared to map elsewhere in Conj21 (11). Additionally, the Conj10 
parental strain used to create Conj21 appeared to also have the dysfunctional tolC phenotype. 
Since we were unable to readily identify the causative allele via whole genome sequencing 
(obvious candidate genes such as tolQ, tolR, tolA, and butB were not mutated), we re-made 
Conj21 using CoS-MAGE (14). This process took 8 cycles of CoS-MAGE and MASC-PCR 
screening (25 calendar days) to convert 30 UAG codons to UAA. We have found that using PCR 
to confirm the loss of tolC during conjugation is generally adequate to ensure robust isolation of 
a desired genotype when it is present at a frequency of greater than 1E-5 in the pre-selection 
population. Therefore, it is advantageous to perform the post-conjugation positive selections first 
to remove undesired genotypes from the population prior to Colicin E1 selection. Additionally, 
we are currently working on identifying dysfunctional tolC alleles with the goal of mitigating 
escape mechanisms and thereby increasing the selective power of the tolC negative selection. 
 
Potential recombination hotspot caused UAGs to be retained in Conj6, Conj19, and Conj26: 
Although rare, several UAG codons were unexpectedly retained (Table S5-16) during CAGE 
despite proper tolC/kan
R
-oriT conjugal junction placement. The Conj6 donor failed to transfer 
UAGs 10.6 – 10.10 during Conjugation 19. In turn, the Conj19 donor failed to transfer UAGs 
9.4, 9.5, 9.10, 10.5, 11.3, and 11.8 during Conjugation 26 (S[UAGs converted in all strains]). 
This region may be a recombination hotspot that promotes several crossovers. We used MAGE 
to convert these undesired UAGs. 
 
Conj25 tolC positive selection: We introduced tolC into the Conj18 donor instead of the Conj17 
recipient for Conjugation 25. Therefore, we performed SDS selection rather than ColE1 
selection. After isolating a desired Conj25 clone, we removed the tolC via λ Red before 
replacing selectable markers and proceeding to the next conjugation. 
 
Conj20, Conj26, and Conj29 putative rearrangement: We found that tolC repeatedly recombined 
into an unknown location when we attempted to use it to delete spec
R
 from Conj20. Therefore, 
we performed Conjugation 26 without tolC negative selection. Unfortunately, the same tolC 
mistargeting was observed in strain Conj26, indicating that the genome feature causing the 
mistargeting had been inherited. Therefore, we identified the position of the undesired tolC 
insertion so that we could remove it. To this end, we first tested several different selectable 
cassettes and found that the tolC cassette’s promoter and terminator sequences were both 
necessary and sufficient for the Conj20 mistargeted tolC insertion (Figure S5-11A).  
 
Next, we used inverse PCR and Sanger sequencing to locate the exact position of the tolC 
mistargeting (Figure S5-11B). Briefly, we purified genomic DNA from a tolC:kanR 
recombinant, sheared it to ~2 kb fragments on a Covaris AFA Ultrasonication machine, end 
repaired the gDNA fragments (NEB end repair kit), and ligated standard Illumina adapters (T4 
DNA Ligase). We then used 3 cycles of nested PCR in which one primer annealed to the 
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Illumina adapter and the other 3 primers annealed facing outwards from the kan
R
 gene to amplify 
each junction between the kan
R
 gene and the surrounding genomic sequence. We gel purified the 
portion of the smear corresponding to ~1 kb PCR products, re-amplified with the third nested 
primer, purified the product (Qiagen PCR purification kit), and then directly Sanger sequenced 
without subcloning to identify the genome sequence flanking tolC. Sequencing indicated that the 
kan
R
 N-terminus was inserted just downstream of nt 3,176,063 (endogenous position of tolC), 
and that the kan
R
 C-terminus was inserted just upstream of nt 3,421,404. These loci are 245,341 
kb apart in the E. coli MG1655 genome. Although we were unable to identify the structural 
variant in Conj20 via whole genome sequencing, we confirmed the putative rearrangement via 
colony PCR using primers that hybridize ~150 bp on either side of the putative kan
R
 insertion 
site, and we observed the expected 1.5 kb amplicon (1.2 kb kan
R
 + 300 bp of flanking genome 
sequence, verified via Sanger sequencing). The same PCR in Conj20 (without tolC:kanR 
inserted) did not produce an amplicon, and PCR amplification of the endogenous tolC locus of 
both strains produced the expected amplicon for a tolC deletion. Taken together, this indicates 
that the region near the endogenous tolC was duplicated and inserted near nt 3,421,404, that a 
large sequence (too large to be detected by PCR) is deleted by tolC:kanR, and that the 
endogenous tolC region was not impacted by the mistargeting.  
  
 
Figure S5-11. Putative Conj20 rearrangement causing tolC mistargeting. (A) Several different 
tolC cassettes repeatedly recombined into an unknown locus (tolC Mis), a kan
R
 cassette having 
homology to the tolC cassette’s promoter and terminator sequences efficiently recombined into 
an unknown locus (kan
R
 Mis), a kan
R
 cassette having homology to spec
R
 efficiently recombined 
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Figure S5-11 (Continued). into the expected locus (Kan
R
 Targ), and the tolC ORF lacking a 
promoter and terminator was not recombinogenic in Conj20. Therefore, the tolC cassette’s 
promoter and terminator were necessary and sufficient to mediate tolC mistargeting in Conj20. 
(B) The position of mistargeting was identified by purifying the genome of C20.DT:kan
R
, 
fragmenting to ~2 kb pieces on a Covaris AFA Ultrasonication machine, repairing DNA ends 
with a NEB End Repair kit, ligating Illumina adaptors, and performing 3 rounds of nested 
inverse PCR. The amplicons were gel purified, re-amplified, Sanger sequenced, and BLASTed 
against the E. coli MG1655 genome (taxid:511145). The N-terminal insertion site was nt 
3,176,063 (endogenous tolC position) and the C-terminal insertion site was nt 3,421,404 
(245,341 bp away).  
 
Since the putative rearrangement in Conj20 and Conj26 (region including nt 3,176,063 – nt 
3,421,404) was distant from the recoded region (nt 633,969 – nt 1,663,144), we easily prevented 
its transfer during Conjugation 29 by placing the Conj25 recipient's positive selectable marker at 
SIR.22.23c (nt 2,627,225) instead of SIR.32.1 (nt 3,921,005). This marker placement permitted a 
tolC/kan
R
-oriT junction between nt 608,541 – nt 629,000 (20,459 bp) and a gentR/zeoR junction 
between nt 1,702,450 and nt 2,627,225 (924,775 bp) (Figure S5-12). 
 
 
Figure S5-12. Strategic marker placement allowed removal of the undesired structural variant 
from Conj26. Rather than placing gent
R
 at the boundary of the Conj25 recoded region, it was 
placed further away to select against inheritance of the Conj26 structural variant. Red lines 
represent Conj26 donor genome sequence, blue lines represent Conj25 recipient genome 
sequence, and purple lines indicate conjugal junction regions. 
 
Inadequate homology for conjugal junction in Conj28 and Conj30: There is an average of 14.3 
kb spanning adjacent UAG codons in E. coli MG1655, but many of these regions are inadequate 
for transferring large genome segments, since conjugal transfer frequency decreases 
exponentially with increasing distance (52). Our first attempts at using small homology regions 
to transfer large genome segments either led to failed selections (Conj28) or produced low 
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complexity populations consisting of few recombinants (Conj30). By increasing the distance 
between kan
R
-oriT and tolC (Table S5-20), complete transfer of the recoded segment was 
achieved, but marker placement sometimes allowed recoded alleles near conjugal junctions to be 
lost (Figure 5-2, Table S5-16). 
 
Our initial attempts at Conjugation 28 failed because 2120 bp of homology between the donor’s 
kan
R
-oriT and the recipient’s tolC were inadequate to transfer all 573,882 bp of recoded donor 
DNA. Instead, the putative Conj28 candidates all retained tolC and 25 or more UAG codons 
proximal to kan
R
-oriT. Therefore, our selections yielded the dysfunctional tolC phenotype that 
was described above for Conj21 and Conj23. However, when we moved tolC so that it was 
13,470 bp away from kan
R
-oriT and repeated Conjugation 28, we easily selected desired clones. 
 
In another case, the inefficient 1/4 genome transfer during Conjugation 30 yielded a low 
complexity population retaining 30 undesired UAGs (segments 18-20) in the middle of the donor 
region (Figure S5-13). Such double crossovers may be caused by two separate conjugations (52), 
or may be formed when the excised recipient genome is partially degraded and recombined back 
into the donor segment that originally displaced it (53). Although the selections did not fail, 
recombination occurred rarely in the desired 8,158 bp tolC/kan
R
-oriT conjugal junction, yielding 
a single isogenic population (46 out of 46 screened clones) retaining the same 30 UAGs from 
segments18-20. Rather than repeating the conjugation with the original conjugants, we chose a 
clone from the first conjugation to carry forward as the recipient in a second conjugation. We 
moved the selectable markers in Conj27 and the new recipient so that there would be 631,353 bp 
between tolC and kan
R
-oriT, and then repeated the conjugation. This time, all remaining alleles 
were properly transferred (Figure S5-13).  
 
 
Figure S5-13. Strain Conj30 was prepared by two serial conjugations. The first Conjugation 30 
was performed using Conj27 and Conj28 (with 8,158 bp of homology between tolC and kan
R
-
oriT). After selecting for Spec
R
, Zeo
R
, and ColE1
R
, 46 out of 46 clones retained ~30 UAG codons 
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Figure S5-13 (Continued). in sets 18-20. After removing spec
R
 (replaced with tolC and then 
deleted tolC) and inserting a new tolC near the remaining UAG alleles in the conjugal progeny 
(providing 631,353 bp between tolC and kan
R
-oriT for proper recombination), we performed a 
second conjugation to transfer the remaining alleles to produce Conj30. 
 
Redundant recoding for Conjugation 31: Based on the above results, the 16.2 kb (kan
R
-oriT/tolC) 
and 61.5 kb (gent
R
/spec
R
) conjugal junctions originally planned for Conjugation 31 were unlikely 
to accommodate transfer of 1/2 of the genome. Therefore, prior to attempting Conjugation 31, 
we transferred 1029 kb of recoded genome from Conj26 into Conj30 (C30.5, Figure 5-2) so that 
this region would be redundantly recoded in both parental strains for Conj31. Additionally, to 
decrease the chance of a failed tolC selection, we inserted tolC into the donor strain so that we 
could positively select on SDS. Thus, Conjugation 31 was successfully performed using a 56.6 
kb oriT/tolC junction and a 463 kb gentR/specR junction (Figure 5-2, Figure S5-14).  
 
 
Figure S5-14. Redundant recoding for Conjugation 31. Conj29 and Conj30 only provide 16.2 kb 
and 61.5 kb of homology for their kan
R
-oriT/tolC and gent
R
/spec
R
 junctions, respectively. 
Therefore, we moved the kan
R
-oriT/tolC junction and created Conj30.5, which has the third 
quadrant of the genome redundantly recoded. This provides a 56.6 kb oriT/tolC junction and a 
463 kb gentR/specR junction. Additionally, we used tolC in the donor genome to permit SDS 
selection, which has a lower escape rate than ColE1 selection. Colored wedges represent recoded 
segments containing 10 UAGUAA conversions, O = kanR-oriT, T = tolC, E = gentR, S = specR. 
 
Removing remaining UAG codons: After the final conjugation, 3 selectable markers (tolC, gent
R
, 
and spec
R
) and 11 UAG codons (Table S5-21) from the original design of 314 UAGs were 
retained. We used tolC to delete these undesired selectable markers and MAGE to convert the 
UAG codons to UAA. 
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Table S5-21. UAG codons that were retained in Conj31 after CAGE 
Gene UAG Pos UAG ID Trans Dir Replichore Why UAG 
b4273 4497523 3.10 + 1 Lost during Conjugation 2 
ybaA 476249 8.1 + 1 Lost during Conjugation 4 
sucB 761962 9.10 + 1 Lost during Conjugation 26 
ybiR 853988 10.6 + 1 Lost during Conjugation 19 
yceF 1145234 11.10 - 1 Lost during Conjugation 6 
ydfP 1637054 15.9 - 2 Lost during Conjugation 20 
rzpQ 1647065 15.10 + 2 Lost during Conjugation 20 
yegW 2180057 20.8 - 2 Reverted by yegV oligo 
ascB 2840436 24.10 + 2 Reverted by Z.24.25 recombination 
hycI 2840595 25.1 - 2 Lost during Conjugation 30 
atpE 3918973 32.10 - 2 Lost during Conjugation 16 
 
Upon closer inspection, we observed that yegV and yegW had overlapping, convergent open 
reading frames so that MAGE oligos individually converting the UAG of one gene would revert 
the UAG of the other gene. Therefore, we designed a MAGE oligo that would simultaneously 
convert the UAGs of both yegV and yegW (Figure S5-15). Such design clashes will become more 
common as genome designs incorporate more mutations in closer proximity. 
 
 
Figure S5-15. MAGE oligo simultaneously converting UAGs of convergently overlapping yegV 
and yegW genes. The top sequence is the desired genomic sequence (shown 5’  3’). The 
bottom sequence is the MAGE oligo that simultaneously converts the UAG codons in yegV and 
yegW (shown 3’  5’). 
 
Removing new UAG codons: Genome annotations and interpretations are incomplete and are 
continually being updated based on empirical results. We initially designed the MAGE oligos 
based on 314 predicted UAGs (NCBI, NC_000913, Feb. 07, 2006). However, we subsequently 
identified 8 additional UAGs from the Apr. 24, 2007 NCBI update. Further analysis of the 
ecocyc.org (45) database (Mar. 19, 2012) identified 3 more UAGs (Table S5-22). Ecocyc also 
flagged 4 previously identified putative UAGs as part of phantom genes (sequences previously 
annotated, but that are not genes, Table S5-23). We efficiently converted the remaining 11 UAGs 
via MAGE. However, the fact that we needed to update our design highlights a central problem 
with using incomplete data to design genomes. Such trivial design changes distributed 
throughout the genome would require significant effort to implement via whole genome 
synthesis. 
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Table S5-22. UAG codons that were not targeted in the original design 
Gene UAG Pos Trans Dir Replichore Identified 
yafF 239378 + 1 NC_000913 (NCBI) 02/07/2006 update 
yliI 879080 + 1 NC_000913 (NCBI) 02/07/2006 update 
ymdF 1067477 + 1 NC_000913 (NCBI) 04/24/2007 update 
yheV 3476614 - 2 NC_000913 (NCBI) 04/24/2007 update 
yjbS 4266832 - 1 NC_000913 (NCBI) 04/24/2007 update 
yjdO 4351104 + 1 NC_000913 (NCBI) 04/24/2007 update 
insB 4517037 + 1 NC_000913 (NCBI) 04/24/2007 update 
ytjA 4610312 + 1 NC_000913 (NCBI) 04/24/2007 update 
mntS 852092 - 1 Ecocyc.org flat file 03/19/2012 
yahH 339313 + 1 Ecocyc.org flat file 03/19/2012 
ykgN 279248 - 1 Ecocyc.org flat file 03/19/2012 
 
 
Table S5-23. UAG codons found in genes re-annotated as phantom 
Gene UAG Pos UAG ID Trans Dir Replichore 
b4250 4481621 3.8 + 1 
b1354 1426575 14.2 + 1 
b1367 1433519 14.4 + 1 
b2191 2296256 21.5 + 2 
 
Cleanly removing RF1 without impairing fitness: The complete deletion of prfA also removes 
the ribosomal binding site (RBS) from the overlapping essential gene, prmC. Therefore, we 
tested three prfA deletion cassettes (ΔprfA::specR, ΔprfA::tolC, and a clean deletion) to remove 
the ability of UAG to terminate translation. While spec
R
 contains an appropriately placed RBS, 
the C-terminus of tolC is C/T rich, so we added a synthetic RBS to ensure adequate prmC 
expression. Finally, we cleanly deleted ΔprfA:tolC while retaining the synthetic RBS for prmC. 
All three designs produced viable ΔprfA strains without significantly impairing fitness (Figure 5-
3). 
 
>ΔprfA::specR 
ctggagtaacagtacatcattttctttttttacagggtgcatttacgcctatgcgctcacgcaactggtccagaaccttgaccgaacgcagcggt
ggtaacggcgcagtggcggttttcatggcttgttatgactgtttttttggggtacagtctatgcctcgggcatccaagcagcaagcgcgttacg
ccgtgggtcgatgtttgatgttatggagcagcaacgatgttacgcagcagggcagtcgccctaaaacaaagttaaacatcatgagggaagc
ggtgatcgccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgtacatttgtacg
gctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccgtaaggcttgatgaaacaacgcggcgagc
tttgatcaacgaccttttggaaacttcggcttcccctggagagagcgagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatc
attccgtggcgttatccagctaagcgcgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatc
gacattgatctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactctttgatccggttcct
gaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactgggctggcgatgagcgaaatgtagtgcttac
gttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgccgaaggatgtcgctgccgactgggcaatggagcgcctgccggccc
agtatcagcccgtcatacttgaagctagacaggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaattt
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gtccactacgtgaaaggcgagatcaccaaggtagtcggcaaataatggaatatcaacactggttacgtgaagcaataagccaacttcaggc
gagc 
 
>ΔprfA::tolC 
ctggagtaacagtacatcattttctttttttacagggtgcatttacgcctatgaagaaattgctccccattcttatcggcctgagcctttctgggttc
agttcgttgagccaggccgagaacctgatgcaagtttatcagcaagcacgccttagtaacccggaattgcgtaagtctgccgccgatcgtga
tgctgcctttgaaaaaattaatgaagcgcgcagtccattactgccacagctaggtttaggtgcagattacacctatagcaacggctaccgcga
cgcgaacggcatcaactctaacgcgaccagtgcgtccttgcagttaactcaatccatttttgatatgtcgaaatggcgtgcgttaacgctgcag
gaaaaagcagcagggattcaggacgtcacgtatcagaccgatcagcaaaccttgatcctcaacaccgcgaccgcttatttcaacgtgttgaa
tgctattgacgttctttcctatacacaggcacaaaaagaagcgatctaccgtcaattagatcaaaccacccaacgttttaacgtgggcctggta
gcgatcaccgacgtgcagaacgcccgcgcacagtacgataccgtgctggcgaacgaagtgaccgcacgtaataaccttgataacgcggt
agagcagctgcgccagatcaccggtaactactatccggaactggctgcgctgaatgtcgaaaactttaaaaccgacaaaccacagccggtt
aacgcgctgctgaaagaagccgaaaaacgcaacctgtcgctgttacaggcacgcttgagccaggacctggcgcgcgagcaaattcgcca
ggcgcaggatggtcacttaccgactctggatttaacggcttctaccgggatttctgacacctcttatagcggttcgaaaacccgtggtgccgct
ggtacccagtatgacgatagcaatatgggccagaacaaagttggcctgagcttctcgctgccgatttatcagggcggaatggttaactcgca
ggtgaaacaggcacagtacaactttgtcggtgccagcgagcaactggaaagtgcccatcgtagcgtcgtgcagaccgtgcgttcctccttc
aacaacattaatgcatctatcagtagcattaacgcctacaaacaagccgtagtttccgctcaaagctcattagacgcgatggaagcgggctac
tcggtcggtacgcgtaccattgttgatgtgttggatgcgaccaccacgttgtacaacgccaagcaagagctggcgaatgcgcgttataacta
cctgattaatcagctgaatattaagtcagctctgggtacgttgaacgagcaggatctgctggcactgaacaatgcgctgagcaaaccggtttc
cactaatccggaaaacgttgcaccgcaaacgccggaacagaatgctattgctgatggttatgcgcctgatagcccggcaccagtcgttcag
caaacatccgcacgcactaccaccagtaacggtcataaccctttccgtaactaagaggaataatggaatatcaacactggttacgtgaagca
ataagccaac 
 
>Clean deletion 
gggctggagtaacagtacatcattttctttttttacagggtggaggaggaataatggaatatcaacactggttacgtgaagcaataagcc 
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D. GRO nomenclature and applications 
 
Although for clarity we have assigned informal names to describe our key recoded strains, we 
have also developed the following GRO nomenclature: C(F/E,M,A)_I, where C is the number of 
codons instances changed, F/E is the number of codons completely removed from the full 
genome (F), or all essential genes (E), M is the number of previously essential codon functions 
manipulated (e.g. release factors, tRNAs, aminoacyl-tRNA synthetases), A is the number of 
codons reassigned to a new amino acid (Awt is wild type function and Ao is without any assigned 
function), and I is a descriptive index to differentiate strain variants. For example, 
C7(E1,M1,A1)_ΔprfA::spec
R.ΔmutS::tolC has UAG changed to UAA in all 7 essential genes, has 
RF1 replaced by spec
R
, incorporates one NSAA at UAG codons, and has mutS replaced by tolC. 
Similarly, C321(F1,M1,Ao)_ΔprfA.ΔmutS::zeo
R.ΔtolC has all 321 known UAG codons changed 
to UAA, has RF1 cleanly deleted, stalls translation at UAG codons, has mutS replaced by zeo
R
, 
and has tolC deleted. 
 
 
Table S5-37. Recoded strains and their genotypes 
Strain
a
 GRO nomenclature
 
Essential 
codons 
changed
b
 
Total 
codons 
changed
c
 
Previously 
essential 
codon 
functions 
manipulated
d 
Expected 
(obs.) UAG 
translation 
function
e
 
EcNR2 - 0/7 0/321 None Stop 
C0.B* C0(M1,Awt)_ΔmutS::zeo
R.prfB 0/7 0/321 prfB‡ Stop 
C0.B*.ΔA::S C0(M2,Ao)_B*.ΔprfA::spec
R.ΔmutS::zeoR.prfB 0/7 0/321 
prfB‡, 
ΔprfA::specR 
None 
(stop*) 
C7 C7(E1,Awt)_ΔmutS::tolC 7/7 7/321 None Stop 
C7.ΔA::S C7(E1,M1,Ao)_ΔprfA::spec
R.ΔmutS::tolC 7/7 7/321 ΔprfA::specR None (sup) 
C13 C13(E1,Awt)_ΔmutS::tolC 7/7 13/321 None Stop 
C13.ΔA::S C13(E1,M1,Ao)_ΔprfA::spec
R.ΔmutS::tolC 7/7 13/321 ΔprfA::specR None (sup) 
C321 C321(F1,Awt)_ΔmutS::zeo
R.ΔtolC 7/7 321/321 None Stop 
C321.ΔA::S C321(F1,M1,Ao)_ΔprfA::spec
R.ΔmutS::zeoR.ΔtolC 7/7 321/321 ΔprfA::specR None (nc) 
C321.ΔA::T C321(F1,M1,Ao)_ΔprfA::tolC.ΔmutS::zeo
R 7/7 321/321 ΔprfA::tolC None (nc) 
C321.ΔA C321(F1,M1,Ao)_ΔprfA.ΔmutS::zeo
R.ΔtolC 7/7 321/321 ΔprfA None (nc) 
aAll strains are based on EcNR2 (Escherichia coli MG1655 ΔmutS::cat Δ(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-
bla]) which is mismatch repair deficient (ΔmutS) to achieve high frequency allelic replacement; C0 and C321 strains 
are ΔmutS::zeoR; C7 and C13 strains are ΔmutS::tolC; C7, C13, and C321 strains have the endogenous tolC deleted, 
making it available for use as a selectable marker. Spectinomycin resistance (S) or tolC (T) were used to delete prfA 
(A). Bacterial genetic nomenclature describing these strains includes :: (insertion) and Δ (deletion). 
bOut of a total of 7 
cOut of a total of 321 
dprfA encodes RF1, terminating UAG and UAA; prfB encodes RF2, terminating UGA and UAA; prfB‡ = RF2 
variant (T246A, A293E, and removed frameshift) exhibiting enhanced UAA termination (16) and weak UAG 
termination (17). 
eObserved translation function: Stop = expected UAG termination; stop* = weak UAG termination from RF2 
variant; sup = strong selection for UAG suppressor mutations; nc = near-cognate suppression in the absence of all 
other UAG translation function. 
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Figure S5-1. Properties of genomically recoded organisms (GROs). We have removed all 321 
UAG codons (blue radial lines) and release factor 1 (RF1; terminates translation at UAG) from 
E. coli MG1655. Our recoded strain provides a dedicated UAG codon for plug-and-play 
translation of nonstandard amino acids (NSAAs). This enables efficient expression of GFP 
variants containing several UAG codons, provides increased resistance to bacteriophage T7 
infection, and establishes a basis for the genetic isolation of GROs. 
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E. Partial recoding strategies for reassigning UAG codon function 
 
Three hypotheses have attempted to explain why RF1-mediated UAG termination is essential: (i) 
inadequate RF2-mediated UAA termination (16, 54), (ii) essential gene (Table S5-5) loss of 
function due to UAG read-through (15), and/or (iii) translational stalling in the absence of UAG 
function (15). The UAG codon appears to tolerate sense suppression at the majority of UAG 
codons (15, 16, 54). As reported by Mukai et al. (15) and illustrated in Figure S5-16, this appears 
to be an evolutionary feature, given that UAA and UGA stop codons are overrepresented at short 
distances triplets downstream of UAG codons. We analyzed GO terms using 
<http://biit.cs.ut.ee/gprofiler/index.cgi>, but we observed no enrichment for any specific 
component, process, or function. 
 
 
 
 
 
Figure S5-16. Distribution of the number of amino acids added to the C-terminus of genes as a 
result of UAG read-through. The inset is zoomed in on the first 20 triplets following the UAG 
codon. 
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Table S5-5. Essential and important genes terminating with UAG. 
Gene  Strand  
Gene size 
(bp) 
MG1655 
UAG 
coordinate  
Essential
a
  Function
b
 
Deletion 
phenotype
c
 
murF  +  1358 96008 Yes Peptidoglycan biosynthesis Essential 
lolA  +  611 937206 Yes Periplasmic lipoprotein chaperone Essential 
lpxK  +  986 968575 Yes LPS biosynthesis Essential 
hemA  +  1256 1264193 Yes Porphyrin biosynthesis Essential 
hda  -  746 2616097 Yes Replication initiation regulation Essential 
mreC  -  1103 3396897 Yes 
Peptidoglycan biosynthesis and 
chromosome segregation 
Essential 
coaD  +  479 3808327 Yes Coenzyme A biosynthesis Essential 
yafF  +  188 239378 No Conserved protein, pseudogene Barely affected 
pgpA  +  518 436331 No Phospholipid processing 
Moderate 
fitness decrease 
sucB  +  1217 761962 No Energy regeneration 
Major fitness 
decrease 
fabH  +  953 1148935 No Fatty acid biosynthesis 
Major fitness 
decrease 
fliN  +  413 2019525 No 
Component of flagellar motor's 
switch complex 
Moderate 
fitness decrease 
atpE  -  239 3918973 No Energy regeneration 
Major fitness 
decrease 
a Essentiality was from the PEC database <http://www.shigen.nig.ac.jp/ecoli/pec/index.jsp> (55). Genes in white are 
essential genes with their UAG replaced in C7.ΔA::S. Genes in gray are additional genes with their UAG replaced in 
C13.ΔA::S. 
b Gene functions were referenced from <http://www.ecocyc.org> (45). 
c The deletion phenotype was based on results from the Keio collection (56). 
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F. Analysis of MAGE and CAGE 
 
Doublings 
 
Our recoded strain construction was performed in an EcNR2 background (Escherichia coli 
MG1655 ΔmutS::cat Δ(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-bla]), which is defective for 
mismatch repair. While this background permits efficient allele replacement, it also increases the 
transition mutation rate ~100 fold. Therefore, continued culturing introduces additional diversity 
due to spontaneous mutagenesis, which can provide beneficial mutations that compensate for 
unforeseen genome design flaws. Additionally, these mutations can introduce deleterious 
mutations that introduce auxotrophies and slow growth, especially when diverse populations are 
forced through monoclonal bottlenecks (57). Although, we have confirmed that the C321.ΔA 
strains are not auxotrophic, off-target mutagenesis probably underlies their reduced fitness. 
Therefore, we have calculated the approximate number of doublings for each genome 
manipulation used in the construction of construction C321.ΔA. Using this information, we 
estimate the maximum number of doublings during strain construction, the maximum number of 
doublings that would be expected if we repeated our strain construction, and the maximum 
number of doublings that would be expected if we improved our strategy by using CoS-MAGE 
(14) to replace 40 UAGs per strain before commencing CAGE. After an estimated 7340 
doublings, the 305 off-target mutations detected in C321.ΔA suggests net mutation rate of 9E-9 
mutations/bp/doubling, which is consistent with a mutS
-
 phenotype (58). 
 
MAGE 
   
Step Divisions per Number Cell divisions 
MAGE cycles 6 25 150 
o/n growths 15 6 90 
Re-dilution 5 6 30 
Colony/plating 30 2 60 
Outgrowth 12 3 36 
Dilute, re-grow, freeze 6 1 6 
MAGE total     372 
 
Selectable marker dsDNA recombinations 
Step Cell divisions per repetition 
o/n growths 10 
Outgrowth, mid-log 10 
Induce @ 42, 15 min 0 
Electroporation 0 
Recover 1 hour 1 
Colony/plating 30 
colony outgrowth, mid-log 10 
Dilute, re-grow, freeze 6 
Divisions/Recombination 67 
Total 134 
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Oligo-mediated tolC deletion 
 
Step Cell divisions per repetition 
o/n growths 10 
Outgrowth, mid-log 10 
Induce @ 42, 15 min 0 
Electroporation 0 
Recover to stationary 10 
Dilute 1/100, outgrowth, mid-log 6 
Dilute 1/100, colE1 selection 16
a 
Colony/plating 30 
colony outgrowth, mid-log 10 
Dilute, re-grow, freeze 6 
Divisions/Recombination 98 
Total 196 
aAssumes 1E-3 frequency of tolC deletion 
 
Final MAGE (Conj31->C321.ΔA 
  
Step Divisions per Number Cell divisions 
MAGE cycles 6 39 234 
o/n growths 15 4 60 
Re-dilution 5 14 70 
Colony/plating 30 7 210 
Outgrowth 12 7 84 
Dilute, re-grow, freeze 6 2 12 
MAGE total     670 
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CoS-MAGE (off/on cycle): 
 
Step Cell divisions per repetition 
o/n growths 10 
Dilute 1/100, outgrowth, mid-log 6 
Induce @ 42, 15 min 0 
Electroporation (inactivate tolC) 0 
Recover for 7 hours, stationary 12 
Dilute 1/100, re-growth 6 
Dilute 1/100, colE1 selection
 
14
a 
Colony/plating 30 
Outgrowth, mig-log 10 
Induce @ 42, 15 min 0 
Electroporation (revert tolC) 0 
Recover for 3 hours, mid-log 10 
Colony/plating 30 
Outgrowth 12 
Dilute, re-grow, freeze 6 
Total 146 
aAssumes 1% frequency of desired tolC genotype 
 
Table S5-2. Total estimated number of doublings required to reassign UAG 
 
Actual
a 
Re-do
b 
CoS-MAGE
c 
Manipulation Number Doublings Number Doublings Number Doublings 
MAGE n/a 372 n/a 372 n/a 0 
CoS-MAGE 0 0 0 0 3 438 
dsDNA Recombinations 19 2546 9 1206 8 1072 
Conjugations 7 1792 6 1536 3 768 
tolC deletions 10 1960 2 392 3 588 
Post-assembly MAGE n/a 670 n/a 0 n/a 0 
Total   7340   3506   2866 
aEstimated maximum number of actual doublings 
bEstimated maximum number of doublings to repeat C321.ΔA 
cEstimated maximum number of doublings using CoS-MAGE to convert 40 UAG codons per strain prior to CAGE 
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G. Analysis of recoded lineage 
 
Cell morphology in the presence or absence of RF1 
 
Given the extreme degree of genome manipulation necessary to remove all native UAG codons, 
we wanted to confirm that the cell morphology was not changed (e.g. cell elongation or a 
filamentous phenotype, which might indicate stress response or problems with cell division (59). 
We imaged MG1655, EcNR2, C321, and C321.ΔA::S on bright field using a Zeiss Axio 
Observer Z1 with a 100X oil immersion objective supplemented with a 1.6X internal lens. Cell 
morphology was consistent across all strains. The slightly shorter cell lengths for C321 and 
C321.ΔA::S may be because these strains grow more slowly than MG1655 and EcNR2. 
 
  
260 
 
 
 
 
 
Figure S5-2. Fully recoded strain cell morphology in the presence or absence of RF1. Recoding 
and RF1 removal does not cause cell aggregation or a filamentous phenotype, which are 
indictors of cell stress. 
 
  
MG1655 
EcNR2 
C321 
C321.ΔA 
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Doubling times for each strain in recoded lineage 
 
Doubling times were determined for each strain in the C321.ΔA lineage, represented with a heat 
map in Figure 5-2, tabulated in Table S5-1. 
 
Table S5-1. Doubling times and Max OD600 of recoded genome lineage 
Strain 
Doubling time 
(min.) 
Doubling time 
standard deviation 
Max 
OD600 
Max OD600 
standard 
deviation 
MG1655 47 1 1.09 0.01 
EcNR2 47 1 1.04 0.03 
rEc1 51 2 0.94 0.01 
rEc2 49 1 1.02 0.03 
rEc3 49 2 1.09 0.02 
rEc4 48 1 1.03 0.01 
rEc5 49 1 0.90 0.03 
rEc6 50 1 0.92 0.02 
rEc7 48 1 1.06 0.02 
rEc8 49 1 1.00 0.02 
rEc9 50 1 1.01 0.01 
rEc10 49 1 1.02 0.02 
rEc11 47 2 1.02 0.01 
rEc12 51 1 1.03 0.02 
rEc13 52 2 1.07 0.02 
rEc14 49 3 1.05 0.00 
rEc21 46 2 1.08 0.01 
rEc22 49 2 1.05 0.01 
rEc23 48 1 1.05 0.02 
rEc24 48 1 0.99 0.01 
rEc25 45 2 1.04 0.02 
rEc26 48 2 1.10 0.01 
rEc27 50 3 1.03 0.01 
rEc28 49 1 1.00 0.01 
rEc29 44 1 1.01 0.01 
rEc30 53 3 1.01 0.02 
rEc31 48 1 1.13 0.01 
rEc32 49 1 1.06 0.02 
Conj1 54 3 1.03 0.04 
Conj2 52 2 1.09 0.04 
Conj3 71 0 0.59 0.08 
Conj4 46 1 1.19 0.02 
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Table S5-1 (Continued). 
Conj5 54 1 1.10 0.05 
Conj6 57 2 1.07 0.04 
Conj7 52 4 1.01 0.03 
Conj8 47 2 1.05 0.01 
Conj11 86 19 0.73 0.16 
Conj12 49 1 1.13 0.02 
Conj13 46 2 1.10 0.03 
Conj14 47 2 1.14 0.01 
Conj15 90 31 0.78 0.32 
Conj16 49 1 1.05 0.13 
Conj17 50 1 1.02 0.03 
Conj18 56 3 1.02 0.01 
Conj19 54 1 1.03 0.04 
Conj20 50 2 1.01 0.01 
Conj21
a 
54 4 1.16 0.05 
Conj22 55 0 1.06 0.01 
Conj23 74 5 1.05 0.02 
Conj24 75 5 1.06 0.06 
Conj25 56 3 0.97 0.03 
Conj26 52 3 1.00 0.02 
Conj27 55 1 1.11 0.02 
Conj28 66 3 1.01 0.01 
Conj29 63 0 0.96 0.03 
Conj30 68 4 0.99 0.04 
Conj30.5 90 8 0.62 0.13 
C321.ΔAa 75 1 0.95 0.01 
a 
Conj21 and C321.ΔA growth curves were performed separately from the others 
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Whole-genome sequencing 
 
 
Figure S5-3. Construction and analysis of C321.ΔA. The genome was conceptually divided into 
32 segments, each containing 10 UAG codons. MAGE (13) was used to convert all 10 UAG 
codons to the synonymous UAA codon in each segment across 32 parallel strains, and CAGE 
(11) was used to hierarchically assemble recoded genome segments into a fully recoded 
chromosome. Blue arrows point from each strain to its conjugal progeny; blue and green arrows 
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Figure S5-3 (Continued). indicate when MAGE was used to convert remaining UAG codons. 
Strain names (top), total UAGs removed (bottom, Table S5-3), new off-target mutations (left), 
total off-target mutations (right, Table S5-2), and doubling times (green to yellow to red gradient 
indicates increasing doubling times; Table S5-1) are reported at the center of each genome. 
Radial lines in each genome indicate the positions of mutations. The outer circle shows all UAG 
codons that have been replaced with UAA (green indicates UAGUAA introduced via MAGE 
and blue indicates UAGUAA transferred via CAGE). The inner circle indicates all off-target 
mutations acquired during recoded genome construction (color indicates mutation severity 
according to snpEFF (34): gray = low, orange = medium, and red = high). Full lines are 
mutations that were transferred by CAGE, and half lines are mutations that were lost during 
conjugation. Approximate positions of conjugal crossovers can be inferred based on which 
mutations were transferred. A complete list of mutations can be found in Table S5-4. Gray 
circles indicate positions of selectable markers immediately before conjugation (O = kan
R
-oriT, 
T = tolC, G = galK, M = malK, S = spec
R
, E = gent
R
, Z = zeo
R, dP = ΔprfA, IS = tolC::IS5). In 
cases where marker symbols overlapped, they were repositioned for clarity. Strains rEC15 
through rEC20 are not included because Conj21 was constructed entirely via CoS-MAGE. 
 
Overview of genome sequencing: Genome sequencing confirmed that all 321 known UAGs have 
been removed from its genome and that 355 additional mutations were acquired during strain 
construction (1E-8 mutations/bp/doubling over ~7340 doublings; Figure S5-3, Table S5-2). Only 
51 of these unintended mutations were predicted to be highly disruptive by snpEFF (Table S5-3) 
(34), providing a tractable number of alleles that could be reverted via MAGE to potentially 
improve fitness. Only one bona fide IS element transposition event (IS5 in Conj11) and one 
putative rearrangement (Conj20) were observed, suggesting that structural variants are rare. We 
also sequenced and characterized the complete CAGE lineage, and observed that the 
intermediate strains exhibited varying fitness (Figure 5-2), as expected for mutator (i.e., ΔmutS) 
strains forced through monoclonal bottlenecks (57). Notably, the fitness defects in Conj3, 
Conj11, Conj15, Conj23, and Conj24 were mitigated in their conjugal progeny even though the 
UAGUAA mutations from these strains were inherited (Figure S5-3 and Table S5-4). This 
suggests that off-target mutations likely caused the observed fitness defects, and that CAGE can 
eliminate deleterious mutations by preferentially selecting healthy alleles from one parent. 
Sequencing indicated that MAGE cycling in the rEc strains resulted in an average of 37.4 
unintended mutations per strain after ~372 doublings (2E-8 mutations/bp/doubling). Across the 
entire lineage, we observed only 39 putative MAGE oligonucleotide synthesis errors and 6 
putative oligonucleotide mistargeting events resulting in mutations at homologous sequences 
elsewhere in the genome, rather than the desired target. Therefore, MAGE oligonucleotides do 
not appear to be a major cause of mutagenesis. Of the remaining 2,225 off-target mutations in the 
lineage (Table S5-3), 92% were transitions (A•TG•C and G•CA•T) (58), suggesting that 
MutS inactivation underlies most of the unintended mutagenesis (58). 
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Off-target mutations: There are many ways that unintended mutations occur. Mismatch repair 
deficiency probably accounted for the majority of the 2270 off-target mutations across all 69 
strains that were sequenced. Additionally, MAGE oligos can introduce off-target mutations via 
recombination. Oligos that contain chemical synthesis errors can introduce off-target mutations 
near their desired UAGUAA mutation, and oligos can mistarget to homologous sequences 
elsewhere in the genome. 
 
Summary of SNPs: The number of mutations introduced into each strain of the C321.ΔA lineage 
is summarized in Table S5-3, including the breakdown of SNP severity according to snpEFF 
(Table S5-24) (34). All mutations and their predicted severity are tabulated in Table S5-4. This 
information could be used to identify off-target mutations that were responsible for the 
transiently reduced fitness of Conj3, Conj11, Conj15, Conj23, and Conj24, but that were not 
propagated inherited via CAGE. Furthermore, by comparing the severity and location of off-
target mutations in C321.ΔA, candidate alleles could be identified for reversion in an attempt to 
ameliorate its reduced fitness. 
 
Table S5-3 is attached separately, and contains a summary of SNP types per strain (UAGUAA 
mutations, SNPs originating from off-target mutagenesis, SNPs due to oligo-synthesis errors and 
MAGE oligo mistargeting) and the number of SNPs transferred by each strain during CAGE. 
This table also summarizes the number of SNPs in each strain according to snpEFF severity (34). 
The categories are as follows: 
 
 SAMPLE = Name of the sample. 
 STRAIN_NUM = Identification number for this strain. 
 NEW_OT_OLIGO = Number of new off-target SNPs in this strain that fall in regions 
targetted by MAGE oligos. 
 NEW_OT = Total number of new off-target SNPs in this strain. 
 NEW_OT_MT = Number of new off-target SNPs in this strain that fall into regions with 
significant homology to MAGE oligos (indicative of MAGE mistargetting). 
 NEW_OT_TS = Number of new off-target SNPs in this strain that are transitions. 
 NEW_OT_NOT_OLIGO_TS = Number of new off-target SNPs in this strain that are 
transitions and not in regions targetted by MAGE oligos. 
 NEW_OT_NOT_XFER = Number of new off-target SNPs in this strain that are 
transferred to the child strain via CAGE. 
 TOTAL_OT = Total number of off-target mutations in this strain. 
TOTAL_MT = Total number of mutations in this strain that fall into regions with 
significant homology to MAGE oligos (indicative of MAGE mistargetting). 
 NEW_AMBER = Number of new UAG to UAA SNPs in this strain. 
 TOTAL_AMBER = Total number of UAG to UAA SNPs in this strain. 
 EFF_NONE* = Number of SNPs in this strain with no known effect on genic regions. 
 EFF_LO* = Number of SNPs in this strain with an effect characterized by snpEFF as 
“low”. 
 EFF_MED* = Number of SNPs in this strain with an effect characterized by snpEFF as 
“moderate”. 
 EFF_HI* = Number of SNPs in this strain with an effect characterized by snpEFF as 
“high”. 
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* In cases where SNPs have multiple effects, the highest is reported.  
 
Table S5-24. Summary of snpEFF types 
High START_LOST 
FRAME_SHIFT 
STOP_GAINED 
STOP_LOST 
Moderate NON_SYNONYMOUS_CODING 
CODON_CHANGE 
CODON_INSERTION 
CODON_CHANGE_PLUS_CODON_INSERTION 
CODON_DELETION 
CODON_CHANGE_PLUS_CODON_DELETION 
Low SYNONYMOUS_START 
NON_SYNONYMOUS_START 
START_GAINED 
SYNONYMOUS_CODING 
SYNONYMOUS_STOP 
 
Table S5-4 is attached separately, and contains an exhaustive list of all called SNPs per strain, 
including those that passed the initial Freebayes filtering but not the more stringent downstream 
filters. The categories are as follows: 
 
 SAMPLE = Name of the strain. 
 POS = Chromosome name and position. 
 seqnames = Chromosome name. 
 start = SNP start position. 
 end = SNP end position. 
 width = Width of event in bases. 
 REF = Reference allele. 
 ALT = Alternate allele(s). 
 QUAL = SNP quality metric. 
 NS = Number of samples in which the SNP was called. 
 DP = Total depth across all samples. 
 AC = Total number of alternate alleles in called genotypes. 
 AF = Estimated allele frequency in the range (0,1]. 
 RO = Reference allele observations. 
 AO = Alternate allele observations. 
 AB = Allele balance ratio. 
 RUN = Run length (the number of consecutive repeats of the alternate allele in the 
reference genome). 
 DPRA = Alternate allele depth ratio (ratio between ALT SNP calls and WT SNP calls for 
a given allele and strain) 
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 TYPE = The type of allele (snp, mnp, ins, del, or complex). 
 LEN = Allele length. 
 MQM = Mean mapping quality of observed alternate alleles. 
 MQMR = Mean mapping quality of observed reference alleles. 
 PAIRED = Proportion of observed alternate alleles which are supported by properly 
paired read fragments. 
 PAIREDR = Proportion of observed reference alleles which are supported by properly 
paired read fragments. 
 EFF = Effect string from snpEFF. 
 EFF_TYPE = Effect types. 
 EFF_SEV = Effect severities. 
 EFF_FUNC = Effect functional class. 
 EFF_CODON = Effect codon data, if SNP changes a codon. 
 EFF_AA = Effect amino acid data, if SNP changes an amino acid. 
 EFF_GENE = Gene(s) which this SNP affects. 
 EFF_SEV_HIGHEST = The highest severity of all effects for this SNP. 
 S_GT = Sample genotype. 
 S_GQ = Genotype quality, the Phred-scaled probability of the called genotype. 
 S_DP = Sample read depth. 
 S_RO = Sample read observations. 
 S_QR = Sum of quality of the alternate observations. 
 S_QA = Sum of quality of the reference observations. 
 S_AO = Alternate allele observation count. 
 GT.A = If heterozygous, WT/ALT status 1. 
 GT.B = If heterozygous, WT/ALT status 2. 
 HET = Is this SNP called as ‘heterozygous’ (see supplemental methods). 
 NC = Is this SNP not called for this genome. 
 CALL = Call status (0 for WT, 1+ for ALT). 
 VAR = Is this SNP not WT. 
 DISPLAY_NAME = Display name of the sample. 
 PARENT = Parent strains for this strain. 
 CHILD = Child strains for this strain. 
 STRAIN = Strain name. 
 STRAIN_TYPE = Strain type. 
 STRAIN_ID = Strain ID. 
 IN_OLIGO = Is this SNP in a region targetted by a MAGE oligo 
 AMBER = Is this an UAG to UAA SNP? 
 AMBER_COUNT = Number of UAG to UAA mutations made in this SNP. 
 IN_CHILD = Number of child strains that received this SNP from this strain. 
 IN_PARENT = Number of parent strains that passed this SNP to this strain. 
 NO_CALL = Was this SNP not called for this strain? 
 NC_COUNT = Number of strains in which this SNP was not called WT/ALT. 
 C_COUNT = Number of strains in which this SNP was called WT/ALT. 
 NC_PCT = Percentage of strains in which this SNP could not be called. 
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 INSUFF_CALLS = Flag for whether or not this SNP was called in too few samples. 
 AO_TOTAL = Total number of alternate observations across all alternate alleles. 
 INSUFF_READS = Flag for whether or not this SNP had too few good quality mapped 
reads across all samples. 
 INSUFF_SAMPLES = Flag for whether or not this SNP was called in too few samples. 
 BAD = Flagged if this SNP had either insufficient calls, reads, or called samples. 
 ANCESTRAL = Does this SNP occur in MG1655 or EcNR2? 
 FILTER = Does this SNP match all the criteria described in the supplemental SNP 
filtering methods? 
 DISPLAY = Should this SNP be displayed in Figure 5-2? (FILTER + !ANCESTRAL) 
 TS = Is this SNP a transition mutation (AG, GA, CT, or TC)? 
 
Chemical synthesis errors: We detected 39 off-target mutation events in regions targeted by 
MAGE oligos in the strains that underwent extensive MAGE cycling (rEc strains and C321). Of 
these, 16 were mismatches, 23 were deletions, and 0 were insertions. A subset of these mutations 
may be caused by spontaneous mutagenesis (ΔmutS). 
 
MAGE oligo mistargeting: We used blastn (default parameters, http://blast.ncbi.nlm.nih.gov/) to 
identify 31 MAGE oligos in regions of the genome that shared homology with the intended oligo 
site (Table S5-25).  
 
Table S5-25. Summary of blastn results for potential MAGE oligo mistargeting regions 
Oligo ID Avg. align length Avg. nt identity Number of alignments
a 
Total align length 
ascB 28.10112 100.0 89 2501 
aslB 91.00000 95.6 1 91 
b0299 76.80000 98.4 5 384 
b0361 58.85714 97.7 7 412 
b1228 91.00000 92.3 1 91 
b1402 56.25000 98.2 8 450 
b1578 56.25000 98.2 8 450 
b1996 57.25000 98.3 8 458 
b2860 57.50000 98.3 8 460 
b3045 59.00000 97.2 8 472 
b4273 57.14286 98.3 7 400 
b4283 54.66667 96.6 3 164 
eaeH 65.00000 98.5 5 325 
hda 28.00000 100.0 1 28 
hokE 61.00000 95.9 2 122 
insB 88.00000 89.8 7 616 
rcsC 35.63333 95.9 60 2138 
rhsA 77.00000 94.8 2 154 
tfaE 90.00000 95.6 1 90 
tfaS 90.00000 94.4 1 90 
tra5_1 78.00000 98.0 5 390 
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Table S5-25 (Continued). 
tra5_2 78.16667 98.3 6 469 
tra5_3 76.83333 98.3 6 461 
tra5_4 77.66667 97.9 6 466 
yafF 35.33333 100.0 3 106 
yafL 34.84483 96.5 58 2021 
yahH 44.83333 91.1 12 538 
ygeP 45.75000 99.2 8 366 
yghQ 48.00000 98.5 11 528 
yjjV 37.32979 96.4 94 3509 
yrhA 76.25000 97.5 4 305 
a 
Number of times each oligo aligns at genomic locations other than the desired target location 
There were 61 total unique mutations in the regions identified by BLAST. Of the 44 that passed 
filter, 4 were already present in EcNR2, 16 were on-target UAGUAA mutations, and 28 were 
potentially caused by oligo mistargeting. Because some mutations were found in multiple strains, 
we detected 32 total off-target mutations that shared homology with at least one MAGE oligo. 
To verify putative mistargeting events, we identified all oligos that satisfied the following 
requirements: (i) the oligo had been MAGE cycled in the mutated strain in question and (ii) the 
oligo was homologous to the region in which the mutation occurred. According to these criteria, 
there were only 6 likely mistargeting events (Table S5-26).  
 
 There were 5 bona fide mistargeting events—putative mistargeting resulted in mutations 
that matched the oligo sequence.  
 There was 1 putative mistargeting event—putative mistargeting resulted in mutation that 
may have been caused by a chemical synthesis error in the MAGE oligo.  
 There were 26 putative false positives: 
o There were 7 putative synthesis errors from proper MAGE oligo targeting that 
were identified as off-target homologies for other oligos (some oligos that target 
repetitive elements share similar sequences to each other). 
o There were 9 putative spontaneous mutations (mutations in mistargeting 
homology regions for MAGE oligos that were not used in the mutated strain). 
o There were 10 heterozygous mutations toward the b1228 oligo sequence in strains 
that had never been exposed to this oligo (probably an artifact of binary 
heterozygous SNP calling). 
 
Off-target structural variants: With the possible exception of the Conj 20 and Conj 26 
rearrangement described above, we found few instances of structural variants that could be 
caused by CAGE. This analysis is based on Pindel (35) and Breakdancer (36) output, which 
primarily identified the known marker insertion sites. Table S5-27 and Table S5-28 report all 
uncharacterized Pindel breakpoint events and all complete structural events, respectively. All 
reported events have at least 20 split reads supporting them. Additionally, Table S5-29 reports all 
high quality Breakdancer events that are supported by a minimum of 8 reads and have a quality 
score of at least 20. False positives and false negatives were observed in output from both Pindel 
and Breakdancer. Therefore, as described in the methods section each structural variant must be 
confirmed by hand using samtools tview <http://samtools.sourceforge.net/tview.shtml> (38).  
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CAGE removes deleterious alleles: We observed several cases in which CAGE improved fitness 
in conjugal progeny by allowing preferential inheritance of healthy alleles from one parental 
strain. This effect is most pronounced during the early stages of CAGE in which the recoded 
segment is small, and the conjugal junctions are less constrained. However, it diminishes with 
increasing recoded region sizes, since random mutations become less likely to be removed by 
chance, and the population of desired genotypes becomes smaller (Table S5-16) (53).  
 
Generating C321.ΔA sequence annotation file (genbank format): We generated an annotated 
sequence file in Genbank format for C321.ΔA using custom software.  This process required us 
to scrutinize the above SNP and structural variant analysis at a deeper level and resulted in 
accepting an additional 19 SNPs and 2 deletions that had been previously identified by Freebayes 
or Pindel or Breakdancer, but which had been triaged based on heuristics intended to remove 
false positives.  
 
The software takes as input: 
 MG1655 reference Genbank with accession number NC_000913 from NCBI 
 List of UAG positions in MG1655 (Table S5-34). 
 List of manual fixes which include cassette insertions and deletions (e.g. delete prfA, 
insert lambda prophage), as well as the 2 structural variations and 19 SNPs that were 
hand-validated as described above (Table S5-35) 
 List of remaining off-target variants as called by Freebayes (Table S5-36) 
 
Our software applies these changes  and outputs an annotated file in Genbank format. We then 
realigned the C321.ΔA fastQ sequencing reads to this genbank file, and re-ran the variant-calling 
pipeline to identify any discrepancies. By repeating this process iteratively, we were able to 
identify variants that were previously filtered out due to insufficient evidence based on the 
MG1655 reference sequence. 
 
Finally, we wrote another custom script to convert our Genbank file into the .sqn submission 
format required by NCBI.  This was done by generating a five-column table format representing 
the feature annotations which is then fed into the NCBI script tbl2asn.  This script performs an 
additional layer of validation on the annotated sequence according to well-established biological 
rules, and generates the submission file to be sent to NCBI.  The sequence and annotation were 
submitted to NCBI for release at time of publication. 
 
 
Current technologies are inadequate:  
 
Modern next-generation sequencing (e.g. Illumina HiSeq) now allows for dozens of bacterial 
strains to be sequenced simultaneously and in a matter of days. Despite the increasing ease of 
generating raw sequencing data for bacterial genomes, there are a lack of purpose-built tools to 
deal with this data.  
 
Our current pipeline combines almost a dozen modular tools, many of which are designed for 
human genome assembly and human population genetics. We know of no existing tools that 
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integrate multi-step genome-scale design, short-read assembly, and SNP and structural variant 
detection. The development of such tools would allow for rapid iteration, testing, and 
troubleshooting of engineered genomes. 
 
Additionally, while the small size of bacterial genomes makes short-read sequencing assembly 
relatively simple, many genomic variants remain beyond the reach of short read sequencing 
alone because they occur in duplicated regions (e.g. tRNAs, IS elements, highly paralogous 
genes, etc.). In many cases, short reads align to all copies of such regions with equal likelihood, 
making it difficult to call SNPs and structural variants in these regions. The creation of genomes 
with removed or diversified paralogous sequences could be combined with longer sequencing 
read lengths to produce correct, short-read genome sequences via resequencing. 
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H. Mass spectrometry 
 
We hypothesized that NSAA incorporation was occurring at native UAG positions of unrecoded 
genomes and we thus aimed to investigate this by directly measuring this effect in the native 
proteome. This has not been achieved for multiple native genes and previous work relied on 
tagging methods (altered genes) or plasmid-based single ORFs. We chose an in-depth 
proteomics approach to provide an unbiased view of the native proteome. This approach comes 
with a few expected technological limitations of mass spectrometry. Currently, no single 
proteomics method, or combination of methods, allows for 100% sequence coverage of all 
proteins. Our shotgun methods, which are slightly better than recent reports (60), have an 
inherent bias towards the detection of higher abundance proteins. We detected over 1,000 
proteins (~1/4
th
 of the proteome) and only 40 to 60 of the proteins detected were UAG containing 
ORFs. The major reason we do not observe more NSAA peptides is that the majority of UAG 
ORFs are lower in abundance and not in the top 1,000 proteins in the cell. We therefore applied a 
more robust method described in the SOM that nearly doubled the number of detectable proteins 
and more than tripled the number of UAG ORFs detected. However, limitations such as depth of 
peptide covered per ORF, observable peptides with mass spectrometry compatibility properties 
(such as peptide length, ionization properties, and ideal trypsin cleavage sites), and non-UAG 
dependent termination sequences are factors that reduce the number of NSAA peptides observed. 
We also expect that UAG read through and NSAA incorporation would destabilize proteins and 
reduce their expression below detectable levels. Based on these limitations, we think our list of 
natural UAG suppression, which is obtained from the most technologically advanced MS 
methods, underrepresents the total number of natural UAG suppression events. Nevertheless, we 
observed a highly reproducible sampling of multiple native ORFs that tolerated two distinct 
types of NSAA insertions. Importantly, these events were erased from the proteome by recoding, 
a property we confirmed by direct observation of the proteome (Figure 5-3D and Figure S5-7). 
We think the native, off target NSAA insertions are relevant at any level and we confirmed that 
NSAA insertions occur at genes essential for viability and fitness (e.g. mreC and sucB; Figure 5-
3C, Table S5-8, and Table S5-11). 
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Supplemental Information p-acetylphenylalanine 
 
Table S5-6. Summary of survey proteomic analysis of strains incorporating pAcF 
Strain OTS NSAA Protein ID's
a 
# 
UAG ORF's
b 
# 
UAG peptides 
# 
FDR
c 
% 
FDR
d 
% 
C0.B*.ΔA::S none none 1101 49 0 1.00 1.34 
C0.B*.ΔA::S none pAcF 1149 53 0 0.86 1.19 
C0.B*.ΔA::S pEVOL-pAcF none 1130 55 0 0.84 1.19 
C0.B*.ΔA::S pEVOL-pAcF pAcF 1131 40 3 1.02 1.29 
C314.ΔA::S none none 1139 60 0 0.85 1.22 
C314.ΔA::S none pAcF 1138 64 0 0.81 1.22 
C314.ΔA::S pEVOL-pAcF none 1042 62 0 0.97 1.31 
C314.ΔA::S pEVOL-pAcF pAcF 1006 55 0 0.96 1.34 
a Protein ID statistics from Yale Protein Expression Database (YPED)  
b Identified by searching UAG only DB, retrieved from MASCOT, 5 % False Discovery Rate (FDR)  
c Peptide matches above identity threshold (YPED)  
d Peptide matches above homology or identity threshold 
 
Table S5-7. Summary of in-depth proteomics of strains incorporating pAcF 
Strain OTS NSAA Protein ID's
a 
# 
UAG ORF's
b 
# 
UAG peptides 
# 
FDR
c 
% 
FDR
d 
% 
C0.B*.ΔA::S pEVOL-pAcF pAcF 1814 137 9e 0.87 2.45 
C314.ΔA::S pEVOL-pAcF pAcF 1803 163 0 1.05 2.58 
a
 Protein ID statistics from YPED 
b
 Identified by searching UAG only DB, pulled from MASCOT 
c
 Peptide matches above identity threshold (YPED) 
d
 Peptide matches above homology or identity threshold 
e 11 suppressed UAG codons (two UAG codons each in SucB and YbjK peptides) 
 
 
 
 
Figure S5-7. Extracted ion 
chromatograms are shown for 
pAcF incorporation into the 
YgaU peptide. Peptides 
containing pAcF were only 
observed in C0.B*.ΔA::S, and 
not in C321.ΔA::S, when 
pEVOL-pAcF was induced and 
pAcF was supplemented. 
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Table S5-8. Summary of identified pAcF containing peptides  
Protein Peptide sequence
a Experimental 
MW 
Calculated 
MW 
Delta mass 
ppm 
MASCOT  
Ion score 
FrmR XLNLLPY 920.5022 920.5007 1.6 16.47 
SucB LLLDVXXFK 1224.6668 1224.6794 10.3 26.44 
YbjK VAGXXISFR 1126.5826 1126.5811 1.3 55.27 
MarA FLHPLNHYNSXLK 1671.8607b 1670.8569 600.8b 33.03 
SpeG TPGQTLLKPTAQXH 1579.8371 1579.8358 0.8 67.53 
YgaU IPEEXLIASHR 1352.7096 1352.7088 0.6 88.36 
LuxS LQELHIXSVNYLHN 1767.8927 1767.8944 1.0 62.2 
LldD GNAAXSFAPPHPNPLPQGEGTVR 2402.1769 2402.1767 0.1 54.39 
IlvA LMXPLFLR 1077.6050 1077.6045 0.5 30.95 
a X = pAcF 
b
 
13
C isotope 
 
 
 
Table S5-9. Summary of all identified proteins with pAcF incorporation at UAG codon(s) 
Protein Description
a C0.ΔA::S + pEVOL 
+ pAcF 
C314.ΔA::S + pEVOL 
+ pAcF 
FrmR Regulator protein that represses frmRAB operon + - 
SucB Dihydrolipoyltranssuccinase + - 
YbjK Predicted DNA-binding transcriptional regulator + - 
MarA 
DNA-binding transcriptional dual activator of 
multiple antibiotic resistance + - 
SpeG Spermidine N1-acetyltransferase + - 
YgaU Predicted protein + - 
LuxS S-ribosylhomocysteine lyase + - 
LldD L-lactate dehydrogenase, FMN-linked + - 
IlvA Threonine deaminase + - 
a Gene functions were referenced from <http://www.ecocyc.org> (45). 
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Supplemental Information: Phosphoserine 
 
Table S5-10a. Summary from the proteomic analysis of the TiO2 enriched fraction of strains 
containing Sep-TECH 
Strain
a 
OTS NSAA 
Protein ID's
b 
# 
UAG ORF's
c 
# 
UAG peptides 
# 
FDR
d 
% 
FDR
e
 
% 
EcNR2.ΔserB SepRS/tRNASep Sep 313 17 0 1.15 3.26 
EcNR2.ΔserB SepRS/tRNASep Sep 292 21 0 0.55 1.76 
C0.B*.ΔA::S.ΔserB SepRS/tRNASep Sep 325 23 6 0.64 1.93 
C0.B*.ΔA::S.ΔserB SepRS/tRNASep Sep 249 21 5 0.82 2.42 
C13.ΔA::S.ΔserB SepRS/tRNASep Sep 188 20 4 1.63 3.05 
C13.ΔA::S.ΔserB SepRS/tRNASep Sep 314 16 5 0.92 1.88 
C321.ΔA::S.ΔserB SepRS/tRNASep Sep 227 12 1
f
 1.25 2.45 
C321.ΔA::S.ΔserB SepRS/tRNASep Sep 335 20 1
f
 0.90 2.65 
a All strains harbored pKD-SepRS-EFsep and pSepT (Sep OTS) and were supplemented with Sep 
b Protein ID statistics from Yale Protein Expression Database (YPED), results from biological replicates are listed 
separately 
c Identified by searching UAG only DB, retrieved from MASCOT, 5 % False Discovery Rate (FDR)  
d Peptide matches above identity threshold (YPED) 
e Peptide matches above homology or identity threshold 
f Carryover levels observed (source of carryover from prior MS run: C13.ΔA::S.ΔserB 
 
We observed only a single NSAA peptide (resulting from native UAG suppression) in two 
samples from C321.ΔA::S.ΔserB. We loaded 4µg of peptides for these LC-MS runs and 
followed each run with 2 different types of blank runs designed to clean the LC column. 
However, we still observed a small amount of carryover, after the two blanks that introduced a 
small amount of a phosphoserine peptide into the C321.ΔA::S.ΔserB sample from the previous 
C13.ΔA::S.ΔserB run. We re-ran the set of 4 samples at 1ug loads with the same blank runs and 
saw no detectable carryover (i.e. this eliminated the detection of the single carryover 
phosphopeptide from the C321.ΔA::S.ΔserB sample). 
 
Table S5-10b. Summary from the proteomic analysis of the TiO2 enriched fraction of strains 
containing Sep-TECH 
Strain
a 
 
OTS 
 
NSAA 
 
Protein 
ID's
b 
# 
UAG 
ORF's
c 
# 
TAG 
peptides 
# 
FDR
d 
% 
FDR
e 
% 
EcNR2.ΔserB SepRS/tRNASep Sep 249 7 0 0.82 2.42 
C0.B*.ΔA::S.ΔserB SepRS/tRNASep Sep 202 9 3 0.29 2.43 
C13.ΔA::S.ΔserB SepRS/tRNASep Sep 188 12 2 1.63 3.05 
C321.ΔA::S.ΔserB SepRS/tRNASep Sep 198 6 0 0.88 1.96 
a All strains harbored pKD-SepRS-EFsep and pSepT (Sep OTS) and were supplemented with Sep  
b Protein ID statistics from Yale Protein Expression Database (YPED), results from biological replicates are listed 
separately  
c Identified by searching UAG only DB, retrieved from MASCOT, 5 % False Discovery Rate (FDR)  
d Peptide matches above identity threshold (YPED)  
e Peptide matches above homology or identity threshold 
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Table S5-11. Summary of Sep-containing peptides identified by proteomics from two biological 
replicates each 
Protein 
 
Peptide sequencea 
 
Experimental  
MW 
Calculated 
 MW 
Delta mass 
ppm 
MASCOT  
Ion score 
LuxS  LQELHIXSVNYLHN 1745.8160 1745.8138 1.3 45.52 
SpeG TPGQTLLKPTAQXH 1557.7579 1557.7552 1.7 76.26 
RlpA  LQTEAQLQSFITTAQXR 2000.9606 2000.9568 1.9 58.17 
MreC  APGGQXWR 937.3808 937.3807 0.1 39.2 
Nei  FGAXVEINR 1071.4735 1071.4750 1.4 53.06 
LldD GNAASXFAPPHPNPLPQGEGTVR 2380.1013 2380.0961 2.2 43.21 
YhbW EELLGXCVLTR 1355.6204 1355.6156 3.5 39.57 
LpxK  LLTQLTLLASGNXLR 1678.9069 1678.9019 3.0 35.78 
a
 X = Sep 
 
 
Table S5-12. Summary of all identified proteins with Sep incorporation at an amber stop codon 
Protein Description
a 
EcNR2.
ΔserB 
+ OTS
b 
C0.B*.ΔA::S.
ΔserB 
+ OTS
b
 
C13.ΔA::S.
ΔserB + 
OTS
b
 
C321.ΔA::S.
ΔserB + 
OTS
b
 
LuxS  S-ribosylhomocysteine lyase - + + +c 
SpeG Spermidine N1-acetyltransferase - + + - 
RlpA  
Septal ring protein, suppressor of prc, 
minor lipoprotein - + + - 
MreC  
Cell wall structural complex MreBCD 
transmembrane component MreC - + - - 
Nei  
Endonuclease VIII/ 5-formyluracil/5-
hydroxymethyluracil DNA glycosylase - + + - 
LldD L-lactate dehydrogenase, FMN-linked - + + - 
YhbW Predicted enzyme - + - - 
LpxK  Lipid A 4'kinase - + - - 
a Gene functions were referenced from <http://www.ecocyc.org> (45). 
b OTS = pKD-SepRS-EFsep and pSepT 
c Contaminant levels observed (source of contamination from prior MS run: C13.ΔA::S.ΔserB) 
 
  
277 
 
I. NSAA incorporation 
 
One of the main goals of reassigning the genetic code is to provide a dedicated channel for plug-
and-play incorporation of NSAAs. To this end, we have created a robust chassis completely 
lacking UAG function, which is capable of accepting orthogonal aaRS/tRNA pairs. We have 
shown that the only known strategy to completely abolish UAG function is to remove all 
instances of UAG from the genome and then delete RF1. We have verified previous reports (17, 
54) that the RF2 variant (frameshift removed, T246A, A293E) can permit RF1 deletion, but also 
weakly terminates at UAG codons (Figure 5-3B). Additionally, NSAA incorporation in these 
strains is highly toxic ((54) and Figure 5-3) probably because it outcompetes termination in some 
essential genes. This effect is particularly apparent upon outgrowth from overnight expression of 
pAcF and pAzF (Figure S5-5). In contrast, removing essential UAGs permits the efficient 
incorporation of NSAAs, but plug-and-play UAG reassignment is difficult because UAG 
function cannot be abolished in these strains (new UAG function must be introduced prior to 
RF1 deletion (15, 17)). Although we were able to delete RF1 without introducing a suppressor in 
C7.ΔA::S and C13.ΔA::S, both strains rapidly selected for efficient natural suppression. 
C321.ΔA::S, C321.ΔA::T, and C321.ΔA were not affected by NSAA expression. All growth 
curves used for this analysis are in Figure S5-17. 
 
 
Figure S5-4. Doubling times in recoded strains +/- RF1. The number of UAGUAA 
conversions are indicated by UAA. RF1 status is denoted as wt prfA (WT), ΔprfA::specR (S), 
ΔprfA::tolC (T), or ΔprfA (Δ). RF2 sup indicates a variant (frameshift removed, T246A, A293E) 
capable of suppressing lethality of RF1 deletion. While C321 has a slower growth rate than the 
other RF1 strains (probably due to off-target mutagenesis; see discussion in main text), RF1 
deletion does not affect fitness. All other strains (C0.prfB*, C7, and C13) exhibited reduced 
fitness upon RF1 deletion. The gray symbols in the first column correspond to MG1655 (wild 
type) doubling time. 
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Figure S5-17. Native UAGs cause detrimental pleiotropic effects after codon reassignment. RF1 
status is denoted as wt prfA (WT), ΔprfA::specR (S), ΔprfA::tolC (T), or ΔprfA (Δ). RF2 sup 
indicates a variant (frameshift removed, T246A, A293E) capable of suppressing lethality of RF1 
deletion. (A) Averaged kinetic growth curves of RF1
+
 (solid lines) and RF1
-
 (dashed lines) 
strains with no UAG suppression. (B) Ratios of doubling times for RF1
+
/RF1
-
 strains with no 
aaRS supplemented to reassign UAG (n = 16). Statistical significance was determined using the 
Kruskal-Wallis test (p < 0.0001) followed by Dunn’s multiple comparison test to compare each 
ratio to unity (* p < 0.05, ** p < 0.01, and *** p < 0.001). RF1 deletion increased doubling time 
and decreased maximum cell density for RF2 variants and partially recoded strains, but not for 
fully recoded strains. (C-F) Average kinetic growth curves of RF1
+
 (solid lines) and RF1
-
 
(dashed lines) strains with pEVOL-pAcF expression and pAcF supplementation. The sense 
suppression of UAG impairs fitness in recoded RF2 variants (natural amino acids are incor- 
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Figure S5-17 (Continued). porated and impair fitness in the presence of pEVOL-pAcF even 
when pAcF is not supplemented) (C), improves fitness in partially recoded strains (D) and (E), 
and does not affect fitness in fully recoded strains (F). 
 
 
 
Figure S5-5. C0.B*.ΔA::S outgrowth is impaired following overnight pAcF and pAzF 
expression. Overnight cultures were grown in LB
L
 supplemented with chloramphenicol (pEVOL 
maintenance), arabinose (induces the aaRS), and NSAA. After 16 hours of growth, these cultures 
were passaged into identical media. Growth at 34°C was monitored via OD600 readings at 10-
minute (pAcF) or 5-minute (pAzF) intervals using a biotek H1 plate reader. 
 
 
GFP expression with UAG reassigned to p-acetylphenylalanine (pAcF) 
 
For each recoded strain, three GFP reporters (0UAG, 1UAG, and 3UAG) were expressed in the 
presence and absence of pAcF, pAzF, and NapA. Figure S5-6 reports the raw fluorescence for 
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each strain, amino acid, and reporter gene. Therefore, fluorescence readings take into account 
both expression levels and cell density, which are both relevant with respect to protein 
overexpression. Regardless of whether this is caused by UAG recoding or off-target mutations 
that non-specifically increase protein production, C321.ΔA::S consistently produces the highest 
fluorescence on par with the wt GFP controls after 17 hours of pAcF, pAzF, or NapA expression 
(Figure S5-6). C0.B*.ΔA::S exhibited low fluorescence, while C7.ΔA::S and C13.ΔA::S 
appeared to read through UAG using canonical amino acids. C321.ΔA::S produced high levels of 
fluorescence, but only when the relevant NSAA was supplemented. Finally, we note that the 
3UAG GFP variant produced higher fluorescence than expected in EcNR2. We verified the 
EcNR2 genotype, confirmed that the correct plasmid was present, and repeated the 
transformation of fresh pZE21G-3UAG into fresh EcNR2, but the 3UAG expression was 
consistently higher than the 1UAG expression in this strain for unknown reasons. 
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Figure S5-6. Complete removal of all native UAGs permits robust NSAA incorporation. 
Regardless of whether this is caused by UAG recoding or off-target mutations that non-
specifically increase protein production, C321.ΔA::S consistently produces the highest 
fluorescence after 17 hours of pAcF, pAzF, or NapA expression (see gray dashed horizontal lines 
as a benchmark). We report raw fluorescence without taking OD600 into account, which may 
contribute to the reduced fluorescence of the partially recodeded strains. We expressed GFP 
variants containing 0, 1, or 3 UAG codons in our panel of recoded strains (Table 1) with UAG 
reassigned to pAcF (top panel; using pEVOL-pAcF (9)), pAzF (middle panel; using pEVOL-
pCNF), and NapA (bottom panel; using pEVOL-pAcF). As evidenced by strong fluorescence for 
all reporters in the RF1+ strains, the pEVOL expression system is extremely active and strongly 
outcompetes RF1 in genes containing up to 3 UAG codons. Notably, C0.B*.ΔA::S yielded less 
fluorescence than its C0.B* precursor (yellow arrows for pAzF and NapA), probably due to 
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Figure S5-6 (Continued). toxicity from UAG read-through in essential genes. In contrast, 
C7.ΔA::S and C13.ΔA::S produced consistent levels of fluorescence in the 1 UAG and 3 UAG 
GFP reporters even when NSAAs were not supplemented in the media (red arrows), suggesting 
that these strains have acquired spontaneous UAG suppressors. Unlike the partially recoded 
strains, C321.ΔA::S yielded robust fluorescence without acquiring a mutational UAG suppressor. 
Although near-cognate suppression (18) may have resulted in residual expression of 1 UAG 
GFP, the expression was extremely low for 3 UAG GFP.  
 
Spontaneous UAG suppressors in C7.ΔA::S and C13.ΔA::S  
 
GFP fluorescence (Figure S5-6, red arrows) and Western blots (Figure 5-3B) indicated that 
C7.ΔA::S and C13.ΔA::S had spontaneously acquired efficient natural UAG suppressors. 
Therefore, we investigated this putative natural suppression in C13.ΔA::S via LC-MS/MS. To 
this end, we expressed an E17* GFP variant in C13.ΔA::S and used LC-MS/MS to identify the 
amino acid(s) incorporated in response to UAG. This analysis found efficient suppression with 
Lys, Gln, and Tyr (Table S5-13). 
 
Cells were cultured and lysed as described in the methods section. Cell free extracts were 
obtained by ultracentrifugation and clarified lysates were applied to Ni-NTA metal affinity resin 
and purified according to the manufacturer's instructions. Wash buffer contained 50 mM Tris pH 
7.5, 500 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 10 mM beta-mercaptoethanol, 50 mM NaF, 
1 mM Na3VO4 and 5 mM imidazole. Proteins were eluted with buffer containing 500 mM 
imidazole. Purified protein fractions were subjected to SDS-PAGE electrophoresis, and the gel 
was stained with Coomassie blue. Protein bands corresponding to the molecular weight of GFP 
(28.5 kDa) were subjected to in-gel digestion using trypsin as previously described (61), and 
peptides were quantified by UV280. LC-MS was carried out using a 90 min gradient with 100 ng 
of the digest for each analysis as described above. 
 
Table S5-13. LC-MS/MS of C13.ΔA::S after appearance of natural suppression 
Protein Peptide sequence
a,b Exp. MW 
Da 
Calc. MW 
Da 
Δ m 
ppm 
MASCOT 
Ion score
c 
GFP E17* SKGEELFTGVVPILVK 1714.9869 1714.9869 0.00 38.81 
GFP E17* GEELFTGVVPILVK 1499.8608 1499.8599 0.60 29.9 
GFP E17* SKGEELFTGVVPILVQLDGDVNGHK 2651.3786 2651.3807 
-
0.75 
84.97 
GFP E17* SKGEELFTGVVPILVQLDGDVNGHK 2650.3889 2650.3967 
-
2.94 
68.35 
GFP E17* GEELFTGVVPILVQLDGDVNGHK 2435.2598 2435.2697 
-
4.02 
43.59 
GFP E17* MSKGEELFTGVVPILVQLDGDVNGHK 2781.4338 2781.4371 
-
1.19 
34.41 
GFP E17* SKGEELFTGVVPILVYLDGDVNGHK 2685.3957 2685.4014 
-
2.12 
29.64 
aUnderlined residues are deamidated.  
bLysine (K) insertion adds a unique trypsin cleavage site and produces two unique peptides. 
cAll reported peptides have MASCOT scores above identity. 
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Western blots: soluble and insoluble fractions 
 
All Western blots not included in Figure 5-3B are included below. Because the anti-GFP 
antibody binds to an epitope between Y45 and Y151, only the 1UAG GFP variant produced 
truncation products that could be probed. We tested an anti-His antibody that would recognize 
the N-terminal 6His tag, but the affinity was too low for robust visualization. The soluble 
fraction primarily contains full-length GFP, while the insoluble fraction primarily contains the 
truncation products. Our strain is based on MG1655, which, unlike BL21, does not have 
important proteases (lon and ompT) inactivated. Therefore, it is possible that the insoluble 
truncation products are being degraded and underrepresenting the total amount of UAG-
mediated termination. 
 
The supernatant Western blots show that C7.ΔA::S and C13.ΔA::S acquired natural suppressors 
of UAG, that pEVOL-pAcF is capable of incorporating natural amino acids when pAcF is not 
supplemented, and that near-cognate UAG suppression (UAG recognition by an anticodon that is 
not CUA) does not cause strong UAG read-through (Figure S5-18). 
 
The crude lysate Western blots were performed in an attempt to show the soluble full length GFP 
and the insoluble truncation products on the same Western blot. Unfortunately, the supernatant 
overwhelms the insoluble fraction, making it difficult to simultaneous visualization of full-length 
GFP (soluble) and truncated peptides (insoluble) (Figure S5-19).  
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Figure S5-18. Western blots of GFP variants in the soluble/insoluble fractions. GFP variants 
containing 0, 1, 2, or 3 UAG codons (Table S5-33) were expressed in recoded strains with UAG 
reassigned to pAcF (strains harbored pEVOL-pAcF (9)). Strain genotypes are indicated as 
follows: RF1 status is denoted as wt prfA (WT), ΔprfA::specR (S), ΔprfA::tolC (T), or ΔprfA (Δ). 
RF2 sup indicates a variant (frameshift removed, T246A, A293E) capable of compensating for 
RF1 deletion. Western blots of the soluble fraction were probed with an anti-GFP antibody that 
recognizes an N-terminal epitope. The “ns” signifies a non-specific band. Truncation products 
(“trunc”) were present primarily in the insoluble fractions. Truncation products are most visible 
for the 1UAG variant because our anti-GFP antibody recognizes an epitope that is not translated 
in the truncated portion of the 3UAG variant (see Table S5-33 for UAG positions). Still, the 
3UAG pellet fractions show faint bands corresponding to the expected size for the 1UAG 
variant, probably due to read-through at the first UAG. C7.ΔA::S and C13.ΔA::S efficiently 
produced all variants of GFP regardless of UAG number and pAcF supplementation, suggesting 
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Figure S5-18 (Continued). that these strains have acquired natural suppressors of UAG. 
Additionally, full-length 1UAG GFP was visible in all strains lacking RF1 when pEVOL-pAcF 
was expressed even when pAcF was not supplemented, showing that pEVOL-pAcF is also 
capable of weakly incorporating natural amino acids. When pEVOL-pAcF was not induced (only 
expression of constitutive gene copy), a small amount of UAG suppression was observed in 
C0.B*, C0.B*.ΔA::S, and C321.ΔA::S. This suppression may be caused by weaker expression of 
the constitutive pAcF-RS copy or by near-cognate suppression (18). However, no full-length 
3UAG was observed in the absence of pEVOL-pAcF induction and pAcF supplementation, 
indicating that UAG read-through is weak unless UAG is explicitly reassigned to new function. 
 
 
 
Figure S5-19. Western blots of GFP variants in a crude lysate. GFP variants containing 0, 1, 2, 
or 3 UAG codons (Table S5-33) were expressed in recoded strains with UAG reassigned to 
pAcF (strains harbored pEVOL-pAcF (9)). Strain genotypes are indicated as follows: RF1 status 
is denoted as wt prfA (WT), ΔprfA::specR (S), ΔprfA::tolC (T), or ΔprfA (Δ). RF2 sup indicates a 
variant (frameshift removed, T246A, A293E) capable of compensating for RF1 deletion. 
Western blots of crude lysates were probed with an anti-GFP antibody that recognizes an N-
terminal epitope. The “ns” signifies a non-specific band. Truncation products (“trunc”) were 
present in the insoluble fraction, but were faint in the Western blots of crude lysates, perhaps due 
to proteolysis. 
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J. Increased T7 resistance 
 
Although T4 bacteriophage did not appear to be affected, T7 bacteriophage exhibited reduced 
fitness in strains lacking UAG function. Further experimentation is required to fully explain this 
difference in behavior, but previous work may offer some clues. We have considered which 
genes might be affected by UAG reassignment for each bacteriophage. 
 
T4: 3 of 19 genes terminating with UAG are essential (Table S5-30a) (62). 
 Gene 60 (DNA topoisomerase): Gene 60 mRNA contains a short region that must be 
skipped by translational bypassing in order to produce full length DNA topoisomerase 
(63). A UAG codon plays a role in bypassing efficiency, and UAG stalling may even aid 
in the translational bypassing. 
 Gene 41 (DNA primase/helicase): The C-terminus of gene 41 helicase is involved in 
Gp59 binding, which is necessary for recombination-dependent replication and for 
double-strand break repair (64). UAG stalling did not significantly impair T4 plaque 
formation, suggesting that there may have been adequate levels of ribosome rescue by 
arfA (65) and/or yeaJ (66) to support normal replication under the conditions tested. 
 Gene 15 (Proximal tail sheath stabilizer): Gp15 plays a crucial role in stabilizing the 
contractile sheath, and forms hexamers that make important contacts with Gp3 and Gp18 
(67). Hexamer formation occurred even with a C-terminal truncation variant. UAG 
stalling did not significantly impair T4 plaque formation, suggesting that there may have 
been adequate levels of ribosome rescue by arfA (65) and/or yeaJ (66) to support normal 
tail sheath formation under the conditions tested. 
 
T7: 1 of 6 genes terminating with UAG is essential (Table S5-30b) (68).  
 Gene 6 (gp6, T7 exonuclease): Gp6 amber mutants are lysis delayed, suggesting that the 
C-terminus of gp6 may be important for function (69). Therefore, ribosome stalling, 
tmRNA-mediated degradation, and/or C-terminal extension could decrease gp6 activity 
in the absence of RF1. This in turn could cause a shortage of nucleotides for phage 
replication and/or inhibit RNA primer removal, recombination, and concatemer 
processing during T7 replication (68).  
 
Table S5-30a. UAG terminating genes in bacteriophage T4 (excerpted from (62)) 
Gene Essential Function 
60 Yes DNA topoisomerase subunit 
modA.3 No Hypothetical protein 
41 Yes Replicative and recombination DNA primase/helicase 
mobB No Putative site-specific intron-like DNA endonuclease 
a-gt.2 No Hypothetical protein 
55.8 No Conserved hypothetical predicted membrane-associated protein 
I-TevII No Endonuclease for nrdD-intron homing 
nrdC.5 No Conserved hypothetical protein 
nrdC.9 No Conserved hypothetical protein 
tk No Thymidine kinase 
vs.5 No Conserved hypothetical protein 
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Table S5-30a (Continued). 
e.2 No Conserved hypothetical predicted membrane-associated protein 
5.4 No Conserved hypothetical protein 
15 Yes Proximal tail sheath stabilizer, connector to gp3 and/or gp19 
segD No Probable site-specific intron-like DNA endonuclease 
uvsY.-2 No Hypothetical protein 
alt.-2 No Hypothetical protein 
I-TevIII No Defective intron homing endonuclease 
frd.2 No Conserved hypothetical protein 
 
Table S5-30b. UAG terminating genes in bacteriophage T7 (excerpted from (68)) 
Gene Essential Function 
0.6B No Unknown function 
3.8 No Homing endonuclease 
5.3 No Homing endonuclease 
6 Yes 5'->3' dsDNA exonuclease activity, RNase H 
18.5 No Holin (lambda Rz analog) 
19.5 No Holin (suppresses gp17.5 mutants) 
 
Plaque area 
 
RF1
-
 strains yielded smaller plaques, indicating increased T7 resistance (Figure 5-4). The raw 
images of plaques on each recoded host are shown in Figure S5-8. We included MG1655 (fastest 
growth) and C30.5 (slowest growth) as benchmarks to demonstrate that plaque area is not 
affected by strain doubling time.  
 
 
Figure S5-8. Bacteriophage T7 plaques on recoded host strains. With the exception of C0.B*.ΔA::S, all RF1- strains 
yielded smaller plaques than their RF1+ counterparts. C13.ΔA::S yielded the smallest plaques, perhaps because 
translational stalling at native UAG codons may sequester ribosomes and reduce translation or because mutational 
suppression introduces C-terminal extensions that impair important phage proteins. 
 
Plaque areas were significantly different (p < 0.0001) based on RF1 status according to a 
Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparison test, where *p < 
0.05, **p < 0.01, and ***p < 0.001 (Figure S5-20). The complete results of the multiple 
comparison test are tabulated in Table S5-14.  
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Table S5-14. Pairwise statistical comparison of plaque areas. 
  C13 C13.ΔA::S C0.B* C0.B*.ΔA::S C321 C321.ΔA::S C321.ΔA::T C321.ΔA 
MG1655 ns *** ns ns ns *** *** *** 
C13 
 
*** ns ns ns *  *  *  
C13.ΔA::S   
 
*** *** *** ns  ns ns 
C0.B*     
 
ns ns **  **  **  
C0.B*.ΔA::S       
 
ns *** *** *** 
C321       
  
***  ***  ***  
C321.ΔA::S       
   
ns ns 
C321.ΔA::T       
    
ns 
C321.ΔA           
   
Statistical significances for pair wise plaque area comparisons were calculated using a Kruskal-
Wallis one-way ANOVA (p < 0.0001) followed by Dunn’s multiple comparison test. On the star 
system, * p < 0.05, ** p < 0.01, and *** p < 0.001. Strains with UAG removed from all essential 
genes are highlighted in green, strains with a compensatory RF2 variant are highlighted in 
magenta, and strains with UAG removed from all genes are highlighted in blue. C0.B*.ΔA::S 
was the only strain that did not show a statistically significant decreased plaque area after RF1 
inactivation. 
 
 
  
 
 
 
 
 
 
 
Figure S5-20. Bacteriophage T7 infection is 
attenuated in GROs lacking RF1. RF1 (prfA) 
status is denoted by symbol shape: ■ is wt prfA 
(WT),  is ΔprfA::specR (S),  is ΔprfA::tolC 
(T), and  is a clean deletion of prfA (Δ). RF2 
“sup” indicates a variant (frameshift removed, 
T246A, A293E) capable of suppressing 
lethality of RF1 deletion. (A) Plaque area 
(mm
2
) distributions for strains with or without 
RF1. Plaque areas were calculated using 
ImageJ, and means +/- 95% confidence 
intervals are presented with the raw plaque area 
data (n > 12 for each strain). In the absence of 
RF1, all strains except for C0.B*.ΔA::S yielded 
significantly smaller plaques, indicating that the 
RF2 variant can terminate UAG adequately to 
maintain T7 fitness. Statistics are based on a 
Kruskal-Wallis one-way ANOVA followed by 
Dunn’s multiple comparison test (*p < 0.05, 
**p < 0.01, and ***p < 0.001). A statistical 
summary can be found in Table S5-8. 
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Kinetic lysis 
 
To confirm the plaque area observations, we performed kinetic lysis curves with T7 infected at a 
multiplicity of infection (MOI) of 5. This ensured that all host cells were rapidly and 
synchronously infected by phage particles. We monitored lysis on a Biotek H4 plate reader with 
OD600 measurements taken every 5 minutes. The mean lysis curves were plotted using average 
OD600 values for each time point (n = 12), and a two-way ANOVA showed that the lysis curves 
were significantly different (p < 0.0001). Each lysis curve was fit to a cumulative normal 
distribution from which mean lysis parameters were calculated using the normcdf function in 
MATLAB (Figure S5-9).  
 
 
Figure S5-9. T7 kinetic lysis curves (MOI = 5). Mean lysis time (+/- standard error of the mean) 
was 47.9 (+/- 0.1) minutes for C321 and 54.5 (+/- 0.2) minutes for C321.ΔA::S, indicating that 
lysis is delayed in the absence of RF1 (n = 12, p < 0.0001, unpaired t test with Welch’s 
correction). Mean lysis OD600 was 0.25 (with negligible standard error of the mean) for both 
strains, showing that both hosts were infected under identical conditions and could be completely 
lysed by T7.  
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One-step growth curves 
 
To determine burst size and eclipse time, one step growth curves were performed as previously 
described (70). Briefly, mid-log phase cultures were infected at MOI = 0.1. At 3 minutes post 
infection, 30 µL of infected culture was diluted 500-fold into 15 mL LB
L
 to minimize further 
phage adsorption. Two aliquots were taken at t = 6 minutes—one aliquot was titered directly and 
the other was treated with chloroform before titering. Adsorption efficiency was determined by 
(pfunoCHCL3 – pfuCHCl3)/ pfunoCHCL3. Additional aliquots of the infection were taken at the 
following time points and were immediately treated with chloroform to release intracellular 
phage particles and to halt infection: 6, 18, 21, 24, 27, 29, 31, 33, 35, 37, 39, 41, 45, and 50 
minutes. These samples were then titered to monitor intracellular phage assembly during a single 
phage life cycle. Six replicates were performed, and each one-step growth curve was analyzed 
separately before their parameters were averaged. We estimated one-step growth parameters by 
using the scipy.optimize.curve_fit function to fit pfu/mL to 
 
ϕ = {
       
 (   )     
 
 
  
    
 
 
  
 
 
where ϕ is the number of phage progeny as a function of time (t), a is eclipse time, r is rise rate, 
and B is burst size (70).  
 
Adsorption efficiency ranged from ~20% – 60%, which is considerably lower than the >95% that 
we observed during the T7 fitness assay (Figure 5-4C). This discrepancy is probably because we 
performed this assay using phage lysate that had been stored at 4 °C for several weeks. Although 
we re-titered before each replicate, infection became less efficient as the phage lysate aged. 
Although this increased variance, T7 infection consistently proceeded more efficiently in C321 
than in C321.ΔA (Figure S5-21).  
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Figure S5-21. One step growth curves were performed using hosts C321 and C321.ΔA in six 
replicates: A = replicate 1, B = replicate 2, C = replicate 3, D = replicate 4, E = replicate 5, and F 
= replicate 6. Although the T7 lysate was properly stored at 4 °C in LB
L
 supplemented with 900 
mM sodium chloride, we found that longterm storage decreased adsorption efficiency (and 
apparent burst size) in both hosts. Therefore, replicates 3 and 4 were taken on the same day and 
replicates 5 and 6 were taken two days later to minimize variance. Even despite the variance, 
C321 consistently yielded larger burst sizes than C321.ΔA in all replicates. 
 
Because the first two replicates yielded higher phage titers than the others, we combined 
replicates 3-6, which were performed over the course of four days (Figure S5-10). RF1 removal 
caused a 30% longer eclipse time (p = 0.01), a 60% smaller burst size (p = 0.02), and a 35% 
slower rise rate (p = 0.04) (Figure S5-22, Table S5-15). Percentage changes were calculated by 
(RF1
-
param
 – RF1+param)/ RF1
+
param. 
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Figure S5-10. One step growth curve averaged across replicates 3-6 (Figure S5-21C-F). Mean 
pfu/mL +/- SEM are plotted for each time point. The one step growth curves for each host were 
significantly different (p = 0.002), as determined by a two way repeated measures ANOVA. 
 
 
Figure S5-22. One step growth curve parameters were calculated as described by You et al. (70). 
Raw data points are plotted with mean +/- SEM. The p values were calculated using an unpaired 
t test with Welch’s correction. Compared to C321 (WT), the C321.ΔA (Δ) supports T7 infection 
with (A) a 30% (+/- 2%) longer eclipse time (p = 0.01), (B) a 59% (+/- 9%) smaller burst size (p 
= 0.02), and (C) a 35% (+/- 5%) slower rise rate (p = 0.04). 
 
 
Table S5-15. One-step growth parameters: eclipse time, rise rate, and burst size 
Metrica C321 C321.ΔA % changeb p valuec 
Eclipse time (min) 19.8 (+/- 0.6) 25.7 (+/- 1.1) 30% longer 0.01 
Burst size (pfu/mL) 3.7E8 (+/- 4.8E7) 1.5E8 (+/- 1.0E7) 59% smaller 0.02 
Rise rate (pfu/mL/min) 1.5E7 (+/- 1.3E6) 9.7E6 (+/- 1.2E6) 35% slower 0.04 
a Data is based on 4 replicates (Replicates 3-6, Figure S5-21C-F) 
b % change in C321.ΔA with respect to C321; (RF1-param
 – RF1+param)/ RF1
+
param 
c p values were calculated using an unpaired t test with Welch’s correction 
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K. Selectable markers used in this study 
 
>mutS::cat (1017 bp) 
gctgatccactagttctagagcggccgctctaaaaaatgccctcttgggttatcaagagggtcattatatttcg
cggaattcatgctatcgacgtcgatatctggcgaaaatgagacgttgatcggcacgtaagaggttccaactttc
accataatgaaataagatcactaccgggcgtattttttgagttatcgagattttcaggagctaaggaagctaaa
atggagaaaaaaatcactggatataccaccgttgatatatcccaatggcatcgtaaagaacattttgaggcatt
tcagtcagttgctcaatgtacctataaccagaccgttcagctggatattacggcctttttaaagaccgtaaaga
aaaataagcacaagttttatccggcctttattcacattcttgcccgcctgatgaatgctcatccggaatttcgt
atggcaatgaaagacggtgagctggtgatatgggatagtgttcacccttgttacaccgttttccatgagcaaac
tgaaacgttttcatcgctctggagtgaataccacgacgatttccggcagtttctacacatatattcgcaagatg
tggcgtgttacggtgaaaacctggcctatttccctaaagggtttattgagaatatgtttttcgtctcagccaat
ccctgggtgagtttcaccagttttgatttaaacgtggccaatatggacaacttcttcgcccccgttttcaccat
gggcaaatattatacgcaaggcgacaaggtgctgatgccgctggcgattcaggttcatcatgccgtctgtgatg
gcttccatgtcggcagaatgcttaatgaattacaacagtactgcgatgagtggcagggcggggcgtaatttgat
atcgagctcgtcagcaggcgcgcctgtaatcacactggctcaccttcgggtgggcctttctgcgtttaaaaaaa
acgggccggcgcgaacgccggcccgcggccgccacccagcttttgttccctttag 
 
>kan
R
-oriT (1949 bp); oriT is from RK2 (28) 
cctgtgacggaagatcacttcgcagaataaataaatcctggtgtccctgttgataccgggaagccctgggccaa
cttttggcgaaaatgagacgttgatcggcacgtaagaggttccaactttcaccataatgaaataagatcactac
cgggcgtattttttgagttgtcgagattttcaggagctaaggaagctaaaatgagccatattcaacgggaaacg
tcgaggccgcgattaaattccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgggca
atcaggtgcgacaatctatcgcttgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggta
gcgttgccaatgatgttacagatgagatggtcagactaaactggctgacggaatttatgcctcttccgaccatc
aagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccggaaaaacagcattccaggt
attagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgcattcga
ttcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataac
ggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgca
taaacttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacg
aggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatccta
tggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctga
tatgaataaattgcagtttcatttgatgctcgatgagtttttctaatttttttaaggcagttattggtgccctt
aaacgcctggttgctacgcctgaataagtgataataagcggatgaatggcagaaattcgaaagcaaattcgacc
cggtcgtcggttcagggcagggtcgttaaatagccgcttatgtctattgctggttggcgctcggtcttgccttg
ctcgtcggtgatgtacttcaccagctccgcgaagtcgctcttcttgatggagcgcatggggacgtgcttggcaa
tcacgcgcaccccccggccgttttagcggctaaaaaagtcatggctctgccctcgggcggaccacgcccatcat
gaccttgccaagctcgtcctgcttctcttcgatcttcgccagcagggcgaggatcgtggcatcaccgaaccgcg
ccgtgcgcgggtcgtcggtgagccagagtttcagcaggccgcccaggcggcccaggtcgccattgatgcgggcc
agctcgcggacgtgctcatagtccacgacgcccgtgattttgtagccctggccgacggccagcaggtaggccga
caggctcatgccggccgccgccgccttttcctcaatcgctcttcgttcgtctggaaggcagtacaccttgatag
gtgggctgcccttcctggttggcttggtttcatcagccatccgcttgccctcatctgttacgccggcggtagcc
ggccagcctcgcagagcaggattcccgttgagcaccgccaggtgcgaataagggacagtgaagaaggaacaccc
gctcgcgggtgggcctacttcacctatcctgcccggctgacgccgttggatacaccaaggaaagtctacacgaa
ccctttggcaaaatcctgtatatcgtgcgaaaaaggatggatataccgaaaaaatcgctataatgaccccgaag
cagggttatgcagcggaaaagcgct 
 
>gent
R
 (831 bp) 
acgcacaccgtggaaacggatgaaggcacgaacccagttgacataagcctgttcggttcgtaaactgtaatgca
agtagcgtatgcgctcacgcaactggtccagaaccttgaccgaacgcagcggtggtaacggcgcagtggcggtt
ttcatggcttgttatgactgtttttttgtacagtctatgcctcgggcatccaagcagcaagcgcgttacgccgt
gggtcgatgtttgatgttatggagcagcaacgatgttacgcagcagcaacgatgttacgcagcagggcagtcgc
cctaaaacaaagttaggtggctcaagtatgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatc
catgcgggctgctcttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggact
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ccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgtt
ggcgctctcgcggcttacgttctgcccaggtttgagcagccgcgtagtgagatctatatctatgatctcgcagt
ctccggcgagcaccggaggcagggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttg
gtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaagttgggcata
cgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaacaattcgttcaagccgagatcggctt
cccgg 
 
>zeo
R
 (761bp) 
ggtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaactaaaccatggc
caagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgaccggc
tcgggttctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagc
gcggtccaggaccaggtggtgccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgc
cgagtggtcggaggtcgtgtccacgaacttccgggacgcctccgggccggccatgaccgagatcggcgagcagc
cgtgggggcgggagttcgccctgcgcgacccggccggcaactgcgtgcacttcgtggccgaggagcaggactga
cacgtccgacggcggcccacgggtcccaggcctcggagatccgtcccccttttcctttgtcgatatcatgtaat
tagttatgtcacgcttacattcacgccctccccccacatccgctctaaccgaaaaggaaggagttagacaacct
gaagtctaggtccctatttatttttttatagttatgttagtattaagaacgttatttatatttcaaatttttct
tttttttctgtacagacgcgtgtacgcatgtaacattatactgaaaaccttgcttgagaaggttttgggacgct
cgaaggctttaatttgcaagct 
 
>spec
R
 (1201 bp) 
cagccaggacagaaatgcctcgacttcgctgctgcccaaggttgccgggtgacgcacaccgtggaaacggatga
aggcacgaacccagtggacataagcctgttcggttcgtaagctgtaatgcaagtagcgtatgcgctcacgcaac
tggtccagaaccttgaccgaacgcagcggtggtaacggcgcagtggcggttttcatggcttgttatgactgttt
ttttggggtacagtctatgcctcgggcatccaagcagcaagcgcgttacgccgtgggtcgatgtttgatgttat
ggagcagcaacgatgttacgcagcagggcagtcgccctaaaacaaagttaaacatcatgagggaagcggtgatc
gccgaagtatcgactcaactatcagaggtagttggcgtcatcgagcgccatctcgaaccgacgttgctggccgt
acatttgtacggctccgcagtggatggcggcctgaagccacacagtgatattgatttgctggttacggtgaccg
taaggcttgatgaaacaacgcggcgagctttgatcaacgaccttttggaaacttcggcttcccctggagagagc
gagattctccgcgctgtagaagtcaccattgttgtgcacgacgacatcattccgtggcgttatccagctaagcg
cgaactgcaatttggagaatggcagcgcaatgacattcttgcaggtatcttcgagccagccacgatcgacattg
atctggctatcttgctgacaaaagcaagagaacatagcgttgccttggtaggtccagcggcggaggaactcttt
gatccggttcctgaacaggatctatttgaggcgctaaatgaaaccttaacgctatggaactcgccgcccgactg
ggctggcgatgagcgaaatgtagtgcttacgttgtcccgcatttggtacagcgcagtaaccggcaaaatcgcgc
cgaaggatgtcgctgccgactgggcaatggagcgcctgccggcccagtatcagcccgtcatacttgaagctaga
caggcttatcttggacaagaagaagatcgcttggcctcgcgcgcagatcagttggaagaatttgtccactacgt
gaaaggcgagatcaccaaggtagtcggcaaataaagctttactgagctaataacaggactgctggtaatcgcag
gcctttttatttctgca 
 
>tolC (1764 bp) 
ttgaggcacattaacgccctatggcacgtaacgccaaccttttgcggtagcggcttctgctagaatccgcaata
attttacagtttgatcgcgctaaatactgcttcaccacaaggaatgcaaatgaagaaattgctccccattctta
tcggcctgagcctttctgggttcagttcgttgagccaggccgagaacctgatgcaagtttatcagcaagcacgc
cttagtaacccggaattgcgtaagtctgccgccgatcgtgatgctgcctttgaaaaaattaatgaagcgcgcag
tccattactgccacagctaggtttaggtgcagattacacctatagcaacggctaccgcgacgcgaacggcatca
actctaacgcgaccagtgcgtccttgcagttaactcaatccatttttgatatgtcgaaatggcgtgcgttaacg
ctgcaggaaaaagcagcagggattcaggacgtcacgtatcagaccgatcagcaaaccttgatcctcaacaccgc
gaccgcttatttcaacgtgttgaatgctattgacgttctttcctatacacaggcacaaaaagaagcgatctacc
gtcaattagatcaaaccacccaacgttttaacgtgggcctggtagcgatcaccgacgtgcagaacgcccgcgca
cagtacgataccgtgctggcgaacgaagtgaccgcacgtaataaccttgataacgcggtagagcagctgcgcca
gatcaccggtaactactatccggaactggctgcgctgaatgtcgaaaactttaaaaccgacaaaccacagccgg
ttaacgcgctgctgaaagaagccgaaaaacgcaacctgtcgctgttacaggcacgcttgagccaggacctggcg
cgcgagcaaattcgccaggcgcaggatggtcacttaccgactctggatttaacggcttctaccgggatttctga
cacctcttatagcggttcgaaaacccgtggtgccgctggtacccagtatgacgatagcaatatgggccagaaca
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aagttggcctgagcttctcgctgccgatttatcagggcggaatggttaactcgcaggtgaaacaggcacagtac
aactttgtcggtgccagcgagcaactggaaagtgcccatcgtagcgtcgtgcagaccgtgcgttcctccttcaa
caacattaatgcatctatcagtagcattaacgcctacaaacaagccgtagtttccgctcaaagctcattagacg
cgatggaagcgggctactcggtcggtacgcgtaccattgttgatgtgttggatgcgaccaccacgttgtacaac
gccaagcaagagctggcgaatgcgcgttataactacctgattaatcagctgaatattaagtcagctctgggtac
gttgaacgagcaggatctgctggcactgaacaatgcgctgagcaaaccggtttccactaatccggaaaacgttg
caccgcaaacgccggaacagaatgctattgctgatggttatgcgcctgatagcccggcaccagtcgttcagcaa
acatccgcacgcactaccaccagtaacggtcataaccctttccgtaactgaaagcttgatatcgaattcctgca
gcccgggggatcccatggtacgcgtgctagaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctt
tcgttttatctgttgtttgtcggtgaacgctctcctgagtaggacaaatccgccgccctaga 
 
>galK (1270 bp) 
 
cctgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaactaaacccagga
ggcagatcatgagtctgaaagaaaaaacacaatctctgtttgccaacgcatttggctaccctgccactcacacc
attcaggcgcctggccgcgtgaatttgattggtgaacacaccgactacaacgacggtttcgttctgccctgcgc
gattgattatcaaaccgtgatcagttgtgcaccacgcgatgaccgtaaagttcgcgtgatggcagccgattatg
aaaatcagctcgacgagttttccctcgatgcgcccattgtcgcacatgaaaactatcaatgggctaactacgtt
cgtggcgtggtgaaacatctgcaactgcgtaacaacagcttcggcggcgtggacatggtgatcagcggcaatgt
gccgcagggtgccgggttaagttcttccgcttcactggaagtcgcggtcggaaccgtattgcagcagctttatc
atctgccgctggacggcgcacaaatcgcgcttaacggtcaggaagcagaaaaccagtttgtaggctgtaactgc
gggatcatggatcagctaatttccgcgctcggcaagaaagatcatgccttgctgatcgattgccgctcactggg
gaccaaagcagtttccatgcccaaaggtgtggctgtcgtcatcatcaacagtaacttcaaacgtaccctggttg
gcagcgaatacaacacccgtcgtgaacagtgcgaaaccggtgcgcgtttcttccagcagccagccctgcgtgat
gtcaccattgaagagttcaacgctgttgcgcatgaactggacccgatcgtggcaaaacgcgtgcgtcatatact
gactgaaaacgcccgcaccgttgaagctgccagcgcgctggagcaaggcgacctgaaacgtatgggcgagttga
tggcggagtctcatgcctctatgcgcgatgatttcgaaatcaccgtgccgcaaattgacactctggtagaaatc
gtcaaagctgtgattggcgacaaaggtggcgtacgcatgaccggcggcggatttggcggctgtatcgtcgcgct
gatcccggaagagctggtgcctgccgtacagcaagctgtcgctgaacaatatgaagcaaaaacaggtattaaag
agactttttacgtttgtaaaccatcacaaggagcaggacagtgctgaaaaaaaaaaccccgcccctgacagggc
ggggtttttttt 
 
>malK (1116 bp) 
 
atggcgagcgtacagctgcaaaatgtaacgaaagcctggggcgaggtcgtggtatcgaaagatatcaatctcga
tatccatgaaggtgaattcgtggtgtttgtcggaccgtctggctgcggtaaatcgactttactgcgcatgattg
ccgggcttgagacgatcaccagcggcgacctgttcatcggtgagaaacggatgaatgacactccgccagcagaa
cgcggcgttggtatggtgtttcagtcttacgcgctctatccccacctgtcagtagcagaaaacatgtcatttgg
cctgaaactggctggcgcaaaaaaagaggtgattaaccaacgcgttaaccaggtggcggaagtgctacaactgg
cgcatttgctggatcgcaaaccgaaagcgctctccggtggtcagcgtcagcgtgtggcgattggccgtacgctg
gtggccgagccaagcgtatttttgctcgatgaaccgctctccaacctcgatgctgcactgcgtgtgcaaatgcg
tatcgaaatctcccgtctgcataaacgcctgggccgcacaatgatttacgtcacccacgatcaggtcgaagcga
tgacgctggccgacaaaatcgtggtgctggacgccggtcgcgtggcgcaggttgggaaaccgctggagctgtac
cactatccggcagaccgttttgtcgccggatttatcggttcgccaaagatgaacttcctgccggtaaaagtgac
cgccaccgcaatcgatcaagtgcaggtggagctgccgatgccaaatcgtcagcaagtctggctgccagttgaaa
gccgtgatgtccaggttggagccaatatgtcgctgggtattcgcccggaacatctactgccgagtgatatcgct
gacgtcatccttgagggtgaagttcaggtcgtcgagcaactcggcaacgaaactcaaatccatatccagatccc
ttccattcgtcaaaacctggtgtaccgccagaacgacgtggtgttggtagaagaaggtgccacattcgctatcg
gcctgccgccagagcgttgccatctgttccgtgaggatggcactgcatgtcgtcgactgcataaggagccgggc
gtttaa 
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Table S5-33. Sequences of GFP variants containing UAG codons (UAG codons are highlighted 
in red). 
 
>GFP-NHis-0UAG 
atgcaccaccaccaccaccacagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcaca
aattttctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatgg
ccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgccatgcccg
aaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaaggtgatacccttgtta
atcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgaatacaactataactcacacaatgtatacatc
acggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaagatggatccgttcaactagcagaccattatca
acaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacacaatctgccctttcgaaagatcccaacgaaaa
gcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacacatggcatggatgagctctacaaataa 
 
>GFP-NHis-1UAG 
atgcaccaccaccaccaccacagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcaca
aattttctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatgg
ccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgccatgcccg
aaggttatgtacaggaacgcactatatctttcaaagatgacgggaacftacaagacgcgtgctgaagtcaagtttgaaggtgatacccttgtta
atcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgaatacaactataactcacacaatgtatagatc
acggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaagatggatccgttcaactagcagaccattatca
acaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacacaatctgccctttcgaaagatcccaacgaaaa
gcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacacatggcatggatgagctctacaaataa 
 
>GFP-NHis-2UAG 
atgcaccaccaccaccaccacagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcaca
aattttctgtcagtggagagggtgaaggtgatgcaacatagggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatgg
ccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgccatgcccg
aaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaaggtgatacccttgtta
atcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgaatacaactataactcacacaatgtatacatc
acggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaagatggatccgttcaactagcagaccattagc
aacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacacaatctgccctttcgaaagatcccaacgaaaa
gcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacacatggcatggatgagctctacaaataa 
 
>GFP-NHis-3UAG 
atgcaccaccaccaccaccacagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcaca
aattttctgtcagtggagagggtgaaggtgatgcaacatagggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatgg
ccaacacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgccatgcccg
aaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaaggtgatacccttgtta
atcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgaatacaactataactcacacaatgtatagatc
acggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaagatggatccgttcaactagcagaccattagc
aacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacacaatctgccctttcgaaagatcccaacgaaaa
gcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacacatggcatggatgagctctacaaataa 
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APPENDIX E 
 
Supplemental Material for Probing the Limits of Genetic Recoding in Essential 
Genes 
 
 
 
 
 
This supplemental material is reproduced with permission from its initial publication: 
 
Lajoie MJ
*
, Kosuri S
*
, Mosberg JA, Gregg CJ, Zhang D, Church GM (2013) Probing the limits 
of genetic recoding in essential genes. Science 342: 361-3. 
 
Tables and Figures have been renamed to be consistent with CHAPTER 6. 
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Materials and Methods: 
All DNA oligonucleotides (Table S6-8) were purchased with standard purification and desalting 
from Integrated DNA Technologies. The Oligo Library Synthesis (OLS) array used for 
synthesizing radically recoded genes was generated on a DNA microchip, processed, and 
delivered as a ~1-10 pmol lyophilized pool of oligos by Agilent Technologies (Carlsbad, CA). 
 
Cultures were grown at 34 °C with aeration in LB-Lennox (LB
L
; 10 g/L Bacto tryptone, 5 g/L 
sodium chloride, 5 g/L yeast extract) and colonies were grown on LB
L
-agar plates (LB
L
 with 15 
g/L Bacto agar). LB
L
 media was supplemented with one or more of the following selective 
agents: carbenicillin (50 g/mL), sodium dodecyl sulfate (SDS; 0.005% w/v), kanamycin (30 
g/mL). Colicin E1 was obtained via expression in strain JC411 (31), and purified as previously 
described. 
 
NAT_kan
R
 cassette preparation 
 
Kanamycin resistance (kan
R
) cassettes were inserted via λ Red recombination (32, 33) 
downstream of essential ribosomal genes, in order to test whether polar effects from inserting 
kan
R
 impair fitness. These “NAT_kanR” cassettes were PCR amplified using primers that 
introduced 50 bp of genomic homology on either side of the intended kan
R
 insertion site (Kapa 
HiFi Ready Mix; manufacturer’s protocols). PCR products were SPRI purified as previously 
described (34), eluted in deionized water (dH2O), and checked on a 1% agarose gel for correct 
size and purity before being recombined as described below. 
 
Recoded gene cassette preparation 
 
Recoded essential genes (Table S6-9) were synthesized from an Agilent OLS array as previously 
described (35). Due to their size, the prfB and rpsA genes were difficult to synthesize in one 
piece, so they were each synthesized in two pieces, which were then assembled via isothermal 
assembly (36). All synthesized recoded cassettes were fused to a downstream kanamycin 
resistance gene (kan
R
) via isothermal assembly (36). The crude isothermal assemblies were PCR 
amplified using primers (Table S6-8) that introduced 50 bp of genomic homology on either side 
of the recoded gene and kan
R
 (Kapa HiFi Ready Mix; manufacturer’s protocols). Full-length 
cassettes were SPRI purified as previously described (34), eluted in dH2O, and checked on a 1% 
agarose gel for correct size and purity before being recombined as described below. 
 
Partially recoded cassette preparation 
 
Partially recoded gene cassettes were prepared using the full-length recoded gene cassettes 
(described above) as template (Kapa HiFi Ready Mix; manufacturer’s protocols). While the 
same reverse primers were used, new forward primers were designed to hybridize inside the 
recoded cassette and to introduce 50 bp homology regions matching the natural sequence, so that 
only the C-terminal portion of the gene would be recoded (Figure 6-1B).  
 
We prepared two types of partially recoded cassettes. The less stringent version recoded exactly 
half of the gene. The more stringent version recoded all except for the first 30 codons of the 
gene. Partially recoded cassettes were SPRI purified as previously described (34), eluted in 
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dH2O, and checked on a 1% agarose gel for correct size and purity before being recombined as 
described below. 
 
CoS-MAGE selectable marker preparation 
 
To maximize the number of alleles that could simultaneously be replaced per recombinant, we 
used Co-Selection Multiplex Automated Genome Engineering (CoS-MAGE) with tolC or bla as 
co-selectable markers (37, 38). In most cases, 90 nt MAGE oligos were designed to replace 
several forbidden codons. We performed CoS-MAGE in an EcNR2.xseA
- 
background, which has 
ExoVII inactivated in order to minimize allele loss near the 3’ end of the MAGE oligos (39). 
Since the ribosomal genes are clustered in different regions of the genome, selectable markers 
needed to be placed in multiple different genomic locations in order to provide co-selection in 
adequate proximity (~500 kb) to the target ribosomal genes. Therefore, we prepared two tolC 
cassettes (tolC.3502900 for rpsL, rplQ, rplO, rpsG, rplD, rpsD, rpsC, and rplB; tolC.4427600 
for rpsR, rplL, and rplJ) using Kapa HiFi Ready Mix (manufacturer’s protocols) and PCR 
primers that introduced 50 bp of flanking genomic homology (Table S6-8). The tolC cassettes 
were purified using Qiagen’s PCR purification kit (manufacturer’s protocols, eluted in dH2O) 
before being recombined as described in the “gene and allele replacement” methods section. For 
rpsA co-selection, bla was already present in the  prophage of EcNR2.  
 
Gene and allele replacement 
 
All CoS-MAGE oligonucleotides and Nat_Kan
R
, fully recoded, and partially recoded cassettes 
(described above) were recombined into EcNR2 (E. coli MG1655 ΔmutS::cat Δ(ybhB-bioAB)::[λcI857 
N(cro-ea59)::tetR-bla]) as previously described (38). Briefly, EcNR2 was grown to mid-log phase 
(OD600 between 0.4 and 0.6), induced to express λ Red for 15 minutes in a 42 °C shaking water 
bath, and chilled on ice. For each recombination, 1 mL of induced culture was washed twice in 1 
mL cold dH2O, and then the cell pellet was  resuspended in 50 µL of dH2O containing the DNA 
to be recombined. For PCR products, 1-2 ng/µL was used; to inactivate selectable markers for 
CoS-MAGE, a 90mer oligonucleotide was used at a final concentration of 1 µM; for CoS-
MAGE, 90mer oligonucleotides were pooled at a final concentration of ≤ 5 µM. A BioRad 
GenePulser™ was used for electroporation (0.1 cm cuvette, 1.78 kV, 200 Ω, 25 µF), and 
electroporated cells were allowed to recover in 3 ml LB
L
 in a rotator drum at 34°C for at least 3 
hours before plating on appropriate selective media.  
 
Recombinant clones were selected on LB
L
-agar supplemented with kanamycin, and then re-
streaked on fresh LB
L
-agar supplemented with kanamycin to ensure monoclonality. Monoclonal 
colonies were then grown in a 96-well format (150 L LBL supplemented with kanamycin) in 
preparation for genetic analysis. 
 
To prepare the EcNR2.xseA
-
 strains for CoS-MAGE, we deleted the endogenous tolC from the 
genome using the tolC.90.del oligo and selected for recombinants via Colicin E1 selection (38).  
We then separately introduced the tolC co-selection cassettes (one per CoS-MAGE strain) and 
selected on LB
L
 supplemented with SDS. Finally, we inactivated tolC by introducing a nonsense 
mutation and a frameshift using the tolC-r_null_mut* oligo. For bla co-selection, we used the 
305 
 
bla_mut* oligo to inactivate bla (present in the  prophage) and screened for carbenicillin-
sensitive recombinants by replica plating on LB
L
 supplemented with carbenicillin. 
 
CoS-MAGE: CoS-MAGE was performed as previously described (37), using 0.5 M of each 
MAGE oligo and 0.5 M of the appropriate co-selection oligo to revert tolC.3502900 (rpsL, 
rplQ, rplO, rpsG, rplD, rpsD, rpsC, rplB), tolC.4427600 (rpsR, rplL, rplJ), or bla (rpsA). MAGE 
(without co-selection) (40) was performed on rpsP and rpsB because they were distant from the 
available co-selectable markers and only had 4 codons to be removed. CoS-MAGE recombinants 
were selected on LB
L
-agar supplemented with SDS (for tolC) or LB
L
-agar supplemented with 
carbenicillin (for bla), and MAGE recombinants were grown on LB
L
-agar without selection. 
Monoclonal colonies were picked into a 96-well plate and grown under the appropriate selection 
at 34 °C with shaking. 
 
Recombinant clone genotyping 
 
Recombinant clones were first screened by PCR, then validated by Sanger sequencing.  
 
PCR screens: For the fully recoded genes, we performed 3 PCR reactions for each clone. As 
diagramed in Figure 6-1B, the three sets of primers hybridized to the natural gene sequence 
(NAT), the recoded gene sequence (SYN), and the flanking genomic region (BND). PCR 
reactions (10 L each) were performed with Kapa 2G Fast Ready Mix according to the 
manufacturer’s protocols. Adequate primer specificity was observed with a 58 °C annealing 
temperature. Desired recombinants had no NAT amplicon, a gene-sized SYN amplicon, and a 
BND amplicon 847 bp larger than that of the wild type negative control. Partially (C-terminally) 
recoded recombinants were screened using the NAT forward and SYN reverse primers (desired 
recombinants had a gene-sized amplicon) and BND primers (desired recombinants showed an 
847 bp increase in amplicon size). All putative recombinants that passed the PCR assay were 
Sanger sequenced (Genewiz or Eton Bioscience Inc.) using the forward BND primers and/or 
kanR.seqOUT-Nr2. 
 
CoS-MAGE recombinants were typically sequenced without initial Multiplex Allele Specific 
Colony PCR (MASC-PCR (38)) screening because the targeted alleles were too close together to 
allow for the amplification of discrete bands. However, well-separated alleles were screened via 
MASC-PCR with standard protocols (38) prior to Sanger sequencing validation. 
 
Doubling time analysis 
 
Doubling times (Figure 6-2, Tables S6-4 to S6-5) were determined for all recoded clones using 
LB
L
 and Teknova HiDef Azure media. Kinetic growth curves were performed in triplicate on a 
Biotek H4 plate reader with OD600 measurements at 5 minute intervals. Cultures were grown in a 
flat-bottom 96-well plate (in 150 µL of LB
L
 supplemented with carbenicillin) with shaking at 34 
°C. Doubling times were determined by tdouble = c*ln(2)/m), where c = 5 minutes per time point 
and m is the maximum slope of ln(OD600) smoothed across 5 contiguous time points (20 
minutes). We typically calculate doubling time in this manner so as to accommodate strains that 
achieve lower maximum optical densities. Each data point in Figure 6-2 represents the average 
doubling time of an individual strain with one ribosomal gene partially or fully recoded (n = 3). 
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Each replicate was prepared by passaging from the previous one. All strains are based on EcNR2 
or EcNR2.xseA
-
 (doubling times under assay conditions for these strains are 49 +/- 4 minutes in 
LB
L
 and 84 +/- 5 minutes in Teknova HiDef Azure Media (12 replicates per condition)). 
 
Supplemental information: 
 
Design parameters for radically recoded genes 
 We removed all instances of 13 rare codons (UAG, AGA, AGG, CUU, CUC, CCC, 
ACC, AUA, GUC, GCC, UCC, CGG, UGA) by replacing them with synonymous 
codons. Since our goal is to radically change the genetic code, codon removal is merely 
the first step toward removing and/or reassigning anticodon function, and all codons 
uniquely recognized by a tRNA or release factor must be changed prior to deletion. 
Therefore, rather than choosing the 13 rarest codons, we instead targeted codons that are 
recognized by the least frequently used anticodons. Removing all instances of these 
codons from the genome would permit the deletion of 10 anticodons (three less than the 
13 codons removed, as both CUC and CUU correspond to the same Leu anticodon, both 
AGG and AGA correspond to the same Arg anticodon, and RF2 is still necessary to 
terminate UAA in the absence of RF1) and the introduction of 4 nonstandard amino acids 
into the genetic code (AUA, UAG, CGG, and AGA/AGG codons can be unambiguously 
reassigned to encode a new amino acid; the introduction of tRNAs for the other codons 
would cause ambiguous amino acid incorporation due redundant anticodon specificities – 
see Figure 6-1A).  
 All start codons were changed to AUG (rpsM GUGAUG). 
 All non-forbidden codons in radically recoded genes (blue segments in Figure 6-3) were 
swapped with a synonymous codon to reduce nucleotide identity to the natural sequence 
(see rpmH example below, page 4 of SOM). We randomly chose the synonymous 
replacement codon from a weighted distribution of the remaining possible codons based 
on their frequency in the E. coli MG1655 genome. 
 Genes that encoded overlapping coding DNA sequences were modified to remove these 
overlaps. If another gene overlapped at the start of the coding sequence, the end of this 
gene was duplicated, and the start codon was removed. If the start codon could not be 
removed, an in-frame stop-codon was added to prevent translation initiation from the 
undesired start codon. If a gene overlapped at the end of the coding sequence, we 
removed the start codon from the recoded sequence. We ensured that the subsequent gene 
was still translated by duplicating the natural sequence downstream of the recoded 
sequence. Table S6-10 provides a list of these refactored overlaps. 
 Genetically encoded frameshifts were removed (prfB CUUU73CUU).  
 The following restriction sites were removed: BtsI, BsaI, BsmBI, BspQI, XbaI, and AatII. 
 The mRNA secondary structure near the ribosomal binding site was minimized. To 
accomplish this, we used UNAFold (41) to calculate the G for the secondary structure 
of a 42 bp window centered at the translation start site. The initial design was optimized 
in order to reduce secondary structure if one of the following two conditions were met: 
(1) the recoded secondary structure was stronger than the original secondary structure and 
less thanG -7.0 kcal/mol, or (2) the recoded secondary structure was less than G = -10 
kcal/mol. To optimize the recoded sequence, all available synonymous codons were 
varied individually and a new sequence with reduced secondary structure was selected.  
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For example, below is the comparison between the natural and recoded sequences for rpmH. 
Nucleotide abbreviations are according to IUPAC notation. Yellow highlighting indicates 
nucleotides that differ in the recoded gene. 
 
>radical recoding rpmH 
ATG AAR CGY ACK TTY CAR CCK WST GTW YTG AAR CGY AAY CGY TCW CAY 
GGY TTY CGY GCK CGY ATG GCW ACK AAR AAY GGY CGY CAR GTK YTG GCR 
CGY CGY CGY GCW AAR GGY CGY GCK CGY YTR ACS GTK TCW AAR TAA 
 
Partial replacement with full-length recoded cassettes 
Fully recoded rpmH and rplT cassettes repeatedly produced partially recoded recombinants (wild 
type until C81 and T147, respectively). In both cases, the position of the crossover was shifted 
upstream by using partially recoded constructs that preserved the wild type N-termini (Figure 
S6-2). This indicates that the full-length cassette 1) had a lethal design element in its N-terminus 
and/or 2) had poorly recominogenic homology sequence. 
 
Double mutants with full-length recoded cassettes 
To understand the effect of combining multiple recoded genes in a single strain, we 
transcriptionally fused the recoded rplM_syn1 variant (third slowest doubling time) or rpsI_syn1 
variant (fourth slowest doubling time) to a spectinomycin resistance gene, generated double 
mutants in rplP_syn1 (slowest doubling time and contains ATA forbidden codon), rpmC_syn1 
(second slowest doubling time), and rplE_syn1 (normal doubling time), and selected the highest 
fitness recombinant exhibiting the desired genotype. When grown in LB
L
 without antibiotic 
supplementation, all double mutants grew faster than expected assuming additive fitness defects 
for independent mutations (Figure S6-1, Table S6-11). It is possible that compensatory off-target 
mutations facilitated by inactive mismatch repair may alleviate growth impairment, and double 
mutants may exhibit varying fitness effects due to ribosomal protein autoregulation (42).  
 
Remaking rplP_syn2, rpsS_syn2, and rpmD_syn2 
We re-sequenced all gene replacement strains (Table S6-4) to confirm that no mutations had 
occurred during extended growth. We observed a G36A mutation in rplP_syn1, which 
introduced a forbidden AUA codon; a C5T mutation in rpsS_syn1, which introduced a forbidden 
CUU codon; and a putative duplication in rpmD_syn1, resulting in the presence of both a natural 
and recoded copy of rpmD in the same genome.  
 
For rplP, the wild type AUG codon resulted in an extreme fitness disadvantage, which provided 
a strong selection for the spontaneous G36A mutation (AUGAUA change). Therefore, we 
attempted to change the forbidden AUA codon to all other Ile (AUC and AUU) and Met (AUG) 
codons using MAGE. While AUG was not observed, presumably due to an extreme fitness 
disadvantage, AUU and AUC were well-tolerated, leading to rplP_syn2. Since this mutation was 
intended, it was not counted as a synthesis error or represented by a yellow line in Figure 6-3. 
 
For rpsS, resequencing revealed a forbidden CUU codon. We re-amplified the rpsS gene with 
primers that changed this forbidden CUU to all permitted Pro (CCA, CCG, and CCU) and Leu 
(UUA, UUG, CUA, and CUG) codons. Codons CCA and CCG (but not CCU) were observed for 
Pro. Codons UUA, UUG, CUA, and CUG were observed for Leu. Additionally, we allowed the 
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subsequent CGC Codon be shuffled to CGA, CGU, and CGC. We selected a clone, rpsS_syn2, 
with intended mutations T6A and C9A. Since these mutations were intended, they were not 
counted as synthesis errors or represented by yellow lines in Figure 6-3. 
 
For rpmD, we repeated the insertion of the original synthetic rpmD gene, yielding a clone, 
rpmD_syn2, with the correct genotype. 
 
Supplemental Figures: 
 
Figure S6-1. Doubling times of double mutants compared to single mutants. Synthetic gene 2 
(rplM or rpsI) was transcriptionally fused to a spectinomycin resistance gene and recombined 
into strains rpmC_syn1, rplE_syn1, and rplP_syn1. Double mutants that were resistant to both 
kanamycin and spectinomycin were isolated, Sanger sequence verified, and assayed for doubling 
time in LB
L
 without antibiotic supplementation. The double mutant exhibiting the fastest 
doubling time for each gene pair was chosen. Data bars represent the doubling times of the gene 
1 syn strain (red), gene 2 syn strain (blue), double mutant (dark purple), and predicted doubling 
time of the double mutant assuming that fitness defects are independent (light purple). Error bars 
are the standard deviation of 3 technical replicates; variances for the predictions are the square 
root of the summed squared variances of the two measured strains.  
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Supplemental Tables: 
 
Table S6-1. Recoded essential gene design attributes 
Table S6-2. Genes with forbidden codons successfully removed after each phase of recoding 
Table S6-3. Forbidden codons remaining after each phase of recoding 
Table S6-4. Gene replacement strain summary and doubling times 
Table S6-5. CoS-MAGE strain summary and doubling times 
Table S6-6. Oligos used to replace rplQ CUU 160-162 
Table S6-7. Successful rplQ CUU 160-162 replacements 
Table S6-8. Primers and oligonucleotides used in this study 
Table S6-9. Recoded gene designs 
Table S6-10. Refactored overlapping genes 
Table S6-11. Doubling times of double mutants compared to single mutants 
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Table S6-1. Recoded essential gene design attributes 
Gene Length 
Forbidden 
codons 
Number of 
changes 
% nt 
identity 
Total 
codons 
Identical 
codons 
Changed 
codons 
% codon 
identity 
rpmH 141 1 46 67.4% 47 3 44 6.38% 
rpmD 180 4 59 67.2% 60 5 55 8.33% 
rpmC 192 2 71 63.0% 64 3 61 4.69% 
rpsR 228 6 84 63.2% 76 2 74 2.63% 
rpmB 237 7 84 64.6% 79 4 75 5.06% 
rpsP 249 1 86 65.5% 83 3 80 3.61% 
rpsQ 255 5 88 65.5% 85 4 81 4.71% 
rpmA 258 3 92 64.3% 86 2 84 2.33% 
rpsS 279 6 96 65.6% 93 5 88 5.38% 
rplW 303 10 101 66.7% 101 6 95 5.94% 
rpsN 306 6 106 65.4% 102 7 95 6.86% 
rplU 312 3 105 66.3% 104 5 99 4.81% 
rpsJ 312 10 104 66.7% 104 3 101 2.88% 
rplX 315 10 111 64.8% 105 4 101 3.81% 
rplV 333 8 119 64.3% 111 3 108 2.70% 
rplS 348 8 127 63.5% 116 4 112 3.45% 
rplR 354 10 124 65.0% 118 2 116 1.69% 
rplT 357 3 126 64.7% 119 4 115 3.36% 
rpsM 357 13 119 66.7% 119 4 115 3.36% 
rplL 366 1 122 66.7% 122 7 115 5.74% 
rplN 372 10 132 64.5% 124 6 118 4.84% 
rpsL 375 9 131 65.1% 125 3 122 2.40% 
rplQ 384 4 138 64.1% 128 5 123 3.91% 
rpsK 390 8 130 66.7% 130 5 125 3.85% 
rpsH 393 13 135 65.6% 131 8 123 6.11% 
rpsI 393 8 140 64.4% 131 6 125 4.58% 
rplP 411 7 137 66.7% 137 9 128 6.57% 
rplM 429 7 134 68.8% 143 10 133 6.99% 
rplO 435 5 152 65.1% 145 7 138 4.83% 
rplJ 498 11 176 64.7% 166 7 159 4.22% 
rpsE 504 15 169 66.5% 168 9 159 5.36% 
rplF 534 12 182 65.9% 178 5 173 2.81% 
rplE 540 14 186 65.6% 180 8 172 4.44% 
rpsG 540 14 192 64.4% 180 8 172 4.44% 
rplD 606 11 210 65.3% 202 10 192 4.95% 
rpsD 621 12 224 63.9% 207 6 201 2.90% 
rplC 630 14 216 65.7% 210 8 202 3.81% 
rpsC 702 9 237 66.2% 234 11 223 4.70% 
rpsB 726 12 250 65.6% 242 14 228 5.79% 
rplB 822 13 284 65.5% 274 10 264 3.65% 
prfB 1098 46 388 64.7% 366 17 349 4.64% 
rpsA 1674 34 583 65.2% 558 17 541 3.05% 
Total 18759 405 6496 65.4% 6253 269 5984 4.44% 
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Table S6-2. Genes with forbidden codons successfully removed after each phase of recoding 
Gene Operon location
a
 Kan
R
 only
b 
Full cassettes
c
 Partial cassettes
d
 CoS-MAGE 
rpmH Start   
  
  
rpmD Middle     
 
  
rpmC Middle     
 
  
rpsR Middle   
 
5/6   
rpmB Complex     
 
  
rpsP Start   
 
0/1   
rpsQ End     
 
  
rpmA End     
 
  
rpsS Middle     
 
  
rpsN Middle     
 
  
rplU Start     
 
  
rpsJ Start     
 
  
rplX Middle     
 
  
rplW Middle     
 
  
rplV Middle     
 
  
rplS End     
 
  
rplR Middle     
 
  
rplT Complex   
  
  
rpsM Start     
 
  
rplL Complex   
 
0/1   
rplN Start     
 
  
rpsL Start   
 
6/9   
rplQ End   
   
rpsK Middle     
 
  
rpsI End 
 
  
 
  
rpsH Middle     
 
  
rplM Start     
 
  
rplP Middle     
 
  
rplO Middle Not observed 
  
  
rplJ Complex   
   
rpsE Middle     
 
  
rplF Middle     
 
  
rplE Middle     
 
  
rpsG Middle   
  
  
rplD Middle   
  
  
rpsD Middle    7/12   
rplC Middle     
 
  
rpsC Middle   
 
3/9   
rpsB Middle   
 
9/12   
rplB Middle   
  
  
prfB Complex   
   
rpsA Complex   
   a Start = first ORF in operon, Middle = flanked on both sides by other ORFs in same operon, End = last 
ORF in operon, Complex = multiple overlapping transcriptional units 
b Purple indicates successful insertion of kanR into the operon without recoding 
c Dark green indicates genes with all forbidden codons removed during that phase 
d Lime green indicates genes that had all forbidden codons removed in a previous phase; light green 
indicates genes with a subset of their forbidden codons removed (instances removed/total instances) by 
partially recoded cassettes 
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Table S6-3. Forbidden codons remaining after each phase of recoding 
Codon 
removed 
Natural 
assignment 
Instances in 
genome 
Instances in 
targeted 
essential genes 
Fully 
recoded 
cassettes
a 
Partially 
recoded 
cassettes
b 
CoS-
MAGE
c 
UAG STOP (RF1) 321 0 0 0 0 
AGA/AGG Arg 4,228 5 1 1 0 
CUU/CUC Leu 30,030 50 19 14 0* 
CCC Pro 7,401 3 1 1 0 
ACC Thr 31,766 133 53 37 0 
AUA Ile 5,797 1 0 0 0 
GUC Val 20,757 59 12 10 0 
GCC Ala 34,747 65 22 18 0 
UCC Ser 11,672 82 35 27 0 
CGG Arg 7,273 3 1 1 0 
UGA STOP (RF2) 1,232 4 2 2 0 
 
Total 
remaining 
155,224 405 146 111 0 
a Instances of each forbidden codon remaining after recombination with fully recoded cassettes 
b Instances of each forbidden codon remaining after recombination with partially recoded cassettes 
c Instances of each forbidden codon remaining after CoS-MAGE 
*Original desired rplQ U162G (CUUCUG) change was not observed, but this was overcome using 
diversity (see Table S6-7) 
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Table S6-4. Gene replacement strain summary 
and doubling times 
NAT_Kan
R
 LB
L
 
doubling time 
(min)
c 
NAT_Ka
n
R
 Azure 
doubling 
time 
(min)
c
 
SYN_Kan
R
 LB
L
 
doubling time 
(min)
d,e 
SYN_Kan
R
 
Azure 
doubling 
time 
(min)
d,e 
Strain 
name
a
 
Gene 
Switch
-over 
index
b 
Forbid
den 
codons 
remov
ed 
Uninten
ded 
mismatc
hes 
Uninten
ded 
deletions 
Total 
mutatio
ns 
Rep1 Rep2 Rep3 
Re
p1 
Re
p2 
Re
p3 
Rep1 Rep2 Rep3 
Re
p1 
Re
p2 
Re
p3 
rpmH_c
him1 
rpmH 69 1 0 0 17 56 60 59 93 102 104 52 52 48 80 77 77 
rpmD_s
yn1 
rpmD 0 4 0 0 59 75 77 76 111 122 130 55 57 46 113 117 116 
rpmD_s
yn2 
rpmD 0 4 0 0 59 75 77 76 111 122 130 89 94 91 169 175 171 
rpmC_s
yn1 
rpmC 0 2 0 0 71 55 56 55 105 102 83 108 104 102 128 110 117 
rpsR_ch
im1 
rpsR 90 5 0 0 54 49 50 52 91 90 79 78 61 61 95 78 92 
rpmB_s
yn1 
rpmB 0 7 2 0 84 51 49 51 106 87 85 58 59 63 137 131 137 
rpsP_ch
im1 
rpsP 92 0 0 0 54 49 49 50 105 79 83 54 53 61 104 115 104 
rpsQ_sy
n1 
rpsQ 0 5 0 0 88 61 60 55 103 98 69 70 68 65 102 97 93 
rpmA_s
yn1 
rpmA 0 3 1 0 91 47 48 47 80 78 79 66 66 74 85 93 90 
rpsS_sy
n1 
rpsS 0 6 1 0 96 51 51 53 100 105 97 64 57 63 123 97 99 
rpsS_sy
n2 
rpsS 0 6 0 0 96 51 51 53 100 105 97 49 50 50 80 79 76 
rplW_sy
n1 
rplW 0 10 2 0 102 42 54 52 114 110 109 67 69 61 113 111 124 
rpsN_sy
n1 
rpsN 0 6 3 0 107 52 52 53 86 92 84 68 69 69 69 91 89 
rplU_sy
n1 
rplU 0 3 0 0 105 49 49 49 85 89 65 74 74 74 140 129 138 
rpsJ_sy
n1 
rpsJ 0 10 1 0 105 54 55 55 77 81 73 59 61 63 82 113 107 
rplX_sy
n1 
rplX 0 10 0 0 111 91 93 88 121 117 113 57 55 53 105 87 83 
rplV_sy
n1 
rplV 0 8 0 0 119 52 53 52 97 101 90 90 69 61 119 107 119 
rplS_sy
n1 
rplS 0 8 2 0 127 48 50 51 97 87 84 57 58 56 105 120 90 
rplR_sy
n1 
rplR 0 10 3 0 125 51 50 50 57 80 75 54 53 47 87 96 79 
rplT_chi
m1 
rplT 92 3 1 0 96 61 56 56 104 96 96 69 67 66 98 94 88 
rpsM_s
yn1 
rpsM 0 13 1 1 119 56 57 59 92 88 81 69 62 62 95 85 104 
rplL_chi
m1 
rplL 90 1 0 0 94 63 63 61 92 110 106 54 56 51 90 88 68 
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Table S6-4 (Continued). 
rplN_sy
n1 
rplN 0 10 2 0 132 61 63 53 60 77 61 49 51 48 92 70 90 
rpsL_ch
im1 
rpsL 186 6 1 1 65 56 54 57 71 83 80 75 78 77 103 101 95 
rpsK_sy
n1 
rpsK 0 8 0 0 130 54 52 54 79 87 93 95 79 83 107 111 95 
rpsI_syn
1 
rpsI 0 8 1 0 141 51 51 42 92 90 85 95 97 90 104 107 124 
rpsH_sy
n1 
rpsH 0 13 0 0 135 53 55 50 101 77 78 64 63 58 97 86 99 
rplP_sy
n1 
rplP 0 7 1 0 137 58 59 54 93 92 110 164 116 106 158 112 158 
rplP_sy
n2 
rplP 0 7 0 0 137 58 59 54 93 92 110 67 65 61 134 136 138 
rplM_sy
n1 
rplM 0 7 1 0 135 58 59 52 95 98 83 110 94 95 141 149 134 
rpsE_sy
n1 
rpsE 0 15 0 0 169 58 62 50 111 134 95 51 54 51 108 105 102 
rplF_sy
n1 
rplF 0 12 1 0 183 71 75 57 139 134 153 60 84 72 105 110 89 
rplE_sy
n1 
rplE 0 14 0 0 186 60 65 46 123 142 125 47 59 54 101 81 89 
rpsD_ch
im1 
rpsD 90 7 0 0 190 70 72 67 98 77 93 74 72 66 119 120 130 
rplC_sy
n1 
rplC 0 14 1 0 216 58 61 58 104 88 83 73 77 97 151 127 127 
rpsC_ch
im1 
rpsC 351 3 0 1 118 57 58 54 93 82 105 60 58 57 129 109 164 
rpsB_ch
im1 
rpsB 90 9 2 0 225 50 45 45 93 87 92 46 53 48 90 79 69 
prfB_sy
n1 
prfB 0 46 1 0 389 55 57 55 86 91 75 56 60 49 110 97 82 
  
Total: 294 26 3 4375 
   
   
   
   
a Strains are named for their recoded genes; “syn” indicates fully recoded; “chim” indicates partially 
recoded; the original “syn” strains rpmD_syn1, rpsS_syn1, and rplP_syn1 gained forbidden codons, so an 
additional clone was generated and characterized for each gene (rpmD_syn2, rpsS_syn2, and rplP_syn2). 
Although the original rpmD_syn1, rpsS_syn1, and rplP_syn1 strains are still reported in gray letters, their 
forbidden codons removed, unintended mismatches, and unintended deletions were not included in the 
totals at the bottom of the table. 
b Beginning of radically recoded portion in partially recoded genes 
c NAT_KanR indicates that a kanR gene was inserted without recoding the target gene 
d SYN_KanR indicates that the target gene was radically recoded 
e
 Some doubling times appear to decrease across subsequent replicates, possibly indicating that 
spontaneous mutagenesis improves fitness. We note that each strain was passaged at least twice 
prior to sequence verification. 
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Table S6-5. CoS-MAGE strain summary and doubling times 
 
   
NAT_Kan
R
 LB
L
 
doubling time 
(min)
c 
NAT_Kan
R
 Azure 
doubling time 
(min)
c
 
CoS-MAGE LB
L
 
doubling time 
(min) 
CoS-MAGE 
Azure 
doubling time 
(min) 
Strain 
name
a Gene 
Alleles 
targeted 
Alleles 
converted
b
 
Rep1
 
Rep2 Rep3 Rep1
 
Rep2 Rep3 Rep1 Rep2 Rep3 
Rep
1 
Rep
2 
Rep
3 
rpsR_Co
S1  
rpsR 1 1 49 50 52 91 90 79 
50 50 51 58 72 56 rpsP 1 1 49 49 50 105 79 83 
rpsB 3 3 50 45 45 93 87 92 
rpsR_Co
S2  
rpsR 1 1 49 50 52 91 90 79 
50 50 53 60 72 61 rplL 1 1 63 63 61 92 110 106 
rpsB 3 3 50 45 45 93 87 92 
rpsL_Co
S1 
rpsL 3 3 56 54 57 71 83 80 49 49 49 44 64 62 
rplQ_Co
S1 
rplQ 4 1 64 66 66 113 109 100 54 50 50 110 90 79 
rplQ_Co
S2 
rplQ 4 1 64 66 66 113 109 100 53 49 50 62 92 74 
rplQ_Co
S3 
rplQ 4 1 64 66 66 113 109 100 49 49 48 80 72 78 
rplQ_Co
S4 
rplQ 4 1 64 66 66 113 109 100 50 50 47 65 80 68 
rplQ_Co
S5 
rplQ 4 1 64 66 66 113 109 100 48 48 48 85 85 71 
rplQ_Co
S6 
rplQ 4 1 64 66 66 113 109 100 49 48 48 75 72 86 
rplQ_Co
S7 
rplQ 4 1 64 66 66 113 109 100 51 50 48 87 74 65 
rplQ_Co
S8 
rplQ 4 1 64 66 66 113 109 100 48 49 48 76 92 92 
rplQ_Co
S9 
rplQ 4 1 64 66 66 113 109 100 50 49 48 69 76 92 
rplQ_Co
S10 
rplQ 4 1 64 66 66 113 109 100 53 52 52 106 95 96 
rplQ_Co
S11 
rplQ 4 1 64 66 66 113 109 100 53 49 50 78 74 40 
rplQ_Co
S12 
rplQ 4 1 64 66 66 113 109 100 
49  54  53  80 116 114 
rpsC 6 2 57 58 54 93 82 105 
rplO_Co
S1 
rplO 5 2 nr nr nr nr nr nr 46 51 49 101 91 100 
rplO_Co
S2 
rplO 5 2 nr nr nr nr nr nr 48 51 50 72 66 72 
rplO_Co
S3 
rplO 5 1 nr nr nr nr nr nr 48 54 51 70 65 72 
rplJ_CoS
1 
rplJ 11 3 51 51 49 114 87 90 48 49 49 67 58 49 
rplJ_CoS
2 
rplJ 11 3 51 51 49 114 87 90 60 57 56 84 59 56 
rplJ_CoS
3 
rplJ 11 3 51 51 49 114 87 90 53 51 52 89 102 87 
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Table S6-5 (Continued). 
rplJ_CoS
4 
rplJ 11 3 51 51 49 114 87 90 52 51 52 83 68 62 
rplJ_CoS
5 
rplJ 11 2 51 51 49 114 87 90 55 51 53 88 78 68 
rplJ_CoS
6 
rplJ 11 2 51 51 49 114 87 90 51 48 49 70 78 68 
rplJ_CoS
7 
rplJ 11 1 51 51 49 114 87 90 
49  51  54  93 88 99 
rpsA 34 1 48 50 44 93 95 100 
rpsG_Co
S1 
rpsG 14 10 49 50 44 84 83 84 51 53 52 61 79 97 
rpsG_Co
S2 
rpsG 14 7 49 50 44 84 83 84 51 53 53 76 82 63 
rpsG_Co
S3 
rpsG 14 7 49 50 44 84 83 84 48 53 52 86 106 72 
rpsD_Co
S1 
rpsD 5 3 70 72 67 98 77 93 52 55 56 98 100 99 
rpsD_Co
S2 
rpsD 5 3 70 72 67 98 77 93 56 51 51 84 94 85 
rplD_Co
S1 
rplD 11 2 52 53 54 104 108 105 51 50 52 97 77 60 
rplD_Co
S2 
rplD 11 4 52 53 54 104 108 105 49 53 49 86 92 90 
rplD_Co
S3 
rplD 11 7 52 53 54 104 108 105 48 52 51 51 78 73 
rplD_Co
S4 
rplD 11 1 52 53 54 104 108 105 
49 48 49  55 83 86 
rpsA 34 1 48 50 44 93 95 100 
rpsC_Co
S1 
rpsC 6 4 57 58 54 93 82 105 52 52 49 102 85 70 
rpsC_Co
S2 
rpsC 6 4 57 58 54 93 82 105 50 54 54 62 56 57 
rplB_Co
S1 
rplB 13 3 50 53 45 88 75 87 50 54 54 73 58 59 
rplB_Co
S2 
rplB 13 1 50 53 45 88 75 87 61 63 63 84 95 93 
rplB_Co
S3 
rplB 13 4 50 53 45 88 75 87 50 56 50 71 77 65 
rplB_Co
S4 
rplB 13 7 50 53 45 88 75 87 50 54 51 76 50 68 
rpsA_Co
S1 
rpsA 34 19 48 50 44 93 95 100 45 50 43 76 53 61 
rpsA_Co
S2 
rpsA 34 7 48 50 44 93 95 100 47 50 44 90 79 91 
rpsA_Co
S3 
rpsA 34 12 48 50 44 93 95 100 47 51 44 103 84 77 
rpsA_Co
S4 
rpsA 34 16 48 50 44 93 95 100 46 51 43 89 85 89 
rpsA_Co
S5 
rpsA 34 15 48 50 44 93 95 100 45 49 45 88 90 89 
a
 45 total CoS-MAGE strains 
b
 187 total forbidden codons (111 unique positions) removed across 45 CoS-MAGE strains 
c
 nr indicates that no recombinants were observed  
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Table S6-6. Oligos used to replace rplQ CUU 160-162 
Oligo Sequence 
rplQ_CTT162YTR* g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttggcYARagtaatcagcggctcaactacgcggcgcagctctttcgct 
rplQ_CTT162ATY* g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttggcRATagtaatcagcggctcaactacgcggcgcagctctttcgct 
rplQ_CTT162GTD* g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttggcHACagtaatcagcggctcaactacgcggcgcagctctttcgct 
rplQ_CTT162GCD* g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttggcHGCagtaatcagcggctcaactacgcggcgcagctctttcgct 
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Table S6-7. Successful rplQ CUU 160-162 replacements 
Amino acid Codon Codon count 
Leu (unchanged) CUU 57 
Leu (synonymous) 
CUA 4 
CUG 0 
UUA 4 
UUG 0 
Ile 
AUC 5 
AUU 6 
Val 
GUU 8 
GUA 5 
GUG 0 
Ala 
GCU 2 
GCA 2 
GCG 3 
 
Total 96 
 
Codons are color-coded for each amino acid. CUG, UUG, and GUG codons (red) were never 
observed to replace CUU at positions 160-162. 
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Table S6-8. Primers and oligonucleotides used in this study. 
Oligo name Purpose Oligo sequence 
gfp-rpmH 
forward gene primer for generating rpmH 
recoded cassette 
ggatatccaataaagccattga 
gfp-rpmD 
forward gene primer for generating rpmD 
recoded cassette 
tcgctgccaagcgtggtaa 
gfp-rpmC 
forward gene primer for generating rpmC 
recoded cassette 
gcagcgaaactgccga 
gfp-rpsR 
forward gene primer for generating rpsR 
recoded cassette 
ggttttgcatgccgagcag 
gfp-rpmB 
forward gene primer for generating rpmB 
recoded cassette 
gccaataccccatacgaag 
gfp-rpsP 
forward gene primer for generating rpsP 
recoded cassette 
actccgttcctcgatgg 
gfp-rpsQ 
forward gene primer for generating rpsQ 
recoded cassette 
cgcgatgtcgcacgcg 
gfp-rpmA 
forward gene primer for generating rpmA 
recoded cassette 
gatgtgaaaattactggcatca 
gfp-rpsS 
forward gene primer for generating rpsS 
recoded cassette 
tgataaattcatcgtacgtcgcc 
gfp-rpsN 
forward gene primer for generating rpsN 
recoded cassette 
ctgctggctgcctttg 
gfp-rplU 
forward gene primer for generating rplU 
recoded cassette 
atagcgcactctgaatcattgaaaa 
gfp-rpsJ 
forward gene primer for generating rpsJ 
recoded cassette 
gtctgaggagtaatcattttcgtt 
gfp-rplX 
forward gene primer for generating rplX 
recoded cassette 
gttcatgaaaattatctctctggc 
gfp-rplW 
forward gene primer for generating rplW 
recoded cassette 
acaaagtcgtaatgactgctg 
gfp-rplV 
forward gene primer for generating rplV 
recoded cassette 
ggccacgctgctgataaa 
gfp-rplS 
forward gene primer for generating rplS 
recoded cassette 
atggcgtaagcccccg 
gfp-rplR 
forward gene primer for generating rplR 
recoded cassette 
ccgacgaagtcgtgcgta 
gfp-rplT 
forward gene primer for generating rplT 
recoded cassette 
cgttaacgtttttaactttttaattagaatataga 
gfp-rpsM 
forward gene primer for generating rpsM 
recoded cassette 
aaacgggcttttcagca 
gfp-rplL 
forward gene primer for generating rplL 
recoded cassette 
aacgcattcgcttacgtataaa 
gfp-rplN 
forward gene primer for generating rplN 
recoded cassette 
cgacctgattttcgggtctc 
gfp-rpsL 
forward gene primer for generating rpsL 
recoded cassette 
acgttttattacgtgtttacgaag 
gfp-rplQ 
forward gene primer for generating rplQ 
recoded cassette 
tgacgagtaaccggatcac 
gfp-rpsK 
forward gene primer for generating rpsK 
recoded cassette 
ccgtaagggtccgcgc 
gfp-rpsI 
forward gene primer for generating rpsI 
recoded cassette 
acgcggcacagcaacc 
gfp-rpsH 
forward gene primer for generating rpsH 
recoded cassette 
aaaaggctagctggtaattgt 
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Table S6-8 (Continued). 
gfp-rplM 
forward gene primer for generating rplM 
recoded cassette 
agacgtttgggtgttca 
gfp-rplP 
forward gene primer for generating rplP 
recoded cassette 
ctcagcctaaaaagcagca 
gfp-rplO 
forward gene primer for generating rplO 
recoded cassette 
gcggtatgatcaacgcgg 
gfp-rplJ 
forward gene primer for generating rplJ 
recoded cassette 
tgaagtgagttccagagatttt 
gfp-rpsE 
forward gene primer for generating rpsE 
recoded cassette 
gcagatgctgcccgtg 
gfp-rplF 
forward gene primer for generating rplF 
recoded cassette 
ctggtcttggtggcgaa 
gfp-rplE 
forward gene primer for generating rplE 
recoded cassette 
cgtttcttcaagtctaacagcg 
gfp-rpsG 
forward gene primer for generating rpsG 
recoded cassette 
ctaaactcgtagagttttggacaa 
gfp-rpsD 
forward gene primer for generating rpsD 
recoded cassette 
aaaaacgtcgcgtataacgcc 
gfp-rplD 
forward gene primer for generating rplD 
recoded cassette 
cggtagcgacctgatcgt 
gfp-rplC 
forward gene primer for generating rplC 
recoded cassette 
cagatcagcctgggtt 
gfp-rpsC 
forward gene primer for generating rpsC 
recoded cassette 
agccacatcactgtggttg 
gfp-rpsB 
forward gene primer for generating rpsB 
recoded cassette 
tatgggatacgtggaggca 
gfp-rplB 
forward gene primer for generating rplB 
recoded cassette 
cagaatctggacttcgttgg 
gfp-prfB 
forward gene primer for generating prfB 
recoded cassette 
tcccgctcttatcaccg 
gfp-rpsA 
forward gene primer for generating rpsA 
recoded cassette 
catccggcatggagcc 
grp-rpmH 
reverse gene primer for generating rpmH 
recoded cassette 
gacgtctttctagattattttgacacc 
grp-rpmD 
reverse gene primer for generating rpmD 
recoded cassette 
gacgtctttctagattattcttccac 
grp-rpmC 
reverse gene primer for generating rpmC 
recoded cassette 
gacgtctttctagattaagcg 
grp-rpsR 
reverse gene primer for generating rpsR 
recoded cassette 
gacgtctttctagattattggtga 
grp-rpmB 
reverse gene primer for generating rpmB 
recoded cassette 
gacgtctttctagattaatatttctcacc 
grp-rpsP 
reverse gene primer for generating rpsP 
recoded cassette 
gacgtctttctagattatgcag 
grp-rpsQ 
reverse gene primer for generating rpsQ 
recoded cassette 
gacgtctttctagattacaacaca 
grp-rpmA 
reverse gene primer for generating rpmA 
recoded cassette 
gacgtctttctagattactccg 
grp-rpsS 
reverse gene primer for generating rpsS 
recoded cassette 
gacgtctttctagattactttttttttg 
grp-rpsN 
reverse gene primer for generating rpsN 
recoded cassette 
gacgtctttctagattaccacga 
grp-rplU 
reverse gene primer for generating rplU 
recoded cassette 
gacgtctttctagattacgcc 
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Table S6-8 (Continued). 
grp-rpsJ 
reverse gene primer for generating rpsJ 
recoded cassette 
gacgtctttctagattagccca 
grp-rplX 
reverse gene primer for generating rplX 
recoded cassette 
gacgtctttctagattatttaatcgtttc 
grp-rplW 
reverse gene primer for generating rplW 
recoded cassette 
gacgtctttctagattattctgcac 
grp-rplV 
reverse gene primer for generating rplV 
recoded cassette 
gacgtctttctagattatcggtc 
grp-rplS 
reverse gene primer for generating rplS 
recoded cassette 
gacgtctttctagattaattcaggc 
grp-rplR 
reverse gene primer for generating rplR 
recoded cassette 
gacgtctttctagattaaaattgcag 
grp-rplT 
reverse gene primer for generating rplT 
recoded cassette 
gacgtctttctagattacgctaac 
grp-rpsM 
reverse gene primer for generating rpsM 
recoded cassette 
gacgtctttctagattactttttaataggc 
grp-rplL 
reverse gene primer for generating rplL 
recoded cassette 
gacgtctttctagattacttcacc 
grp-rplN 
reverse gene primer for generating rplN 
recoded cassette 
gacgtctttctagattataacacct 
grp-rpsL 
reverse gene primer for generating rpsL 
recoded cassette 
gacgtctttctagattacgcttt 
grp-rplQ 
reverse gene primer for generating rplQ 
recoded cassette 
gacgtctttctagattattcagcc 
grp-rpsK 
reverse gene primer for generating rpsK 
recoded cassette 
gacgtctttctagattacactcgg 
grp-rpsI 
reverse gene primer for generating rpsI 
recoded cassette 
gacgtctttctagattagcg 
grp-rpsH 
reverse gene primer for generating rpsH 
recoded cassette 
gacgtctttctagattacgcaac 
grp-rplM 
reverse gene primer for generating rplM 
recoded cassette 
gacgtctttctagattaaatatccag 
grp-rplP 
reverse gene primer for generating rplP 
recoded cassette 
gacgtctttctagattacataacag 
grp-rplO 
reverse gene primer for generating rplO 
recoded cassette 
gacgtctttctagattactcctca 
grp-rplJ 
reverse gene primer for generating rplJ 
recoded cassette 
gacgtctttctagattacgctg 
grp-rpsE 
reverse gene primer for generating rpsE 
recoded cassette 
gacgtctttctagattacttacct 
grp-rplF 
reverse gene primer for generating rplF 
recoded cassette 
gacgtctttctagattatttttttttcg 
grp-rplE 
reverse gene primer for generating rplE 
recoded cassette 
gacgtctttctagattatttacgaaatgg 
grp-rpsG 
reverse gene primer for generating rpsG 
recoded cassette 
gacgtctttctagattagttcagataa 
grp-rpsD 
reverse gene primer for generating rpsD 
recoded cassette 
gacgtctttctagattattttgaatac 
grp-rplD 
reverse gene primer for generating rplD 
recoded cassette 
gacgtctttctagattacgcc 
grp-rplC 
reverse gene primer for generating rplC 
recoded cassette 
gacgtctttctagattatgctttaac 
grp-rpsC 
reverse gene primer for generating rpsC 
recoded cassette 
gacgtctttctagattactttcgt 
322 
 
Table S6-8 (Continued). 
grp-rpsB 
reverse gene primer for generating rpsB 
recoded cassette 
gacgtctttctagattattccgc 
grp-rplB 
reverse gene primer for generating rplB 
recoded cassette 
gacgtctttctagattacttcgat 
grp-prfB 
reverse gene primer for generating prfB 
recoded cassette 
gacgtctttctagattataggc 
grp-rpsA 
reverse gene primer for generating rpsA 
recoded cassette 
tgacgtctttctagattattcacc 
kfp-rpmH 
forward kanR primer for generating rpmH 
recoded cassette 
gtgcgcgcttaacggtgtcaaaataatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpmD 
forward kanR primer for generating rpmD 
recoded cassette 
cgtttatggtgaaggtggaagaataatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpmC 
forward kanR primer for generating rpmC 
recoded cassette 
tgttgaatgaaaaagctggcgcttaatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rpsR 
forward kanR primer for generating rpsR 
recoded cassette 
taccttatacggaccgtcaccaataatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rpmB 
forward kanR primer for generating rpmB 
recoded cassette 
tacgcgcgcgcggtgagaaatattaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpsP 
forward kanR primer for generating rpsP 
recoded cassette 
ttaaggaggtgaataaggctgcataatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpsQ 
forward kanR primer for generating rpsQ 
recoded cassette 
gtgtggtggaaaaggctgtgttgtaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpmA 
forward kanR primer for generating rpmA 
recoded cassette 
agttcatttcgattgaggcggagtaatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rpsS 
forward kanR primer for generating rpsS 
recoded cassette 
cagacaagaaggcaaaaaaaaagtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rpsN 
forward kanR primer for generating rpsN 
recoded cassette 
caggcctaaagaaagcatcgtggtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rplU 
forward kanR primer for generating rplU 
recoded cassette 
taaagatcacaggtatttcggcgtaatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rpsJ 
forward kanR primer for generating rpsJ 
recoded cassette 
tggatgttcaaattagtttgggctaatctagaaagacgttgagttgtcgag
attttcagg 
kfp-rplX 
forward kanR primer for generating rplX 
recoded cassette 
aaagcaattcggaaacgattaaataatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rplW 
forward kanR primer for generating rplW 
recoded cassette 
tggattttgtaggaggtgcagaataatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rplV 
forward kanR primer for generating rplV 
recoded cassette 
ttacggttgtggtaagcgaccgataatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rplS 
forward kanR primer for generating rplS 
recoded cassette 
cgcgaattaaggaacgcctgaattaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rplR 
forward kanR primer for generating rplR 
recoded cassette 
cacgcgaggcgggactgcaattttaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rplT 
forward kanR primer for generating rplT 
recoded cassette 
agaaggctaaggctgcgttagcgtaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpsM 
forward kanR primer for generating rpsM 
recoded cassette 
gcccacgtaagcctattaaaaagtaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rplL 
forward kanR primer for generating rplL 
recoded cassette 
caggtgcagaggtagaggtgaagtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rplN 
forward kanR primer for generating rplN 
recoded cassette 
ttagcttggcgccggaggtgttataatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rpsL 
forward kanR primer for generating rpsL 
recoded cassette 
acggtgttaaacgaccgaaagcgtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rplQ 
forward kanR primer for generating rplQ 
recoded cassette 
aaaaggctgaggcagcggctgaataatctagaaagacgttgagttgtc
gagattttcagg 
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Table S6-8 (Continued). 
kfp-rpsK 
forward kanR primer for generating rpsK 
recoded cassette 
gccctccaaagaagcgccgagtgtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rpsI 
forward kanR primer for generating rpsI 
recoded cassette 
gccgacctcaatttagtaagcgctaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpsH 
forward kanR primer for generating rpsH 
recoded cassette 
gtgagatcatttgttatgttgcgtaatctagaaagacgttgagttgtcgag
attttcagg 
kfp-rplM 
forward kanR primer for generating rplM 
recoded cassette 
aacagcctcaggtgctggatatttaatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rplP 
forward kanR primer for generating rplP 
recoded cassette 
cattcgtgacgaaaactgttatgtaatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rplO 
forward kanR primer for generating rplO 
recoded cassette 
cggcgggtggcaagattgaggagtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rplJ 
forward kanR primer for generating rplJ 
recoded cassette 
tgcgtgacgctaaggaggcagcgtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rpsE 
forward kanR primer for generating rpsE 
recoded cassette 
gcgtggaggagatcctaggtaagtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rplF 
forward kanR primer for generating rplF 
recoded cassette 
gcactaaggaagcgaaaaaaaaataatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rplE 
forward kanR primer for generating rplE 
recoded cassette 
cgttcgattttccatttcgtaaataatctagaaagacgttgagttgtcgag
attttcagg 
kfp-rpsG 
forward kanR primer for generating rpsG 
recoded cassette 
aaccggcgttaggttatctgaactaatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rpsD 
forward kanR primer for generating rpsD 
recoded cassette 
taattgtggaattgtattcaaaataatctagaaagacgttgagttgtcgag
attttcagg 
kfp-rplD 
forward kanR primer for generating rplD 
recoded cassette 
aacaggtagaagaaatgttggcgtaatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rplC 
forward kanR primer for generating rplC 
recoded cassette 
ttgtgaagccggcggttaaagcataatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpsC 
forward kanR primer for generating rpsC 
recoded cassette 
aacaacaacgcaagggacgaaagtaatctagaaagacgttgagttgtc
gagattttcagg 
kfp-rpsB 
forward kanR primer for generating rpsB 
recoded cassette 
aggagtcttttgttgaggcggaataatctagaaagacgttgagttgtcga
gattttcagg 
kfp-rplB 
forward kanR primer for generating rplB 
recoded cassette 
ttattgtgcgccgtcgatcgaagtaatctagaaagacgttgagttgtcga
gattttcagg 
kfp-prfB 
forward kanR primer for generating prfB 
recoded cassette 
aggcgtctttaaaggcgggcctataatctagaaagacgttgagttgtcg
agattttcagg 
kfp-rpsA 
forward kanR primer for generating rpsA 
recoded cassette 
atttaaggcggcgaagggtgaataatctagaaagacgtctgagttgtcg
agattttcagg 
krp-rpmH 
reverse kanR primer for generating rpmH 
recoded cassettes and NAT_kan
R
 
agcgtaactccctgggaaatgcgagcttaaccactcaggggttagcttt
attagaaaaactcatcgagcatc 
krp-rpmD 
reverse kanR primer for generating rpmD 
recoded cassettes and NAT_kan
R
 
cccgcctttttggagccttcggccggagacagagtatttaaacgcatct
cttagaaaaactcatcgagcatc 
krp-rpmC 
reverse kanR primer for generating rpmC 
recoded cassettes and NAT_kan
R
 
cattttgtcgctaacaacgcgaccttgcagagtacggattttatcggtcat
tacgcacccgccttcttagaaaaactcatcgagcatc 
krp-rpsR 
reverse kanR primer for generating rpsR 
recoded cassettes and NAT_kan
R
 
aacttgcattaccttatcctctcaaagtcgtattaatggaccgtgaccgat
tagaaaaactcatcgagcatc 
krp-rpmB 
reverse kanR primer for generating rpmB 
recoded cassettes and NAT_kan
R
 
cttgattttctcacgaatacctttagccatgatttatttcctctaagtacttag
aaaaactcatcgagcatc 
krp-rpsP 
reverse kanR primer for generating rpsP 
recoded cassettes and NAT_kan
R
 
acaggtgcttgcgcggtgagttgtttgctcatcatgaccaccgtgacag
attagaaaaactcatcgagcatc 
krp-rpsQ 
reverse kanR primer for generating rpsQ 
recoded cassettes and NAT_kan
R
 
taaacggctcatttctgagccgtttattcgtattgagagagtgtactgtatt
agaaaaactcatcgagcatc 
krp-rpmA 
reverse kanR primer for generating rpmA 
recoded cassettes and NAT_kan
R
 
gccccgcaacgtgttgcggggctttcatccgttaccgggacgcgaaaa
acttagaaaaactcatcgagcatc 
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Table S6-8 (Continued). 
krp-rpsS 
reverse kanR primer for generating rpsS 
recoded cassettes and NAT_kan
R
 
agaacgagcatggcgatgtttagcgatagtttccatctcttcctcctacct
tagaaaaactcatcgagcatc 
krp-rpsN 
reverse kanR primer for generating rpsN 
recoded cassettes and NAT_kan
R
 
ggatcttgcatgctcatctgtctttactcccgtgattcaattggtgacaatt
agaaaaactcatcgagcatc 
krp-rplU 
reverse kanR primer for generating rplU 
recoded cassettes and NAT_kan
R
 
tgtggagccgccagcctttttatgtgccatttgaaatctctcctcaggtctt
agaaaaactcatcgagcatc 
krp-rpsJ 
reverse kanR primer for generating rpsJ 
recoded cassettes and NAT_kan
R
 
accgactaaaccaatcattgtttcaacctctcaatcgctcaatgacctgat
tagaaaaactcatcgagcatc 
krp-rplX 
reverse kanR primer for generating rplX 
recoded cassettes and NAT_kan
R
 
tacttcgtctttgtagtaatcatgcagtttcgccatcgtactactccaaatta
gaaaaactcatcgagcatc 
krp-rplW 
reverse kanR primer for generating rplW 
recoded cassettes and NAT_kan
R
 
cggagatgtcggtttacatttaacaactgccattgtattactcctccgactt
agaaaaactcatcgagcatc 
krp-rplV 
reverse kanR primer for generating rplV 
recoded cassettes and NAT_kan
R
 
gcgaataccattaggatgtactttctgacccattgctagtctccagagtct
tagaaaaactcatcgagcatc 
krp-rplS 
reverse kanR primer for generating rplS 
recoded cassettes and NAT_kan
R
 
gccagccaattggccagcccttcttaacaggatgtcgcttaagcgaaat
cttagaaaaactcatcgagcatc 
krp-rplR 
reverse kanR primer for generating rplR 
recoded cassettes and NAT_kan
R
 
ctgcagttcgccagcttgtttttcgatgtgagccatcttacacctctacctt
agaaaaactcatcgagcatc 
krp-rplT 
reverse kanR primer for generating rplT 
recoded cassettes and NAT_kan
R
 
tgatggcgttgaaacgaaaagagggagactagctccctctttcaactg
gcttagaaaaactcatcgagcatc 
krp-rpsM 
reverse kanR primer for generating rpsM 
recoded cassettes and NAT_kan
R
 
cacgtttacgtgcacgaattggtgcctttgccattattcaatcaccccgat
tagaaaaactcatcgagcatc 
krp-rplL 
reverse kanR primer for generating rplL 
recoded cassettes and NAT_kan
R
 
agtcaccagccatcagcctgatttctcaggctgcaaccggaagggttg
gcttagaaaaactcatcgagcatc 
krp-rplN 
reverse kanR primer for generating rplN 
recoded cassettes and NAT_kan
R
 
acacgataacttcgtcatcacgacggattttcgctgccatgattcgctcct
tagaaaaactcatcgagcatc 
krp-rpsL 
reverse kanR primer for generating rpsL 
recoded cassettes and NAT_kan
R
 
ttagtttgacatttaagttaaaacgtttggccttacttaacggagaaccatt
agaaaaactcatcgagcatc 
krp-rplQ 
reverse kanR primer for generating rplQ 
recoded cassettes and NAT_kan
R
 
tacgggtataaaaaaacccgccggggcgggtttttttacgttgcttcaga
ttagaaaaactcatcgagcatc 
krp-rpsK 
reverse kanR primer for generating rpsK 
recoded cassettes and NAT_kan
R
 
cccaaatatcttgccattttctttctccaacaaacctggaaaacgaggcgt
tagaaaaactcatcgagcatc 
krp-rpsI 
reverse kanR primer for generating rpsI 
recoded cassettes and NAT_kan
R
 
cgccgaagcgggttttttcgaaaattgttttctgccggagcagaagcca
attagaaaaactcatcgagcatc 
krp-rpsH 
reverse kanR primer for generating rpsH 
recoded cassettes and NAT_kan
R
 
gcaggaacaacgaccggtgctttagcaacacgagacattttttcctccg
attagaaaaactcatcgagcatc 
krp-rplM 
reverse kanR primer for generating rplM 
recoded cassettes and NAT_kan
R
 
cggcgaccagtgccgtagtattgattttcagccattgcctataatcccga
ttagaaaaactcatcgagcatc 
krp-rplP 
reverse kanR primer for generating rplP 
recoded cassettes and NAT_kan
R
 
ctcggtgttcagctcttcaacgctcttctcacgcagctcttttgctttcatta
catcaccgtcttattagaaaaactcatcgagcatc 
krp-rplO 
reverse kanR primer for generating rplO 
recoded cassettes and NAT_kan
R
 
cacctttggcactttgaaaatctaatcccggttgtttagccatctgctactt
agaaaaactcatcgagcatc 
krp-rplJ 
reverse kanR primer for generating rplJ 
recoded cassettes and NAT_kan
R
 
tatcagaataagtttatacgtaagcgaatgcgttaaaaagataactgcga
ttagaaaaactcatcgagcatc 
krp-rpsE 
reverse kanR primer for generating rpsE 
recoded cassettes and NAT_kan
R
 
cgaccgattgcactgcgggtttgagtaattttaatagtctttgccatggttt
agaaaaactcatcgagcatc 
krp-rplF 
reverse kanR primer for generating rplF 
recoded cassettes and NAT_kan
R
 
gcgcgggtcgcacgacggatacgagcagatttcttatccatagtgttac
cttagaaaaactcatcgagcatc 
krp-rplE 
reverse kanR primer for generating rplE 
recoded cassettes and NAT_kan
R
 
ttttacttcgcgtgctttcattgattgcttagccatttagtaaccctaccttag
aaaaactcatcgagcatc 
krp-rpsG 
reverse kanR primer for generating rpsG 
recoded cassettes and NAT_kan
R
 
gcgatgggtgttgtacgagccatttgtttcctcgtttatcttttaggcgttta
gaaaaactcatcgagcatc 
krp-rpsD 
reverse kanR primer for generating rpsD 
recoded cassettes and NAT_kan
R
 
gaaactctgtcacagaaccctgcattgtgtcctctctttggtactaagcttt
agaaaaactcatcgagcatc 
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Table S6-8 (Continued). 
krp-rplD 
reverse kanR primer for generating rplD 
recoded cassettes and NAT_kan
R
 
tcagaaacgtgcggtgcacgcagcaccttcagcagacgttcttcacga
atcatgccagcatctcctcattagaaaaactcatcgagcatc 
krp-rplC 
reverse kanR primer for generating rplC 
recoded cassettes and NAT_kan
R
 
cagtcagcgcgctctgcgcgtctttcaatactaattccattgctatctcctt
agaaaaactcatcgagcatc 
krp-rpsC 
reverse kanR primer for generating rpsC 
recoded cassettes and NAT_kan
R
 
tgcattttacggaattttgtacgctttggttgtaacatcagcgacgctcctt
agaaaaactcatcgagcatc 
krp-rpsB 
reverse kanR primer for generating rpsB 
recoded cassettes and NAT_kan
R
 
ttgccgcctttctgcaactcgaactattttgggggagttatcaagccttatt
agaaaaactcatcgagcatc 
krp-rplB 
reverse kanR primer for generating rplB 
recoded cassettes and NAT_kan
R
 
caataaaaggacctttcttgagagaacgtggcatggcttatcctctaaaa
ttagaaaaactcatcgagcatc 
krp-prfB 
reverse kanR primer for generating prfB 
recoded cassettes and NAT_kan
R
 
tcgactaccgcgtcagcgccctgtgcgtgttgttcagacatgttggttcc
ttagaaaaactcatcgagcatc 
krp-rpsA 
reverse kanR primer for generating rpsA 
recoded cassettes and NAT_kan
R
 
tcaagtaaactcaacaaacttcggaataaaaatcccgaagagtcagag
aattagaaaaactcatcgagcatc 
prfB-1r 
prfB split synthesis N-terminus reverse 
primer 
cacccgaaatcttaatagtaacgct 
prfB-2f 
prfB split synthesis C-terminus forward 
primer 
gacggagattattgaggaatctgag 
rpsA-1r 
rpsA split synthesis N-terminus reverse 
primer 
gtaacacgccctgttaacttcg 
rpsA-2f 
rpsA split synthesis C-terminus forward 
primer 
gcaattgcgaagcgctac 
rpmH-early 
C-terminal cassette forward primer for 
rpmH; All but 90 bp is recoded 
gttctcacggcttccgtgctcgtatggctactaaaaatggtcgtcaggttt
tggcgcgccgccgc 
rpsR-early 
C-terminal cassette forward primer for 
rpsR; All but 90 bp is recoded 
ccgcggaaggcgttcaagagatcgactataaagatatcgctacgctga
aaaattatattacggagtctggcaaaa 
rpsP-early 
C-terminal cassette forward primer for 
rpsP; All but 90 bp is recoded 
gtccgttctaccaggttgttgtcgctgacagccgtaatgcacgcaacgg
tcgttttattgaacgtgtgggc 
rplT-early 
C-terminal cassette forward primer for 
rplT; All but 90 bp is recoded 
acaagaaaattttgaaacaagctaaaggctactacggtgcgcgttctcg
cgtgtatcgtgtagcttttcaagc 
rplL-early 
C-terminal cassette forward primer for 
rplL; All but 90 bp is recoded 
ctatgtctgtaatggacgttgtagaactgatctctgcaatggaagaaaaa
tttggcgtatcagcagcg 
rpsL-early 
C-terminal cassette forward primer for 
rpsL; All but 90 bp is recoded 
gcaaagttgcgaaaagcaacgtgcctgcgctggaagcatgcccgcaa
aaacgcggggtttgcacg 
rplQ-early 
C-terminal cassette forward primer for 
rplQ; All but 90 bp is recoded 
gcagccatcgccaggctatgttccgcaatatggcaggttcactggttcg
tcacgagattattaaaactacattaccga 
rplO-early 
C-terminal cassette forward primer for 
rplO; All but 90 bp is recoded 
aggcgggtaaacgcctgggtcgtggtatcggttctggcctcggtaaaa
ccggcggacgcggccat 
rplJ-early 
C-terminal cassette forward primer for 
rplJ; All but 90 bp is recoded 
aagtcagcgaagtagccaaaggcgcgctgtctgcagtagttgcggatt
cccgcggtgtgacagtgg 
rpsG-early 
C-terminal cassette forward primer for 
rpsG; All but 90 bp is recoded 
cggatccgaagttcggatcagaactgctggctaaatttgtaaatatcctg
atggtggacgggaaaaaga 
rpsD-early 
C-terminal cassette forward primer for 
rpsD; All but 90 bp is recoded 
gtgagggcaccgacttattccttaagtctggcgttcgcgcgatcgatac
caaatgcaagatcgagcaggc 
rplD-early 
C-terminal cassette forward primer for 
rplD; All but 90 bp is recoded 
tttccgaaactaccttcggtcgtgatttcaacgaagcgctggttcaccag
gtagtggtggcgtacgc 
rpsC-early 
C-terminal cassette forward primer for 
rpsC; All but 90 bp is recoded 
ttgtaaaaccatggaactctacctggtttgcgaacaccaaagaattcgct
gataatttagatagtgacttcaaggttcg 
rpsB-early 
C-terminal cassette forward primer for 
rpsB; All but 90 bp is recoded 
ttcacttcggtcaccagacccgttactggaacccgaaaatgaagccgtt
catttttggcgcacgcaa 
rplB-early 
C-terminal cassette forward primer for 
rplB; All but 90 bp is recoded 
gccacgtagttaaagtggttaaccctgagctgcacaagggcaaaccttt
tgcgccattattagagaagaattct 
rpsA-early 
C-terminal cassette forward primer for 
rpsA; All but 90 bp is recoded 
aagaaatcgaaacccgcccgggttctatcgttcgtggcgttgttgttgct
attgataaggatgttgtgttggtg 
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Table S6-8 (Continued). 
rpmH-middle 
C-terminal cassette forward primer for 
rpmH; Half of gene is recoded 
cgtctgtactgaagcgcaaccgttctcacggcttccgtgctcgtatggct
acgaagaacggccgc 
rpsR-middle 
C-terminal cassette forward primer for 
rpsR; Half of gene is recoded 
actataaagatatcgctacgctgaaaaactacatcaccgaaagcggtaa
gatcgttccttcacgcattaca 
rpsP-middle 
C-terminal cassette forward primer for 
rpsP; Half of gene is recoded 
gtaatgcacgcaacggtcgcttcatcgagcgcgttggtttcttcaaccc
aattgcgtctgagaaggagg 
rplT-middle 
C-terminal cassette forward primer for 
rplT; Half of gene is recoded 
gtcagtatgcttaccgtgaccgtcgtcaacgtaagcgtcagttccgtca
attatggatcgcacgcattaatg 
rplL-middle 
C-terminal cassette forward primer for 
rplL; Half of gene is recoded 
cggttgaagctgctgaagaaaaaactgaattcgacgtaattctgaaagc
tgcgggggcgaataagg 
rpsL-middle 
C-terminal cassette forward primer for 
rpsL; Half of gene is recoded 
actccgcgctgcgtaaagtatgccgtgttcgtctgactaacggtttcgaa
gttacgtcttatattggcggag 
rplQ-middle 
C-terminal cassette forward primer for 
rplQ; Half of gene is recoded 
ttgagccgctgattactcttgccaagactgatagcgttgctaatcgtcgtt
tggcgtttgctcgca 
rplO-middle 
C-terminal cassette forward primer for 
rplO; Half of gene is recoded 
ctctgtaccgtcgtctgccgaaattcggcttcacttctcgtaaagcagcg
attactgcggagatccgc 
rplJ-middle 
C-terminal cassette forward primer for 
rplJ; Half of gene is recoded 
ctccgttcgagtgcctgaaagacgcgtttgttggtccgaccctgattgca
tatagcatggagcatcctgg 
rpsG-middle 
C-terminal cassette forward primer for 
rpsG; Half of gene is recoded 
aagttaagtctcgccgcgttggtggttctacttatcaggtaccagttgaa
gtgcgacctgtacgcc 
rpsD-middle 
C-terminal cassette forward primer for 
rpsD; Half of gene is recoded 
gtgaaaacctgttggctctgctggaaggtcgtctggacaacgttgtata
ccgcatggggtttggcg 
rplD-middle 
C-terminal cassette forward primer for 
rplD; Half of gene is recoded 
ttgctgctcgtccgcaggaccacagtcaaaaagttaacaagaagatgt
accgaggggcattaaagtctatttt 
rpsC-middle 
C-terminal cassette forward primer for 
rpsC; Half of gene is recoded 
tcaacatcgccgaagttcgtaagcctgaactggacgcaaaactggttg
ctgatagtattacaagccaattagagcg 
rpsB-middle 
C-terminal cassette forward primer for 
rpsB; Half of gene is recoded 
aaaccgttcgtcagtccatcaaacgtctgaaagacctggaaactcagtc
tcaagatggcacgtttgataaattaa 
rplB-middle 
C-terminal cassette forward primer for 
rplB; Half of gene is recoded 
atgctgcaatcaaaccaggtaacaccctgccgatgcgcaacatcccgg
ttggaagcacggtgcaca 
rpsA-middle 
C-terminal cassette forward primer for 
rpsA; Half of gene is recoded 
gcgaagatccgtgggtagctatcgctaaacgttatccggaaggtacca
aattaacagggcgtgttactaatttg 
NAT_krp-rpmH 
forward kanR primer for generating rpmH 
NAT_kan
R
 cassette 
tcgtgctaaaggccgcgctcgtctgaccgtttctaagtaatgagttgtcg
agattttcagg 
NAT_krp-rpmD 
forward kanR primer for generating rpmD 
NAT_kan
R
 cassette 
gatcaacgcggtttccttcatggttaaagttgaggagtaatgagttgtcg
agattttcagg 
NAT_krp-rpmC 
forward kanR primer for generating rpmC 
NAT_kan
R
 cassette 
acgcgttaagactttactgaacgagaaggcgggtgcgtaatgagttgtc
gagattttcagg 
NAT_krp-rpsR 
forward kanR primer for generating rpsR 
NAT_kan
R
 cassette 
ctacctgtccctgctgccgtacactgatcgccatcagtaatgagttgtcg
agattttcagg 
NAT_krp-rpmB 
forward kanR primer for generating rpmB 
NAT_kan
R
 cassette 
agttctggctgaactgcgtgcccgtggcgaaaagtactaatgagttgtc
gagattttcagg 
NAT_krp-rpsP 
forward kanR primer for generating rpsP 
NAT_kan
R
 cassette 
cgttgctgcgctgatcaaagaagtaaacaaagcagcttaatgagttgtc
gagattttcagg 
NAT_krp-rpsQ 
forward kanR primer for generating rpsQ 
NAT_kan
R
 cassette 
ctggacgctggttcgcgttgtagagaaagcggttctgtaatgagttgtc
gagattttcagg 
NAT_krp-rpmA 
forward kanR primer for generating rpmA 
NAT_kan
R
 cassette 
cccgaaaaaccgtaaatttatcagcatcgaagctgaataatgagttgtc
gagattttcagg 
NAT_krp-rpsS 
forward kanR primer for generating rpsS 
NAT_kan
R
 cassette 
tcgcggccacgctgctgataaaaaagcgaagaagaaataatgagttgt
cgagattttcagg 
NAT_krp-rpsN 
forward kanR primer for generating rpsN 
NAT_kan
R
 cassette 
gcgcggtgaaatcccgggtctgaaaaaggctagctggtaatgagttgt
cgagattttcagg 
NAT_krp-rplU 
forward kanR primer for generating rplU 
NAT_kan
R
 cassette 
gtggttcactgatgtgaaaattactggcatcagcgcctaatgagttgtcg
agattttcagg 
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NAT_krp-rpsJ 
forward kanR primer for generating rpsJ 
NAT_kan
R
 cassette 
tctggctgccggtgtagacgtgcagatcagcctgggttaatgagttgtc
gagattttcagg 
NAT_krp-rplX 
forward kanR primer for generating rplX 
NAT_kan
R
 cassette 
agtccgtttcttcaagtctaacagcgaaactatcaagtaatgagttgtcg
agattttcagg 
NAT_krp-rplW 
forward kanR primer for generating rplW 
NAT_kan
R
 cassette 
agaaggccagaatctggacttcgttggcggcgctgagtaatgagttgt
cgagattttcagg 
NAT_krp-rplV 
forward kanR primer for generating rplV 
NAT_kan
R
 cassette 
gcgcaccagccacatcactgtggttgtgtccgatcgctgatgagttgtc
gagattttcagg 
NAT_krp-rplS 
forward kanR primer for generating rplS 
NAT_kan
R
 cassette 
tactggtaaggctgctcgtatcaaagagcgtcttaactaatgagttgtcg
agattttcagg 
NAT_krp-rplR 
forward kanR primer for generating rplR 
NAT_kan
R
 cassette 
actggcagatgctgcccgtgaagctggccttcagttctaatgagttgtc
gagattttcagg 
NAT_krp-rplT 
forward kanR primer for generating rplT 
NAT_kan
R
 cassette 
caccgctctggttgaaaaagcgaaagcagctctggcataatgagttgtc
gagattttcagg 
NAT_krp-rpsM 
forward kanR primer for generating rpsM 
NAT_kan
R
 cassette 
acgtacccgtaagggtccgcgcaaaccgatcaagaaataatgagttgt
cgagattttcagg 
NAT_krp-rplL 
forward kanR primer for generating rplL 
NAT_kan
R
 cassette 
agctctggaagaagctggcgctgaagttgaagttaaataatgagttgtc
gagattttcagg 
NAT_krp-rplN 
forward kanR primer for generating rplN 
NAT_kan
R
 cassette 
gttcatgaaaattatctctctggcaccagaagtactctaatgagttgtcga
gattttcagg 
NAT_krp-rpsL 
forward kanR primer for generating rpsL 
NAT_kan
R
 cassette 
ggctcgttccaagtatggcgtgaagcgtcctaaggcttaatgagttgtc
gagattttcagg 
NAT_krp-rplQ 
forward kanR primer for generating rplQ 
NAT_kan
R
 cassette 
ggttgatcgttcagagaaagcagaagctgctgcagagtaatgagttgtc
gagattttcagg 
NAT_krp-rpsK 
forward kanR primer for generating rpsK 
NAT_kan
R
 cassette 
tcataacggttgtcgtccgccgaaaaaacgtcgcgtataatgagttgtc
gagattttcagg 
NAT_krp-rpsI 
forward kanR primer for generating rpsI 
NAT_kan
R
 cassette 
gcgtaaagcacgtcgtcgtccgcagttctccaaacgttaatgagttgtc
gagattttcagg 
NAT_krp-rpsH 
forward kanR primer for generating rpsH 
NAT_kan
R
 cassette 
ggctggtcttggtggcgaaattatctgctacgtagcctaatgagttgtcg
agattttcagg 
NAT_krp-rplM 
forward kanR primer for generating rplM 
NAT_kan
R
 cassette 
caaccacgcggcacagcaaccgcaagttcttgacatctaatgagttgtc
gagattttcagg 
NAT_krp-rplP 
forward kanR primer for generating rplP 
NAT_kan
R
 cassette 
gccgattaaaaccacctttgtaactaagacggtgatgtaatgagttgtcg
agattttcagg 
NAT_krp-rplO 
forward kanR primer for generating rplO 
NAT_kan
R
 cassette 
tgctgctatcgaagctgctggcggtaaaatcgaggaataatgagttgtc
gagattttcagg 
NAT_krp-rplJ 
forward kanR primer for generating rplJ 
NAT_kan
R
 cassette 
tactctggctgctgtacgcgatgcgaaagaagctgcttaatgagttgtc
gagattttcagg 
NAT_krp-rpsE 
forward kanR primer for generating rpsE 
NAT_kan
R
 cassette 
caagcgtggtaaatccgttgaagaaattctggggaaataatgagttgtc
gagattttcagg 
NAT_krp-rplF 
forward kanR primer for generating rplF 
NAT_kan
R
 cassette 
cgacgaagtcgtgcgtaccaaagaggctaagaagaagtaatgagttgt
cgagattttcagg 
NAT_krp-rplE 
forward kanR primer for generating rplE 
NAT_kan
R
 cassette 
cgctctgctggctgcctttgacttcccgttccgcaagtaatgagttgtcg
agattttcagg 
NAT_krp-rpsG 
forward kanR primer for generating rpsG 
NAT_kan
R
 cassette 
cgcttccagtaagcagcccgctttgggctacttaaattgatgagttgtcg
agattttcagg 
NAT_krp-rpsD 
forward kanR primer for generating rpsD 
NAT_kan
R
 cassette 
cattaacgaacacctgatcgtcgagctttactccaagtaatgagttgtcg
agattttcagg 
NAT_krp-rplD 
forward kanR primer for generating rplD 
NAT_kan
R
 cassette 
tgctgatgctgttaagcaagttgaggagatgctggcatgatgagttgtc
gagattttcagg 
NAT_krp-rplC 
forward kanR primer for generating rplC 
NAT_kan
R
 cassette 
cggtagcgacctgatcgttaaaccagctgtgaaggcgtaatgagttgtc
gagattttcagg 
NAT_krp-rpsC 
forward kanR primer for generating rpsC 
NAT_kan
R
 cassette 
tgctcagcctaaaaagcagcagcgtaaaggccgtaaataatgagttgt
cgagattttcagg 
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NAT_krp-rpsB 
forward kanR primer for generating rpsB 
NAT_kan
R
 cassette 
ggcttcccaggcggaagaaagcttcgtagaagctgagtaatgagttgt
cgagattttcagg 
NAT_krp-rplB 
forward kanR primer for generating rplB 
NAT_kan
R
 cassette 
gcgtactgataaattcatcgtacgtcgccgtagcaaataatgagttgtcg
agattttcagg 
NAT_krp-prfB 
forward kanR primer for generating prfB 
NAT_kan
R
 cassette 
ggatcaatttatcgaagcaagtttgaaagcagggttatgatgagttgtcg
agattttcagg 
NAT_krp-rpsA 
forward kanR primer for generating rpsA 
NAT_kan
R
 cassette 
cgcaatggctgaagctttcaaagcagctaaaggcgagtaatgagttgt
cgagattttcagg 
bndfp-rpmH rpmH forward boundary primer tcggtgtccatcgtttca 
bndfp-rpmD rpmD forward boundary primer ttgatggcctggaaaatatgaat 
bndfp-rpmC rpmC forward boundary primer tgaagcattcaagctggc 
bndfp-rpsR rpsR forward boundary primer caaagaacggactgagcaaa 
bndfp-rpmB rpmB forward boundary primer gctgtaaagcctgacgag 
bndfp-rpsP rpsP forward boundary primer ttcgggcttttaatatgacacc 
bndfp-rpsQ rpsQ forward boundary primer gtctcacctgttgaagcaag 
bndfp-rpmA rpmA forward boundary primer gccatcgtcagtggttca 
bndfp-rpsS rpsS forward boundary primer taagaagacccgcagcaa 
bndfp-rpsN rpsN forward boundary primer tgcgaaatctgacgaagaag 
bndfp-rplU rplU forward boundary primer tattcgcgccctattgtga 
bndfp-rpsJ rpsJ forward boundary primer cactctcccatcaatcgtaatg 
bndfp-rplX rplX forward boundary primer ctcgtgagcttcgtagtga 
bndfp-rplW rplW forward boundary primer ggttagcctgatcgcctt 
bndfp-rplV rplV forward boundary primer aattcgcaccgactcgta 
bndfp-rplS rplS forward boundary primer cgcacaacagcaacataaac 
bndfp-rplR rplR forward boundary primer ccttataaaggcaagggtgttc 
bndfp-rplT rplT forward boundary primer ctggtaatcgcgtgcctg 
bndfp-rpsM rpsM forward boundary primer tctgtgcgtttccatttgag 
bndfp-rplL rplL forward boundary primer gaagctgcttaatcgcagt 
bndfp-rplN rplN forward boundary primer gccctcgatatggggatt 
bndfp-rpsL rpsL forward boundary primer aaattcggcgtcctcatattg 
bndfp-rplQ rplQ forward boundary primer catgcgcctggaaaactg 
bndfp-rpsK rpsK forward boundary primer gtaccaagaccaacgcac 
bndfp-rpsI rpsI forward boundary primer gtttacgcgggtaacgag 
bndfp-rpsH rpsH forward boundary primer ctatgcgcggtgaaatcc 
bndfp-rplM rplM forward boundary primer tttgtcgtgtgaacctcaac 
bndfp-rplP rplP forward boundary primer ctgttgaacaaccggaaaaac 
bndfp-rplO rplO forward boundary primer gcgaggatactcctgctatt 
bndfp-rplJ rplJ forward boundary primer attaagacgctctctccgtt 
bndfp-rpsE rpsE forward boundary primer caatatcatggtcgtgtccag 
bndfp-rplF rplF forward boundary primer acctctaaaggtgttatgactga 
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bndfp-rplE rplE forward boundary primer ggctttagattcgaagacgg 
bndfp-rpsG rpsG forward boundary primer ccgttaagtaaggccaaacg 
bndfp-rpsD rpsD forward boundary primer ctcataacggttgtcgtcc 
bndfp-rplD rplD forward boundary primer ctggttaaaggtgctgtcc 
bndfp-rplC rplC forward boundary primer ctctgatgcgtctggatct 
bndfp-rpsC rpsC forward boundary primer tgcagatcgcatcctgaa 
bndfp-rpsB rpsB forward boundary primer cacatattccggggtgcc 
bndfp-rplB rplB forward boundary primer agcttacgtcaccctgaaa 
bndfp-prfB prfB forward boundary primer aaaaagagcgtggattggg 
bndfp-rpsA rpsA forward boundary primer gaatgacagcgggtatgtt 
bndrp-rpmH rpmH reverse boundary primer gaatgtgaattgactgggagtt 
bndrp-rpmD rpmD reverse boundary primer gaaccgataccacgaccc 
bndrp-rpmC rpmC reverse boundary primer gttcgatagcaacaacaatgga 
bndrp-rpsR rpsR reverse boundary primer ctacccaggtttgctactttatc 
bndrp-rpmB rpmB reverse boundary primer agtaccagcagaagaaacca 
bndrp-rpsP rpsP reverse boundary primer catttttcccaaaacgatggg 
bndrp-rpsQ rpsQ reverse boundary primer gcttcaaggatatgggtagaaaa 
bndrp-rpmA rpmA reverse boundary primer gcatttttaccggttatcgaatg 
bndrp-rpsS rpsS reverse boundary primer caacaaggcgaaccttctg 
bndrp-rpsN rpsN reverse boundary primer cgttacggatacgggtca 
bndrp-rplU rplU reverse boundary primer tctgaatcgcgaccgtta 
bndrp-rpsJ rpsJ reverse boundary primer acgggtcatacccactttt 
bndrp-rplX rplX reverse boundary primer aactcagtcatgagttttttaac 
bndrp-rplW rplW reverse boundary primer ttaaccactttaactacgtggc 
bndrp-rplV rplV reverse boundary primer caggtagagttccatggttttac 
bndrp-rplS rplS reverse boundary primer caccagcaaacagataaaaaagg 
bndrp-rplR rplR reverse boundary primer gtttaccgcgatcagcttt 
bndrp-rplT rplT reverse boundary primer ctacggcgataaaagtcaatgt 
bndrp-rpsM rpsM reverse boundary primer ccgtcagagacttgttttctt 
bndrp-rplL rplL reverse boundary primer tacagcgcaaaaaggctg 
bndrp-rplN rplN reverse boundary primer tttaccgcgtttacctttatctt 
bndrp-rpsL rpsL reverse boundary primer ttcaggattgtccaaaactctac 
bndrp-rplQ rplQ reverse boundary primer cagctattgtagataagtgggga 
bndrp-rpsK rpsK reverse boundary primer gctcagcttgagcttagga 
bndrp-rpsI rpsI reverse boundary primer tttacgctgattcagattttagc 
bndrp-rpsH rpsH reverse boundary primer gttgatttttacgtcaacgcc 
bndrp-rplM rplM reverse boundary primer cgagctgcggaacttttg 
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bndrp-rplP rplP reverse boundary primer caggttgaactgctcacg 
bndrp-rplO rplO reverse boundary primer cagcagtctgcgtttcag 
bndrp-rplJ rplJ reverse boundary primer gtgatagacatttaaattgttcc 
bndrp-rpsE rpsE reverse boundary primer agcgttgccttgtgtttc 
bndrp-rplF rplF reverse boundary primer ccagctcctggagcttgc 
bndrp-rplE rplE reverse boundary primer gtttcgcgaagtatttatcagc 
bndrp-rpsG rpsG reverse boundary primer cactgataccgatgttacgg 
bndrp-rpsD rpsD reverse boundary primer tcgaactcacttgctcgata 
bndrp-rplD rplD reverse boundary primer tggatttttccatcgcagtag 
bndrp-rplC rplC reverse boundary primer ttcgttgaaatcacgaccg 
bndrp-rpsC rpsC reverse boundary primer taacatccgtaccctgcg 
bndrp-rpsB rpsB reverse boundary primer cggtcacttactgatgtaagc 
bndrp-rplB rplB reverse boundary primer ctttctctaccttcttcagcaa 
bndrp-prfB prfB reverse boundary primer cgacgcgttttcagttca 
bndrp-rpsA rpsA reverse boundary primer tgcttgattacaggacgaaac 
natfp-rpmH rpmH forward natural sequence primer ctgtactgaagcgcaacc 
natfp-rpmD rpmD forward natural sequence primer cagtgcaatcggtcgtct 
natfp-rpmC rpmC forward natural sequence primer gagcgttgaagagctgaac 
natfp-rpsR rpsR forward natural sequence primer aagttctgccgtttcacc 
natfp-rpmB rpmB forward natural sequence primer ccaagttactggcaagcg 
natfp-rpsP rpsP forward natural sequence primer cgctaaaaagcgtccgttc 
natfp-rpsQ rpsQ forward natural sequence primer gcaaggtcgcgttgttag 
natfp-rpmA rpmA forward natural sequence primer gtaacggtcgcgattcag 
natfp-rpsS rpsS forward natural sequence primer gtccttttattgacctgcact 
natfp-rpsN rpsN forward natural sequence primer tgaaagcacgcgaagtaaaa 
natfp-rplU rplU forward natural sequence primer acaacaccgagtaagcga 
natfp-rpsJ rpsJ forward natural sequence primer tgaaagcgtttgatcatcgt 
natfp-rplX rplX forward natural sequence primer gtgatgacgaagttatcgtgtta 
natfp-rplW rplW forward natural sequence primer aacgtctgctgaaggtgc 
natfp-rplV rplV forward natural sequence primer catgctcgttcttctgctc 
natfp-rplS rplS forward natural sequence primer acttgaacaagagcagatgaag 
natfp-rplR rplR forward natural sequence primer ctgctcgtatccgtcgtg 
natfp-rplT rplT forward natural sequence primer cgtgcacgtcacaagaaa 
natfp-rpsM rpsM forward natural sequence primer ctgatcataagcatgccgtaa 
natfp-rplL rplL forward natural sequence primer ttgaagcagttgcagctatg 
natfp-rplN rplN forward natural sequence primer gactatgctgaacgtcgc 
natfp-rpsL rpsL forward natural sequence primer accagctggtacgcaaac 
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natfp-rplQ rplQ forward natural sequence primer tcaactgaaccgcaacag 
natfp-rpsK rpsK forward natural sequence primer cacgtaaacgtgtaagaaaacaa 
natfp-rpsI rpsI forward natural sequence primer atactacggcactggtcg 
natfp-rpsH rpsH forward natural sequence primer gctgacccgtatccgtaa 
natfp-rplM rplM forward natural sequence primer agaaaccgtaaaacgcgac 
natfp-rplP rplP forward natural sequence primer aaattccgtaaaatgcacaaagg 
natfp-rplO rplO forward natural sequence primer ccgaaggctccaaaaagg 
natfp-rplJ rplJ forward natural sequence primer acaagcgattgttgctgaa 
natfp-rpsE rpsE forward natural sequence primer ggcgaactgcaggaaaag 
natfp-rplF rplF forward natural sequence primer taaagcaccggtcgttgt 
natfp-rplE rplE forward natural sequence primer ctgcatgattactacaaagacga 
natfp-rpsG rpsG forward natural sequence primer tcagcgtaaaattctgccg 
natfp-rpsD rpsD forward natural sequence primer taagctcaagctgagccg 
natfp-rplD rplD forward natural sequence primer gagcgcgctgactgtttc 
natfp-rplC rplC forward natural sequence primer gtgggtatgacccgtatctt 
natfp-rpsC rpsC forward natural sequence primer atggtattcgcctgggtatt 
natfp-rpsB rpsB forward natural sequence primer caaggctggtgttcacttc 
natfp-rplB rplB forward natural sequence primer gttaaatgtaaaccgacatctcc 
natfp-prfB prfB forward natural sequence primer ttcaggacctcacggaac 
natfp-rpsA rpsA forward natural sequence primer ctcaactctttgaagagtcctt 
natrp-rpmH rpmH reverse natural sequence primer ggcctttagcacgacgac 
natrp-rpmD rpmD reverse natural sequence primer ggaaaccgcgttgatcatac 
natrp-rpmC rpmC reverse natural sequence primer agtcttaacgcgtgcgac 
natrp-rpsR rpsR reverse natural sequence primer tcagtgtacggcagcagg 
natrp-rpmB rpmB reverse natural sequence primer gttcagccagaactgtatcg 
natrp-rpsP rpsP reverse natural sequence primer cagcaacgcgatcagaaa 
natrp-rpsQ rpsQ reverse natural sequence primer aaccagcgtccaggattt 
natrp-rpmA rpmA reverse natural sequence primer ggtttttcgggcctttaact 
natrp-rpsS rpsS reverse natural sequence primer ggccgcgataagtacgag 
natrp-rpsN rpsN reverse natural sequence primer ggatttcaccgcgcatag 
natrp-rplU rplU reverse natural sequence primer atgccagtaattttcacatcagt 
natrp-rpsJ rpsJ reverse natural sequence primer atctgcacgtctacaccg 
natrp-rplX rplX reverse natural sequence primer gttagacttgaagaaacggactt 
natrp-rplW rplW reverse natural sequence primer tctggccttctttcaggg 
natrp-rplV rplV reverse natural sequence primer acagtgatgtggctggtg 
natrp-rplS rplS reverse natural sequence primer cagccttaccagtacgct 
natrp-rplR rplR reverse natural sequence primer atctgccagtgcctggac 
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natrp-rplT rplT reverse natural sequence primer ttcaaccagagcggtgaa 
natrp-rpsM rpsM reverse natural sequence primer ttacgggtacgtgcgttg 
natrp-rplL rplL reverse natural sequence primer cagcttcttccagagcttttt 
natrp-rplN rplN reverse natural sequence primer ggtgccagagagataattttcat 
natrp-rpsL rpsL reverse natural sequence primer catacttggaacgagcctg 
natrp-rplQ rplQ reverse natural sequence primer tgctttctctgaacgatcaac 
natrp-rpsK rpsK reverse natural sequence primer aaccgttatgagggatcgg 
natrp-rpsI rpsI reverse natural sequence primer gacgtgctttacgcagac 
natrp-rpsH rpsH reverse natural sequence primer cagataatttcgccaccaaga 
natrp-rplM rplM reverse natural sequence primer gcgtggttgtgctcgtta 
natrp-rplP rplP reverse natural sequence primer ttaatcggcagtttcgctg 
natrp-rplO rplO reverse natural sequence primer gcttcgatagcagcacga 
natrp-rplJ rplJ reverse natural sequence primer cagccagagtacgaacca 
natrp-rpsE rpsE reverse natural sequence primer ttcttcaacggatttaccacg 
natrp-rplF rplF reverse natural sequence primer cttcgtcggcgtaacgaa 
natrp-rplE rplE reverse natural sequence primer gaagtcaaaggcagccag 
natrp-rpsG rpsG reverse natural sequence primer aaagcgggctgcttactg 
natrp-rpsD rpsD reverse natural sequence primer cgatcaggtgttcgttaatgtc 
natrp-rplD rplD reverse natural sequence primer cttaacagcatcagcagtcatt 
natrp-rplC rplC reverse natural sequence primer cagctggtttaacgatcagg 
natrp-rpsC rpsC reverse natural sequence primer ttacgctgctgctttttagg 
natrp-rpsB rpsB reverse natural sequence primer gaagctttcttccgcctg 
natrp-rplB rplB reverse natural sequence primer ttatcagtacgcttgttgctg 
natrp-prfB prfB reverse natural sequence primer gctttcaaacttgcttcgataaa 
natrp-rpsA rpsA reverse natural sequence primer cttcagccattgcgttgt 
synfp-rpmH rpmH forward recoded sequence primer gtgttttgaaacgtaatcgctc 
synfp-rpmD rpmD forward recoded sequence primer acacagactcgttctgctatt 
synfp-rpmC rpmC forward recoded sequence primer cgaaaaatctgtggaggaactaa 
synfp-rpsR rpsR forward recoded sequence primer aattttgtcgctttacggct 
synfp-rpmB rpmB forward recoded sequence primer gggaaacgcccagttaca 
synfp-rpsP rpsP forward recoded sequence primer gcgaagaaacgcccatttt 
synfp-rpsQ rpsQ forward recoded sequence primer acgtgtggtgtcggataa 
synfp-rpmA rpmA forward recoded sequence primer gtggatcaactcgcaatgg 
synfp-rpsS rpsS forward recoded sequence primer cgttcatcgatttgcatctgt 
synfp-rpsN rpsN forward recoded sequence primer gtgaggtgaagcgagttg 
synfp-rplU rplU forward recoded sequence primer cagcatcgtgtttcagagg 
synfp-rpsJ rpsJ forward recoded sequence primer gactaaaggctttcgaccac 
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synfp-rplX rplX forward recoded sequence primer gatgaggtaattgttctgacgg 
synfp-rplW rplW forward recoded sequence primer gcgcttgttgaaagtattgc 
synfp-rplV rplV forward recoded sequence primer gcgatcaagtgcacaaaaag 
synfp-rplS rplS forward recoded sequence primer agcaggaacaaatgaaacaaga 
synfp-rplR rplR forward recoded sequence primer tacacgtgctcgtcgtaa 
synfp-rplT rplT forward recoded sequence primer gcgctcgccataaaaaga 
synfp-rpsM rpsM forward recoded sequence primer atatcccggaccacaaaca 
synfp-rplL rplL forward recoded sequence primer ccagattatcgaggcggt 
synfp-rplN rplN forward recoded sequence primer aaatgtagctgataatagtgggg 
synfp-rpsL rpsL forward recoded sequence primer aatcaattagttcgtaagcctcg 
synfp-rplQ rplQ forward recoded sequence primer cgccagttaaatcgtaattcatc 
synfp-rpsK rpsK forward recoded sequence primer aagcgcgttcgtaagcag 
synfp-rpsI rpsI forward recoded sequence primer cgtcgtaagtcaagtgctg 
synfp-rpsH rpsH forward recoded sequence primer ctgacatgttaacgcgca 
synfp-rplM rplM forward recoded sequence primer aacggtgaagcgtgattg 
synfp-rplP rplP forward recoded sequence primer tttcgcaagatgcataaggg 
synfp-rplO rplO forward recoded sequence primer tgcagagggaagcaagaa 
synfp-rplJ rplJ forward recoded sequence primer gcaggataagcaggcaatc 
synfp-rpsE rpsE forward recoded sequence primer gggtgagttacaagagaaattga 
synfp-rplF rplF forward recoded sequence primer aaggctcctgtagtggtg 
synfp-rplE rplE forward recoded sequence primer ataaggatgaggtggtgaagaa 
synfp-rpsG rpsG forward recoded sequence primer gcaagatcttaccagaccct 
synfp-rpsD rpsD forward recoded sequence primer attatctcgccgcgaagg 
synfp-rplD rplD forward recoded sequence primer agtgcactaacggtatctgaa 
synfp-rplC rplC forward recoded sequence primer atgacgcgcatttttactga 
synfp-rpsC rpsC forward recoded sequence primer atccgtttgggcatcgtg 
synfp-rpsB rpsB forward recoded sequence primer aagcaggcgtacattttgg 
synfp-rplB rplB forward recoded sequence primer gcaagcctacgtcacctg 
synfp-prfB prfB forward recoded sequence primer acaaccgtatccaagatttaaca 
synfp-rpsA rpsA forward recoded sequence primer aggaaagcctgaaggagatt 
synrp-rpmH rpmH reverse recoded sequence primer gttaagcgcgcacgacc 
synrp-rpmD rpmD reverse recoded sequence primer tactgcattaatcattccacgg 
synrp-rpmC rpmC reverse recoded sequence primer tgtttttacacgcgccac 
synrp-rpsR rpsR reverse recoded sequence primer acggtccgtataaggtagtaaa 
synrp-rpmB rpmB reverse recoded sequence primer gctagcaccgtgtcaatc 
synrp-rpsP rpsP reverse recoded sequence primer cttaatcaatgctgccacac 
synrp-rpsQ rpsQ reverse recoded sequence primer ccaatgtccaagacttcgttt 
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synrp-rpmA rpmA reverse recoded sequence primer attctttggtcccttcacct 
synrp-rpsS rpsS reverse recoded sequence primer atgcccacggtacgttcg 
synrp-rpsN rpsN reverse recoded sequence primer ggaatctcgcctcgcatc 
synrp-rplU rplU reverse recoded sequence primer gatctttacgtccgtaaaccatt 
synrp-rpsJ rpsJ reverse recoded sequence primer taatttgaacatccacgccc 
synrp-rplX rplX reverse recoded sequence primer aaaaaagcgcaccttcttg 
synrp-rplW rplW reverse recoded sequence primer atccaagttttgaccctcct 
synrp-rplV rplV reverse recoded sequence primer acaaccgtaatatgagatgtacg 
synrp-rplS rplS reverse recoded sequence primer cgcttttcctgtgcgttc 
synrp-rplR rplR reverse recoded sequence primer cgtcagccaacgcttgta 
synrp-rplT rplT reverse recoded sequence primer ctactaacgccgtaaatgcc 
synrp-rpsM rpsM reverse recoded sequence primer gagtgcgagcattcgttt 
synrp-rplL rplL reverse recoded sequence primer ctccaacgccttcttcaac 
synrp-rplN rplN reverse recoded sequence primer ccaagctaatgatcttcataaat 
synrp-rpsL rpsL reverse recoded sequence primer gtatttgctgcgcgcttg 
synrp-rplQ rplQ reverse recoded sequence primer cgatcggtccaccaattca 
synrp-rpsK rpsK reverse recoded sequence primer ccattgtgcggaattggc 
synrp-rpsI rpsI reverse recoded sequence primer gcttactaaattgaggtcggc 
synrp-rpsH rpsH reverse recoded sequence primer aaatgatctcaccgccca 
synrp-rplM rplM reverse recoded sequence primer ctgttgcgctgcatgatta 
synrp-rplP rplP reverse recoded sequence primer gtcgtcttgattggcaactta 
synrp-rplO rplO reverse recoded sequence primer acccgccgcctcaatt 
synrp-rplJ rplJ reverse recoded sequence primer gctaatgtgcgcactaact 
synrp-rpsE rpsE reverse recoded sequence primer atctcctccacgctctttc 
synrp-rplF rplF reverse recoded sequence primer acctcatcagcatatcgca 
synrp-rplE rplE reverse recoded sequence primer caataatgcacgtccctcc 
synrp-rpsG rpsG reverse recoded sequence primer tgttttgatgacgcaccag 
synrp-rpsD rpsD reverse recoded sequence primer gctcattgatatctgcgctt 
synrp-rplD rplD reverse recoded sequence primer tctacctgtttcacagcgt 
synrp-rplC rplC reverse recoded sequence primer aatcactacccgtcgctc 
synrp-rpsC rpsC reverse recoded sequence primer gtttctttggttgcgctg 
synrp-rpsB rpsB reverse recoded sequence primer ttggcttgctaagtcttgtg 
synrp-rplB rplB reverse recoded sequence primer aaacttgtctgtgcgtttatttg 
synrp-prfB prfB reverse recoded sequence primer tcaatgaactggtccaaactc 
synrp-rpsA rpsA reverse recoded sequence primer cttaaatgcctccgccatc 
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kanR.seqOUT-Nr2 
Primer for sequencing the C-terminus of 
recoded essential genes (hybridizes near 
the N-terminus of kanR and faces toward 
the recoded essential gene) 
gaatttaatcgcggcctc 
3502900.tolC-f 
forward primer for generating tolC 
insertion cassette at nt 3502900 
gcgcgttgaattttacatcccgtacgttcccctcaccctaaccctctccct
tgaggcacattaacgcc 
3502901.tolC-r 
reverse primer for generating tolC 
insertion cassette at nt 3502900 
atagcaccgtcaagctaaattccgtactgaacggtcccctcgccccttt
gtctagggcggcggatt 
4427600.tolC-f 
forward primer for generating tolC 
insertion cassette at nt 4427600 
tgaagtcgaactgctggaaatcctctaagcagcgcattctgttcccctcg
ttgaggcacattaacgcc 
4427601.tolC-r 
reverse primer for generating tolC 
insertion cassette at nt 4427600 
cgtttggcaaactgaagggtttattgctgaatgcctgctcccctctcgttt
ctagggcggcggatt 
3502822.seq-f 
forward primer for screening tolC 
insertion at nt 3502900 
cattaaccgtaggccggataaga 
3503081.seq-r 
reverse primer for screening tolC 
insertion at nt 3502900 
tcccgccgctcttttatcg 
4427507.seq-f 
forward primer for screening tolC 
insertion at nt 4427600 
ctggcatatggcgagc 
4427776.seq-r 
reverse primer for screening tolC 
insertion at nt 4427600 
tcgatattaggtaacaatacgcgg 
tolC.90.del deletes endogenous tolC 
gaatttcagcgacgtttgactgccgtttgagcagtcatgtgttaaagcttc
ggccccgtctgaacgtaaggcaacgtaaagatacgggttat 
tolC-r_null_mut* inactivates tolC for CoS-MAGE 
a*g*caagcacgccttagtaacccggaattgcgtaagtctgccgctaa
atcgtgatgctgcctttgaaaaaattaatgaagcgcgcagtcca 
tolC-r_null_revert* tolC co-selection oligo 
c*a*gcaagcacgccttagtaacccggaattgcgtaagtctgccgcc
gatcgtgatgctgcctttgaaaaaattaatgaagcgcgcagtcca 
bla_mut* inactivates bla in lambda prophage 
g*c*c*a*catagcagaactttaaaagtgctcatcattggaaaacgtta
ttaggggcgaaaactctcaaggatcttaccgctgttgagatccag 
bla_restore* bla co-selection oligo 
g*c*c*a*catagcagaactttaaaagtgctcatcattggaaaacgttc
ttcggggcgaaaactctcaaggatcttaccgctgttgagatccag 
rplJ_12-54 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*tactgcagacagcgcgcctttcgctacttcgcttacttcagcaac
aatcgcttgtttgtcttgcagatttaaagccattagctttgct 
rplJ_42-87 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*g*tcattttatctacagttacgccacgcgaatccgcaactactgcag
acagcgcgcctttcgctacttcgcttacttcagcaacaatcgc 
rplJ_321-333 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
g*g*tcgatctgagacgccgggatcagctcaccttcaaacgcagccg
cttttacctcaaattttgcattcgctttcgcgaactctttgaaca 
rplJ_390-423 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*c*agtttgccagccgaagcttctttcatcgttgccatcaggcgtgca
attgcttcttcgtacgtcggcagagttgccaggcggtcgatct 
rpsB_12-57 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*t*tttcgggttccagtaacgcgtctggtgaccgaagtgaacaccag
ccttcagcatgtcgcgcatagaaacagttgccatgattaaaacc 
rplB_147-117 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*g*cttgtggccaccaccgatatgacgagtcgtgatacggccattgtt
gttacgaccaccacttttgctgtttttttccagcaacggagca 
rplB_240-261 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*cgtctttgtacagaaccagcgcgatgttcgccgaacggttcgga
tcgtactccagacgttcaacaactgccgggataccgtctttgtt 
rplB_468-516 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*c*accagaacgcagacgcagcgtcacataagcaccatcacgagc
aacgatctgaacgtaagtaccagcactacgtgccagctgaccgcct 
rplB_654-666 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*g*accttcaccaccaccatgtgggtggtctaccgggttcatcgccg
taccgcgaacagtcggacgaacaccacgccagcgtgcagcacct 
rplB_753-768 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*gtacgatgaatttatcagtacgcttgttgctgcgagtcttcttacctt
tcgtctgaacgccccacggagttaccgggtgcttaccaaa 
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rplD_42-51 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*a*cctggtgaaccagcgcttcgttgaaatcacgaccgaatgtagttt
cagaaacagtcagcgcgctctgcgcgtctttcaatactaattc 
rplD_162-192 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
g*g*gctcttgatagaaccagaacgcgcacggccagtgcctttctgg
cgccacggttttttacctgaaccagttacttcagcacgagtcttc 
rplD_327-360 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*t*tcggcgcttctacagagaacttctctacaacgatcagacgatcctg
acgtaccagttccgacaggatgcttttcagcgcgccgcggta 
rplD_543-603 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*g*ttcttcacgaattatgccagcatctcctcaacttgcttaacagcatc
agcagtcattacaactttgtcgaacgcgatcaggctaaccg 
rplO_24-33 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*g*aaccgataccacgacccaggcgtttacccgcctttttgctgcctt
ctgccggagacagagtatttaaacgcatctcttactcctcaac 
rplO_78-87 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
g*c*cagaacgagacttctgacctttgtgaccacgaccacccgttttac
ccaggccagaaccgataccacgacccaggcgtttacccgcctt 
rplQ_159-201 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*gatctcgttatcacgagtacgagcgaatgccagacgacgattag
caacgctatcagtcttagccagagtaatcagcggctcaactacg 
rpsC_60-75 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*t*ttaaaatcgctgtccaggttgtcagcgaattcttttgtgttcgcaaa
ccaagtagagttccatggttttacaatacccaggcgaatac 
rpsC_150-198 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*c*gggcgagcagtgtgaatagttacacggatgctcttagccggac
gctcgataacgatacgagatactgacgctttagccagttccttag 
rpsC_267-309 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*c*cagttcaggcttacgaacttcagcgatgttgatctgtgcaggaac
gccagcgatgtccgctactaccttacgcagtttttctacgtct 
rpsD_6-60 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*ttcaggaataagtccgtgccctcacgacggctcagcttcagctta
ggacccaaatagcgtgccattttctttctccaacaaacctgga 
rpsD_48-87 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*g*ctggccaggagcttgttcaattttacacttagtatcgatcgcgcga
acgccagacttcaggaataagtccgtgccctcacgacggctc 
rpsG_144-195 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*g*tcgggcgcacgttttccagagctacttcgaatgcttccagttcag
atttaccagagcgctgagccagtgtctccagcgcgctgtatac 
rpsG_342-369 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*a*ctgcagtacctttgttttctgcagcatcagacagttcgttcgccag
gcgcagagccatgcttttatcaccgcgtttacgagcagcttc 
rpsG_432-438 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*g*cgcagagataaccaacggtagtgtgcgaacgccttgtttgcttca
gccatacggtgaacgtcttcacgtttcttaactgcagtacctt 
rpsG_471-516 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*t*ttaagtagcccaaagccggctgcttacttgaagcgcccgcctgg
tgactaaaactgcgcagagataaccaacggtagtgtgcgaacgc 
rpsG_504-537 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
g*c*gatgggtgttgtacgagccatttgtttcctcgtttatcttttaggcgt
ttaatttaagtagcccaaagccggctgcttacttgaagcg 
rpsA_21-51 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*aacgccacgaacgatagaacccgggcgcgtttcgatttcttttaa
gctctcttcaaataattgagcaaaagattcagtcatgtttaat 
rpsA_135-165 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*c*acctacctggatttccagctcgccctgagcgtttttgaactgctca
gccgggatcgcgctctcagatttcagaccagcgtcaaccagt 
rpsA_252-324 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*c*agtaacagtttcagcatcttcgtaagctttttccagcgtgatccaa
gcttcgtgacgtttagctttctcacggctcagcagagtttca 
rpsA_453 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*aacgttgttgcgcttctgatccagcttgattactttaaattccagctc
tttgccttccaggtgcagagtgtcacgcaccggacgaacg 
rpsA_513-525 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*g*gttttccagcagctgatcgcgctctgcgctgttttccgattcgata
acagcacgacgagaaacaacaacgttgttgcgcttctgatcc 
rpsA_603 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*a*cgccgcccagatcaacgaatgcaccgtagtcagtcaggttctta
acgatacctttaacttccatgccttcctg 
337 
 
Table S6-8 (Continued). 
rpsA_669-702 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*t*taacagtgatttcgtcgcccacgttaacgatttcgctcggatgctta
acgcgtttccaagccatgtcagtgatgtgcagcaggccgtc 
rpsA_756-765 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
g*a*tagctacccacggatcttcgcccagctgtttcaggcccagtgata
cacgagtacgttcgcggtcgaacttcagcactttaacagtgat 
rpsA_831-861 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*c*ttcgatttcaacgaagcagccgtagtcagtcaggttagtcacgcg
accagtcagtttcgtaccttccggataacgtttagcgatagct 
rpsA_918-954 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*tacatcgccaacgttaacaactttactcgggtggatgtttttgttag
tccagtccatttcgctaacgtgtaccaggccttcaacgcct 
rpsA_1026-1077 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
a*c*ggtcgcccttgttgtgcgtttccgcgaactgctgccacgggttag
ctttgcactgtttcagacccagtgagatacgacgacgttcttc 
rpsA_1188 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*t*ttttgtattcacgaactgcttcttcgcctgcaacgttccaagagatgt
cagacaggtgaaccaggccgtcgatgccgccgtccaagcc 
rpsA_1287-1305 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*t*tgttcagagcaacccagttgttgaacggatcttctgctaactgttta
acgcccagagagatacgttcacgttctgcgtcaacctgcag 
rpsA_1362-1398 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
c*t*tcaacgccgtcagccagttctaccgttgcgcctttagcgtcaact
gcagttactttaccagttacgatagcgcctttcttgttcagag 
rpsA_1449-1515 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
g*a*tcaacgcccgtgaatttagcttcaacttcgtcgccaacgctcaga
accagcgtagcgtcttcaacgcggtcacgcgatgcttcagaag 
rpsA_1626 
CoS-MAGE oligo that simultaneously 
changes multiple nearby codons 
t*t*actcgcctttagctgctttgaaagcttcagccattgcgttgttactga
agtttgcatcttcctgtttgttaacagttgcgattgcatc 
rplJ_ACC171ACG CoS-MAGE oligo that changes one codon 
g*a*ccaacaaacgcgtctttcaggcactcgaacggagtaccttcaac
agcacggcgcagcagcgtgttacgaacaacacgcatgtatacgc 
rplJ_ACC237ACG CoS-MAGE oligo that changes one codon 
a*g*acgagcagcagcgcccgggtgttccatagagtatgcaatcagc
gtcggaccaacaaacgcgtctttcaggcactcgaacggagtacct 
rpsR_ACC39ACG CoS-MAGE oligo that changes one codon 
a*g*cgtagcgatatctttatagtcgatctcttgaacgccttccgccgtg
aaacggcagaacttgcgacgacggaaataacgtgccatatgg 
rplL_TCC99TCA CoS-MAGE oligo that changes one codon 
g*c*agcttcaaccgggccagcagctacagctacagcagcagcagc
tgaaacaccgaatttttcttccattgcagagatcagttctacaacg 
rpsP_GTC60GTT CoS-MAGE oligo that changes one codon 
t*t*gaagaaaccaacgcgctcgatgaagcgaccgttgcgtgcattac
ggctgtcagcaacaacaacctggtagaacggacgctttttagcg 
rplB_ACC384ACA CoS-MAGE oligo that changes one codon 
a*c*gttatgaacagtagaaccaaccgggatgttgcgcatcggcagt
gtgttacctggtttgattgcagcatcaacgccagactgaatctgg 
rplB_GCC315GCG CoS-MAGE oligo that changes one codon 
c*a*tcaacgccagactgaatctggtcgccagctttcaggcctttaggc
gccaggatgtaacggcgttcaccgtctttgtacagaaccagcg 
rplD_ACC249ACG CoS-MAGE oligo that changes one codon 
t*t*cttgttaactttttgactgtggtcctgcggacgagcagcaaacgtc
acgccaccagaacgccagatcgggctcttgatagaaccagaa 
rplD_ACC447ACG CoS-MAGE oligo that changes one codon 
t*g*caggttgcgcgcagccaggaacaggttttcgtccagctcaccc
gtgatgatcagcacatcttccagagccatgtctttcagtttctgt 
rplO_GCC222GCG CoS-MAGE oligo that changes one codon 
a*c*tacaccgccttctactttagccaggtcagacagacgaatttccgc
tgtaatcgctgctttacgagaagtgaagccgaatttcggcaga 
rplQ_GCC270GCG CoS-MAGE oligo that changes one codon 
t*c*gcctgcacggaagccacacttcagaatacgagtgtaaccaccc
gcacggctcgcgaaacgcgggcccagttcgttaaacagttttgcc 
rpsG_GTC15GTT CoS-MAGE oligo that changes one codon 
t*c*tgatccgaacttcggatccggcagaattttacgctgaccaataac
gcgacgacgtggcatggaaatactccgttgttaattcaggatt 
rpsG_GTC270GTG CoS-MAGE oligo that changes one codon 
t*c*aacgatccaacgcattgccagagcattacgacgaaccggacgc
acttcaactggtacctgataagtagaaccaccaacgcggcgagac 
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rplJ_GCC333GCG 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
c*a*gagttgccaggcggtcgatctgagacgccgggatcagctcacc
ttcaaacgcagcggctttgacctcaaattttgcattcgctttcgc 
rplD_TGA603TAA_ref
actor 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
g*t*gcggtgcacgcagcaccttcagcagacgttcttcacgaatcatta
tgccagcatctcctcaacttgcttaacagcatcagcagtcat 
rplQ_CTT162CTG 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
c*g*ggcgaatgccagacgacgattagcaacgctatcagtcttggcc
agagtaatcagcggctcaactacgcggcgcagctctttcgcttta 
rpsA_ACC324ACT 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
c*a*gctcaacagtgaagccgcccttaactttgccgttgataacacca
gtaacagtttcagcatcttcgtaagctttttccagcgtgatcca 
rpsL-1 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
a*g*tcagacgaacacggcatactttacgcagcgcgctgttcggtttttt
aggagtcgtagtatatacacgagtacatacgccacgtttttg 
rpsL-2 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
a*c*cgccacggatcaggatcacactgtgctcctgcaggttgtgacct
tcaccaccgatgtaagaagtcacttcgaaaccgttagtcagacg 
rpsL-3 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
g*c*ttacggtctttaacgccagagcagtctaacgcaccacgtactgtg
tggtaacgaacacccggcaggtctttaacacgaccgccacg 
rpsL-4 
redesigned CoS-MAGE oligos to convert 
remaining forbidden codons 
a*c*gcttcacgccatacttgctacgagcctgcttacggtctttaacgcc
agagcagtctaacgcaccacgtactgtgtggtaacgaacacc 
rplQ_CTT162YTR* 
CoS-MAGE oligo to change rplQ CUU 
160-162 to all Leu codons 
g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttg
gcyaragtaatcagcggctcaactacgcggcgcagctctttcgct 
rplQ_CTT162ATY* 
CoS-MAGE oligo to change rplQ CUU 
160-162 to all Ile codons 
g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttg
gcratagtaatcagcggctcaactacgcggcgcagctctttcgct 
rplQ_CTT162GTD* 
CoS-MAGE oligo to change rplQ CUU 
160-162 to all Val codons 
g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttg
gchacagtaatcagcggctcaactacgcggcgcagctctttcgct 
rplQ_CTT162GCD* 
CoS-MAGE oligo to change rplQ CUU 
160-162 to all Ala codons 
g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttg
gchgcagtaatcagcggctcaactacgcggcgcagctctttcgct 
rplQ_CTT162ATG* 
CoS-MAGE oligo to change rplQ CUU 
160-162 to the Met ATG codon 
g*t*acgggcgaatgccagacgacgattagcaacgctatcagtcttg
gccauagtaatcagcggctcaactacgcggcgcagctctttcgct 
rplP_syn_fix_G 
MAGE oligo to convert rplP_syn1 AUA 
to AUG, AUC, or AUU 
c*g*acacgtcagttccttgagctaggccacgattgcgtcccttatgC
atcttgcgaaacttcgttcgtttcggctgcagcatcagcgacgc 
rplO_24-33_wt-f wt forward mascPCR primer cccgcctttttggagccttcg 
rplO_78-87_wt-f wt forward mascPCR primer ggttctggcctcggtaaaacc 
rplO_GCC222GCG_wt
-f 
wt forward mascPCR primer cgtaaagcagcgattacagcc 
rplQ_159-201_wt-f wt forward mascPCR primer gcaacgctatcagtcttggcaag 
rplQ_GCC270GCG_wt
-f 
wt forward mascPCR primer cgtttcgcgagccgtgcc 
rpsC_60-75_wt-f wt forward mascPCR primer cgaattctttggtgttcgcaaaccag 
rpsC_150-198_wt-f wt forward mascPCR primer taaggaactggctaaagcgtcc 
rpsC_267-309_wt-f wt forward mascPCR primer cctgcacagatcaacatcgcc 
rpsD_6-60_wt-f wt forward mascPCR primer gcttgagcttaggacccaaatatct 
rpsD_48-87_wt-f wt forward mascPCR primer gcgttcgcgcgatcgatacc 
rpsR_ACC39ACG_wt-f wt forward mascPCR primer gtcgcaagttctgccgtttcacc 
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rplL_TCC99TCA_wt-f wt forward mascPCR primer gcaatggaagaaaaattcggtgtttcc 
rpsP_GTC60GTT_wt-f wt forward mascPCR primer gtccgttctaccaggttgttgtc 
rpsB_12-57_wt-f wt forward mascPCR primer actgtttccatgcgcgacatgctc 
rplJ_GCC333GCG-wt-f wt forward mascPCR primer ttgaggtcaaagccgctgcc 
rplD_TGA603TAA_ref
actor-wt-f 
wt forward mascPCR primer aagttgaggagatgctggcatg 
rplQ_CTT162CTG-wt-f wt forward mascPCR primer gtagttgagccgctgattactctt 
rpsA_ACC324ACT-wt-
f 
wt forward mascPCR primer cttacgaagatgctgaaactgttacc 
rplO_24-33_mut-f mutant forward mascPCR primer cccgcctttttgctgccttct 
rplO_78-87_mut-f mutant forward mascPCR primer ggttctggcctgggtaaaacg 
rplO_GCC222GCG_mu
t-f 
mutant forward mascPCR primer cgtaaagcagcgattacagcg 
rplQ_162-201_mut-f mutant forward mascPCR primer gcaacgctatcagtcttagccag 
rplQ_GCC270GCG_mu
t-f 
mutant forward mascPCR primer cgtttcgcgagccgtgcg 
rpsC_60-75_mut-f mutant forward mascPCR primer cgaattcttttgtgttcgcaaaccaa 
rpsC_150-198_mut-f mutant forward mascPCR primer taaggaactggctaaagcgtca 
rpsC_267-309_mut-f mutant forward mascPCR primer cctgcacagatcaacatcgct 
rpsD_6-60_mut-f mutant forward mascPCR primer cttcagcttaggacccaaatagcg 
rpsD_48-87_mut-f mutant forward mascPCR primer gcgttcgcgcgatcgatact 
rpsR_ACC39ACG_mut
-f 
mutant forward mascPCR primer gtcgcaagttctgccgtttcacg 
rplL_TCC99TCA_mut-
f 
mutant forward mascPCR primer gcaatggaagaaaaattcggtgtttca 
rpsP_GTC60GTT_mut-
f 
mutant forward mascPCR primer gtccgttctaccaggttgttgtt 
rpsB_12-57_mut-f mutant forward mascPCR primer actgtttctatgcgcgacatgctg 
rplJ_GCC333GCG-
mut-f 
mutant forward mascPCR primer ttgaggtcaaagccgctgcg 
rplD_TGA603TAA_ref
actor-mut-f 
mutant forward mascPCR primer aagttgaggagatgctggcata 
rplQ_CTT162CTG-
mut-f 
mutant forward mascPCR primer gtagttgagccgctgattactctg 
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rpsA_ACC324ACT-
mut-f 
mutant forward mascPCR primer cttacgaagatgctgaaactgttact 
rplO_24-33_rev reverse mascPCR primer tgaacgcgctctggaaaaagg 
rplO_78-87_rev reverse mascPCR primer gcatctgaccaccctcgaaacc 
rplO_GCC222GCG_rev reverse mascPCR primer cagcggtgaagtagaatgcaaagc 
rplQ_159-201_rev reverse mascPCR primer ctgagaaggataaggtcatgcgc 
rplQ_GCC270GCG_rev reverse mascPCR primer ggtaagcaaccggcattcttcag 
rpsC_60-75_rev reverse mascPCR primer caagaaagttctggaatctgccattg 
rpsC_150-198_rev reverse mascPCR primer cgccagcgatgtccgctac 
rpsC_267-309_rev reverse mascPCR primer aggtgttgtagtcgatgtcagcac 
rpsD_6-60_rev reverse mascPCR primer ggtccgcgcaaaccgatc 
rpsD_48-87_rev reverse mascPCR primer aaactctgtcacagaaccctgc 
rpsR_ACC39ACG_rev reverse mascPCR primer gtttcgagcgagtgccgcag 
rplL_TCC99TCA_rev reverse mascPCR primer cgaatacgttttttctcggtataggagtaaacc 
rpsP_GTC60GTT_rev reverse mascPCR primer tgataacctgcccatcgaggaac 
rpsB_12-57_rev reverse mascPCR primer ccaggctgttttccagtttctcc 
rplJ_GCC333GCG-r reverse mascPCR primer cctgaatatcagaataagtttatacgtaagcgaatg 
rplD_TGA603TAA_ref
actor-r 
reverse mascPCR primer ccttgtgcagctcagggttaac 
rplQ_CTT162CTG-r reverse mascPCR primer cgctggagatcgctttcggtatatag 
rpsA_ACC324ACT-r reverse mascPCR primer caacgaatgcaccgtagtcagt 
vsr_mut* 
MAGE oligo that inactivates vsr by 
adding two in-frame stop codons 
g*g*c*c*ctgcccggttaacagactggcgaggcgcttctcttatcac
gtatcacgcgtggcaatcgcgcgcatatttttgctg 
vsr_wt-f wt forward mascPCR primer ccacgcgtgatacggc 
vsr_mut-f mutant forward mascPCR primer gccacgcgtgatacgtg 
vsr-r reverse mascPCR primer cgcactcccagacaatcaatac 
rplP_syn_fix_wt-f wt forward mascPCR primer acgaacgaagtttcgcaagatA 
rplP_syn_fix_mut-f mutant forward mascPCR primer acgaacgaagtttcgcaagatB 
rplP_syn_fix_305-r reverse mascPCR primer catccatctcgtataataccttgcc 
rpsS-Leu-fix-f 
Primer converts the rpsS_syn1 forbidden 
CUU codon to CUA, CUG, UUA, or 
UUG 
GATAAATTCATCGTACGTCGCCGTAGCAAA
TAATTTTAGAGGATAAGCCATGytrCGhAGC
TTAAAAAAGGGACC 
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rpsS-Pro-fix-f 
Primer converts the rpsS_syn1 forbidden 
CUU codon to CCA, CCG, or CCU 
GATAAATTCATCGTACGTCGCCGTAGCAAA
TAATTTTAGAGGATAAGCCATGccdCGhAGC
TTAAAAAAGGGACC 
rpsS-Syn-r Reverse primer for rpsS_syn cassette AGAACGAGCATGGCGATG 
An asterisk (*) indicates a phosphorothioate bond used to protect against exonuclease activity. 
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Table S6-9. Recoded gene designs 
 
>rpmH 
ATGAAGCGTACGTTCCAGCCTAGTGTTTTGAAACGTAATCGCTCACATGGTTTTCGCGCGCGCATGGCAACGAAGAA
CGGCCGCCAAGTGTTGGCGCGCCGCCGCGCAAAGGGTCGTGCGCGCTTAACGGTGTCAAAATAATCTAGAAAGACGT
C 
 
>rpmD 
ATGGCGAAAACGATCAAGATCACACAGACTCGTTCTGCTATTGGGCGCTTGCCTAAGCATAAAGCTACATTACTGGG
GTTAGGCTTACGACGCATCGGACATACGGTTGAACGTGAGGACACGCCGGCAATCCGTGGAATGATTAATGCAGTAT
CGTTTATGGTGAAGGTGGAAGAATAATCTAGAAAGACGTC 
 
>rpmC 
ATGAAGGCGAAGGAATTGCGCGAAAAATCTGTGGAGGAACTAAATACGGAATTGTTAAATTTATTGCGAGAACAATT
TAATTTACGCATGCAAGCAGCGTCGGGACAATTGCAGCAAAGCCATCTACTGAAACAGGTACGCCGTGACGTGGCGC
GTGTAAAAACACTGTTGAATGAAAAAGCTGGCGCTTAATCTAGAAAGACGTC 
 
>rpsR 
ATGGCGCGCTACTTTCGCCGCCGTAAATTTTGTCGCTTTACGGCTGAGGGTGTGCAGGAAATTGATTACAAGGACAT
TGCGACTTTAAAGAATTATATTACGGAGTCTGGCAAAATCGTTCCTTCACGCATTACAGGCACTCGAGCTAAGTATC
AACGCCAATTAGCGCGTGCAATTAAGCGTGCGCGTTATTTAAGTTTACTACCTTATACGGACCGTCACCAATAATCT
AGAAAGACGTC 
 
>rpmB 
ATGTCTCGTGTATGTCAGGTGACGGGGAAACGCCCAGTTACAGGCAATAATCGCAGCCATGCTCTAAATGCTACGAA
GCGTCGCTTTTTGCCAAATTTACATAGCCATCGCTTTTGGGTGGAATCAGAAAAACGATTCGTGACTTTACGTGTGA
GCGCAAAGGGCATGCGCGTTATTGACAAGAAGGGGATTGACACGGTGCTAGCAGAGCTACGCGCGCGCGGTGAGAAA
TATTAATCTAGAAAGACGTC 
 
>rpsP 
ATGGTGACGATCCGACTGGCTCGCCATGGAGCGAAGAAACGCCCATTTTATCAAGTGGTGGTTGCAGATTCACGAAA
CGCTCGTAATGGCCGTTTTATTGAACGTGTGGGCTTTTTTAATCCGATTGCGTCTGAGAAGGAGGAGGGAACGCGTT
TAGACTTGGACCGTATTGCGCATTGGGTGGGTCAAGGTGCTACGATCTCGGACCGTGTGGCAGCATTGATTAAGGAG
GTGAATAAGGCTGCATAATCTAGAAAGACGTC 
 
>rpsQ 
ATGACGGACAAGATTCGCACATTACAGGGACGTGTGGTGTCGGATAAGATGGAAAAGAGCATCGTGGTGGCAATTGA
GCGCTTCGTAAAGCATCCTATTTATGGGAAGTTTATTAAACGCACTACGAAGTTACATGTTCACGATGAAAATAATG
AGTGTGGAATTGGCGATGTAGTGGAGATTCGAGAGTGTCGCCCATTAAGCAAAACGAAGTCTTGGACATTGGTGCGT
GTGGTGGAAAAGGCTGTGTTGTAATCTAGAAAGACGTC 
 
>rpmA 
ATGGCGCACAAGAAAGCGGGTGGATCAACTCGCAATGGCCGTGACTCTGAGGCGAAGCGATTGGGGGTAAAACGCTT
TGGCGGTGAGAGTGTGTTAGCTGGGTCAATTATTGTGCGACAGCGCGGAACGAAGTTTCATGCGGGGGCAAATGTGG
GATGTGGCCGCGATCATACGTTATTCGCGAAGGCTGATGGGAAGGTTAAGTTTGAGGTGAAGGGACCAAAGAATCGC
AAGTTCATTTCGATTGAGGCGGAGTAATCTAGAAAGACGTC 
 
>rpsS 
ATGCCTCGCAGCTTAAAAAAGGGACCGTTCATCGATTTGCATCTGTTAAAAAAAGTGGAAAAGGCTGTTGAGTCAGG
CGATAAAAAACCGTTGCGTACGTGGTCGCGACGCAGCACAATTTTCCCAAATATGATTGGCCTGACAATTGCGGTGC
ACAACGGACGCCAACATGTACCAGTGTTCGTTACGGATGAGATGGTGGGCCATAAGTTGGGCGAGTTTGCTCCAACG
CGAACGTACCGTGGGCATGCGGCAGACAAGAAGGCAAAAAAAAAGTAATCTAGAAAGACGTC 
 
>rplW 
ATGATTCGCGAGGAGCGCTTGTTGAAAGTATTGCGCGCGCCACATGTGTCAGAGAAGGCTAGTACAGCAATGGAAAA
GAGCAATACGATTGTTTTAAAGGTAGCGAAGGATGCAACAAAGGCGGAGATTAAGGCGGCAGTTCAAAAGTTGTTCG
343 
 
AGGTAGAGGTGGAGGTAGTGAATACGTTAGTGGTGAAGGGCAAGGTGAAGCGACATGGCCAACGCATTGGACGCCGC
TCAGATTGGAAGAAGGCGTATGTGACTTTGAAGGAGGGTCAAAACTTGGATTTTGTAGGAGGTGCAGAATAATCTAG
AAAGACGTC 
 
>rpsN 
ATGGCAAAACAGAGCATGAAGGCGCGTGAGGTGAAGCGAGTTGCGCTGGCAGACAAGTATTTTGCTAAGCGTGCAGA
GCTAAAGGCTATTATTAGCGACGTTAATGCGTCGGATGAGGACCGCTGGAATGCTGTGTTAAAATTGCAAACATTGC
CTCGCGACAGCTCTCCATCGCGACAACGCAATCGTTGTCGCCAGACTGGCCGACCACACGGCTTTTTGCGTAAATTT
GGCCTGAGTCGCATCAAAGTTCGCGAGGCGGCGATGCGAGGCGAGATTCCAGGCCTAAAGAAAGCATCGTGGTAATC
TAGAAAGACGTC 
 
>rplU 
ATGTATGCAGTGTTTCAGTCTGGCGGGAAGCAGCATCGTGTTTCAGAGGGGCAAACTGTGCGTTTGGAGAAATTGGA
TATTGCTACGGGAGAAACGGTGGAATTTGCAGAGGTTTTAATGATTGCGAATGGCGAGGAGGTGAAGATTGGTGTGC
CGTTTGTGGACGGTGGTGTTATTAAGGCGGAGGTGGTAGCACATGGGCGCGGAGAAAAGGTGAAGATTGTGAAATTC
CGACGACGAAAGCATTACCGAAAACAACAAGGGCACCGCCAATGGTTTACGGACGTAAAGATCACAGGTATTTCGGC
GTAATCTAGAAAGACGTC 
 
>rpsJ 
ATGCAAAATCAGCGCATTCGAATTCGACTAAAGGCTTTCGACCACCGATTGATTGACCAGGCTACGGCAGAGATTGT
GGAAACAGCGAAACGTACGGGCGCACAAGTTCGCGGCCCTATTCCTCTACCAACGCGTAAGGAACGTTTTACAGTAC
TAATTAGTCCTCATGTGAATAAGGATGCTCGTGACCAATATGAGATTCGCACGCATCTGCGATTGGTAGATATTGTG
GAACCTACGGAAAAGACGGTAGACGCATTGATGCGCCTAGACCTAGCAGCGGGCGTGGATGTTCAAATTAGTTTGGG
CTAATCTAGAAAGACGTC 
 
>rplX 
ATGGCTGCAAAAATTCGCCGCGACGATGAGGTAATTGTTCTGACGGGAAAGGACAAGGGCAAGCGAGGCAAGGTAAA
AAACGTGTTGAGCAGCGGAAAAGTTATCGTGGAGGGCATTAATCTAGTGAAAAAGCACCAAAAACCTGTACCTGCAT
TGAATCAGCCAGGCGGTATTGTGGAGAAGGAGGCGGCGATCCAAGTGAGCAATGTTGCGATTTTTAACGCAGCGACG
GGAAAAGCAGATCGCGTTGGTTTCCGTTTTGAGGATGGCAAGAAGGTGCGCTTTTTTAAAAGCAATTCGGAAACGAT
TAAATAATCTAGAAAGACGTC 
 
>rplV 
ATGGAGACAATTGCAAAGCACCGTCACGCGCGATCAAGTGCACAAAAAGTACGTCTGGTGGCGGATTTGATCCGTGG
GAAAAAGGTTAGCCAAGCGTTAGACATCCTGACTTATACGAATAAAAAGGCAGCGGTGTTAGTAAAAAAGGTGTTAG
AGTCGGCGATCGCGAATGCGGAGCATAATGACGGAGCGGATATCGATGACTTAAAGGTGACTAAGATCTTTGTGGAT
GAGGGTCCTAGTATGAAACGTATCATGCCTCGCGCGAAGGGCCGCGCGGACCGTATTTTAAAACGTACATCTCATAT
TACGGTTGTGGTAAGCGACCGATAATCTAGAAAGACGTC 
 
>rplS 
ATGTCAAATATCATCAAACAGCTGGAGCAGGAACAAATGAAACAAGATGTGCCAAGCTTTCGCCCTGGAGACACAGT
AGAGGTAAAGGTGTGGGTGGTAGAGGGGAGCAAGAAGCGCTTGCAAGCTTTTGAAGGTGTAGTGATTGCAATCCGCA
ATCGTGGCTTACATAGCGCGTTTACAGTGCGCAAGATCAGTAATGGTGAGGGGGTGGAACGCGTTTTTCAAACGCAT
AGCCCAGTGGTAGATTCGATCAGCGTAAAGCGCCGAGGCGCGGTGCGCAAGGCGAAGCTATATTATTTGCGCGAACG
CACAGGAAAAGCGGCGCGAATTAAGGAACGCCTGAATTAATCTAGAAAGACGTC 
 
>rplR 
ATGGACAAAAAGAGTGCACGAATTCGCCGCGCTACACGTGCTCGTCGTAAACTGCAAGAATTAGGTGCTACACGTTT
AGTAGTGCACCGCACGCCACGCCATATCTATGCGCAAGTGATCGCTCCAAATGGCAGCGAGGTATTGGTGGCGGCGA
GTACGGTTGAGAAGGCGATTGCAGAGCAGTTGAAATATACGGGCAATAAGGATGCTGCGGCGGCGGTAGGCAAGGCG
GTGGCGGAGCGAGCATTGGAGAAGGGTATTAAGGACGTGTCTTTCGATCGAAGTGGCTTTCAGTACCACGGCCGCGT
ACAAGCGTTGGCTGACGCAGCACGCGAGGCGGGACTGCAATTTTAATCTAGAAAGACGTC 
 
>rplT 
ATGGCACGTGTGAAGCGCGGCGTGATCGCTCGCGCTCGCCATAAAAAGATCCTGAAGCAGGCGAAGGGGTATTATGG
AGCTCGCTCGCGTGTGTATCGTGTAGCTTTTCAAGCTGTGATTAAGGCGGGGCAATACGCATATCGCGATCGCCGCC
AGCGAAAACGCCAATTTCGCCAGTTATGGATCGCACGCATTAATGCTGCGGCGCGCCAAAATGGCATCAGCTATTCA
344 
 
AAGTTTATTAACGGTTTAAAGAAGGCAAGCGTGGAGATTGATCGCAAAATTTTAGCGGACATTGCTGTGTTTGATAA
GGTGGCATTTACGGCGTTAGTAGAGAAGGCTAAGGCTGCGTTAGCGTAATCTAGAAAGACGTC 
 
>rpsM 
ATGGCTCGCATTGCTGGTATCAATATCCCGGACCACAAACACGCGGTGATTGCTTTAACGTCTATCTACGGAGTGGG
GAAAACTCGAAGTAAGGCAATTTTGGCGGCGGCAGGAATTGCGGAGGACGTGAAAATTAGCGAATTGTCGGAGGGCC
AGATTGATACATTGCGCGATGAGGTGGCGAAGTTCGTTGTAGAGGGCGACTTACGTCGCGAGATTAGTATGTCTATT
AAACGTTTGATGGACCTGGGCTGTTACCGTGGCCTGCGCCACCGACGCGGCCTGCCTGTGCGTGGCCAACGCACTAA
AACGAATGCTCGCACTCGAAAAGGCCCACGTAAGCCTATTAAAAAGTAATCTAGAAAGACGTC 
 
>rplL 
ATGTCGATTACGAAGGACCAGATTATCGAGGCGGTAGCGGCGATGAGCGTTATGGATGTGGTGGAGCTAATTTCAGC
GATGGAGGAGAAGTTTGGCGTATCAGCAGCGGCGGCTGTGGCGGTGGCGGCGGGACCTGTGGAGGCGGCGGAGGAAA
AGACAGAGTTTGATGTTATCTTAAAGGCAGCGGGGGCGAATAAGGTAGCGGTAATTAAGGCGGTTCGCGGAGCGACA
GGTTTAGGCTTGAAGGAGGCAAAGGATTTGGTGGAGTCGGCTCCTGCGGCGTTAAAGGAGGGTGTTTCGAAGGATGA
TGCTGAGGCGTTGAAGAAGGCGTTGGAGGAGGCAGGTGCAGAGGTAGAGGTGAAGTAATCTAGAAAGACGTC 
 
>rplN 
ATGATTCAGGAGCAAACAATGTTAAATGTAGCTGATAATAGTGGGGCGCGACGTGTGATGTGCATTAAAGTGTTGGG
AGGTAGCCATCGCCGTTATGCGGGTGTTGGTGATATTATTAAAATTACGATTAAGGAGGCGATCCCTCGCGGAAAAG
TTAAGAAGGGCGACGTATTAAAAGCTGTTGTTGTTCGAACAAAAAAAGGCGTGCGTCGTCCAGATGGAAGTGTGATC
CGTTTTGACGGCAACGCATGCGTGCTGCTAAATAATAATTCAGAACAACCGATTGGCACTCGCATCTTCGGCCCTGT
TACGCGCGAATTACGCTCTGAAAAATTTATGAAGATCATTAGCTTGGCGCCGGAGGTGTTATAATCTAGAAAGACGT
C 
 
>rpsL 
ATGGCTACAGTAAATCAATTAGTTCGTAAGCCTCGCGCGCGTAAGGTAGCAAAGAGTAATGTTCCGGCATTAGAGGC
TTGTCCTCAGAAGCGCGGGGTTTGCACGCGCGTGTACACGACGACACCGAAGAAGCCAAATAGCGCATTACGAAAGG
TTTGTCGCGTACGCTTAACGAATGGCTTTGAGGTTACGTCTTATATTGGCGGAGAGGGACATAATTTGCAAGAACAT
AGTGTAATTTTGATTCGCGGTGGGCGCGTAAAGGATCTGCCAGGAGTACGCTATCATACAGTGCGAGGGGCTTTAGA
TTGTTCTGGTGTGAAGGATCGAAAACAAGCGCGCAGCAAATACGGTGTTAAACGACCGAAAGCGTAATCTAGAAAGA
CGTC 
 
>rplQ 
ATGCGTCACCGCAAATCTGGCCGCCAGTTAAATCGTAATTCATCTCACCGTCAAGCAATGTTTCGTAACATGGCGGG
CTCGTTAGTGCGCCACGAGATTATTAAAACTACATTACCGAAGGCTAAGGAACTACGTCGTGTGGTAGAACCTTTAA
TCACGCTGGCTAAAACGGACTCGGTGGCGAACCGCCGCTTGGCGTTTGCTCGCACGCGCGACAATGAAATTGTTGCT
AAGTTATTCAATGAGTTGGGACCACGCTTTGCTTCGCGCGCGGGCGGGTATACACGCATCTTAAAATGCGGGTTTCG
CGCGGGTGATAATGCACCTATGGCGTATATTGAATTGGTGGACCGATCGGAAAAGGCTGAGGCAGCGGCTGAATAAT
CTAGAAAGACGTC 
 
>rpsK 
ATGGCTAAAGCACCGATCCGCGCGCGCAAGCGCGTTCGTAAGCAGGTTAGTGATGGTGTTGCACACATTCACGCGTC
GTTTAATAATACAATTGTTACAATTACAGACCGCCAAGGGAATGCACTGGGATGGGCTACTGCTGGGGGGTCTGGCT
TTCGCGGCTCGCGAAAGTCTACACCTTTCGCGGCACAAGTGGCGGCGGAACGCTGTGCGGATGCGGTTAAGGAGTAT
GGGATTAAAAACTTGGAGGTGATGGTGAAGGGCCCTGGGCCTGGTCGTGAGAGCACAATCCGCGCATTAAATGCTGC
GGGATTTCGTATTACAAATATCACGGACGTTACGCCAATTCCGCACAATGGCTGCCGCCCTCCAAAGAAGCGCCGAG
TGTAATCTAGAAAGACGTC 
 
>rpsI 
ATGGCGGAGAACCAGTATTATGGTACGGGCCGTCGTAAGTCAAGTGCTGCGCGTGTGTTTATTAAGCCAGGAAATGG
CAAGATTGTGATTAATCAGCGCAGCCTAGAGCAATATTTTGGCCGCGAAACGGCTCGTATGGTTGTGCGCCAACCTT
TGGAGTTAGTGGATATGGTAGAAAAGTTAGATTTATATATTACTGTAAAGGGGGGGGGAATTTCGGGCCAAGCGGGA
GCTATTCGCCATGGGATTACACGTGCATTAATGGAGTATGATGAATCGTTGCGCAGCGAGTTACGCAAGGCAGGTTT
TGTGACGCGCGATGCACGCCAAGTGGAGCGCAAAAAGGTGGGGTTGCGCAAGGCGCGCCGCCGACCTCAATTTAGTA
AGCGCTAATCTAGAAAGACGTC 
 
345 
 
>rpsH 
ATGAGTATGCAGGACCCTATTGCTGACATGTTAACGCGCATTCGCAATGGACAAGCGGCAAATAAGGCAGCTGTGAC
AATGCCGTCGTCGAAATTGAAGGTTGCTATTGCGAATGTTTTAAAAGAGGAGGGCTTCATCGAGGACTTCAAGGTGG
AGGGTGATACAAAACCGGAGTTGGAGCTAACATTAAAATACTTTCAAGGGAAGGCTGTGGTGGAGTCGATCCAACGC
GTGTCACGTCCGGGCTTACGTATTTACAAGCGCAAGGACGAATTACCTAAGGTGATGGCTGGATTGGGCATTGCGGT
AGTGAGCACAAGTAAGGGGGTGATGACGGACCGCGCTGCTCGTCAAGCGGGCCTGGGCGGTGAGATCATTTGTTATG
TTGCGTAATCTAGAAAGACGTC 
 
>rplM 
ATGAAAACATTTACTGCGAAGCCGGAAACGGTGAAGCGTGATTGGTACGTGGTGGATGCTACAGGCAAGACGCTAGG
TCGCCTAGCGACAGAGTTGGCGCGCCGTCTACGTGGGAAACATAAGGCAGAGTATACGCCACATGTGGACACTGGCG
ACTATATTATTGTGTTAAATGCGGATAAGGTGGCTGTGACTGGTAATAAACGCACAGATAAGGTATATTACCATCAT
ACGGGGCATATTGGGGGGATTAAGCAGGCAACGTTCGAGGAAATGATCGCGCGTCGCCCGGAACGCGTTATCGAGAT
TGCTGTGAAGGGTATGCTGCCGAAGGGTCCATTGGGCCGCGCGATGTTTCGCAAGTTGAAGGTGTATGCTGGGAATG
AACATAATCATGCAGCGCAACAGCCTCAGGTGCTGGATATTTAATCTAGAAAGACGTC 
 
>rplP 
ATGCTGCAGCCGAAACGAACGAAGTTTCGCAAGATGCATAAGGGACGCAATCGTGGCCTAGCTCAAGGAACTGACGT
GTCGTTTGGGTCATTTGGCTTGAAGGCGGTGGGACGAGGACGCTTGACGGCTCGCCAAATTGAGGCGGCTCGACGCG
CGATGACTCGCGCGGTGAAACGCCAGGGCAAAATTTGGATTCGCGTTTTTCCAGATAAGCCAATTACGGAGAAACCA
TTAGCGGTACGCATGGGCAAGGGCAAGGGCAATGTTGAATACTGGGTGGCGCTGATCCAACCTGGCAAGGTATTATA
CGAGATGGATGGGGTGCCAGAGGAATTAGCGCGCGAGGCGTTTAAATTAGCGGCGGCTAAGTTGCCAATCAAGACGA
CATTCGTGACGAAAACTGTTATGTAATCTAGAAAGACGTC 
 
>rplO 
ATGCGCTTGAACACATTAAGTCCTGCAGAGGGAAGCAAGAAAGCTGGCAAGCGTTTAGGCCGCGGGATTGGTAGTGG
ACTGGGCAAGACGGGCGGACGCGGCCATAAGGGCCAAAAAAGCCGTAGTGGTGGCGGAGTGCGCCGTGGATTTGAAG
GGGGGCAAATGCCGTTATATCGACGCTTACCTAAGTTTGGGTTTACGTCACGCAAGGCTGCTATTACTGCGGAGATC
CGCTTATCGGATTTAGCGAAGGTGGAGGGGGGCGTTGTGGATTTAAATACTTTGAAGGCTGCGAATATCATTGGCAT
TCAAATTGAATTTGCAAAGGTTATTTTAGCGGGAGAGGTTACTACGCCTGTGACGGTGCGAGGTTTGCGCGTGACAA
AGGGAGCGCGCGCGGCAATTGAGGCGGCGGGTGGCAAGATTGAGGAGTAATCTAGAAAGACGTC 
 
>rplJ 
ATGGCGCTAAACCTGCAGGATAAGCAGGCAATCGTGGCGGAGGTATCTGAGGTGGCGAAGGGAGCATTGAGCGCTGT
GGTGGCAGACTCGCGCGGTGTGACAGTGGACAAGATGACGGAGTTACGAAAGGCTGGCCGTGAGGCGGGGGTGTATA
TGCGCGTAGTACGCAATACGTTATTACGTCGAGCGGTGGAGGGCACACCATTTGAATGTTTAAAGGATGCATTCGTA
GGGCCAACGTTGATCGCGTATAGCATGGAGCATCCTGGAGCGGCAGCACGCTTGTTTAAGGAATTTGCTAAGGCAAA
CGCGAAGTTCGAAGTAAAGGCGGCAGCGTTCGAGGGCGAATTAATTCCTGCTAGTCAAATTGATCGTTTGGCGACAT
TACCTACGTATGAGGAGGCGATCGCGCGTCTAATGGCTACGATGAAGGAGGCAAGCGCGGGTAAGTTAGTGCGCACA
TTAGCGGCGGTGCGTGACGCTAAGGAGGCAGCGTAATCTAGAAAGACGTC 
 
>rpsE 
ATGGCTCATATTGAGAAGCAGGCGGGTGAGTTACAAGAGAAATTGATTGCAGTTAATCGTGTGAGTAAGACTGTGAA
GGGCGGCCGAATCTTTAGTTTTACTGCGTTAACAGTGGTAGGTGACGGGAATGGGCGTGTAGGGTTCGGCTATGGCA
AGGCTCGCGAGGTGCCGGCGGCTATTCAAAAGGCAATGGAGAAGGCACGCCGTAACATGATCAATGTAGCTTTGAAC
AATGGTACGTTGCAGCATCCAGTAAAGGGCGTGCATACTGGCAGTCGTGTTTTTATGCAACCAGCAAGTGAGGGCAC
AGGCATTATTGCAGGCGGCGCGATGCGTGCAGTATTGGAGGTAGCGGGAGTGCACAATGTGTTGGCGAAGGCGTACG
GCAGCACTAATCCAATTAATGTTGTGCGCGCGACGATCGACGGGTTGGAGAACATGAACTCACCGGAGATGGTTGCA
GCGAAACGCGGAAAGAGCGTGGAGGAGATCCTAGGTAAGTAATCTAGAAAGACGTC 
 
>rplF 
ATGAGTCGCGTGGCAAAGGCTCCTGTAGTGGTGCCGGCAGGTGTAGATGTGAAGATTAATGGGCAAGTGATCACTAT
TAAGGGAAAGAATGGTGAACTAACACGCACGCTGAATGACGCTGTGGAGGTAAAGCACGCTGACAACACTTTGACGT
TTGGCCCACGCGACGGATATGCTGATGGCTGGGCGCAAGCGGGGACGGCACGCGCGTTATTGAATAGCATGGTGATT
GGCGTAACAGAGGGGTTTACAAAAAAATTACAATTAGTAGGCGTGGGATATCGCGCGGCTGTGAAGGGGAACGTAAT
CAATTTGAGTTTAGGATTTTCACACCCGGTGGATCACCAATTGCCGGCAGGCATTACAGCGGAGTGCCCAACGCAAA
CGGAGATTGTATTAAAGGGGGCGGACAAACAAGTAATTGGGCAAGTGGCGGCTGACTTGCGAGCGTATCGCCGCCCG
346 
 
GAACCGTACAAGGGTAAAGGCGTGCGATATGCTGATGAGGTAGTACGCACTAAGGAAGCGAAAAAAAAATAATCTAG
AAAGACGTC 
 
>rplE 
ATGGCAAAGTTACACGACTATTATAAGGATGAGGTGGTGAAGAAGCTGATGACGGAATTCAATTATAACAGCGTGAT
GCAGGTGCCACGCGTGGAAAAAATTACGTTGAATATGGGCGTGGGCGAGGCAATTGCGGATAAGAAGTTGCTAGACA
ATGCTGCGGCTGATTTGGCGGCTATTAGTGGACAGAAGCCATTAATTACGAAGGCGCGTAAGAGCGTAGCTGGTTTT
AAGATTCGCCAAGGATACCCAATTGGTTGCAAGGTGACGTTGCGCGGTGAGCGTATGTGGGAATTTTTCGAACGTTT
AATTACGATCGCGGTTCCGCGCATTCGCGATTTTCGCGGATTATCAGCGAAATCATTTGATGGGCGAGGCAATTATT
CGATGGGCGTGCGCGAACAAATTATTTTTCCGGAGATTGATTATGACAAGGTAGATCGTGTGCGCGGCCTGGACATC
ACAATCACAACGACGGCAAAGAGTGATGAGGAGGGACGTGCATTATTGGCGGCGTTCGATTTTCCATTTCGTAAATA
ATCTAGAAAGACGTC 
 
>rpsG 
ATGCCGCGCCGCCGAGTTATCGGCCAACGCAAGATCTTACCAGACCCTAAATTTGGTTCGGAGCTATTAGCGAAGTT
CGTGAACATTTTGATGGTGGACGGGAAAAAGAGTACGGCAGAGTCAATTGTGTATAGTGCATTAGAAACATTAGCGC
AACGTAGCGGCAAGTCGGAGTTGGAGGCGTTTGAGGTTGCGCTGGAGAATGTTCGACCTACGGTGGAGGTGAAAAGC
CGTCGTGTGGGCGGCAGCACGTACCAAGTGCCTGTGGAGGTGCGACCTGTACGCCGAAACGCATTAGCTATGCGATG
GATTGTGGAGGCGGCGCGCAAGCGTGGCGACAAGAGCATGGCGTTGCGTTTAGCTAATGAGCTGAGCGACGCAGCGG
AGAATAAGGGCACGGCTGTGAAAAAGCGCGAGGATGTACATCGCATGGCTGAGGCAAATAAAGCATTTGCGCATTAT
CGCTGGCTGTCTCTGCGCAGCTTCAGCCATCAAGCTGGTGCGTCATCAAAACAACCGGCGTTAGGTTATCTGAACTA
ATCTAGAAAGACGTC 
 
>rpsD 
ATGGCGCGCTACTTAGGCCCGAAACTGAAATTATCTCGCCGCGAAGGTACGGATTTGTTTCTGAAAAGTGGGGTGCG
TGCAATTGACACTAAATGCAAGATCGAGCAGGCGCCGGGTCAACATGGGGCTCGCAAGCCACGCTTAAGCGATTACG
GAGTACAACTGCGCGAGAAACAGAAGGTGCGTCGCATTTACGGAGTACTAGAACGCCAATTTCGAAATTATTATAAG
GAGGCGGCTCGCCTAAAGGGTAATACGGGCGAGAATTTACTGGCGTTGTTGGAGGGACGCTTAGATAATGTGGTGTA
TCGCATGGGGTTTGGCGCGACGCGCGCGGAGGCGCGCCAACTAGTGTCGCACAAGGCGATCATGGTGAATGGCCGAG
TAGTGAATATTGCGTCGTACCAAGTATCACCAAACGATGTGGTGTCTATCCGAGAAAAGGCTAAAAAACAAAGTCGT
GTTAAGGCGGCATTGGAACTAGCGGAACAACGCGAGAAACCGACTTGGTTAGAGGTGGACGCGGGGAAAATGGAGGG
AACTTTCAAACGCAAACCAGAACGATCAGACTTAAGCGCAGATATCAATGAGCATTTAATTGTGGAATTGTATTCAA
AATAATCTAGAAAGACGTC 
 
>rplD 
ATGGAACTGGTTCTGAAGGATGCACAAAGTGCACTAACGGTATCTGAAACGACATTTGGCCGCGACTTTAATGAGGC
ATTGGTGCATCAAGTAGTGGTGGCGTACGCTGCAGGGGCGCGCCAAGGGACACGCGCGCAAAAAACGCGCGCGGAGG
TGACAGGCTCAGGCAAGAAGCCATGGCGTCAAAAGGGTACTGGTCGAGCACGATCAGGGAGCATTAAAAGTCCAATT
TGGCGCAGCGGGGGTGTAACGTTCGCAGCGCGACCTCAAGATCATTCTCAGAAGGTAAATAAAAAAATGTATCGAGG
GGCATTAAAGTCTATTTTGTCGGAGTTAGTGCGCCAAGACCGCCTAATTGTGGTAGAAAAATTTAGCGTTGAGGCAC
CAAAGACGAAATTATTAGCGCAAAAGTTGAAGGATATGGCGCTAGAGGACGTACTAATTATTACGGGGGAATTGGAT
GAGAATTTGTTTTTAGCGGCTCGTAATTTACATAAAGTGGATGTTCGTGACGCTACGGGGATTGATCCAGTGTCATT
GATTGCGTTTGATAAGGTTGTGATGACGGCGGACGCTGTGAAACAGGTAGAAGAAATGTTGGCGTAATCTAGAAAGA
CGTC 
 
>rplC 
ATGATCGGCCTGGTTGGGAAGAAGGTAGGCATGACGCGCATTTTTACTGAGGATGGAGTGAGTATTCCGGTTACGGT
GATTGAGGTGGAGGCGAATCGTGTGACGCAAGTGAAGGATTTGGCAAATGACGGATATCGCGCAATCCAAGTTACTA
CGGGCGCGAAGAAGGCAAATCGCGTTACTAAACCGGAGGCGGGTCATTTTGCAAAGGCGGGTGTTGAGGCGGGACGA
GGGTTGTGGGAGTTTCGTTTGGCGGAGGGTGAGGAATTTACAGTTGGACAATCAATCTCGGTGGAGTTATTCGCGGA
TGTGAAGAAGGTGGATGTGACGGGTACGAGCAAGGGGAAGGGGTTTGCGGGCACAGTGAAACGTTGGAATTTTCGCA
CGCAAGATGCAACACATGGCAATTCACTGTCACATCGTGTACCTGGGAGCATTGGCCAAAATCAAACGCCAGGAAAG
GTATTTAAGGGTAAAAAGATGGCGGGACAAATGGGAAATGAGCGCGTTACAGTGCAATCGCTGGATGTGGTTCGTGT
GGATGCGGAACGTAATTTGTTGTTAGTAAAGGGCGCGGTACCAGGAGCGACGGGTAGTGATTTGATTGTGAAGCCGG
CGGTTAAAGCATAATCTAGAAAGACGTC 
 
>rpsC 
347 
 
ATGGGACAAAAGGTGCACCCGAACGGCATCCGTTTGGGCATCGTGAAGCCGTGGAATTCAACTTGGTTCGCTAATAC
AAAGGAGTTTGCGGATAATTTAGATAGTGACTTCAAGGTTCGCCAATATCTAACAAAAGAGTTGGCGAAGGCTTCAG
TGAGCCGCATTGTGATTGAACGCCCAGCAAAAAGTATTCGCGTTACTATCCATACAGCACGTCCAGGGATTGTGATT
GGCAAGAAGGGAGAGGATGTGGAGAAGTTACGCAAAGTAGTGGCAGATATTGCGGGTGTGCCGGCTCAAATTAATAT
TGCTGAGGTACGAAAACCAGAGCTAGATGCGAAGTTAGTGGCGGATAGTATTACAAGCCAATTAGAGCGCCGAGTGA
TGTTTCGCCGCGCAATGAAACGCGCAGTTCAAAATGCGATGCGCTTAGGTGCGAAGGGCATCAAGGTAGAGGTATCA
GGTCGCTTAGGTGGTGCAGAGATTGCTCGAACGGAGTGGTATCGAGAGGGCCGTGTTCCTTTACATACGTTGCGAGC
AGATATTGATTATAATACGTCGGAGGCACATACGACGTATGGGGTTATTGGTGTGAAGGTATGGATTTTTAAGGGAG
AAATTTTAGGCGGCATGGCGGCTGTGGAGCAGCCTGAGAAGCCAGCAGCGCAACCAAAGAAACAACAACGCAAGGGA
CGAAAGTAATCTAGAAAGACGTC 
 
>rpsB 
ATGGCGACGGTGTCTATGCGTGATATGCTGAAAGCAGGCGTACATTTTGGCCATCAAACGCGATATTGGAATCCAAA
GATGAAACCATTTATTTTTGGCGCACGCAATAAGGTACATATTATTAATCTGGAAAAGACGGTTCCTATGTTTAATG
AGGCGTTGGCAGAGTTAAATAAAATCGCGAGCCGAAAGGGCAAGATTCTGTTTGTAGGCACAAAGCGTGCGGCGTCA
GAGGCTGTAAAGGATGCGGCGTTGTCATGTGATCAATTTTTTGTTAATCACCGTTGGTTGGGGGGCATGTTGACGAA
TTGGAAAACAGTACGCCAAAGTATTAAGCGATTGAAGGATTTGGAAACGCAAAGTCAAGATGGCACGTTTGATAAAT
TAACTAAAAAGGAGGCTCTAATGCGTACACGAGAATTGGAAAAGTTGGAGAATTCGTTGGGAGGCATTAAGGATATG
GGGGGCTTACCAGATGCATTATTCGTGATTGACGCGGATCATGAGCATATCGCGATTAAGGAGGCGAATAATTTAGG
CATCCCTGTTTTCGCGATTGTAGACACGAATAGCGACCCAGATGGCGTGGATTTTGTGATTCCAGGCAATGATGATG
CTATTCGCGCGGTTACGTTGTATTTGGGAGCGGTGGCGGCGACGGTGCGCGAGGGTCGCTCACAAGACTTAGCAAGC
CAAGCTGAGGAGTCTTTTGTTGAGGCGGAATAATCTAGAAAGACGTC 
 
>rplB 
ATGGCGGTGGTGAAGTGCAAGCCTACGTCACCTGGGCGCCGACATGTGGTAAAGGTTGTGAATCCGGAATTACATAA
AGGAAAGCCATTCGCGCCATTATTAGAGAAGAATTCTAAGAGTGGAGGCCGCAATAATAACGGGCGCATTACGACAC
GCCACATTGGAGGCGGACATAAACAAGCATATCGCATCGTAGATTTTAAGCGTAATAAGGATGGCATTCCAGCGGTA
GTGGAGCGCCTGGAATATGACCCAAATCGCTCGGCAAATATTGCTTTGGTGCTATATAAGGATGGCGAGCGACGCTA
TATTTTAGCGCCGAAGGGTTTGAAGGCGGGAGATCAAATCCAATCGGGTGTGGACGCGGCGATTAAGCCTGGAAATA
CATTGCCTATGCGTAATATTCCTGTGGGAAGCACGGTGCACAATGTTGAGATGAAGCCGGGCAAGGGGGGACAATTA
GCGCGAAGTGCGGGCACGTATGTGCAAATTGTGGCGCGCGACGGCGCGTACGTGACGTTACGCTTGCGTAGTGGCGA
GATGCGCAAGGTGGAGGCGGATTGTCGCGCGACATTGGGTGAGGTGGGTAACGCAGAACACATGTTACGTGTGTTAG
GGAAGGCTGGCGCAGCGCGTTGGCGCGGCGTGCGCCCAACTGTGCGTGGCACGGCTATGAATCCTGTGGATCATCCG
CACGGGGGCGGCGAGGGCCGCAATTTCGGCAAACATCCTGTTACGCCATGGGGTGTGCAAACGAAGGGCAAAAAAAC
TCGTTCAAATAAACGCACAGACAAGTTTATTGTGCGCCGTCGATCGAAGTAATCTAGAAAGACGTC 
 
>prfB 
ATGTTCGAGATCAACCCAGTGAACAACCGTATCCAAGATTTAACAGAGCGTAGTGATGTGCTGCGCGGATACCTAGA
TTATGATGCGAAAAAGGAACGCTTGGAGGAGGTGAATGCTGAATTAGAGCAACCTGACGTGTGGAATGAGCCGGAGC
GTGCTCAAGCACTAGGGAAGGAACGCTCGAGCCTGGAGGCGGTGGTGGATACACTGGATCAGATGAAGCAAGGTTTG
GAGGACGTGAGCGGCTTGTTGGAGTTGGCAGTTGAGGCAGATGATGAGGAGACTTTCAATGAGGCTGTGGCAGAGTT
GGATGCGTTGGAGGAGAAGTTAGCACAACTGGAATTTCGTCGCATGTTTAGCGGTGAGTACGATTCAGCAGATTGTT
ATCTGGACATCCAAGCAGGCAGCGGGGGCACAGAGGCGCAAGATTGGGCATCGATGCTGGAACGCATGTACTTACGA
TGGGCGGAGTCTCGCGGCTTTAAGACGGAGATTATTGAGGAATCTGAGGGCGAGGTAGCTGGCATCAAGAGCGTTAC
TATTAAGATTTCGGGTGACTATGCGTATGGTTGGTTGCGCACGGAAACGGGTGTGCATCGATTGGTTCGCAAGTCAC
CATTCGATAGCGGGGGGCGTCGTCATACAAGCTTTTCATCAGCTTTCGTGTACCCTGAGGTAGACGACGACATCGAC
ATTGAGATTAATCCAGCAGACTTACGTATCGATGTGTACCGTACAAGCGGAGCAGGGGGCCAACATGTGAATCGCAC
TGAGAGCGCTGTTCGCATCACTCATATTCCAACAGGTATTGTAACACAATGTCAAAATGATCGATCACAACATAAAA
ATAAGGACCAAGCTATGAAACAAATGAAGGCTAAACTGTACGAGTTAGAAATGCAAAAAAAGAACGCGGAAAAGCAA
GCAATGGAGGACAATAAGAGCGATATTGGGTGGGGATCTCAAATCCGATCGTACGTGCTGGACGATAGTCGTATCAA
GGACTTGCGTACTGGTGTTGAAACGCGTAATACTCAAGCGGTTTTAGATGGGAGTTTGGACCAGTTCATTGAGGCGT
CTTTAAAGGCGGGCCTATAATCTAGAAAGACGTC 
 
>rpsA 
ATGACAGAGTCGTTCGCACAGTTATTCGAGGAAAGCCTGAAGGAGATTGAAACGCGTCCAGGATCGATTGTGCGCGG
GGTGGTGGTGGCAATTGATAAGGATGTTGTGTTGGTGGATGCAGGCTTAAAGAGTGAAAGCGCGATTCCTGCGGAAC
AATTTAAGAATGCTCAAGGTGAATTGGAGATTCAAGTGGGAGATGAGGTGGATGTGGCGTTAGATGCGGTGGAGGAT
348 
 
GGTTTTGGGGAAACGTTGTTAAGCCGCGAAAAGGCAAAGCGCCATGAGGCTTGGATTACTTTGGAGAAGGCGTATGA
GGACGCAGAGACAGTGACTGGCGTGATTAATGGAAAGGTGAAAGGGGGGTTTACGGTAGAATTAAATGGGATCCGCG
CATTTTTACCTGGCAGCTTGGTGGATGTGCGCCCAGTTCGCGATACATTGCATTTAGAGGGTAAGGAACTGGAGTTC
AAGGTGATTAAATTGGACCAAAAACGTAATAATGTGGTGGTGAGCCGCCGCGCTGTGATTGAGTCGGAGAATTCGGC
GGAACGTGACCAACTATTGGAGAATTTGCAAGAGGGTATGGAGGTGAAGGGGATTGTGAAAAATCTGACAGATTATG
GAGCTTTTGTAGACTTGGGTGGAGTGGATGGTTTGTTACATATTACGGATATGGCTTGGAAGCGTGTGAAACACCCA
TCTGAGATTGTTAATGTTGGTGATGAGATTACGGTGAAGGTTTTGAAATTTGATCGTGAGCGCACTCGCGTTTCATT
AGGGCTAAAGCAATTAGGTGAGGACCCATGGGTGGCAATTGCGAAGCGCTACCCTGAGGGAACGAAGTTAACAGGGC
GTGTTACTAATTTGACTGATTATGGTTGTTTTGTGGAGATTGAGGAGGGAGTGGAGGGATTAGTTCATGTGAGCGAG
ATGGATTGGACTAATAAGAATATTCATCCTAGTAAGGTGGTGAATGTGGGTGACGTGGTTGAGGTGATGGTGTTAGA
CATTGATGAGGAGCGCCGCCGCATTTCATTAGGATTAAAGCAATGTAAGGCGAATCCATGGCAACAATTTGCTGAAA
CGCATAATAAAGGGGATCGCGTGGAGGGCAAGATTAAATCGATTACGGATTTTGGCATTTTTATTGGACTGGATGGT
GGAATTGATGGTTTAGTGCATTTATCGGATATTTCTTGGAATGTAGCGGGTGAGGAGGCTGTGCGCGAGTATAAGAA
GGGTGATGAGATTGCAGCGGTGGTGTTGCAAGTAGATGCTGAGCGCGAGCGCATTTCTTTAGGTGTGAAGCAATTAG
CGGAGGACCCTTTTAATAATTGGGTGGCATTGAATAAAAAGGGTGCAATTGTGACTGGGAAGGTGACAGCGGTGGAT
GCGAAGGGTGCGACGGTGGAGTTAGCGGATGGGGTAGAGGGATATTTACGCGCATCGGAGGCGTCGCGCGATCGTGT
GGAGGATGCGACGTTGGTGTTGTCAGTGGGTGATGAGGTGGAGGCGAAGTTTACGGGTGTGGACCGCAAGAATCGTG
CGATTAGTTTGAGTGTGCGCGCTAAGGATGAGGCAGATGAAAAGGACGCGATTGCGACAGTAAATAAGCAAGAGGAC
GCTAATTTTAGTAATAATGCGATGGCGGAGGCATTTAAGGCGGCGAAGGGTGAATAATCTAGAAAGACGTCA 
 
>kanR (with upstream ribosome binding site) used for transcriptional fusion 
with recoded genes (start codon is in lower case) 
TGAGTTGTCGAGATTTTCAGGAGCTAAGGAAGCTAAAatgAGCCATATTCAACGGGAAACGTCGAGGCCGCGATTAA
ATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTAT
CGCTTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGA
TGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATG
ATGCATGGTTACTCACCACTGCGATCCCCGGAAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAA
AATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGA
TCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGC
GTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAACTTTTGCCATTCTCACCGGATTCAGTCGTCACT
CATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGG
AATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGC
TTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAA 
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Table S6-10. Refactored overlapping genes 
Gene Gene terminus overlapped Length of overlap 
rplD C-terminus 4 bp 
rplP C-terminus 1 bp 
rplW N-terminus 4 bp 
rpmC N-terminus 1 bp 
rpmC C-terminus 1 bp 
rpsQ N-terminus 1 bp 
 
 
Table S6-11. Doubling times of double mutants compared to single mutants 
Gene(s) 
Actual 
fitness
a 
Predicted 
fitness
b
 
Actual doubling 
time 
Predicted 
doubling time
c
 
rplP 0.381 - 128.7 - 
rpmC 0.468 - 104.7 - 
rplM 0.491 - 99.7 - 
rplE 0.919 - 53.3 - 
rpsI 0.521 - 94.0 - 
rpmC-rplM-1 - 0.230 88.0 213.0 
rplE-rplM-6 - 0.452 94.2 108.4 
rpmC-rpsI-4 - 0.244 86 200.9 
rplP-rplM-1 - 0.187 160.8 261.9 
aActual fitness is the measured doubling time divided by wild type doubling time (49 minutes under the conditions 
used in this study) 
bPredicted fitness is the product of the actual fitness measured for each synthetic gene corresponding to a double 
mutant. 
cPredicted doubling time is the wild type doubling time (49 minutes under the conditions used in this study) divided 
by the predicted fitness 
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